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Abstract 
Globally, cardio-metabolic diseases and their associated complications are the leading cause 
of mortality and morbidity, and also the single largest contributor to health care expenditure 
(World Health Organisation, 2017). Hitherto, much effort has been placed on attempting to 
cure rather than prevent these diseases; hence rates are projected to increase over the next 25 
years (Cho et al., 2018). Consequently, a change in approach towards prevention would be 
more effective at minimising the burden of these diseases. Hence, this thesis focussed on 
implementing lifestyle interventions, Montmorency tart cherries (MTC) (Prunus cerasus L.) 
and FATMAX exercise, to improve biomarkers associated with Metabolic Syndrome (MetS), 
the precursor to developing cardiovascular disease and type II diabetes (Wilson et al., 2005). 
Tart cherries are a dietary source rich in many polyphenolic compounds, particularly 
anthocyanins, which have been increasingly investigated for their ability to optimise health 
over the past 20 years (Wang, 1998; Seeram et al., 2001; Bell et al., 2014a; Kelley, Adkins and 
Laugero, 2018). In vitro (Wang, 1998; Seeram et al., 2001; Keane et al., 2016a) and animal 
(Seymour et al., 2008, 2009) models have provided strong evidence for the anti-oxidative, anti-
inflammatory, anti-diabetic and cardio-protective properties of tart cherries. Inconsistent 
findings from human trials limit the conclusions that can be drawn, however positive results 
relating to improved cardio-metabolic function (Ataie‐Jafari et al., 2008; Martin et al., 2010; 
Keane et al., 2016b; Keane et al., 2016c; Chai et al., 2018) and recovery from exercise 
(Howatson et al., 2010; Bell et al., 2014d) have been reported. These cardio-metabolic 
responses were observed in various human populations, but never in a MetS cohort, and 
mechanisms of observed effects have not been delineated. Consequently, the overarching aim 
of this thesis was to establish whether MTC supplementation with and without FATMAX 
exercise could improve biomarkers associated with cardio-metabolic health; and delineate 
potential mechanisms of action. 
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The results from this thesis have corroborated previous literature but also identified novel and 
clinically relevant findings. The first study (Chapter 4), examined health responses to a 
combination of MTC juice supplementation with exercise for the first time. However, no 
significant improvements on cardio-metabolic biomarkers with MTC consumption were 
observed in healthy humans. Additionally, based on hormesis, chapter 4 also suggested short-
term MTC supplementation may be most effective. The next investigation (Chapter 5) was 
the first to assess cardio-metabolic responses to MTC consumption, in humans with MetS. 
Results indicated acute supplementation of MTC capsules and juice reduced insulin 
concentrations; demonstrating a health benefit of MTC capsules for the first time in any human 
population. However, responses between MTC juice and capsules were not different. 
Corroborating previous research, MTC juice reduced systolic blood pressure acutely, by a 
clinically relevant margin. Similarly, and arguably the most clinically important finding of this 
thesis was reported in chapter 6, as 7 days MTC juice consumption significantly reduced 24-
hour ambulatory blood pressure in a population of individuals with MetS. Hence, these findings 
indicate MTC juice may be used as an anti-hypertensive intervention. Moreover, chapter 6 
revealed for the first time an MTC intervention improved fasting glucose, total cholesterol, 
TC:HDL ratio and lowered resting RER in any human population, after 6 days of MTC juice 
supplementation compared to a control group. The last experimental study attempted to 
elucidate the mechanistic pathways for observed responses with MTC (Chapter 7). Findings 
demonstrated dilutions of MTC concentrate extended lifespan in Caenorhabditis elegans; and 
identified MTC may act as a calorie restriction mimetic via the PPAR signalling pathway.  
Together these observations promote the integration of MTC, as a safe, pragmatic, naturally-
occurring dietary intervention, into habitual consumption for the prevention and amelioration 
of cardio-metabolic dysfunction. Substantiation of these results from future, well-designed 
clinical trials is necessitated to support the implementation of MTC in practice. 
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Prevention is better than cure, especially when there is no cure! Founded on this ideology, the 
research conducted as part of this thesis set out to use lifestyle interventions to prevent the 
development of cardio-metabolic diseases.  
Cardio-metabolic disease encompasses cardiovascular diseases (CVD), type II diabetes 
mellitus (T2D) and chronic kidney disease which are associated with modifiable risk factors 
including excess adiposity, hypertension, hypercholesterolaemia and hyperglycaemia (Danaei 
et al., 2014). Cardio-metabolic disease has become a major, global public health concern 
(Kraushaar and Krämer, 2009) as its constituent diseases are the leading cause of mortality and 
morbidity worldwide, and is also the single largest contributor to health care expenditure 
(World Health Organisation, 2017). Globally in 2015, there was an estimated 422.7 million 
prevalent cases of CVD and 17.92 million deaths (Roth et al., 2017), representing 31% of all 
deaths (World Health Organisation, 2017). Moreover, global prevalence of diabetes amongst 
individuals aged 18-99 years was 8.4% (451 million) as of 2017 and is expected to increase to 
9.9% (693 million) by 2045; suggesting a concomitant increase in CVD related deaths and 
placing evermore pressure on healthcare systems (Cho et al., 2018). These figures starkly 
highlight the magnitude and urgent need to reverse this pandemic.  
Metabolic Syndrome (MetS) encompasses a cluster of different cardio-metabolic criteria 
(abdominal obesity, pre-hyperglycaemia, pre-hypertension and atherogenic dyslipidaemia), 
and has become of increased interest in clinical and academic settings (O’Neill and O’Driscoll, 
2015). MetS is considered to be the precursor to CVD and T2D and confers a 2- and 5-fold 
greater risk of developing these diseases, respectively (Alberti et al., 2009). Approximately, a 
quarter of the global population are thought to have MetS, equating to 1.75 billion people 
(Saklayen, 2018). This thesis targeted individuals with MetS, yet to be diagnosed with a cardio-
metabolic disease, to provoke a meaningful contribution towards lessening the burden of 
cardio-metabolic dysfunction on a global and individual scale. This was primarily achieved 
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through focussing on reducing incidence rates of cardio-metabolic disease and therefore 
curbing the physical and financial resources spent on treating disease.  
Cardio-metabolic disease is commonly caused by an unhealthy lifestyle characterised by high 
levels of sedentary behaviour and disproportionately higher caloric intake relative to 
expenditure (Kaur, 2014). Strikingly, 80% of diagnosed cardio-metabolic diseases are 
preventable through improving lifestyle (Piepoli et al., 2017). Since CVD and T2D are closely 
interrelated, a multifactorial approach to prevent complications is recommended through diet, 
exercise, aggressive blood pressure control and treatment of dyslipidaemia (Einarson et al., 
2018). 
The efficacy of exercise and improving habitual dietary practice on the risk of developing 
cardio-metabolic disease is remarkable, such that medical associations recommend these as 
primary tools for the prevention of CVD and T2D (Sigal et al., 2004; Rosenzweig et al., 2008). 
Yamaoka and Tango (2012) reported either dietary intervention or a combination of dietary 
and exercise interventions resolved MetS in twice as many people compared to a control group. 
Subsequently, this provides rationale for the use of dietary and exercise interventions, in the 
present thesis, as a two-pronged approach to elicit cardio-metabolic health improvements.  
Modest daily improvements in health from food consumed throughout a lifetime is more 
noteworthy and safer than ‘higher risk’ pharmacological drugs consumed in the short-term to 
treat specific conditions (Chiva-Blanch and Visioli, 2012). Diets rich in fruits, vegetables, 
legumes and whole grains provide protection from cardio-metabolic dysregulation typical of 
MetS (Pitsavos et al., 2006; Kastorini et al., 2011). These foodstuffs contain polyphenols, 
which are ubiquitous, naturally-occurring phytochemicals derived from plant-based foods 
(Manach et al., 2004). Polyphenols have been heavily researched over the past 25 years to 
exploit their myriad of health-promoting properties, including anti-oxidant, anti-inflammatory, 
anti-hypertensive, anti-hyperglycaemic and lipid-lowering (Manach et al., 2004); thus may 
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defend against CVD and diabetes development (Scalbert et al., 2002; Stevenson and Hurst, 
2007; Bahadoran, Mirmiran and Azizi, 2013). Polyphenols are divided into many different 
subclasses, of which anthocyanins are one (Manach et al., 2004). Recently, anthocyanins have 
gained plentiful attention for their health-promoting properties, particularly due to their potent 
anti-inflammatory and anti-oxidant properties (He and Giusti, 2010). There is growing 
evidence that anthocyanins and anthocyanin-rich foods confer significant improvements to 
cardio-metabolic health (Pojer et al., 2013; Wallace, Slavin and Frankenfeld, 2016; Fairlie-
Jones et al., 2017; Yang et al., 2017). 
A food source which has received substantial attention in clinical and exercise science fields 
over the past 10 years, are tart cherries (Prunus cerasus L.). Tart cherries have been shown to 
possess a high phytochemical content, including phenolic acids, catechins, proanthocyanidins, 
melatonin, quercetin, kaempferol and particularly anthocyanins (Seymour et al., 2009; Ou et 
al., 2012). These phytochemicals are thought to contribute to the potent anti-oxidative and anti-
inflammatory properties of tart cherries, which exceed that of common non-steroidal anti-
inflammatory drugs such as ibuprofen (Wang et al., 1999). Human studies have shown tart 
cherries to effectively combat oxidative stress (Traustadottir et al., 2009; Bell et al., 2014c; 
Bell et al., 2016), inflammation (Howatson et al., 2010; Martin et al., 2011; Bell et al., 2014bc) 
and promote post-exercise recovery (Howatson et al., 2010; Bowtell et al., 2011; Bell et al., 
2015; Levers et al., 2016). The anti-inflammatory and anti-oxidative properties of tart cherries 
conveniently target the underlying chronic low-grade inflammation and pro-oxidant status that 
is central to MetS pathophysiology. Indeed, tart cherries were demonstrated to improve body 
composition and cardio-metabolic markers in rodents (Seymour et al., 2008, 2009) and humans 
(Ataie‐Jafari et al., 2008; Martin et al., 2010; Bell et al., 2014b; Keane et al., 2016; Chai et al., 
2018), suggesting this fruit may ameliorate symptoms associated with MetS. However, human 
trials with tart cherry interventions in individuals with MetS have yet to be conducted. 
Chapter 1. Introduction 
5 
 
Despite prolonged interest in polyphenols, researchers have been unable to delineate the 
mechanisms of their health-promoting effects (Watson, Preedy and Zibadi, 2013). Improved 
cardio-metabolic health makes the expectation tenable that lifespan may also be extended 
(Heilbronn and Ravussin, 2003). Hence, this thesis attempted to delineate the mechanisms of 
action of observed effects with Montmorency tart cherries (MTC) and determine whether they 
act as a calorie restriction mimetic to extend lifespan in a Caenorhabditis elegans (C. elegans) 
model. 
Lastly, some of the issues with current interventions include the lack of individualisation of 
interventions and limited knowledge of the cause and effect relationship between interventions 
and their overall impact on disease (Kraushaar and Krämer, 2009). Currently, reversal of the 
cardio-metabolic disease epidemic will not be achieved without more effective preventative 
interventions (Kraushaar and Krämer, 2009). Thus, identification of more efficacious 
interventions is required; this programme of research aimed to contribute to resolving this issue 
by examining MTC and individualised FATMAX exercise (the intensity of maximal fat 
oxidation conveyed as %V̇O2max) as potential interventions with simple and feasible 
application to daily life. Presently, no research has been conducted in participants with MetS 
nor has MTC supplementation been combined with exercise in any population. Therefore, this 
thesis addressed these gaps and aimed to present data evaluating the use of these interventions 
as preventative measures against cardio-metabolic diseases, in the view to conduct future large-
scale clinical trials. 
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This literature review is partitioned into 3 parts. Part 2.1 will review literature pertaining to 
functional foods and their health-promoting properties. Particular focus will be attributed to 
polyphenols, mainly anthocyanins as they are the most abundant polyphenol in tart cherries, 
and their metabolism in humans before reviewing literature on their effects on health. This 
section will end with a comprehensive review of research examining metabolism of cherry 
products and their effects in both exercise science and clinical nutrition domains. Part 2.2 will 
review the epidemiology, pathophysiology and interventions used to combat MetS. As both 
areas encompass a wide range of sub-topics in relation to health, a detailed analysis of each is 
beyond the remit of this review. Subsequently, focus will be placed on cardio-metabolic health. 
Part 2.3 will review literature relating to the use of the model organism, Caenorhabditis 
elegans, for human health, particularly cardio-metabolic. The literature explores potential 
mechanisms through which polyphenolic dietary interventions may extend lifespan and 
improve healthspan, thus propose mechanistic pathways for the action of MTC. 
Part 2.1. Polyphenols and Health 
2.1.1. Functional Foods and Nutraceuticals 
“Let food be thy medicine and medicine be thy food”. This belief was first embraced 2500 
years ago by Hippocrates (Hasler, 2002). Since the development of modern drugs, this concept 
has been marginalised until relatively recently; and the role of diet in disease prevention and 
amelioration has now become tremendously topical (Hasler, 2002; Bultosa, 2015). ‘Functional 
foods’ is a term that was marketed by the food industry to describe the health benefits of food 
and therefore a universal definition has not been formulated (Hasler, Bloch and Thomson, 
2004). However, the British Nutrition Foundation (2016) define functional foods as foodstuffs 
that deliver enhanced benefits over and above their basic nutritional value. Herein lies the 
benefit of functional foods, since all foods are ‘functional’, the ability of certain foodstuffs with 
added physiological and psychological benefits that prevent or ameliorate chronic disease 
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renders them extremely desirable (Hasler, 2002; Hasler, Bloch and Thomson, 2004; Bultosa, 
2015). The health promoting effects of functional foods pertain mainly to growth and 
development, cardio-metabolic and gastrointestinal physiology, defence against oxidative 
stress, improved cognition and physical performance and fitness (Tur and Bibiloni, 2016).  
Functional foods are whole foods occurring in their natural form or fortified/enhanced with 
bioactive components such as fish oils, vitamins and minerals (Hasler, Bloch and Thomson, 
2004). In contrast, nutraceuticals refer to non-conventional foods with health promoting 
properties but occurring as an isolated or purified product, commonly consumed in capsule, 
tablet or liquid form (Hasler, Bloch and Thomson, 2004). The advantage of functional foods 
over nutraceuticals lie in the greater safety of consuming conventional whole foods, since 
nutraceuticals provide bioactive agents in dosages that far exceed those attainable from 
conventional whole foods (Hasler, 2002). 
Research has reported positive results on the effect of both functional foods and nutraceuticals 
against chronic diseases including CVD (Sikand, Kris-Etherton and Boulos, 2015), diabetes 
mellitus (Sikand, Kris-Etherton and Boulos, 2015), cancer (Aghajanpour et al., 2017), 
respiratory (Hwang and Ho, 2018), gastrointestinal (Salminen et al., 1998; Cencic and 
Chingwaru, 2010) and cognitive diseases (Lang et al., 2013).  
Examples of functional foods which have demonstrated health benefits include beetroot 
(Clifford et al., 2015), green tea (Cabrera, Artacho and Giménez, 2006), chocolate (Ackar et 
al., 2013), red wine (grapes) (Yoo, Saliba and Prenzler, 2010), berries (Paredes-López et al., 
2010; Vendrame et al., 2016) and cherries (Bell et al., 2014a; Kelley, Adkins and Laugero, 
2018). A commonality between these foods is their abundance of polyphenols. Polyphenols 
are a group of phytochemical compounds ubiquitously found in various plant-based dietary 
sources and the most abundant anti-oxidants in the human diet (Scalbert et al., 2002). In the 
UK, average consumption of polyphenols (1521 mg.day-1) is surprisingly higher than other 
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European regions such as the Mediterranean (1011 mg.day-1) (Zamora-Ros et al., 2016). 
Polyphenols are divided into many classes including hydroxybenzoic acids, hydroxycinnamic 
acids, flavonoids, stilbenes, and lignans, of which flavonoids have sub-classes including 
anthocyanidins, proanthocyanidins, flavonols, flavones, flavanols, flavanones and isoflavones 
(Manach et al., 2005) (Figure 2.1). Although not considered a polyphenol, phenolic acids are 
increasingly being recognised for their health promoting attributes. Phenolic acids are 
secondary metabolites of parent polyphenols after they undergo metabolism (Scalbert et al., 
2002). They are significantly more bioavailable thus responsible for a greater contribution of 
the anti-oxidant potential than parent polyphenols (Manach et al., 2005).  
Polyphenols have traditionally been targeted for their powerful anti-oxidative properties, 
however the mechanism through which they exert their health effects extends beyond just their 
free radical scavenging ability (Chiva-Blanch and Visioli, 2012). Alternative mechanisms that 
polyphenols may operate via include activation of endogenous anti-oxidant and phase II 
detoxification enzymes, modulation of gut microbiota and activation of molecular and cellular 
signalling cascades regulating inflammation and cardio-metabolic function (Chiva-Blanch and 
Visioli, 2012). 
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Figure 2.1. Classification of phytochemicals and the main natural compounds in each group (Ramos, Lima and Pereira-Wilson, 2011).
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2.1.2. Polyphenol Structure 
The chemical structure of phenolics is characterised by attachment of one or more hydroxyl 
groups to at least one aromatic ring (Zhong, 2011). Over 8000 phenolic compounds have been 
discovered, with many occurring naturally in plants (Strack, 2007). These compounds are 
concentrated in the skin and flesh of fruits and vegetables and are occasionally found in other 
plant parenchyma such as bark, leaves, seeds and roots (Zhong, 2011).  
Flavonoids are a large group of C15 polyphenolic compounds arranged as two aromatic-rings 
(A and B) linked by a three-carbon bridge (C6-C3-C6) that forms an oxygenated heterocycle (C 
ring) (Zhong, 2011). Flavonoid sub-classes are thus determined by the variation of the type of 
heterocycle (C ring) (Figure 2.2). 
Figure 2.2. Generic chemical structure of major flavonoids. 
 
Structural differences in relation to anthocyanidins, are responsible for determining variants of 
anthocyanidins (cyanidin, delphinidin, petunidin, peonidin, pelargonidin and malvidin) and 
consequently anthocyanins (Pojer et al., 2013) (Figure 2.3). Sugar moieties attached to 
anthocyanidins include glucose, galactose, rhamnose, arabinose and xylose (Mazza and 
Miniati, 2018). Amongst aglycones, hydroxyl groups attached to the B-ring display blue/purple 
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pigments and while attachment of methoxyl groups present red pigmentation (He and Giusti, 
2010). 
Figure 2.3. Generic anthocyanidin chemical structure.  
2.1.3. Polyphenol Absorption, Distribution, Metabolism and Excretion 
Polyphenol absorption is affected by molecular weight and the degree of glycosylation and 
esterification with heavier molecules (Scalbert et al., 2002). Flavonoids, apart from catechins 
and proanthocyanidins, in whole foods are present in glycosylated forms, which the body is 
unable to absorb (Scalbert et al., 2002). Thus, metabolism of flavonoids is initiated in the oral 
cavity by salivary enzymes and β-glucosidase derived from oral epithelial cells (Fernandes et 
al., 2014). Furthermore, oral microbiota has been shown to enact phase II metabolism on 
anthocyanins, indicating the oral cavity as an important region of polyphenol metabolism 
(Larsen et al., 2011). 
Intestinal enzymes, lactase phlorizin hydrolase and β-glucosidase, facilitate the hydrolysis 
process in the gut to produce a polyphenolic aglycone and a glycoside (sugar) moiety; 
considered phase I metabolism (D’Archivio et al., 2010) (Figure 2.4). However, anthocyanins 
are an exception in that the glycosylated moieties attached to the anthocyanidin can be absorbed 
and detected in systemic circulation (D’Archivio et al., 2010). Absorption of anthocyanins has 
A 
B 
C 
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been shown to occur from the stomach, small intestine and colon via active transporters, 
sodium-glucose cotransporter-1 (SGLT-1) and glucose transporter 2 (GLUT-2) (Faria et al., 
2009). In contrast to other flavonoids, anthocyanin absorption from the stomach via 
bilitranslocase is common and likely responsible for their rapid appearance in systemic 
circulation, between 6-20 minutes post-consumption (Pojer et al., 2013). The acidic conditions 
in the stomach facilitates anthocyanin stability and thus augments bioavailability, however 
during intestinal transit, stability decreases since pH increases (McGhie and Walton, 2007). 
After deglycosylation, the aglycones and glycoside moieties are absorbed across the gut lumen 
into epithelial cells via passive diffusion or epithelial transporters (Cassidy and Minihane, 
2017). Once absorbed, metabolites undergo some phase II metabolism (conjugation reactions 
including, glucuronidation, methylation, sulphation and to a lesser extent acetylation) in the 
gut epithelium and are then transported to the liver via the portal vein where further phase II 
metabolism may occur; after which metabolites enter into systemic circulation for distribution 
to other tissues (Marín et al., 2015) (Figure 2.4). Phenolics not absorbed in the stomach or 
small intestine, travel downstream to the colon where they undergo hydrolysis or deconjugation 
by colonic microbiota to further promote absorption (Marín et al., 2015). 
Efflux of aglycones, phenolic acids and conjugated metabolites from the body occurs either 
through the kidneys in urine, or biliary excretion from the liver into the intestine (Cassidy and 
Minihane, 2017). Intestinal enzymes hydrolyse metabolites while microbial enzymes (β-
glucosidase, β-glucuronidase, α-rhamnosidase) deconjugate metabolites into deconjugated 
compounds and aglycones in the colon (Duda-Chodak et al., 2015) (Figure 2.4). Deconjugated 
compounds and aglycones undergo demethylation to phenolic acids and aldehydes by colonic 
microbiota, then secondary reabsorption in an enterohepatic cycle to further promote 
absorption (Corona et al., 2013). Any unabsorbed metabolites after colonic microbiota 
metabolism are excreted in faeces (Marín et al., 2015).
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Figure 2.4. General absorption and metabolism routes of parent flavonoid compounds, their secondary metabolites and phase II conjugates (Adapted 
from Cassidy and Minihane, 2017). CBG (cytosolic β-glucosidase); LPH (lactase phlorizin hydrolase).
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2.1.4. Anthocyanin Bioavailability  
Porrini and Riso (2008) defined bioavailability as the portion of an ingested compound or 
nutrient, relative to the total amount consumed, that reaches the site where it can exert its 
biological action. 
As mentioned previously, glycosylated anthocyanins are able to be absorbed into systemic 
circulation intact and pass into urine as such without undergoing hydrolysis or phase II 
conjugation, unlike other flavonoids (D’Archivio et al., 2010). However, similar to other 
flavonoids, glycosylated and acylated forms of anthocyanins are less bioavailable and thus 
undergo hydrolysis into their aglycone (anthocyanidin) and the sugar moiety (Wallace, 2011). 
This process increases the bioefficacy of dietary anthocyanins but at the expense of stability, 
hence previous literature consistently reporting low bioavailability of anthocyanins (~0.4%) 
(Wallace, 2011). More recently however, Kay et al. (2017) found anthocyanins may be more 
bioavailable than first thought when considering their secondary metabolites and phenolic 
catabolites. These are suggested to be the main bioactive components responsible for the 
health-promoting properties of anthocyanins (Espín, González-Sarrías and Tomás-Barberán, 
2017; Kay et al., 2017). Czank et al. (2013) found similar anthocyanin recovery rates (12.3%) 
to flavan-3-ols and flavones (2.5-18.5%). Specifically, when a major anthocyanin of tart 
cherries, 500 mg cyanidin-3-glucoside, was provided to humans, 0.18% was recovered from 
blood, 5.37% from urine, 6.91% from breath and 32.13% from faeces, with the remaining 
56.1% unaccounted for (Czank et al., 2013). This is likely due to methodological procedures 
which examined anthocyanin bioavailability being setup to detect disappearance of the main 
flavylium cation only; and not other smaller phenolic compounds after biotransformation, 
which are more abundant in vivo (McGhie and Walton, 2007). Consequently, this is a major 
reason for the poor understanding of anthocyanin bioavailability (McGhie and Walton, 2007). 
After phase I metabolism of 500 mg cyanidin-3-glucoside, secondary metabolites, 
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protocatechuic acid (PCA) and phloroglucinaldehyde, were detected in serum 6 hours post-
bolus at concentrations of 0.72 µmol.L-1 (Czank et al., 2013); indicating rapid metabolic 
transformation. However, PCA-derived metabolites were observed in serum up to 48 hours 
after cyanidin-3-glucoside consumption, prolonging bioavailability (Czank et al., 2013). 
In human pharmacokinetic studies, anthocyanin plasma concentrations peaked between 1.4-
592 nmol.L-1 and occurred at 0.5-4 hours post-consumption of dosages ranging from 68-1300 
mg (Kay, 2006). Peak concentrations (~100 nmol.L-1 after dosages ≤500 mg anthocyanins) of 
secondary metabolites occurred between 0.5-3 hours in systemic circulation and remained in 
urine up to 24 hours after consumption (Czank et al., 2013). Approximately 32% of the 
compounds found in serum and urine were parent anthocyanins with secondary metabolites 
accounting for the remaining 68% (Kay, Mazza and Holub, 2005). 
Phytochemical bioavailability is affected by a variety of factors as shown in Table 2.1. 
Anthocyanin bioavailability is particularly low due to poor intestinal absorption, high 
metabolism rates and rapid elimination (Manach et al., 2004). Bioavailability of polyphenols 
in humans is notoriously poor (Porrini and Riso, 2008) as highlighted by the literature above. 
Therefore, it has been posited that augmenting bioavailability of a polyphenol would enhance 
its effectiveness on health (Bohn, 2014). 
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Table 2.1. Factors affecting bioavailability of polyphenols in humans. Adapted from 
D’Archivio et al. (2010). 
 
2.1.4.1. Effect of Food Matrix on Anthocyanin Bioavailability  
Consideration of the vehicle by which anthocyanins are delivered into the body must be made 
when assessing their bioavailability. Anthocyanins can be provided in a variety of 
matrices/forms including whole fruit, dried fruit, juice concentrate, juice drink (extract with 
water) and capsules. Greater absorption of anthocyanins occurs in supplements provided in 
liquid form, however at the expense of bioavailability (McGhie and Walton, 2007). This is due 
to the exposure of anthocyanins to external factors that affect their stability such as pH, 
temperature, light, oxygen, enzymes, oral microbiota and sugars (Robert and Fredes, 2015). 
Capsules are a medium by which the influence of these factors may be mitigated due to 
protection of the anthocyanins by the exterior capsule shell (Robert and Fredes, 2015). 
Oidtmann et al. (2012) compared encapsulated (pectin or whey protein isolate shells) and non-
encapsulated bilberry anthocyanin concentrations after in vitro incubation with gastric and fed-
Pre-Harvest Factors Cultivation procedures; harvesting timings; climate conditions 
(temperature, light, water, altitude, UV radiation), physical (soil); 
use of fertilisers and pesticides; attack by pathogens and pests. 
Post-Harvest Factors Thermal treatments; homogenisation; lyophilisation; methods of 
cooking; storage and shipping conditions. 
Polyphenol Related Factors Chemical structure and size; concentration in food; dosage 
administered. 
Food Related Factors Food matrix; co-ingestion of positive (e.g. dietary fat) or negative 
(e.g. dietary fibre, protein) effectors of absorption; in vivo 
structural interaction with other compounds (binding with 
proteins e.g. albumin) or with polyphenols possessing similar 
mechanism of absorption. 
Host Physiological Factors Host characteristics (genetics, illness history, sex, age, training 
status, habitual polyphenol intake); enteric and intestinal pH 
concentration; enzyme activity; intestinal transit time; colonic 
microbiota. 
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state intestinal fluids. During and after incubation, total anthocyanin concentrations were 23% 
higher with the encapsulated bilberry extract compared to non-encapsulated, suggesting 
encapsulation protected anthocyanins from enteric degradation. An obvious limitation is that 
in vitro incubation of anthocyanins with gastric and intestinal fluids does not mimic the 
complexity of in vivo anthocyanin metabolism in humans. The role of salivary amylase and 
colonic microbiota as part of the metabolism of anthocyanins (McGhie and Walton, 2007) has 
been overlooked in this study, limiting the application of the findings. 
Kamonpatana et al. (2012) found oral microbiota significantly degraded cyanidin glycosides 
from chokeberry extracts by 50%, one hour after incubation with human saliva. This finding 
suggests that a glycoside of the main anthocyanidin found in tart cherries is considerably 
affected by salivary degradation, indicating that consideration of the method of delivering tart 
cherry anthocyanins to ensure maximal bioavailability is necessary. Capsules, which bypass 
the salivary degradation of anthocyanins, may therefore be a suitable option of achieving this. 
However, the bioavailability of anthocyanin-rich cherry capsules has not been assessed nor 
have their health effects. 
2.1.5. Effects of Anthocyanins on Cardio-Metabolic Health  
Anthocyanins are predominantly responsible for the dark red, blue, black and purple pigments 
found in various fruits and vegetables (Wu et al., 2006). Anthocyanins are abundant in a variety 
of common dietary sources (e.g. berries, cherries, red/black grapes, pomegranates, purple corn, 
purple cabbage) which are available all year round, particularly in well-developed regions (He 
and Giusti, 2010). Thus, of all the polyphenols, anthocyanins are thought to be consumed in 
the greatest amounts from food sources present in habitual diet (He and Giusti, 2010). 
Considering this greater intake, it has been postulated that anthocyanins may exert a greater 
effect on health compared to other polyphenols (Landete, 2013). However, the abundance of 
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anthocyanins in the diet does not necessarily correlate with high bioavailability in systemic 
circulation or target tissues (D’Archivio et al., 2010). 
The average estimated anthocyanin intake from habitual diet in the United States is 12.5 
mg.day-1 (Wu et al., 2006), whereas in Europe consumption differs significantly from 19.8 
(Netherlands) to 64.9 mg.day-1 (Italy) for men, and for women, from 18.4 (Spain) to 44.1 
mg.day-1 (Italy) (Zamora-Ros et al., 2011). Incidentally, UK average anthocyanin consumption 
for men (22 mg.day-1) and women (24 mg.day-1) tends to fall near the lower range amongst 
European countries (Zamora-Ros et al., 2011). 
Many reviews and meta-analyses have reported largely beneficial cardio-metabolic health 
responses from anthocyanin consumption (Wallace, 2011; Reis et al., 2016; Wallace, Slavin 
and Frankenfeld, 2016; Yang et al., 2017; Daneshzad et al., 2018; Kimble et al., 2018). 
Epidemiological evidence suggested anthocyanin consumption reduced risk of coronary heart 
disease and CVD mortality by 9% and 8%, respectively (Kimble et al., 2018). Dietary 
anthocyanin consumption was associated with a 15% T2D risk reduction, and berry 
consumption with an 18% risk reduction (Tan et al., 2016). Recently an epidemiological study 
monitoring 124,086 individuals for up to 24 years, provided encouraging evidence that 
anthocyanins may aid weight management (Bertoia et al., 2016).  
Randomised control trials (RCT) investigating the impact of anthocyanins on cardio-metabolic 
biomarkers in humans, have reported some equivocal findings (Wallace, Slavin and 
Frankenfeld, 2016; Yang et al., 2017; Daneshzad et al., 2018). Overall, anthocyanins improved 
biomarkers that were not optimal at baseline (Wallace, 2011; Wallace, Slavin and Frankenfeld, 
2016; Yang et al., 2017; Daneshzad et al., 2018). However, the RCTs included in these reviews 
displayed much variation in the supplements administered (purified/whole food/extract), form 
(matrix), supplementation length, anthocyanin dose administered, composition of the 
Chapter 2. Literature Review 
20 
 
anthocyanin-rich extracts, dietary control measures, control comparators, baseline status of the 
biomarkers, and differences in the reporting of outcome measures. Subsequently, it is difficult 
to reach a consensus on optimal anthocyanin supplementation strategies to improve particular 
aspects of cardio-metabolic health. Hence, further well-designed trials are required to explore 
the optimal dosage, duration, matrix and anthocyanin formula for improving cardio-metabolic 
health through specific manipulation of individual parameters in various populations. 
2.1.5.1. Acute and Short-term Anthocyanin Feeding Studies on Cardio-Metabolic Health 
The low feasibility and high economic cost of consuming anthocyanins for extended periods 
has led to interest in assessing the benefits of acute (≤24 hours) and short-term (≤7 days) 
supplementation. Short-term supplementation of anthocyanin-rich dietary interventions (mean 
244 mg.day-1, range from 6.8–724 mg.day-1) has led to improved insulin sensitivity (Willems 
et al., 2017; Solverson et al., 2018), lowered brachial systolic blood pressure (SBP) (Keane et 
al., 2016b; Stote et al., 2017), central SBP (Jennings et al., 2012), increased 24-hour fat 
oxidation rate (Solverson et al., 2018) and flow-mediated dilatation (FMD) (Rodriguez-Mateos 
et al., 2013, 2016). Anthocyanins were able to modulate arterial stiffness, measured by pulse 
wave velocity (PWV) and analysis (PWA) (Fairlie-Jones et al., 2017), and improve cardiac 
haemodynamic parameters including stroke volume (SV), total peripheral resistance (TPR), 
cardiac output (CO) (Willems et al., 2015) and mean arterial pressure (MAP) (Jennings et al., 
2012; Cook et al., 2017a). 
The main advantage of acute anthocyanin supplementation is maximising its bioavailability 
and coinciding parent anthocyanin and metabolite pharmacokinetics with observed health 
effects. However, a limitation of these studies is the lack of follow-up after discontinuing 
supplementation. Therefore, the biological significance of these anthocyanin-rich interventions 
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in relation to long-term cardio-metabolic health remains unknown. Further research would be 
required to provide greater biological significance, ecological validity and clinical benefit. 
2.1.5.2. Mechanisms of Anthocyanins on Health  
2.1.5.2.1. Anti-oxidant Theorem and Hormesis 
Oxidative stress has been considered an important characteristic of ageing and chronic disease 
due to the free radical theory of ageing (Harman, 1956). The theory posits that organisms age 
because cells accumulate oxidative damage induced by free radicals (Sohal and Weindruch, 
1996). Free radicals can inflict damage in various ways: destructing deoxyribonucleic acid 
(DNA) and cellular structures, activating signalling pathways that increase reactive oxygen 
species (ROS) production, altering gene and enzyme function and disrupting normal repair 
processes (Poulsen et al., 2000). Age-related chronic diseases including CVD, T2D and MetS 
(section 2.2.4) have oxidative stress ascribed as a core component of their underlying 
pathophysiology (Liguori et al., 2018); based on many studies reporting a low anti-oxidant 
status/pro-oxidant balance being associated with ageing (Sohal and Weindruch, 1996). This led 
to the ‘anti-oxidant theorem/hypothesis’ that age-related chronic diseases may be prevented 
with provision of anti-oxidants to return the oxidant balance to homeostasis (Stanner et al., 
2004). 
The concept of hormesis, emerged from toxicology, and describes the biphasic dose-response 
where a chemical can induce biologically opposite effects at different doses (Calabrese et al., 
2007). Commonly, at low doses the chemical has stimulatory/beneficial effects and at high 
doses inhibitory/toxic effects (Calabrese et al., 2007), giving rise to an inverted-U curve 
(Figure 2.5). In relation to oxidative stress, evoking a slight stress response from low 
concentrations of ROS prompts a stronger, more potent anti-oxidative response against 
subsequent deleterious bouts of oxidative stress and thus protects against free radical damage 
(Masoro, 2000). 
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Figure 2.5. Hormetic curve indicating optimum dose of polyphenols for beneficial effects (De 
Roos, Arbones-Mainar and Gutiérrez, 2010). 
Dietary phytochemicals operate via hormetic mechanisms and are therefore termed ‘hormetins’ 
(Rattan, 2008). The action of polyphenols and specifically anthocyanins against chronic disease 
is thought to operate via direct and indirect anti-oxidant mechanisms (Stevenson and Hurst, 
2007). Direct anti-oxidant action against oxidative stress was initially purported to be the 
mechanism of action of anthocyanins, as in vitro studies have demonstrated their ability to 
quench free radical damage, particularly lipid peroxidation (Stevenson and Hurst, 2007). 
However, in vivo studies have suggested anthocyanins are unlikely to significantly contribute 
to the overall total anti-oxidant capacity given the relatively low bioavailability and plasma 
concentrations in which they appear (Landete, 2013). Anthocyanins in plasma only reach nM 
and low µM concentrations, thus it has been reported that anthocyanins would only contribute 
a transient 2-4% increase in plasma total anti-oxidant capacity (Stevenson and Hurst, 2007). In 
further discouragement of the direct anti-oxidant mechanism, anthocyanins in plasma typically 
occur in their phase II metabolite form, which have significantly less anti-oxidant potential 
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than their parent compounds (Liu, 2003). Consequently, this would explain the lack of effect 
in studies supplementing single anti-oxidant nutrients to improve chronic diseases (Liu, 2003). 
An indirect anti-oxidant mechanism may therefore be in play. The concept of hormesis 
inducing slight oxidative stress and upregulating endogenous anti-oxidant enzyme production 
has been proposed as an indirect mechanism (Stevenson and Hurst, 2007). Traustadottir et al. 
(2009) proposed three mechanisms by which tart cherries act against oxidative stress. These 
include scavenging free radicals directly, formation of cyanidin–DNA complexes resistive to 
oxidative damage and activation of protective xenobiotic responses via the upregulation of 
endogenous anti-oxidants and Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) activation 
(Traustadottir et al., 2009). Nrf2 also transactivates anti-oxidant response elements, under 
oxidative stress conditions encountered in cardio-metabolic diseases (Reis et al., 2016). 
Therefore, Nrf2 is a key regulator of endogenous anti-oxidant enzymes including but not 
limited to glutathione-S-transferase, glutathione peroxidase and haem oxygenase-1 (Sykiotis 
et al., 2011). Šarić et al. (2009) found upregulation of the endogenous enzymes superoxide 
dismutase (SOD) and glutathione peroxidase (GPx) in mice after consumption of tart cherry 
juice. In addition to the anti-oxidant activity, Nrf2 also contributes to anti-inflammatory 
processes through crosstalk with the nuclear factor kappa-light-chain-enhancer of activated B 
cells (NF-κB) signalling pathway (Ahmed et al., 2017). Low-grade, chronic inflammation is 
inherent in vascular and metabolic pathologies; thus the ability of anthocyanins to influence 
the NF-κB signalling pathway and reduce the inflammatory response plays an important role 
in improving vascular and metabolic function (Wallace, 2011).  
Overall, hormetic pathways that polyphenols, including anthocyanins, function through 
include: Nrf2/anti-oxidant response element pathway, NF-κB pathway and sirtuin-FOXO 
pathway (Son, Camandola and Mattson, 2008). This provides evidence that polyphenols 
including anthocyanins exert their health-promoting effects via a myriad of hormetic signalling 
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pathways. Importantly, the anti-oxidant dose required to elicit the positive effects are small, so 
as not to induce the toxic effects of anti-oxidants and thus comply with the hormetic curve. 
2.1.5.2.2. Modulation of Gut Microbiota  
Lastly, modulation of gut microbiota is increasingly recognised as a potential mechanism of 
the cardio-metabolic protective effects of polyphenols (Cardona et al., 2013; Espín, González-
Sarrías and Tomás-Barberán, 2017), including anthocyanins (Faria et al., 2014; Igwe et al., 
2018). A systematic review by Igwe et al. (2018), examining the effects of anthocyanins on 
gut microbiota showed upregulation of beneficial microbiota including Bifidobacterium and 
Lactobacillus and simultaneous reductions of pathogenic microbiota including Clostridium.  
2.1.6. Cherries 
Cherries belong to the Rosaceae family and the genus Prunus; they are commonly found in 
temperate climates in northern regions (McCune et al., 2011). There are over a hundred 
cultivars of cherries, but the main types are sweet (Prunus avium L.) and tart (or sour) (Prunus 
cerasus L.) (McCune et al., 2011). The sweet cherry is commonly grown from the Bing cultivar 
and the tart cherry from the Montmorency cultivar (Kelley, Adkins and Laugero, 2018). 
2.1.6.1. Phytochemical Content of Cherries  
Tart, sweet and Cornelian (Cornus mas L.) cherries have been assessed for their health-
promoting abilities (McCune et al., 2011; Kelley, Adkins and Laugero, 2018). Cherries possess 
a high variety of bioactive compounds including vitamin C, fibre, carotenoids, 
hydroxycinnamates, melatonin, anthocyanins, flavonols and flavan-3-ols such as catechin, 
epicatechin, quercetin-3-glucoside, quercetin-3-rutinoside and kaempferol (Ferretti et al., 
2010). Of these, anthocyanins were found to be the most abundant (Ferretti et al., 2010). The 
anthocyanin content of Montmorency tart cherries (MTC) compares favourably to other 
anthocyanin-rich dietary sources (Table 2.2). 
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Table 2.2. Anthocyanin content of various whole foods and beverages [adapted from Clifford 
(2000)].  Units for whole foods in mg.kg-1 and for juices/wine in mg.L-1. 
Food Source 
Anthocyanin Content 
(mg.L-1 or mg.kg-1) 
Montmorency Tart Cherry (juice) 9117 
Blackberry 1150 
Blueberry 825-4200 
Blackcurrant 1300-4000 
Cabbage (purple) 250 
Chokeberry 5060-10000 
Elderberry 2000-10000 
Grape (red) 300-7500 
Blood Orange (juice) 2000 
Raspberry (black) 1700-4277 
Raspberry (red, whole fruit) 100-600 
Raspberry (red, juice) 4-1101 
Strawberry 150-350 
Sweet Cherry 20-4500 
Wine (red) 240-350 
 
In whole tart cherries the parent anthocyanidin, cyanidin, accounts for 93% of anthocyanins in 
the Montmorency cultivar (Kirakosyan et al., 2009). In MTC concentrate the most abundant 
anthocyanins include, cyanidin-3-glucosylrutinoside, cyanidin-3-rutinoside and peonidin-3-
rutinoside (Bell et al., 2014b). 
MTC possess less anthocyanins than other tart cherry varieties but contain more total phenolics 
(Kirakosyan et al., 2009; McCune et al., 2011). It has been postulated that this greater quantity 
of total phenolics may increase bioavailability and thus improve MTC bioefficacy in vivo 
(Seymour et al., 2008). Kirakosyan et al. (2009) assessed the quantity of total anthocyanins 
and phenolics in dried (with and without added sugar), frozen, concentrate and individually 
quick-frozen powdered Montmorency cherries. Frozen whole tart cherries contained the most 
total anthocyanins and phenolics, followed by individually quick-frozen powder, concentrate, 
dried without sugar and dried with sugar (Kirakosyan et al., 2009); suggesting increased acidity 
provides more phenolics and anthocyanins.  
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In another study, analysis of MTC in dried, frozen and diluted juice (30 mL, equivalent to 90-
110 whole tart cherries, and 60 mL concentrate) forms showed the greatest concentrations of 
total anthocyanins, phenolics, anti-oxidant capacity (Trolox), PCA, vanillic acid (VA) and 
chlorogenic acid were in juice form, with values linearly increasing in a dose-dependent 
manner (Keane et al., 2016a). Total anthocyanin and (phenolic) content of 30 mL concentrate, 
60 mL concentrate, dried and frozen MTC were 312.7 mg.L-1 cyanidin-3-glucoside equivalents 
(713.7 GAE.L-1), 624.7 mg.L-1 (1427.3 GAE.L-1), 0.08 mg.g-1 (0.05 GAE.g-1) and 0.3 mg.g-1 
(0.06 GAE.g-1), respectively (Keane et al., 2016a). Moreover, tart cherry concentrate was 
shown to have the highest oxygen radical absorbance capacity (ORAC) capacity of any other 
tart cherry product (frozen, canned, dried) and other anthocyanin-rich foods (plums, grapes, 
strawberries and blueberries) at common habitual intake portion sizes (Ou et al., 2012). 
Therefore, MTC concentrate may be the most suitable form of supplementation to induce 
beneficial health responses.  
2.1.6.2. Cherry Pharmacokinetics 
Plasma concentrations of the anthocyanins cyanidin-3-glucosylrutinoside and cyanidin-3-
rutinoside, were found to be greatest in healthy human participants after consuming whole tart 
cherries (Seymour et al., 2014). After consuming 45 (total anthocyanins 12.96 mg) whole 
cherries, concentrations peaked at 2 hours post-ingestion, cyanidin-3-rutinoside also peaked 2 
hours after consuming 90 (total anthocyanins 25.83 mg) whole cherries, however cyanidin-3-
glucosylrutinoside peaked at 4 hours with 90 cherries (Seymour et al., 2014). Consumption of 
45 whole cherries was not significantly different compared to 90 cherries in terms of plasma 
anthocyanin concentrations over a 12-hour time period, although 90 cherries tended to be more 
bioavailable (Seymour et al., 2014). The authors also noticed a delayed yet statistically 
significant elevation in plasma anti-oxidant capacity between 8-12 hours post-ingestion of 45 
and 90 cherries compared to baseline. Time of appearance of metabolites in urine peaked 6-8 
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hours post-ingestion with 90 cherries. These findings align with the general pharmacokinetics 
of anthocyanins in humans (Kay, Mazza and Holub, 2005). 
Keane et al. (2016a) studied plasma concentrations of secondary metabolites after human 
consumption of Montmorency tart cherry juice (MTCJ) made with 30 or 60 mL concentrate in 
a randomised, counterbalanced design. Plasma concentrations of PCA, VA and chlorogenic 
acid in twelve, healthy, males were measured at baseline, 1, 2, 3, 5- and 8-hours post-
consumption. PCA was significantly elevated from baseline one-hour post-consumption in 
both conditions (Figure 2.6), however peak concentrations and total AUC between conditions 
were not significantly different. A significant time effect was observed for VA after 60 mL 
consumption (Figure 2.6). A similar response was observed with 30 mL as demonstrated by 
non-significant differences between AUC responses, however peak concentration occurred 2-
hours post-consumption, suggesting the lower total anthocyanin and phenolic content may have 
been a limiting step for the slower production of VA after metabolism by gut microbiota. The 
pharmacokinetics of these secondary metabolites are in accordance with Seymour et al. (2014). 
Two limitations of Keane’s et al. (2016a) study include the lack of a standardised washout 
between conditions (minimum 10 days). This may have affected baseline values of the second 
trial, particularly given the high inter-individual variance of anthocyanin metabolism (Czank 
et al., 2013). Secondly, blood sampling time points limited complete examination of 
metabolites as enterohepatic anthocyanin metabolism occurs up to 48 hours post-consumption 
(Czank et al., 2013). 
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Figure 2.6. (A) PCA responses to 30 and 60 mL Montmorency cherry concentrate (MC). 
Absolute baseline values were 1.16 ± 0.326 and 1.70 ± 0.435 μg/mL for 30 and 60 mL, 
respectively. Asterisk indicates a significant time effect (P < 0.05) (30 and 60 mL dose); data 
presented as mean ± SEM. (B) VA responses to 30 and 60 mL Montmorency cherry concentrate 
(MC). Absolute baseline values were 0.158 ± 0.031 and 0.093 ± 0.024 μg/mL for 30 and 60 
mL, respectively. Asterisk indicates a significant time effect (P < 0.05) (60 mL dose only); data 
presented as mean ±SEM (Keane et al., 2016a). 
2.1.6.3. Tissue Bioavailability of Cherries 
Understanding the effectiveness of tart cherry anthocyanins requires awareness of the tissue 
bioavailability. Kirakosyan et al. (2015) identified tart cherry anthocyanins in several tissues 
in healthy rats using liquid chromatography-mass spectrometry, after supplementation of 1% 
or 10% wet weight tart cherry powder. The anthocyanins found by Bell et al. (2014b) in MTC 
concentrate, were differentially distributed in various tissues within the rats (Kirakosyan et al., 
A 
B 
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2015). Bladder and kidney tissue contained the greatest amounts of total anthocyanins, with 
moderate amounts in cardiac, brain and liver tissues and none found in retroperitoneal fat. 
Currently, it is unknown in which tissues tart cherry anthocyanins would be most bioavailable 
in humans. Further research is required in assessing tissue bioavailability of anthocyanins, 
phenolics and secondary metabolites after consumption of MTC in healthy and diseased human 
populations. 
2.1.6.4. Cherries and Exercise 
The effects of cherries within the exercise science field have predominantly focused on 
treatment of exercise-induced muscle damage (EIMD) and associated complications, including 
exercise-induced oxidative stress, inflammation and delayed onset muscle soreness (DOMS). 
The ability of athletes to recover and return to play after strenuous activity is important for 
performance (Howatson and van Someren, 2008). Cherry supplementation, especially the 
Montmorency cultivar, has been shown to alleviate DOMS, upper respiratory tract infection 
(URTI), inflammation, oxidative stress and recover muscle function quicker after strenuous 
exercise (Bell et al., 2014a; Connolly, 2015) (Table 2.3). However, the mechanisms of action 
by which tart cherries exert their beneficial effects to improve functional and performance 
parameters are unknown (Bell et al., 2014a). 
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Table 2.3. Summary of studies examining the effects of tart cherry supplementation on physiological and functional parameters after exercise. 
Study 
Study Design, 
Sample Size and 
Cohort 
Cherry Supplementation 
Strategy and Dietary Control 
Study Details 
Significant Results 
with Cherry 
Supplementation 
compared to Placebo 
Conclusion 
Connolly, McHugh 
and Padilla-
Zakour, (2006) 
Randomised, 
Crossover, 
Placebo 
Controlled 
 
16 healthy, 
active, males 
355 mL twice daily for 8 days 
– Juice  
 
No dietary control 
Eccentric elbow flexion 
contractions (2 x 20 
maximum contractions) 
was performed on the 
fourth day of 
supplementation 
↓ Strength Loss  
↓ Pain 
Improved muscle function and reduced pain 
with cherry supplementation. 
Howatson et al. 
(2010) 
 
 
 
 
 
 
 
Randomised, 
Parallel, Placebo 
Controlled 
 
20 (13 male,  
7 female) 
recreational 
marathon runners 
237 mL twice daily for 8 days 
- Juice 
 
Food diary during 
supplementation phase to 
monitor compliance 
Marathon run 
MVIC pre-post exercise 
Faster isometric 
muscle strength 
recovery 
 
Post-Exercise: 
↓ IL-6 
↓ CRP 
↓ Uric Acid 
↑ TAS 
↓ TBARS  
 
 
Cherry supplementation improved muscle 
function in a shorter timeframe and reduced 
inflammation, oxidative stress post-exercise 
coinciding with greater anti-oxidant status. 
Bowtell et al. 
(2011) 
Randomised, 
Crossover, 
Placebo 
Controlled, 
Double-Blinded 
 
10 well-trained 
males 
30 mL twice daily for 10 days 
– Juice concentrate 
 
Habitual diet for first 5 days 
of supplementation period. 
Participants recorded their diet 
for 48 h before the first main 
trial and then repeated this 
diet before the second trial. 
 
10 x 10 single-leg knee 
extensions at 80% one-
repetition maximum on 
the eighth day of 
supplementation 
Faster isometric 
muscle strength 
recovery 
 
↓ Protein oxidation 
Cherry supplementation improved muscle 
function in a shorter timeframe with reduced 
protein oxidative stress. 
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Bell et al. (2014c) Randomised, 
Parallel, Placebo 
Controlled, 
Double-Blinded 
 
16 trained male 
cyclists 
30 mL twice daily for 7 days – 
Juice concentrate 
 
 
Low-polyphenolic diet during 
loading phase 
109 min cycling trial 
completed on days 5, 6 
and 7 of the 
supplementation phase 
↓ IL-6 
↓ hsCRP 
↓ Lipid 
Hydroperoxides 
Cherry supplementation reduced inflammation 
and lipid oxidation with repeated metabolically 
induced muscle damage. 
Bell et al. (2015) Randomised, 
Parallel, Placebo 
Controlled, 
Double-Blinded 
 
16 trained male 
cyclists 
30 mL twice daily for 8 days – 
Juice concentrate 
 
 
Low-polyphenolic diet during 
loading phase 
 
109 minutes cycling trial 
on the fifth day of 
supplementation 
Improved muscle 
function post-
exercise 
 
↓ IL-6 
↓ hsCRP 
Cherry supplementation improved muscle 
function in a shorter timeframe and reduced 
inflammation with metabolically induced 
muscle damage. 
Dimitriou et al. 
(2015) 
Randomised, 
Parallel, Placebo 
Controlled 
 
20 (13 male,  
7 female) 
recreational 
marathon runners 
2 x 236 mL on the day of 
exercise – Juice 
 
No dietary control 
Marathon run ↓ CRP 
↓ Incidence and 
severity of URTS 
post-exercise 
Systemic inflammation and upper-respiratory 
tract symptoms significantly lower post-exercise 
with cherry supplementation. 
Levers et al. (2015) Randomised, 
Parallel, Placebo 
Controlled, 
Double-Blinded 
 
23 healthy, 
resistance-trained 
males 
480 mg.day-1 for 10 days – 
Powdered tart cherry capsules  
 
Monitor dietary intake for 4 
days. No dietary restriction 
enforced 
10 x 10 repetitions at 
70% of a one-repetition 
maximum back squat 
exercise 
↓ Muscle soreness 
↓ Total Bilirubin 
↓ ALT 
↓ AST 
 
↑ Serum Creatinine 
↑ Total Protein 
 
Powdered tart cherry significantly reduced 
muscle catabolism markers and muscle soreness 
after resistance exercise. 
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Levers et al. (2016) Randomised, 
Parallel, Placebo 
Controlled, 
Double-Blinded 
 
27 (18 male,  
9 female) 
endurance trained 
or triathletes 
480 mg.day-1 for 10 days – 
Powdered tart cherry capsules  
 
No dietary control reported 
Half-marathon run on the 
eighth day of 
supplementation 
Faster half-distance 
split and final finish 
time 
 
↓ IL-12p70 
↓ IL-2 
↓ IL-5 
↑ IL-6 
Powdered tart cherry significantly reduced 
inflammation after aerobic exercise.  
Bell et al. (2016) Randomised, 
Parallel, Placebo 
Controlled, 
Double-Blinded 
 
16 semi-
professional male 
soccer players 
30 mL twice daily for 7 days  
– Juice concentrate 
 
Low-polyphenolic diet 48hr 
before each trial and during 
loading phase 
12 x 20m sprints every 
60s followed by an 
adapted LIST Protocol  
(6 x 15 min sections) 
 
↑ Muscle function 
post-exercise 
↓ Muscle soreness 
 
↓ IL-6 
 
Reducing the post-exercise inflammatory 
response significantly improved functional 
markers of muscle function after damaging 
exercise from prolonged intermittent sprinting. 
McCormick et al. 
(2016) 
Randomised, 
Crossover, 
Placebo 
Controlled, 
Double-Blinded 
 
9 highly-trained 
Water Polo 
players 
2 boluses of 30 mL and 60 mL 
– Juice concentrate 
 
No dietary control reported 
Battery of swimming-
based tests: in-water 
vertical jump test, 10 m 
sprint test, the repeat 
sprint test and WIST 
No difference 
between conditions 
for: 
IL-6 
CRP 
Uric Acid 
F2-Isoprostanes 
DOMS 
Performance in 
Battery Test 
6 consecutive days of tart cherry juice 
supplementation has no effect on athletic 
performance or recovery in highly-trained Water 
Polo athletes. Intermittent, non-weight 
bearing exercise may not induce a sufficient 
inflammatory response or oxidative stress; 
thereby negating any potential beneficial effects 
associated with tart cherry supplementation. 
Hillman, Taylor 
and Thompkins 
(2017) 
Randomised, 
Parallel, Placebo 
Controlled, 
Single-Blinded 
 
16 healthy, 
recreationally 
active 
participants 
2x240 mL twice daily for 10 
days – Tart cherry and whey 
drink 
 
No dietary restriction enforced 
5 x 20 Drop Jumps with 
60s rest between intervals 
↑ 67% ORAC No change in markers of muscle damage, 
however increased ORAC with a tart cherry and 
whey blend. Indicates that addition of whey may 
limit the efficacy of tart cherry phytochemicals. 
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ALT (Alanine aminotransferase); AST (Aspartate aminotransferase); CRP (C-reactive Protein); hsCRP (high-sensitivity C-reactive Protein); IL (Interleukin); LIST 
(Loughborough Intermittent Shuttle Test); MVIC (Maximal Voluntary Isometric Contraction); ORAC (Oxygen Radical Anti-oxidant Capacity); RER (Respiratory Exchange 
Ratio); TAS (Total Anti-oxidant Status); TBARS (Thiobarbituric Acid Reactive Substances); TT (Time Trial); URTS (Upper Respiratory Tract Symptoms); WIST (Water Polo 
Intermittent Shuttle Test).
Brown, Stevenson 
and Howatson 
(2019) 
Randomised, 
Parallel, Placebo 
Controlled, 
Double-Blinded 
 
20 physically 
active females 
30 mL twice daily for 8 days – 
Juice concentrate 
 
No dietary restriction enforced 
Repeated sprint protocol 
15 x 30m maximal 
sprints with 60s rest 
between bouts 
↑ Muscle function 
post-exercise 
 
In a female only cohort, tart cherry consumption 
improves muscle function and tends to lower 
muscle soreness after a damaging bout of 
exercise. 
 
Morgan, Barton 
and Bowtell (2019) 
Randomised, 
Crossover, 
Placebo 
Controlled, 
Double-Blinded 
 
8 trained male 
cyclists 
462.8 mg.day-1 for 7 days – 
Powdered tart cherry capsules  
 
No dietary restriction enforced 
10 min steady-state at  
~65% V̇O2peak. 
Followed by 15 km 
cycling TT 
Faster TT completion 
time 
↑ Blood Lactate after 
steady-state 
↑ Resting Tissue 
Oxygenation Index 
 
No difference 
between conditions 
for: 
RER during steady 
state and TT exercise 
7 consecutive days of Montmorency tart cherry 
capsule consumption increased muscle 
oxygenation and thus improved time trial 
performance. RER during moderate-intensity 
exercise was not different between conditions, 
however 10 minutes was likely to short a 
timeframe to observe significant changes. 
 
Chapter 2. Literature Review 
34 
 
The general design of these studies was randomised, crossover with a placebo control 
comparator. Most studies incorporated dietary control 3-7 days prior to and during the loading 
phase, which consisted of a low-polyphenolic diet monitored through food diaries (Table 2.3), 
to isolate the effects of cherry phytochemicals on outcome variables. This could be deemed a 
weakness as the addition of cherry phytochemicals may serve to only replace the polyphenol 
intake that would be lost after ceasing consumption of other polyphenol-rich sources. 
Consequently, any effects between placebo and cherry conditions cannot be differentiated from 
being due to an absolute loss of polyphenols or the addition of cherry phenolics. Secondly, 
cherry juice was commonly supplemented twice daily for a short loading phase, varying 
between 7-10 days (Table 2.3). Thus, physiological responses to long term supplementation 
(>10 days) in an exercise paradigm remain unknown. 
In summary, Table 2.3 shows a clear trend for attenuating inflammation and oxidative stress 
with tart cherry supplementation in various forms including juice, juice from concentrate and 
encapsulated powder. Due to variations in inflammatory and oxidative stress biomarkers, 
supplementation strategy, exercise protocol and the lack of absolute data reported in studies, it 
is not possible to distinguish which form of cherry supplementation was most effective. The 
timing of supplementation pre-, during and post-exercise likely augmented total phenolic and 
anthocyanin concentrations in systemic circulation, regardless of the high metabolism and 
rapid elimination rates. A discernible relationship between greater bioavailability of cherry 
phytochemicals and effective mitigation of symptoms associated with EIMD was observed. 
Predictably, acute supplementation immediately before exercise was therefore effective at 
attenuating DOMS, inflammation and oxidative stress. Future studies are required where 
supplementation occurs at points where plasma concentrations of cherry phytochemicals are 
not maximal as a result of consumption immediately before, during or after exercise. An 
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understanding of the pharmacodynamics and pharmacokinetics of cherry anthocyanins and 
other phytochemicals is therefore required in an exercise paradigm. 
2.1.6.5. Cherries and Health 
A recent review analysed 29 (tart 20, sweet 7, unspecified 2) published studies, which assessed 
the effects of cherries (juice, powder, concentrate, capsules) on health markers in humans 
ranging from young athletes to older individuals with chronic conditions (Kelley, Adkins and 
Laugero, 2018). Nineteen studies employed a randomised, placebo-controlled design, with the 
remaining 10 only assessing pre-post responses to the cherry intervention. Study design varied 
considerably, with supplementation length commonly lasting <2 weeks (range 5 hours – 3 
months) and daily equivalent dosages of 45-270 whole cherries (55–720 mg.day-1 
anthocyanins) provided in single or split doses (Kelley, Adkins and Laugero, 2018). 
Furthermore, other factors including habitual anthocyanin intake and metabolism of various 
forms of MTC affect bioavailability and thus bioefficacy of the intervention against health 
biomarkers; making comparisons between studies difficult.  
Given the potent anti-oxidant and anti-inflammatory properties of cherries, Kelley, Adkins and 
Laugero (2018), found 8/10 and 11/16 studies reported reductions in oxidative stress and 
inflammatory biomarkers, respectively. Moreover, glycated haemoglobin (HbA1c) was reduced 
in participants with T2D, VLDL and TG:HDL ratio were reduced in 2/5 studies, blood pressure 
in 5/7, arthritic pain and gout in 5/5 and sleep and cognitive function improved in 4/4 studies 
(Kelley, Adkins and Laugero, 2018). These findings were corroborated by Mayta-Apaza, 
Marasini and Carbonero (2017) and highlighted the impact of cherry interventions at improving 
health markers in humans; which is explored in more detail below. 
 
 
Chapter 2. Literature Review 
36 
 
2.1.6.5.1. Role of Cherries on Inflammation and Oxidative Stress 
The health effects of cherries were first considered in in vitro experiments conducted by Wang, 
(1998) and Wang et al. (1999), who demonstrated their potent anti-oxidative and anti-
inflammatory properties. Through in vitro analysis, it is thought cyanidin-3-glucosylrutinoside 
and cyanidin-3-rutinoside, exert their anti-inflammatory and anti-oxidative effects via 
inhibition of the cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes 
(Seeram et al., 2001). The anti-inflammatory power of the cyanidin aglycone in tart cherries 
was shown to exceed that of the common non-steroidal anti-inflammatory drug aspirin (Wang 
et al., 1999).  
More recently, these results were corroborated by Kirakosyan et al. (2018) also in in vitro 
experiments. The COX-1, COX-2, lipoxygenase (LOX) and xanthine oxidase (XO) inhibitory 
activity of constituent phytochemicals within MTC were compared to MTC extract at 
physiologically relevant human dosages (Kirakosyan et al., 2018). MTC extract inhibited 
COX-1, COX-2, LOX and XO by 65%, 38%, 64% and 26%, respectively, emphasising the 
anti-inflammatory and anti-oxidative properties of MTC. Strong LOX inhibition was observed 
with MTC compared to red raspberry, grape and blueberry extracts (Kirakosyan et al., 2018). 
COX-1 and XO inhibition was greater with tart cherry extract compared to its constituent 
compounds, suggesting synergistic activity of the individual compounds. COX-2 inhibition 
showed greater effects with individual compounds (quercetin and isorhamnetin-3-rutinoside) 
of MTC compared to tart cherry extract itself. The inhibition of COX-1, COX-2, LOX and XO 
indicates MTC may be a suitable intervention for the management of MetS and its 
complications (Kirakosyan et al., 2018). 
Chronic low-grade inflammation is associated with a host of diseases (McCune et al., 2011). 
Cherry consumption has been found to be beneficial at combating the inflammatory disease, 
gout in humans (Jacob et al., 2003; Bell et al., 2014c). Kelley et al. (2013) showed ingestion 
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of 45 whole sweet Bing cherries (280 g.day-1) amongst healthy humans, for 28 days decreased 
plasma concentrations of extracellular newly identified receptor for advanced glycation end-
products binding protein (EN-RAGE) (29%), CRP (20.1%), ferritin (20.3%), plasminogen 
activator inhibitor-1 (PAI-1) (19.9%), endothelin-1 (13.7%), IL-18 (8.1%) and increased that 
of IL-1 receptor antagonist (27.9%) compared with baseline values. The reduction of EN-
RAGE, PAI-1, CRP and endothelin-1 as inflammatory markers influencing cardio-metabolic 
function provides support that cherry phenolics may be effective in regulating symptoms of 
MetS.  
In healthy humans, MTCJ supplementation (240 mL twice daily for 14 days, 118 mg.day-1 
anthocyanins) lowered the oxidative stress markers, F2-isoprostanes and basal urinary 
excretion of oxidised nucleic acids (Traustadottir et al., 2009). This provides preliminary 
evidence for a calorie restriction mimetic (CRM) effect of tart cherries through suppression of 
oxidative stress, as this mechanism has been cited by Speakman and Mitchell (2011) during 
calorie restriction (CR). 
2.1.6.5.2. Role of Cherries on Cardio-Metabolic Health  
Lastly and most importantly for this thesis, the role of cherries on cardio-metabolic parameters 
will be discussed from experiments performed in vitro, in animals and humans. 
The positive influence of MTC on enzymes associated with MetS were mentioned above 
(Kirakosyan et al., 2018). Angiotensin II is an enzyme involved in BP regulation but also 
stimulates COX-2 expression and induces oxidative stress in cardiovascular tissues (Quilley, 
2011). Kirakosyan et al. (2018) showed a strong inhibitory potential (89% inhibition) of MTC 
extract on angiotensin-converting enzyme (ACE), signifying MTC may be a suitable treatment 
of pre-hypertension related to MetS through this mechanism. Moreover, impaired glycaemic 
function is also associated with MetS, and MTC extract was shown to inhibit α-amylase (IC50 
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3.46 mg.mL-1) and α-glucosidase (IC50 11.64 mg.mL-1) (Kirakosyan et al., 2018). Although 
physiologically relevant concentrations were used, in vivo data is required to strengthen claims 
that MTC can prevent or ameliorate complications associated with MetS through inhibiting 
enzymes relevant to cardio-metabolic function (Kirakosyan et al., 2018). 
In vivo investigations into the effects of cherry consumption on cardio-metabolic markers were 
first conducted in rodents (Seymour et al., 2008, 2009; Wu et al., 2014). The ability to 
overcome insulin resistance is crucial for preventing and ameliorating MetS, CVD and diabetes 
(Jayaprakasam et al., 2005). Cyanidin-3-glucoside and delphindin-3-glucoside in Cornelian 
cherries (Cornus mas L.) increased insulin secretion in rodents by 1.3-fold and 1.8-fold, 
respectively, in the presence of glucose at similar physiological levels in humans (4 mmol.L-1) 
(Jayaprakasam et al., 2005). In a follow-up study, mice were fed either a normal diet or high-
fat diet for 4 weeks and thereafter a high-fat diet with Cornelian cherry anthocyanins (1 g.kg-1 
of high fat diet) for a further 8 weeks (Jayaprakasam et al., 2006). Mice fed anthocyanins 
exhibited decreased hepatic triglyceride accretion and a 24% decrease in weight gain compared 
to control mice. Insulin levels were extremely elevated with anthocyanin supplementation. 
However, islet of Langerhans structural integrity was the same in normal diet and anthocyanin-
rich diet, signifying that these anthocyanins elevated insulin secretion and/or insulin sensitivity 
(Jayaprakasam et al., 2006). Similarly, a human clinical trial with Cornus mas L. extract 
showed greater insulin concentrations, lower HbA1c and triglycerides after consuming 600 
mg.day-1 anthocyanins for 6 weeks in patients with T2D (Soltani et al., 2015). The role of 
anthocyanin-mediated insulin secretion is equivocal, as in vitro and animal models primarily 
report anthocyanins to increase insulin secretion (Jayaprakasam et al., 2005; Naseri et al., 
2018), whereas human studies indicate reduced secretion based on lower insulin concentrations 
(Udani et al., 2011; Jennings et al., 2013; Willems et al., 2017).  
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Reductionist approaches to nutritional research have relevance in identifying the mechanisms 
of action of an intervention (Seymour et al., 2008). However, these studies tend to supplement 
nutrients at supra-physiological dosages, thus studies that supplement at normal physiological 
levels are required to assess biological relevance (Seymour et al., 2008). Seymour et al. (2008) 
therefore supplemented 1% MTC powder by weight of Dahl-Salt Sensitive rats for 90 days. 
This species of rat naturally exhibits hyperlipidaemia and insulin resistance where peroxisome 
proliferator-activated receptor (PPAR) agonist drugs have been shown to reverse these 
symptoms (Wilson, Alonso-Garcia and Roman, 1998). After supplementation, rats fed the 
cherry-rich diet presented significantly lower total cholesterol, triglycerides, fasting blood 
glucose, insulin and hepatic steatosis compared to controls (Seymour et al., 2008). 
Mechanistically, this was thought to be induced by greater PPARα mRNA and hepatic PPARα 
target acyl-CoA oxidase mRNA expression, resulting in increased fatty acid oxidation 
(Seymour et al., 2008). A follow-up study similar to Seymour et al. (2008) assessed abdominal 
gene transcription and adiposity in Zucker fatty rats (Seymour et al., 2009). Cherry-fed rats 
had significantly greater PPARα mRNA and lower IL-6, TNF-α and NF-κB mRNA expression 
in retroperitoneal tissue, lower plasma IL-6 and TNF-α, percentage fat mass, retroperitoneal 
fat mass, total cholesterol, triglycerides, glucose and insulin (Seymour et al., 2009). These 
findings were corroborated more recently in mice supplemented sweet cherries (Wu et al., 
2014). In addition to the above biomarkers, Wu et al. (2014) also reported smaller adipocytes, 
reduced leptin secretion and upregulation of endogenous anti-oxidant enzymes, SOD and GPx, 
with cherries. 
These rodent studies provide exciting results that cherries may ameliorate symptoms associated 
with MetS, however human responses must be studied. Kelley et al. (2006) were the first to 
examine cherry supplementation with emphasis on cardio-metabolic markers. Healthy 
participants consumed 45 sweet cherries per day for 28 days and CRP, regulated upon 
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activation, normal T-cell expressed, and secreted (RANTES) and nitric oxide (NO) 
concentrations were reduced after 28 days. No significant differences were observed after 
cherry consumption for plasma total-, LDL-, HDL-, VLDL (very low-density lipoproteins) 
cholesterol, triglycerides, glucose and insulin. A number of reasons can be cited for these 
results, firstly, participants were healthy. Secondly, 45 cherries were unlikely to increase 
plasma phytochemical concentrations sufficiently to significantly improve the above markers; 
although the authors should be commended for providing realistic portion sizes. Finally, due 
to their lower pH, tart cherries are thought to be more bioavailable than sweet cherries and 
possess more phenolics (Seymour et al., 2008). Similar weaknesses were apparent as with the 
other study (Kelley et al., 2013) conducted by this research group, including the absence of a 
control comparator and the imbalance in male (n = 2) to female (n = 16) participant ratios. 
Secondly, both studies (Kelley et al., 2006, 2013) restricted consumption of other polyphenol-
rich sources. The lack of a control group means any differences observed over time cannot be 
differentiated from an absolute lack of polyphenols or the addition of cherry phenolics.  
Garrido et al. (2013) examined responses to 5 days consumption of reconstituted freeze-dried 
sweet Jerte Valley cherry powder (27.85 g) mixed with 125 mL water in young (20-30 years), 
middle-aged (35-55 years) and older (65-85 years) participants. Urinary anti-oxidant capacity 
was increased in all age groups and remained 3-times higher than baseline in older participants, 
however returned to baseline in young and middle-aged participants after 5 days. Blood glucose 
between placebo and cherry conditions was not significantly different; potentially explained 
by normal baseline values for all age groups. 
Vargas et al. (2014), also conducted a study using sweet cherries, and examined their effects 
on inflammatory and cardiac markers, in thirty-seven overweight men. Participants consumed 
three servings of 142 g cherries per day for four weeks, substantially greater than any previous 
whole cherry feeding study, to determine tolerance of regular sweet cherry intake and 
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biological benefit. Measurements of BMI, waist circumference, BP, heart rate (HR), serum 
high-sensitivity CRP (hsCRP), urinary prostaglandin E, urinary thromboxane B2 and serum 
homocysteine were obtained pre- and post-intervention. Tolerance to supplementation was 
high, with participants consuming a median daily intake of 415 g, equating to 6.77 mg.day-1 of 
anthocyanins. No significant changes for inflammatory and functional markers were found, 
except waist circumference which interestingly increased despite a significant decrease in daily 
total dietary fat consumption. Although participants were overweight/obese, all were healthy 
therefore basal inflammation in these subjects may not have been elevated enough for sweet 
cherries to be effective. 
Another study examined the effects of 6 weeks MTCJ supplementation on blood-based lipid 
biomarkers and arterial stiffness (Lynn et al., 2014). Forty-seven, healthy participants were 
randomly allocated into an experimental (consumption of 30 mL MTC concentrate with 220 
mL water) or control group (consumption of 250 mL lemonade). The timing of supplement 
consumption was at participants’ discretion, therefore pharmacokinetics and plasma 
concentrations of MTC phytochemicals would likely have varied between individuals. 
Subsequently, this may have contributed to the non-significant results obtained between 
conditions for total cholesterol, HDL, arterial stiffness (brachial-knee PWV), SBP, diastolic 
blood pressure (DBP) and CRP. Additionally, participants were fasted overnight therefore 
bioavailability of cherry phenolics were likely not at peak levels. Similar to aforementioned 
studies, due to participants being healthy, short-term changes in blood-based biomarkers and 
arterial stiffness were likely more difficult to detect. 
In contrast, daily 40 g (anthocyanins 720 mg.day-1) tart cherry juice concentrate 
supplementation for 6 weeks significantly reduced body mass, SBP, DBP and HbA1c in 20 
women with T2D (Ataie‐Jafari et al., 2008). Moreover, in a dyslipidaemic cohort (n = 12), 
LDL was also significantly reduced after cherry consumption. However, this study did not 
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include a control group and only compared baseline to week 6 values, therefore it should be 
questioned whether participants were expecting an improvement in these variables with cherry 
juice consumption. Secondly, only female participants were recruited. Third, the anthocyanin 
dose was much higher than typically consumed from habitual diet; limiting ecological validity.  
Martin et al. (2010) (only abstract published) also reported daily consumption of tart cherry 
juice (237 mL) for 4 weeks significantly reduced plasma triglycerides (10%), TG:HDL ratio 
(17%) and VLDL (15%), compared to a placebo in 10 individuals that were overweight or 
obese. Total cholesterol, LDL, HDL and homeostatic model assessment of insulin resistance 
(HOMA-IR) were not different between conditions. The significant differences observed may 
have been due to participants presenting high baseline hsCRP, signifying elevated chronic 
inflammation and risk of CVD. 
A significant reduction in SBP (6 mmHg), DBP (6 mmHg) and HR (5 beats.min-1) was 
observed in 13 patients (6 young and 7 older) with hypertension and dysphagia, 2 hours after 
consuming a bolus of 300 mL sweet Bing cherry juice (total anthocyanin 207 mg) compared 
to placebo (Kent et al., 2015b). Values returned to baseline 6 hours after ingestion, coinciding 
with general anthocyanin and tart cherry pharmacokinetics (Seymour et al., 2014). 
Interestingly, a split-dosage, 100 mL serving at 0, 1 and 2 hours (3 x 100 mL) did not result in 
significant alterations of SBP, DBP or HR (Kent et al., 2015b). Perhaps indicating lower 
bioavailability of cherry metabolites after ingestion of multiple smaller servings of cherry juice 
than a large single bolus; although statistical analysis was not conducted to confirm this. 
Additionally, there were no significant differences for SBP, DBP and HR between younger and 
older participants highlighting the underlying pathology (hypertension) is of more importance 
for observing a positive effect with cherry supplementation than age. Furthermore, another 
study by the same authors (Kent et al., 2015a) also reported a significant reduction in SBP, 
after 6 and 12 weeks, in older (70+ years) participants with dementia after consuming sweet 
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Bing cherry juice for 12 weeks (200 mL.day-1) compared to a control group. These participants 
presented elevated baseline SBP (138 mmHg), whilst DBP was normal (79 mmHg), perhaps 
explaining only a trend towards significance for DBP (Kent et al., 2015a). Similarly, Keane et 
al. (2016b) reported a single bolus of 60 mL MTC concentrate (total anthocyanins 547 mg) 
significantly reduced SBP up to 3-hours post-ingestion compared to placebo, in 15 early 
hypertensive males. Peak reductions (7 mmHg) at 2-hours post-ingestion coincided with 
elevated PCA and VA concentrations, suggesting these secondary metabolites may be 
responsible for the observed effects. No differences were observed for arterial stiffness or 
endothelial function (microvascular vasodilation by laser Doppler imaging). Keane et al. 
(2016c) also reported 60 mL MTC concentrate significantly reduced SBP up to 3 hours post-
ingestion with peak reductions of 6 mmHg 1-hour post-consumption compared to placebo in 
27 middle-aged (45-60 years) participants. Observations from Kent’s et al. (2015ab) and 
Keane’s et al. (2016bc) research demonstrated acute supplementation of cherry juice improved 
BP and HR in participants with elevated baseline values.  
More recently, Chai et al. (2018) reported significant reductions in SBP (4 mmHg) and LDL 
(0.05 mmol.L-1) compared to a control group, after 12 weeks MTCJ consumption in 34 older 
(65-80 years) adults. In alignment with previous studies (Ataie‐Jafari et al., 2008; Kent et al., 
2015a; Keane et al., 2016bc), elevated baseline SBP in the MTCJ group facilitated 
improvements. Improvements in LDL with MTCJ may be contrived since the high fructose 
content in the placebo was thought to spike LDL concentrations (Chai et al., 2018). However, 
Chai et al. (2018) explained MTCJ may have been able to bind bile acids thus dampening the 
rise in LDL concentrations. Compared to baseline, MTCJ also significantly lowered total 
cholesterol and increased fasting glucose, triglycerides and BMI. Moreover, there was no effect 
on body mass, HDL, DBP, fasting insulin or HOMA-IR, likely due to healthy baseline values. 
Chapter 2. Literature Review 
44 
 
A strength of the study was participants maintained habitual diet throughout the 
supplementation period, upholding ecological validity. 
The only study to have examined responses to tart cherries in humans with MetS was conducted 
by Johnson et al. (2017) (only abstract published). In a randomised, parallel-arm, single-blind 
trial, participants consumed either 480 mL of MTCJ (n = 9, 5M/4F) or isocaloric placebo           
(n = 10, 5M/5F) daily for 12 weeks. Endothelial function markers, oxidised LDL and soluble 
vascular cell adhesion molecule-1 (sVCAM-1), were significantly lowered with MTCJ 
compared to placebo after 12 weeks and total cholesterol tended (P = 0.08) to be lower; no 
other differences in the lipid profile were observed. Similarly, no differences between 
conditions were observed for body composition, glucose, insulin, HOMA, brachial BP, central 
haemodynamics, arterial stiffness (PWA and PWV), FMD, inflammatory or oxidative stress 
markers. The limited information relating to specific biomarkers, participant baseline 
characteristics, dietary guidelines and anthocyanin content of MTCJ hinders explanation of 
non-significant results. Yet, in a MetS population, long-term MTCJ consumption attenuated 
biomarkers involved in accelerating atherogenesis. 
Mechanisms for improved BP with cherry supplementation have yet to be confirmed. 
Modulation of vasomotor tone through proper functioning of vascular smooth muscle cell 
(Keane et al., 2016a), increased NO bioavailability (Kent et al., 2015b; Keane et al., 2016a; 
Chai et al., 2018) and/or inhibition of ACE (Hidalgo et al., 2012; Kirakosyan et al., 2018) have 
been proposed.  
As mentioned in section 2.1.5.2.2, anthocyanins have been shown to positively modulate gut 
microbiota; potentially explaining health promoting effects. In relation to gut microbiota 
modulation by anthocyanin-rich cherries, research is very limited. Currently, only one study 
(Mayta-Apaza et al., 2018) has assessed the gut microbiota profile of humans in vivo, after 
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supplementing tart cherries. After consumption of 230 mL MTCJ for 5 days, significant 
reductions in Bacteroides and increases in Firmicutes (Ruminococcus, Lachnospiraceae, 
Clostridium and Clostridium XI, Lactobacillus and Streptococcus) were observed (Mayta-
Apaza et al., 2018). Unexpectedly, Bifidobacterium and Faecalibacterium, microbiota 
generally hallmarked for healthy gut microbiome, were lower in abundance after MTCJ 
consumption; other health-promoting Actinobacteria were increased (Mayta-Apaza et al., 
2018). The change in gut microbiota profile was influenced by carbohydrates in MTCJ (Mayta-
Apaza et al., 2018). Also, PCA, caffeic and p-coumaric acids in MTCJ were metabolised by 
most Lactobacillus strains, explaining the greater bioavailability of phenolic acid derivatives 
from MTCJ after gut microbial metabolism (Filannino et al., 2015); which may be responsible 
for tart cherries’ beneficial health responses. 
2.1.6.5.3. Cherries and Health Summary 
In summation, the positive effect of cherries in humans with elevated pre-existing cardio-
metabolic values seems to be more pronounced than in healthy individuals. There is sufficient 
evidence that cherries improve markers associated with MetS in humans; however, research is 
necessitated in a MetS population itself. The mechanisms of action through which cherry 
phenolics may prevent or ameliorate chronic disease are summarised in Figure 2.7. Speculation 
remains over the ideal supplementation strategy to improve cardio-metabolic function. 
Strategies previously implemented were not always economically viable or examined under 
ecologically valid conditions (AbuMweis, Jew and Jones, 2010). Hence, subsequent chapters 
of this thesis aim to address these research pitfalls by manipulating aspects of MTC 
supplementation strategy and observing subsequent responses in healthy and individuals and 
those with MetS. Ultimately, studies in chapters 4-6 were designed to uphold ecological 
validity and ensure economic viability to maximise impact and ease of translating basic 
research into daily habitual practice.
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Figure 2.7. Proposed mechanisms of action through which cherry polyphenols act in the management of chronic disease. Adapted from Ferretti et 
al. (2010).
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Part 2.2. Metabolic Syndrome 
The second part of this literature review will assess the epidemiology, pathophysiology and 
interventions used to combat Metabolic Syndrome. A brief explanation and examination of the 
role of lipid metabolism in the aetiology of cardio-metabolic diseases will be presented, 
followed by a short commentary and analysis of calorie restriction and its mimetics. Finally, a 
detailed discussion of the effect of anthocyanins in humans with MetS will be provided. 
2.2.1. Introduction 
Obesity is generally recognised as storage of excessive body fat at various subcutaneous and 
visceral fat depots (Snel et al., 2012); and global rates are rapidly rising annually (Ng et al., 
2014). In 1947, it was noted that obesity predisposed individuals to T2D and atherosclerosis, 
supporting observations from the 1920s of an association with hypertension, hyperglycaemia 
and hyperuricaemia (Kaur, 2014). The term ‘Metabolic Syndrome’ was first coined by Haller 
in 1977, when describing obesity, T2D, hyperlipoproteinaemia, hyperuricaemia and hepatic 
steatosis as risk factors associated with atherosclerosis (Haller, 1977). However, it was not until 
the 1988 Banting lecture, when Gerald Reaven proposed insulin resistance as the underlying 
cause of developing the cluster of risk factors previously stated, termed ‘Syndrome X’ (Reaven, 
1988). Crucially however, Reaven omitted obesity as a risk factor for his ‘Syndrome X’ but it 
was later added. Many different terms have been used to describe the cluster of risk factors, 
although Metabolic Syndrome is now commonly used and has gained an International 
Classification of Diseases coding (E88.81) (Han and Lean, 2016). 
A consequence of the distinctive cardio-metabolic features of MetS, is that over 5-10 years 
individuals with MetS have a 2- and 5-fold greater risk of developing CVD and T2D, 
respectively (Alberti et al., 2009). Moreover, MetS patients have an increased risk of 
myocardial infarction (3- to 4-fold), stroke (2- to 4-fold) and dying from these events (2-fold) 
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than individuals without MetS (Alberti, Zimmet and Shaw, 2005), regardless of a previous 
history of CVD (Olijhoek et al., 2004).  
As it is increasingly apparent that MetS is a precursor of T2D and CVD (Wilson et al., 2005), 
clinicians and researchers should be addressing MetS and its individual components with 
greater priority and importance; as a preventative measure to minimise the health, financial and 
social burden imparted on patients, health services and society in general.  
2.2.2. Diagnosis 
MetS is defined as a collection of interrelated physiological, biochemical, metabolic and 
clinical risk factors that directly augment the development of atherosclerotic CVD, T2D and 
all-cause mortality (Wilson et al., 2005; Grundy et al., 2006). Typically, an individual with 
MetS presents with abdominal obesity, pre-hyperglycaemia, pre-hypertension and atherogenic 
dyslipidaemia. However, this is often accompanied by endothelial dysfunction and a               
pro-inflammatory, pro-oxidant and pro-thrombotic state (Srikanthan et al., 2016). 
The diagnosis of MetS has proven to be an issue in clinical and epidemiological settings. 
Various organisations have attempted to outline criteria for diagnosing MetS (Table 2.4). All 
organisations agree on the core components for diagnosing MetS, however differences remain 
between thresholds of individual components and the specific combinations required to be met. 
Consequently, in 2009 a joint statement was issued (Alberti et al., 2009), detailing obesity and 
insulin resistance need not be pre-requisites for MetS diagnosis, but any 3 of 5 criteria would 
suffice. The statement also detailed specific thresholds for waist circumference based on sex 
and ethnicity (Table 2.5). This extra stratification was important in delimiting the criteria used 
to diagnose MetS, particularly as ethnicity influences an individuals’ predisposition to certain 
risk factors regardless of abdominal obesity severity (Han and Lean, 2016). Asians with a lower 
abdominal obesity cut-off are at greater risk of developing T2D than Europeans (Kaur, 2014).
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Table 2.4. Criteria proposed for clinical diagnosis of MetS. 
IGT (impaired glucose tolerance) defined as a 2 hour post glucose load of >7.8 mmol.L-1 and <11.1 mmol.L-1 (in the presence of a normal or elevated fasting glucose), and 
impaired fasting glucose (IFG) is defined as glucose levels >6.1 mmol.L-1 and <6.9 mmol.L-1. American Association for Clinical Endocrinology (AACE); Body Mass Index 
(BMI); European Group for the Study of Insulin Resistance (EGIR); Insulin Resistance (IR); International Diabetes Federation (IDF); National Cholesterol Education Program-
Third Adult Treatment Panel (NCEP-ATP III); Type 2 Diabetes (T2D); World Health Organisation (WHO). 
Clinical 
Measures 
WHO (1998) EGIR (1999) 
NCEP-ATP III 
(2001) 
AACE (2003) IDF (2005) 
Harmonised  
(Alberti et al., 2009) 
Insulin 
Resistance 
High Insulin, IGT, 
IFG or T2D and 2 
of the following: 
 
High Fasting 
Insulin and 2 of 
the following: 
No IR pre-requisite, 
any 3 of the 
following: 
IGT or IFG (but not 
T2D) and any 2 of 
the following: 
No IR pre-requisite No IR pre-requisite, 
any 3 of the 
following: 
Obesity Waist-to-hip ratio 
Male: > 0.90; 
Female: > 0.85 
and/or  
BMI > 30 kg.m-2 
 
Waist 
Circumference  
≥ 94 cm (male) 
≥ 80 cm (female) 
Waist Circumference 
≥ 102 cm (male) 
≥ 88 cm (female) 
BMI > 25 kg.m-2 Ethnicity and sex 
specific Waist 
Circumference and 
any 2 of the 
following: 
Ethnicity and sex 
specific Waist 
Circumference 
Triglycerides ≥ 1.69 mmol.L-1 ≥ 2 mmol.L-1 ≥ 1.69 mmol.L-1 ≥ 1.69 mmol.L-1 ≥ 1.69 mmol.L-1  ≥ 1.69 mmol.L-1 
HDL < 0.9 mmol.L-1 
(male)  
< 1 mmol.L-1 
(female) 
< 1 mmol.L-1 ≥ 1.03 mmol.L-1 
(male) 
≥ 1.29 mmol.L-1 
(female) 
≥ 1.03 mmol.L-1 
(male) 
≥ 1.29 mmol.L-1 
(female) 
≥ 1.03 mmol.L-1 
(male) 
≥ 1.29 mmol.L-1 
(female) 
≥ 1.03 mmol.L-1 
(male) 
≥ 1.29 mmol.L-1 
(female) 
 
Blood Pressure ≥ 140/90 mmHg ≥ 140/90 mmHg 
or on anti-
hypertensive 
medication 
 
≥ 130/85 mmHg ≥ 130/85 mmHg ≥ 130/85 mmHg ≥ 130/85 mmHg 
Glucose  IGT or IFG  
(but not T2D) 
≥ 6.1 mmol.L-1  ≥ 5.6 mmol.L-1 or 
T2D 
≥ 5.6 mmol.L-1 
Other Microalbuminuria: 
albumin: creatinine 
ratio of >30 mg.g-1 
  Family history of 
T2D 
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Table 2.5. Waist circumference thresholds based on ethnicity and sex (Alberti et al., 2009). 
Country/Ethnic Group 
   Waist Circumference Threshold (cm) 
Male Female 
Europids ≥ 94 ≥ 80 
USA ≥ 102 ≥ 88 
Middle East and Eastern 
Mediterranean 
 
Use Europid data until more specific data is available 
Sub-Saharan African Use Europid data until more specific data is available 
South Asian (including 
Malay and Indian 
population) 
 
 
≥ 90 
 
≥ 80 
Japanese ≥ 90 ≥ 80 
Chinese ≥ 90 ≥ 80 
South and Central 
American 
Use South Asian data until more specific data is available 
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2.2.3. Epidemiology 
The prevalence and incidence rates of MetS by region, sex, ethnicity and age are difficult to 
ascertain given the variability in the diagnostic criteria used. It was estimated global prevalence 
rates of MetS ranges between <10% up to 84%, depending on the diagnosis criteria used and 
the population studied (region, sex, ethnicity and age) (Kaur, 2014). Approximately, a quarter 
of the global population are thought to have MetS, equating to 1.75 billion individuals 
(Saklayen, 2018). 
Cross-sectional studies predominately from European countries approximate prevalence 
around 24.3%, where rates increase parallel with advancing age (Grundy, 2008; Scuteri et al., 
2015). Aguilar et al. (2015) estimated MetS prevalence rates in the United States increased by 
1.8% from 2003-2004 to 2011-2012, with approximately 35% of all adults having MetS. 
Of great concern is the increasing prevalence rates of MetS in children and adolescents. 
Prevalence in adolescents between National Health and Nutrition Examination Survey 
(NHANES) 1988-1994 and NHANES 1999-2000 increased from 4.2% to 6.4%, respectively 
(Kassi et al., 2011). Prevalence between NHANES 2001-2006 was estimated to be 8.6%, 
indicating the upward trend in prevalence rates amongst adolescents (Johnson et al., 2009). 
The implications of such high prevalence rates are stark, as CVD is the leading cause of death 
worldwide, representing 31% of all deaths (World Health Organisation, 2017). Moreover, 
global prevalence of diabetes amongst individuals aged 18-99 years was 8.4% (451 million) as 
of 2017 and is expected to increase to 9.9% (693 million) by 2045, indicating a concomitant 
increase in CVD related deaths and placing evermore pressure on healthcare systems (Cho et 
al., 2018). The global financial burden of treating T2D as of 2005 was thought to be in excess 
of 286 billion international dollars, rising to 396 billion international dollars by 2025; 
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accounting for 13% of the entire global healthcare budget (Yach et al., 2006). Strikingly, these 
figures do not account for treating diabetes associated CVD complications. 
Finally, it is important that past and future MetS prevalence statistics be generated based on 
the harmonised criteria set out by Alberti et al. (2009). This would help clinicians, 
epidemiologists and researchers detect trends and understand problems associated with MetS; 
in-turn assisting development of interventions to reduce MetS prevalence and incidence.  
2.2.4. Pathophysiology 
The aetiology of MetS has yet to be fully understood, however it is accepted that genetic and 
environmental factors are inherent to the underlying pathophysiology, suggesting epigenetic 
mechanisms (Kassi et al., 2011). Specifically, visceral obesity and insulin resistance are 
considered to be central to MetS pathophysiology, with atherogenic dyslipidaemia, 
dysregulation of the renin-angiotensin-aldosterone system, endothelial dysfunction, 
hypercoagulable state and chronic stress contributing to its pathogenesis (Kaur, 2014)       
(Figure 2.8). 
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Figure 2.8. Schematic highlighting the interactions of adipokines, cytokines and inflammatory 
markers that contribute to the pathogenesis of MetS (Srikanthan et al., 2016).  
2.2.4.1. Obesity 
Obesity manifests a state of chronic low-grade inflammation and oxidative stress, which 
underpins the development of insulin resistance; suggesting that at its core, MetS is a pro-
oxidative and pro-inflammatory condition (Chiva-Blanch and Badimon, 2017). 
Generally, adipose tissue, comprising of adipocytes and stromal vascular fraction, acts as the 
main site of lipid storage but also exerts an endocrine, inflammatory and oxidative stress 
response (Thompson, Pederick and Santhakumar, 2016). Such a response is mediated through 
secretion of adipokines, pro-inflammatory cytokines, free fatty acids (FFA), glycerol 
(Fernández-Sánchez et al., 2011), ROS and species contributing to endothelial dysfunction 
from hypertrophied adipocytes (Table 2.6) (Thompson, Pederick and Santhakumar, 2016). The 
dysregulated secretion of FFAs, adipocytokines and thrombogenic factors facilitates the 
development of insulin resistance and all other components of MetS (Kaur, 2014). 
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Preventing adipocyte hypertrophy through augmenting fat mobilisation and oxidation would 
regulate adipocyte function and prevent ectopic accumulation in sites such as cardiac and 
skeletal muscle; thus, mitigate MetS related symptoms (Snel et al., 2012). Ectopic 
accumulation is mediated by insulin-dependent suppression of white adipose tissue lipolysis 
and a concomitant reduction in FFA oxidation (Snel et al., 2012); thus, dysregulating normal 
cellular function and inducing insulin resistance (Kwak, 2013). Therefore, normal lipid 
metabolism in skeletal muscle is crucial for ameliorating diseases associated with excessive 
lipid accumulation (Watt and Hoy, 2012). Skeletal muscle, accounting for ~40% of total body 
mass, is an adaptive organ with a plethora of physical and physiological functions, critical to 
maintaining whole-body homeostasis (Egan and Zierath, 2013). One physiological function is 
its role in lipid uptake, storage and oxidation (Watt and Hoy, 2012). Skeletal muscle is the most 
important target tissue for insulin action and is the main site of post-prandial glucose disposal 
(Roberts, Hevener and Barnard, 2014). Cellular signalling induced by ROS has been shown to 
be implicated in contraction-mediated increase in skeletal muscle glucose uptake (Merry and 
McConell, 2009). Hence, low concentrations of ROS, conforming to a hormetic response, 
produced during muscle contractions may be beneficial at preventing hyperglycaemia.  
The ability of skeletal muscle to transition between fat and carbohydrate (CHO) oxidation 
under different physiological and environmental conditions is an important quality for 
maintaining homeostasis and is known as metabolic flexibility (Snel et al., 2012). This 
transition is dependent on substrate availability where substrate oxidation dysfunction is 
associated with accumulation of intramuscular lipids and insulin resistance (Galgani, Moro and 
Ravussin, 2008). Due to their sedentary lifestyle, patients with MetS, obesity and T2D are 
unable to alter lipid oxidation rates to lipid availability resulting in intramuscular lipid accretion 
and metabolic inflexibility (Kelley et al., 1999). Hence, reversing metabolic inflexibility by 
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facilitating fat oxidation at the skeletal muscle and whole-body levels would be an effective 
strategy to mitigate MetS (Roberts, Hevener and Barnard, 2014). 
Table 2.6. Characteristic status of cardio-metabolic biomarkers in individuals with MetS. 
Biomarker Source Status in MetS 
Visceral Obesity  ↑ 
Leptin Adipocytes, VSM ↑ 
Adiponectin Adipocytes ↓ 
Resistin Adipocytes, SM, Stomach ↑ 
Visfatin Adipocytes ↑ 
Ghrelin Stomach ↓ 
Insulin Resistance  ↑ 
Fasting Glucose Liver ↑ 
HbA1c Erythrocytes ↑ 
Fasting Insulin Pancreas ↑ 
Fasting C-peptide Pancreas ↑ 
Dyslipidaemia  ↑ 
Fasting FFAs Adipocytes, Liver ↑ 
Fasting Triglycerides Adipocytes, Liver ↑ 
Fasting Total Cholesterol Liver, Intestines ↑ 
Fasting HDL Liver, Intestines ↓ 
Small, dense LDL Liver ↑ 
Fasting VLDL Liver ↑ 
Hypertension  ↑ 
Angiotensin II Kidney ↑ 
Endothelial Dysfunction  ↑ 
Nitric Oxide 
Adhesion Molecules 
ox-LDL 
Endothelium 
Endothelium 
Adipocytes 
↓ 
↑ 
↑ 
Pro-thrombotic State  ↑ 
Fibrinogen Liver ↑ 
PAI-1 Endothelium, Adipocytes ↑ 
Platelet Aggregation  ↑ 
Pro-inflammatory State  ↑ 
IL-6 Adipocytes, M1 macrophage ↑ 
TNF-α Adipocytes, M1 macrophage ↑ 
CRP Adipocytes ↑ 
IL-10 Monocytes, M2 macrophage ↓ 
Pro-oxidative State  ↑ 
ox-LDL Adipocytes ↑ 
Superoxide Dismutase Cytosol and Mitochondria ↓ 
Glutathione Peroxidase Mitochondria ↓ 
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Catalase Peroxisomes ↓ 
Malondialdehyde Mitochondria ↑ 
Hyperuricaemia  ↑ 
Uric Acid Liver ↑ 
Microalbuminuria  ↑ 
Urine Albumin Kidney ↑ 
CRP (C-reactive protein); FFA (Free Fatty Acids); HbA1c (Glycated Haemoglobin); HDL (High-density 
Lipoprotein); IL-6 (interleukin-6); IL-10 (interleukin-10); LDL (Low-density Lipoprotein); ox-LDL (oxidised 
LDL); PAI-1 (Plasminogen Activator Inhibitor-1); SM (Skeletal Muscle); TNF-α (Tumour Necrosis Factor 
Alpha); VLDL (Very low-density Lipoprotein); VSM (Vascular Smooth Muscle). 
 
2.2.4.2. Insulin Resistance 
Reaven proposed MetS pathophysiology stemmed from insulin resistance, based on the 
observed pleiotropic effects of insulin resistance on each component of MetS (Roberts, 
Hevener and Barnard, 2014). Insulin resistance defined by a state where secretion of normal 
insulin concentrations to a glucose load, does not produce the desired response of sufficient 
peripheral glucose uptake and suppression of hepatic glucose production; leading to 
hyperglycaemia, a component of MetS, and then hyperinsulinaemia (Lebovitz, 2001). 
The development of insulin resistance in MetS manifests from excessive FFA production from 
visceral adipocytes. The ectopic deposition of FFAs particularly in hepatic and skeletal muscle 
parenchyma contributes to increased hepatic glucose production and impaired glucose uptake 
in skeletal muscle (de Luca and Olefsky, 2008) (Figure 2.9). Insulin resistance in these organs 
induces a state of hyperinsulinaemia which stimulates lipogenesis, inhibits lipolysis and further 
augments adipocyte hypertrophy in a vicious cycle (de Luca and Olefsky, 2008). Moreover, 
chronic hyperinsulinaemia due to a continuous insult on pancreatic β-cells leads to β-cell 
dysfunction, and prevents sufficient insulin production thus inducing hyperglycaemia, in 
another vicious cycle (Han and Lean, 2016). 
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Figure 2.9. Manifestation of insulin resistance in various organs central to MetS (de Luca and 
Olefsky, 2008). 
2.2.4.3. Dyslipidaemia 
Dyslipidaemia in MetS is characterised by atherogenic hypertriglyceridaemia and 
hyperlipoproteinaemia (Kolovou, Anagnostopoulou and Cokkinos, 2005). Lipolysis and 
subsequent mobilisation of FFAs from adipose tissue is augmented under insulin resistant 
conditions, but also contributes to insulin resistance development (Kolovou, Anagnostopoulou 
and Cokkinos, 2005). Therefore, dyslipidaemia is not only a hallmark of MetS but also 
responsible for the underlying pathophysiology (Kaur, 2014). In addition to facilitating insulin 
resistance, the overproduction of FFAs acts as a substrate for hepatic triglyceride synthesis, 
eventually promoting LDL formation (Kolovou, Anagnostopoulou and Cokkinos, 2005). 
Triglyceride-rich LDL are hydrolysed into small, dense particles highly susceptible to 
oxidation, subsequently causing endothelial dysfunction and atherogenesis (Kolovou, 
Anagnostopoulou and Cokkinos, 2005). 
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2.2.4.4. Hypertension 
Research indicates insulin resistance activates the sympathetic nervous and renin-angiotensin-
aldosterone systems by expressing the potent vasoconstrictor angiotensin-II (Kaur, 2014).  
The cellular cascade implicating insulin resistance and hypertension involves the mitogen-
activated protein kinase (MAPK) pathway (Kaur, 2014). Under insulin resistant conditions, 
MAPK remains unaltered thus promotes production of the vasoconstrictor endothelin-1, 
expression of vascular cell adhesion molecules and proliferation of vascular smooth muscle 
cells (Zhou, Wang and Yu, 2014). Subsequently, this increases the risk of atheroma formation 
and arterial stiffness, which facilitates hypertension (Touyz et al., 2018). Conclusive evidence 
has been provided showing the manifestation of arterial stiffness in individuals with MetS 
independent of age or sex (Schillaci et al., 2005; Scuteri et al., 2014). 
2.2.5. Treatments 
Given the pro-inflammatory and pro-oxidative pathophysiology of MetS, interventions which 
elicit anti-inflammatory and anti-oxidative responses are particularly sought after. 
Pharmacological drugs, exercise, calorie restriction and diet, especially polyphenols are 
interventions capable of exerting anti-inflammatory and anti-oxidative responses (Golbidi, 
Mesdaghinia and Laher, 2012). Lifestyle interventions are increasingly recommended as they 
are a safer and more tolerable alternative to pharmacological drugs. Significantly, diet and 
exercise interventions were found to reverse MetS, with these interventions being 87% more 
clinically effective than pharmacological therapy (Dunkley et al., 2012). 
2.2.5.1. Exercise and MetS 
The importance of exercise in mitigating MetS has been repeatedly proven by numerous 
authors (Roberts, Hevener and Barnard, 2014). An inverse dose-response association was 
found between volume of exercise and MetS prevalence (Kaur, 2014). Individuals engaging in 
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moderate-intensity activity for 1 hour or less per week were at 60% greater risk of developing 
MetS than those exercising >3 hours per week (Kaur, 2014). Few studies have used exercise 
as an intervention in individuals with MetS per se, however these studies demonstrated various 
forms of exercise reversed MetS or reduced the number of MetS components (Roberts, 
Hevener and Barnard, 2014). Importantly, in a cohort of 19,223 males aged 20-83 years, this 
translated into lower mortality risk as evidenced by 5.18% mortality risk in healthy, unfit 
individuals, 5.15% in non-exercising individuals with MetS and 2.69% in exercising 
individuals with MetS (Katzmarzyk, Church and Blair, 2004). Notably, exercising individuals 
with MetS had a significantly lower mortality risk than apparently healthy, sedentary 
individuals. 
The ability to transition from carbohydrate to fat oxidation when in a glucose-depleted state is 
impaired in metabolically inflexible subjects, thus individuals oxidise carbohydrate with and 
without insulin stimulation (Kelley et al., 1999). Exercise reduces insulin resistance by 
activating adenosine monophosphate kinase (AMPK) and thus augmenting fat oxidation 
(Auwerx et al., 2010). The ability to stimulate fat oxidation with exercise and thus reverse 
metabolic inflexibility and insulin resistance is an effective strategy to prevent MetS and/or 
treat its complications (Roberts, Hevener and Barnard, 2014). 
2.2.5.1.1. FATMAX Exercise and Fat Oxidation 
The development of cardio-metabolic risk factors is associated with impaired fat oxidation 
(Robinson et al., 2016). Robinson et al. (2015) demonstrated maximal fat oxidation (MFO) 
rate during exercise is associated with 24-hour fat oxidation rate and insulin sensitivity as 
markers of long-term metabolic health. Hence, augmenting MFO rates may prove useful for 
optimising cardio-metabolic health; thus, researchers set out to determine optimal fat oxidation 
rates during exercise (Achten and Jeukendrup, 2004). 
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Romijn et al. (1993) were one of the first to assess fat oxidation rates over a range of exercise 
intensities. Fat oxidation rate was greatest at 65% V̇O2max compared to 25% and 85% V̇O2max, 
in trained athletes (Romijn et al., 1993). Achten, Gleeson and Jeukendrup (2002) devised a 
protocol to more accurately determine MFO, using a greater range of intensities. The 
incremental protocol was conducted on a cycle ergometer amongst 18 moderately trained males 
and consisted of starting at 95 W with increments of 35 W every 5 minutes until respiratory 
exchange ratio (RER) was >1. This protocol allowed identification of MFO, FATMAX (the 
intensity of MFO conveyed as %V̇O2max), FATMAX zone (area where fat oxidation is within 
10% of FATMAX) and regions of low fat oxidation rates (FATMIN) from a FATMAX curve 
(Figure 2.10). FATMAX occurred at 64% V̇O2max corresponding to 74% HRmax (maximal 
heart rate) with an MFO of 0.6 g.min-1 and FATMIN at >89% V̇O2max (92% HRmax) (Achten, 
Gleeson and Jeukendrup, 2002). 
Figure 2.10. Graph depicting a typical fat oxidation curve determined from an incremental 
exercise protocol (Randell, 2013). 
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Venables, Achten and Jeukendrup (2005), showed individuals with markedly different V̇O2max 
had similar fat oxidation rates; demonstrating high inter-individual variance in fat oxidation 
rates. Subsequently, studies implementing a protocol at a set percentage of V̇O2max or Wmax 
(percentage of maximal power output) should be criticised. Due to the large variation, 
identifying a universal exercise intensity for MFO is not possible. Therefore, identification of 
individual FATMAX using an incremental test with stringent control over diet and exercise at 
least 24-36 hours before the test, is considered the most reliable method of determining valid 
FATMAX intensity (Meyer, Gäßler and Kindermann, 2007). 
2.2.5.1.2. Health Effects of Exercise at FATMAX 
Individualised FATMAX exercise provides an opportunity to oxidise lipids, particularly from 
skeletal muscle, at accelerated rates thus potentially ameliorating symptoms associated with 
MetS (Brun, Romain and Mercier, 2011). 
Sari-Sarraf et al. (2015) recommended FATMAX training in weight loss and health-related 
exercise programs for individuals with MetS. FATMAX training effectively reduced total body 
mass and fat mass, spared FFM and, reduced cholesterol and HbA1c in patients with T2D (Brun, 
Romain and Mercier, 2011). 
Continuous running at FATMAX (4 weeks, 5 days per week) for 1 hour induced 44% greater 
fat oxidation and improved insulin-sensitivity index by 27% compared to interval exercise at 
FATMAX in 8 males with obesity (Venables and Jeukendrup, 2008). Dumortier et al. (2003) 
reported similar findings with 8 weeks cycling at FATMAX compared to no exercise in 28 
MetS patients. Compared to the controls, the training group lost significantly more body mass, 
fat mass and MFO increased from 0.12 to 0.18 g.min-1 (Dumortier et al., 2003). The transition 
from fat to carbohydrate oxidation (crossover point) occurred significantly later in the 
exercising group (31.5% v 52.6% V̇O2max) and FATMAX occurred at higher intensities 
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(27.7% vs 44.8% Wmax). The increased fat oxidation rate and loss of fat mass may have 
contributed to the significantly improved insulin sensitivity and resistance indexes (HOMA) 
after FATMAX training compared to controls (Dumortier et al., 2003). 
Similar results were obtained when 136 women with obesity cycled at either FATMAX for 55 
minutes, 60% V̇O2max for 35 minutes or home-based moderate-intensity exercise for 30 
minutes (4 times per week for 5 months) (Besnier et al., 2015). In addition, all participants 
were provided with a diet rich in fruit and vegetables (5 pieces per day) throughout the study. 
Anthropometrics, BP and lipid profile were not significantly different between groups, likely 
due to the relatively low MFO rates (0.153 g.min-1). However, all exercise interventions 
significantly reduced fat mass, HOMA-IR and augmented MFO after 5 months. Notably, MFO 
was significantly greater during FATMAX exercise resulting in improved glycaemic control, 
likely due to reduced insulin and HOMA-IR. 
Mechanistically, the beneficial effect of fat oxidation during FATMAX exercise is thought to 
be accentuated by the release of adiponectin, leptin and the anti-inflammatory myokine IL-6, 
via phosphorylation and thus activation of AMPK (Brun, Romain and Mercier, 2011). Since 
exercise stimulates skeletal muscle contractions, expression of IL-6 is increased 100-fold 
during prolonged exercise (Roberts, Hevener and Barnard, 2014). The release of the myokine 
IL-6 has pleiotropic effects including enhancing lipolysis and glucose disposal, inhibiting pro-
inflammatory molecules TNF-α and IL-1β, and expressing anti-inflammatory cytokines 
interleukin-1 receptor antagonist (IL-1ra) and IL-10 (Roberts, Hevener and Barnard, 2014). 
Mechanisms behind improved insulin resistance and sensitivity relate to increased glycogen 
synthase and GLUT-4 expression (Roberts, Hevener and Barnard, 2014). Activation of 
pathways emanating from improved skeletal muscle function, mediated by exercise, would be 
of significant benefit for the amelioration of insulin resistance and associated morbidities. 
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A meta-analysis of FATMAX training in patients with obesity, MetS and T2D confirmed a 
shift of fat oxidation to higher exercise intensities and reductions in body mass, fat mass, waist 
circumference, insulin sensitivity and total cholesterol (Romain et al., 2012). Overall, exercise 
at individual FATMAX may ameliorate the symptoms associated with MetS, and prevent the 
onset of the syndrome in healthy, asymptomatic individuals (Brun, Romain and Mercier, 2011). 
2.2.5.1.3. Polyphenolic Interventions, Exercise and Fat Oxidation 
Given the benefits that increasing fat oxidation during exercise has on cardio-metabolic health, 
dietary interventions to further augment rates have been researched (Jeukendrup and Randell, 
2011; Kim and Park, 2016). Table 2.7 details studies examining polyphenol-rich supplements 
in tandem with exercise on cardio-metabolic parameters. Polyphenols have been identified in 
in vitro and pre-clinical human trials to increase fat oxidation through a myriad of mechanisms 
including inhibition of catechol-O-methyltransferase and malonyl-coA and activation of 
sirtuin-1 (SIRT-1), AMPK, PPARα and carnitine palmitoyltransferase 1 (Rupasinghe et al., 
2016). 
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Table 2.7. Studies examining the effects of polyphenol supplementation in combination with exercise on substrate metabolism, particularly fat 
oxidation, and its effects on symptoms associated with cardio-metabolic diseases. 
Study 
Study Design, 
Sample Size and 
Cohort 
Supplementation Strategy Study Details 
Results with 
Intervention compared 
to Placebo 
Conclusion 
Venables et al. 
(2008) 
Randomised, 
Crossover, Placebo 
Controlled 
 
12 healthy, males 
(50.9 mL.kg.min-1 
V̇O2peak) 
 
24 hours before participants consumed  
3 capsules containing either decaffeinated 
GTE (total: 890 mg polyphenols and 366 
mg EGCG) or placebo. 
30 mins cycling at 60% 
V̇O2peak 
 
2-hour OGTT 
 
↑ 17% Fat Oxidation  
↑ EE from Fat 
↑ Plasma glycerol 
 
↓ Serum insulin 
↑ 13% Insulin Sensitivity 
 
Fat oxidation and lipolysis 
during exercise and insulin 
sensitivity at rest improves 
with GTE consumption. 
 
 
Eichenberger, 
Colombani and 
Mettler (2009) 
Randomised, 
Crossover, Placebo 
Controlled, 
Double-Blinded 
 
10 endurance 
trained males  
(55 mL.kg.min-1 
V̇O2peak) 
Caffeinated GTE (total polyphenols: 160 
mg.day-1; EGCG: 70 mg.day-1) for 3 weeks. 
2 hours cycling at 50% 
Wmax 
↑ HDL at rest 
 
No difference: 
Fat Oxidation 
Body Fat % 
RER 
EE 
TG 
LDL 
Cholesterol 
 
These non-significant 
findings may be a result of 
supplementing greatly 
reduced amounts of 
polyphenols daily compared 
to Venables et al. (2008).  
 
 
Allgrove et al. 
(2011) 
 
Randomised, 
Crossover, Placebo 
Controlled, Single-
Blinded 
 
10 healthy males 
(53.1 mL.kg.min-1 
V̇O2peak) 
40 g Dark Chocolate (catechins: 15.6 mg, 
epicatechins 38.7 mg) or placebo for  
2 weeks and 2 hours before exercise bout. 
90 mins cycle at 60% 
V̇O2max with intermittent 
30 second sprints at 90% 
V̇O2max every 10 mins to 
simulate road race 
↑ FFA 
↓ F2-isoprostanes 
↓ Oxidised LDL 
Tendency for ↓ RER 
 
No difference: 
TG 
Glucose 
Insulin 
Lactate 
TAS 
Cortisol 
Catechins and epicatechins 
from dark chocolate improve 
markers of oxidative stress 
and lipid metabolism after 
prolonged cycling exercise, 
thus highlighting the 
efficacy of polyphenols from 
various dietary sources on 
health markers after 
exercise. 
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Alkhatib (2014) Randomised, 
Crossover, Placebo 
Controlled, 
Double-Blinded 
 
14 (7 male,  
7 females), healthy  
1000 mg Yerba Maté (Ilex paraguariensis) 
or placebo. 
Consumed 1 hour before exercise. 
Incremental cycling test 
 
Initiated at and increased 
by 0.5 W.kg−1 of body 
mass 
During exercise: 
↓ RER 
↑ Fat Oxidation at 40% 
and 50% V̇O2peak 
↑ EE from Fat 
 
 
 
Yerba Maté increases fat 
oxidation at low exercise 
intensities primarily due to 
the thermogenic properties 
of supplement. 
 
 
Randell et al. 
(2014) 
Randomised, 
Crossover, Placebo 
Controlled, 
Double-Blinded 
 
19 healthy, males 
(55.4 mL.kg.min-1 
V̇O2peak) 
 
Decaffeinated GTE (total catechins 284 
mg.day-1; EGCG 156 mg.day-1) or placebo 
for 1, 7 and 28 days. 
30 mins cycle at 50% 
Wmax 
No difference: 
Fat Oxidation 
FFA 
Glycerol 
 
 
 
No difference in fat 
oxidation and lipid markers 
between acute and long-term 
supplementation. 
 
Alkhatib et al. 
(2015) 
Randomised, 
Crossover, Placebo 
Controlled, 
Double-Blinded 
 
12 recreationally 
active, male and 
female  
 
4.5g of either placebo or multi-ingredient 
(caffeine, green tea, Yerba Maté, capsaicin 
and guarana) supplement. 
Consumed 150 mins before exercise. 
 
150 mins rest before 
exercise 
 
30 mins FATMAX 
cycling 
↑ Fat Oxidation during 
rest  
 
↓ RPE 
 
 
 
Fat oxidation increased at 
rest through the thermogenic 
properties of the supplement. 
 
 
Cook et al. 
(2015) 
Randomised, 
Crossover, Placebo 
Controlled, 
Double-Blinded 
 
14 healthy males 
(53 mL.kg.min-1 
V̇O2peak) 
300 mg active cassis NZBE (containing  
105 mg anthocyanins) per day for 7 days 
or placebo.  
Cycle at 45, 55 and 65% 
V̇O2peak for 10 mins at 
each intensity 
↑ 27% Fat Oxidation at 
65% V̇O2max   
↓ RER at 65% V̇O2peak    
 
Tendency ↑ RER and Fat 
Oxidation at 45% and 
55% V̇O2peak 
Anthocyanin rich NZBE 
increases fat oxidation 
possibly via upregulation of 
PPARα. 
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AUC (Area Under Curve); CHO (Carbohydrate); EE (Energy Expenditure); EGCG (Epigallocatechin gallate); FFA (Free Fatty Acid); GTE (Green Tea Extract); HDL (High-
density Lipoprotein); HOMA-IR (Homeostatic Model Assessment for Insulin Resistance); LDL (Low-density Lipoprotein); NZBE (New Zealand Blackcurrant Extract); OGTT 
(Oral Glucose Tolerance Test); PPARα (Peroxisome Proliferator-Activated Receptor Alpha); RER (Respiratory Exchange Ratio); RPE (Rating of Perceived Exertion); TAS 
(Total Anti-oxidant Status); TG (Triglycerides).  
 
Roberts et al. 
(2015) 
Randomised, 
Parallel, Placebo 
Controlled, 
Double-Blinded  
 
14 healthy, males 
(39 mL.kg.min-1 
V̇O2peak) 
Decaffeinated GTE (total catechins  
571 mg.day-1; EGCG 400 mg.day-1) or 
placebo for 4 weeks. 
1-hour cycle at 50% 
V̇O2peak at baseline,  
weeks 2 and 4. 
 
Additional 1-hour cycle 
three times per week 
during supplementation 
period. 
 
↑ 24.9% Fat Oxidation  
↓ RER 
↑ EE from Fat 
↓ EE from CHO 
 
↓ RPE 
↓ Body Fat % 
Long term supplementation 
of decaffeinated GTE is 
required to elevate fat 
oxidation rate. 
Cook et al. 
(2017b) 
Randomised, 
Crossover, Placebo 
Controlled, 
Double-Blinded  
 
15 endurance-
trained males  
(57 mL.kg.min-1 
V̇O2peak) 
 
300, 600 or 900 mg.day-1 active cassis 
NZBE (containing 105 mg anthocyanins per 
300 mg capsule) for day for 7 days or 
placebo. 
2-hour cycle at 65% 
V̇O2max  
↓ RER with 600 and  
900 mg 
↑ 21.5% Fat Oxidation 
with 600 mg 
↑ 24.1% Fat Oxidation 
with 900 mg 
 
 
Dose-dependent increase in 
fat oxidation with 
anthocyanin-rich NZBE. 
However, only high 
anthocyanin doses exceeding 
habitually consumed levels 
alter substrate utilisation. 
 
Solverson et al. 
(2018) 
Randomised, 
Crossover, Placebo 
Controlled, 
Double-Blinded  
 
17 overweight and 
obese males 
High-fat (40% of energy from fat) diet 
which contained either 600 g.day-1 
blackberries (1500 mg.day-1 flavonoids) or a 
calorie matched diet for 7 days. 
30 minutes treadmill 
walking (3 mph) 
↓ RER  
↑ 12% Fat Oxidation 
during exercise 
↑ 14% Fat Oxidation at 
rest 
 
↓ Insulin AUC 
↓ HOMA-IR 
 
Blackberry anthocyanins 
increase fat oxidation rate at 
rest and during exercise in 
an overweight/obese 
population. 
Improved metabolic function 
in response to high CHO 
load. 
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Table 2.7 suggests enhanced metabolic flexibility, through greater fat oxidation, may have 
contributed to the observed improvements in lipid, insulin and oxidative stress biomarkers. 
Cook et al. (2015, 2017b) provided encouraging results that fat oxidation rate increases with 
anthocyanin-rich New Zealand blackcurrant extract (NZBE) supplementation during exercise. 
The mechanism was hypothesised to relate to AMPK activation and thus inhibition of        
acetyl-coA carboxylase and upregulation of PPARα mRNA (Cook et al., 2015; Cook et al., 
2017b). Furthermore, blackberries, containing a different anthocyanin profile (cyanidin-3-
glucoside) compared to blackcurrants (delphinidin-3-rutinoside, cyanidin-3-rutinoside, 
delphinidin-3-glucoside, cyanidin-3-glucoside), increased fat oxidation during short-duration, 
low-intensity exercise in an overweight/obese but otherwise healthy population (Solverson et 
al., 2018). Indicating various anthocyanins can increase fat oxidation during exercise in 
different populations. Although the literature is limited, these studies provide promising data 
that tart cherry anthocyanins may also augment fat oxidation rate during exercise and 
subsequently improve cardio-metabolic markers. 
2.2.5.2. Diet and MetS 
Various dietary strategies have been implemented against MetS, including calorie restriction, 
macronutrient manipulation, provision of vitamins, minerals, probiotics, prebiotics, synbiotics 
and polyphenols (de la Iglesia et al., 2016; He and Shi, 2017). Some of these are discussed in 
greater depth below. 
2.2.5.2.1. Calorie Restriction 
Calorie restriction (CR) is an intervention requiring the reduction of daily calorie intake 
normally by 10-40%, but maintaining provisions of essential macronutrients and 
micronutrients, thus preventing malnutrition (Testa et al., 2014). CR operates primarily on 
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reducing body mass and subsequently visceral adiposity; and has been practiced for centuries 
to prolong longevity and improve general wellbeing (Speakman and Mitchell, 2011).  
Humans under CR tend to lower metabolic rate, energy expenditure and shift substrate 
metabolism towards greater fat oxidation (Martin et al., 2007; Redman et al., 2007). 
Improvements in MetS components such as body composition, fasting blood glucose, lipid 
profile, insulin sensitivity, BP, CRP, IL-6 and TNF-α have been noted in adults undergoing 
30% CR (approximately 1800 kcal.day-1) for periods between 2-15 years (Fontana et al., 2004). 
Furthermore, 6 weeks calorie restriction (600-800 kcal.day-1) in individuals with MetS resulted 
in rapid body mass loss (-8 kg) and significantly improved glucose, insulin, triglycerides and 
leptin concentrations compared to individuals without MetS (Xydakis et al., 2004). It has been 
postulated that CR may regulate impaired substrate metabolism thus preventing MetS and other 
cardio-metabolic disease development (Speakman and Mitchell, 2011).  
The mechanisms of action for these responses are similar to those exerted by exercise 
(Huffman, 2010) and dietary interventions, such as polyphenols (Testa et al., 2014). Hence, 
exercise and polyphenols are considered CRMs. 
2.2.5.2.1.1. Biological Mechanisms 
A variety of biological mechanisms have been proposed to explain the effects of CR on 
longevity and wellbeing (Figure 2.11). The health effects of the most studied topic in the 
ageing/nutrition field, CR, are based on the hormetic concept (Martucci et al., 2017). Other 
pathways through which CR may prolong lifespan include autophagy, nucleotide repair,       
anti-oxidant activity and metabolic shift involving sirtuins (Rattan, 2008).  
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Figure 2.11. Potential biological mechanisms suggested to extend lifespan and healthspan via 
CR (Testa et al., 2014). 
 
2.2.5.2.1.2. Molecular Mechanisms 
Researchers hypothesise regulation of physiological processes and lifespan extension in 
humans may be mediated via evolutionary conserved mechanisms (Lee and Min, 2013). 
The insulin signalling pathway is key to the health benefits observed with CR (Testa et al., 
2014). Downregulation of insulin signalling increases forkhead box protein O1 (FOXO1) 
activity, a transcription factor involved in metabolic control (Testa et al., 2014). Insulin via 
protein kinase B (Akt) induces irreversible phosphorylation and consequently nuclear 
exclusion of FOXO1 (Nakae et al., 2001). Thus, dampening gluconeogenesis and 
glycogenolysis via downregulation of glucose-6-phosphatase transcription (Nakae et al., 
2001). Nuclear exclusion of FOXO1 also removes inhibition of PPARγ, thus enabling 
adipocyte maturation and therefore adipogenesis (Nakae et al., 2003). This demonstrates the 
importance between the insulin signalling pathway and subsequent molecular cascades on 
glucose and lipid metabolism (Nakae et al., 2003). 
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Sirtuin proteins are implicated in numerous cascades involving ageing, metabolism and stress 
resistance (Testa et al., 2014). Sirtuins are classed as histone deacetylases and are therefore 
involved in epigenetic mechanisms (Mai et al., 2008). SIRT-1 modulates inflammatory 
responses by inhibiting NF-κB and promotes fat oxidation in skeletal muscle by activating 
peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) and its 
coactivator PPARα (Salminen et al., 2008). SIRT-1 also alters substrate metabolism by 
simultaneously inhibiting PPARγ and reducing glycolytic flux, therefore enhancing lipid 
mobilisation from white adipose tissue and subsequent oxidation (Picard et al., 2004). SIRT-1 
and AMPK are co-activated during CR, and both share common targets including PGC-1α, 
FOXO, NF-κB and endothelial nitric oxide synthase (eNOS) (Ruderman et al., 2010). 
Dysregulation of SIRT-1 and AMPK has been attributed as a cause for the development of 
MetS (Ruderman et al., 2010). AMPK is a critical enzyme implicated in substrate metabolism 
and plays a pivotal role during CR as it is activated during conditions of energy and nutrient 
depletion (Bordone and Guarente, 2005). AMPK alters substrate metabolism towards fatty acid 
oxidation and simultaneously inhibits cholesterol and triglyceride synthesis and lipogenesis 
(Canto and Auwerx, 2011). Additionally, AMPK improves insulin sensitivity and resistance to 
inflammation and oxidative stress (Canto and Auwerx, 2011). 
Although adherence to prolonged CR (≥6 weeks) is difficult and discomforting for humans, 
the benefits of CR to improve cardio-metabolic health have been repeatedly observed (Larson-
Meyer et al., 2006). Biological and molecular cascades have been identified and therefore 
interventions which focus on these pathways should be examined to provide a targeted 
approach for maximising the benefits of CR. CRMs simulate the molecular and physiological 
effects of CR without reducing long-term caloric intake and its associated difficulties. 
Polyphenols are such compounds that activate similar mechanistic pathways as CR (Testa et 
al., 2014). 
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2.2.5.2.1.3. Polyphenols as Calorie Restriction Mimetics 
Polyphenols including resveratrol, EGCG (epigallocatechin-3-gallate), curcumin and quercetin 
have been identified as potential CRMs (Madeo et al., 2014). Resveratrol, found in grape skins, 
has demonstrated the greatest effect as a CRM by activating and mimicking SIRT-1 (Li, Daniel 
and Tollefsbol, 2011). Resveratrol and quercetin allosterically modulate SIRT-1 and therefore 
suppress genes through epigenetic histone deacetylation (Bass et al., 2007). Quercetin is 
present in tart cherry, therefore tart cherries may epigenetically modulate genes associated with 
CR, to improve cardio-metabolic function and extend lifespan. 
2.2.5.2.2. Polyphenols and MetS  
This section focusses on the effects of polyphenols and particularly anthocyanins on cardio-
metabolic health in humans with MetS, although much work had been conducted in in vitro 
and animal models.  
The effect of polyphenols on aspects of MetS has been studied extensively in various 
populations, with largely encouraging results (Chiva-Blanch and Visioli, 2012; Patti et al., 
2018). However, in comparison the influence of polyphenols in humans with MetS has received 
much less attention, with variable responses on certain components of MetS (Amiot, Riva and 
Vinet, 2016), thus more data is required to formulate conclusive recommendations in this 
population.  
A negative association between MetS rates and polyphenol consumption has been observed 
based on epidemiological data (Chiva-Blanch and Badimon, 2017). Specifically, the highest 
tertile of flavonoid consumption was associated with a 31% lower risk in developing MetS, 
amongst 1265 participants after a 6-year follow-up (Sohrab et al., 2018). Grosso et al. (2017) 
demonstrated the highest quartile of polyphenol intake amongst 8800 individuals presented 
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with significantly lower triglycerides, waist circumference and BP; highlighting the potential 
of polyphenols in combating MetS in various cohorts. 
A brief summary of the effects of polyphenolic classes and sub-classes on cardio-metabolic, 
inflammatory and oxidative stress markers in humans with MetS is provided herein. Strong 
evidence from multiple studies demonstrated green tea catechins reduced waist circumference, 
BMI, body fat, LDL and malondialdehyde (Amiot, Riva and Vinet, 2016). Cocoa flavanols 
improved glucose, insulin resistance, HDL, LDL and BP but not CRP, total cholesterol, 
triglycerides or waist circumference (Shrime et al., 2011). Polymers of flavanols, ellagitannins 
and proanthocyanidins beneficially modulated glucose (Selma et al., 2018) and the lipid profile 
(Bladé, Arola and Salvadó, 2010) only. Citrus flavanone supplementation increased FMD by 
2.48% and HDL, while significantly decreasing apolipoprotein B, total cholesterol and the 
inflammatory markers, CRP, amyloid A and E-selectin compared to placebo (Rizza et al., 
2011). Additionally, soy isoflavone supplementation improved LDL concentrations, body 
mass, body fat percentage and waist circumference but not BP, HDL or triglycerides (Amiot, 
Riva and Vinet, 2016). Lastly, the flavanol quercetin, was shown to reduce SBP, TNF-α and 
ox-LDL but not fasting blood glucose or triglycerides (Egert et al., 2009), while the individual 
effects of flavones have yet to be examined in humans with MetS. 
Of the non-flavonoid polyphenols, the stilbenoid, resveratrol has been associated with the most 
research, yet findings are equivocal in humans with MetS. Resveratrol was unable to change 
triglycerides, glucose (Fujitaka et al., 2011; Dash et al., 2013; van der Made, Plat and Mensink, 
2015), HDL or inflammatory markers (Fujitaka et al., 2011; van der Made, Plat and Mensink, 
2015), however apoB lipoproteins (Dash et al., 2013), BP (van der Made, Plat and Mensink, 
2015) and endothelial function (Fujitaka et al., 2011) were improved in individual studies. 
Lastly, high intake of lignans was associated with significantly lower waist circumference, but 
also higher fasting glucose and triglycerides (Grosso et al., 2017).  
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In all, the effects of polyphenols in humans with MetS are largely positive. To strengthen this 
evidence, further research is required in larger cohorts to recommend polyphenols as a 
prophylactic or therapeutic intervention against MetS. 
2.2.5.2.2.1. Anthocyanins and MetS 
A major polyphenol sub-class not mentioned above were anthocyanidins and their glycosylated 
compounds, anthocyanins. Naseri et al. (2018) recently published a review of anthocyanins in 
the management of MetS. Findings indicated anthocyanins improved pathologies associated 
with MetS, including body composition, insulin resistance, insulin sensitivity, hyperglycaemia, 
dyslipidaemia and pre-hypertension (Naseri et al., 2018). Anthocyanins also maintained 
endothelial function through heightened anti-inflammatory activity and mediated pancreatic   
β-cell protection from hyperglycaemia-induced oxidative stress (Naseri et al., 2018). The 
mechanisms are purported to be through activation of AMPK and its downstream transcription 
factors (FOXO1, PPARs), modulation of adipokines, inhibition of NF-κB, induction of Nrf2 
transcription and increased eNOS expression (Tsuda, 2008, 2016; Naseri et al., 2018). 
However, much of the evidence was derived from in vitro and animal studies. So, what are the 
effects of anthocyanins on humans with MetS and are there any discernible trends? The 
following section provides a detailed review of the effects of supplementing various forms of 
anthocyanin-rich foods and extracts in humans with MetS.  
Studies were selected based on specific criteria namely: intervention group included humans 
diagnosed with MetS; provision of whole foods, extracts or liquids predominately rich in 
anthocyanins; assessment of biomarkers relating to MetS criteria or associated 
pathophysiology (insulin resistance, inflammation, oxidative stress and endothelial function). 
In total 16 studies were included (Table 2.8), with a total sample size of 643 participants 
(healthy and MetS), of which 355 had MetS and consumed the anthocyanin-rich intervention. 
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Table 2.8. Overview of trials examining the effects of anthocyanin-rich interventions on health biomarkers in humans with MetS. 
Form of 
Supplementation 
Authors Study Design 
Participant 
Characteristics 
Supplementation 
Strategy 
Total Daily 
ACN Content 
Dietary Control 
Results (sig changes are effect of 
INT relative to PLA, unless 
specified) 
Liquid 
Basu et al.  
(2009) 
Pre-Post 
Intervention 
Design 
 
N=16 (all women) 
age 51 years; 
(BMI 38.6 kg.m-2) 
 
4 weeks 
INT: 240 mL juice twice 
daily (50 g.day-1 freeze-
dried strawberries 
reconstituted in water) 
 
INT: 154 mg 
 
Usual diet. Avoid 
products containing 
berries, cocoa, green 
tea and soy. 
Post-supplement changes relative to 
baseline 
↓ TC, LDL, MDA, HNE 
 
↔ BM, WC, SBP, DBP, glucose, TG, 
HDL, VLDL, adiponectin, CRP, ox-LDL 
 
Basu et al. 
(2010a) 
Randomised, 
Parallel, Placebo 
Controlled, 
Single-Blinded 
 
N=48 (4 male, 44 female) 
INT: N=25 
age 52 years; 
(BMI 38.1 kg.m-2) 
CON: N=23 
age 48 years; 
(BMI 37.5 kg.m-2) 
 
 
8 weeks 
INT: 240 mL juice twice 
daily (50 g.day-1 freeze-
dried blueberries 
reconstituted in water) 
(~350 g fresh blueberries). 
CON: 480 mL water twice 
daily 
INT: 742 mg 
 
CON: 0 mg 
Usual diet. Avoid 
products containing 
berries, cocoa, green 
tea and soy. 
 
↓ SBP, DBP, ox-LDL, MDA, HNE 
 
↔ BM, WC, HbA1c, HOMA-IR, 
glucose, insulin, TG, TC, HDL, LDL, 
CRP, IL-6, sVCAM-1, sICAM-1, 
adiponectin 
 
Basu et al. 
(2010b) 
Randomised, 
Parallel, Placebo 
Controlled 
N=27 (2 male, 25 female) 
INT: N=15 
age 48 years; 
(BMI 39 kg.m-2) 
CON: N=12 
age 45 years; 
(BMI 36.4 kg.m-2) 
 
8 weeks 
INT: 240 mL juice twice 
daily (50 g.day-1 freeze-
dried strawberries 
reconstituted in water) 
(~500 g fresh strawberries). 
CON: 480 mL water twice 
daily 
INT: 154 mg 
 
CON: 0 mg 
Usual diet. Avoid 
products containing 
berries. 
↓ TC, LDL, small LDL particles, 
VCAM-1 
 
↔ WC, glucose, TG, HDL, VLDL, SBP, 
DBP, sICAM-1 
 
Basu et al.  
(2011) 
Randomised, 
Parallel, Placebo 
Controlled, 
Double-Blinded 
N=31 (all female); 
age 52 years; 
BMI 40 kg.m-2 
8 weeks 
INT: 240 mL cranberry 
juice twice daily. 
CON: 240 mL placebo 
twice daily 
INT: 24.8 mg 
 
CON: 0 mg 
Usual diet. Avoid 
products containing 
berries, cocoa, green 
tea and soy. 
↓ ox-LDL, MDA, HNE 
 
↑ TAC 
 
↔ WC, SBP, DBP, glucose, TG, HDL, 
LDL, IL-6, CRP 
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Simão et al. 
(2013) 
Randomised, 
Parallel, Single-
Blinded 
N=56 (14 male,  
42 female); 
age 50 years; 
BMI 32.5 kg.m-2 
8 weeks 
INT: 700 mL.day-1 
cranberry juice. 
CON: Normal diet (no 
drink supplied) 
INT: 66 mg 
 
CON: 0 mg 
Usual diet. 
 
↑ Folic Acid, Adiponectin 
 
↓ Homocysteine, Lipoperoxidation and 
Protein Oxidation 
 
↔ IL-1, IL-6, TNF-α 
 
 
 
 
Stull et al.  
(2015) 
Randomised, 
Parallel, Placebo 
Controlled, 
Double-Blinded 
N=44 (16 male, 
28 female) 
INT: N=23; 
age 55 years; 
(BMI 35.2 kg.m-2) 
CON: N=21 
age 59 years; 
(BMI 36 kg.m-2) 
 
 
6 weeks 
INT: 340 mL yoghurt and 
skim-milk smoothie twice 
daily (45 g.day-1 freeze-
dried blueberries). 
CON: 340 mL placebo 
twice daily 
 
 
INT: 290.3 mg 
 
CON: 0 mg 
Usual diet. Avoid 
products containing 
berries. 
 
↑ Endothelial Function 
 
↔ BM, BF%, SBP, DBP, glucose, 
insulin, insulin sensitivity, TG, TC, 
HDL, LDL, 24-hr SBP, 24-hr DBP 
 
 
 
Johnson et al. 
(2017) * 
*Data obtained 
from abstract 
only. 
Randomised, 
Parallel, Placebo 
Controlled, 
Single-Blinded 
N=19 (10 males,  
9 females) 
age 20-60 years 
INT: N=9 
CON: N=10 
 
12 weeks 
INT: 480 mL Montmorency 
tart cherry juice 
CON: 480 mL isocaloric 
placebo 
INT: NR 
 
CON: NR 
NR 
↓ ox-LDL, sVCAM-1 
 
↔ TC, SBP, DBP, aortic 
haemodynamics, arterial stiffness 
Capsule 
Barona et al. 
(2012a) 
Randomised, 
Crossover, 
Placebo 
Controlled, 
Double-Blinded 
N=25 (all male);  
age 51 years; 
BMI 31.5 kg.m-2 
 
4 weeks 
INT: 46 g.day-1 grape 
powder (2 servings/day 
grapes = 160 g) 
CON: 46 g.day-1 placebo 
powder 
 
 
INT: 35.42 mg 
 
CON: 0 mg 
Usual diet. Avoid 
products containing 
berries, tea, grapes 
and wine. 
↑ Peak FMD 
 
↓ SBP, sICAM-1 
 
↔ BM, WC, DBP, TG, HDL, glucose, 
NOx, sVCAM-1 
 
 
Barona et al. 
(2012b) 
Randomised, 
Crossover, 
Placebo 
Controlled, 
Double-Blinded 
N=24 (all male);  
BMI 31.9 kg.m-2 
N=11 MetS with 
dyslipidaemia; 
age 48 years 
N=13 MetS without 
dyslipidaemia; 
age 54 years 
4 weeks 
INT: 46 g.day-1 grape 
powder (equivalent 
252 g grapes) 
CON: 46 g.day-1 placebo 
powder 
INT: 35.42 mg 
 
CON: 0 mg 
Usual diet. Avoid 
products containing 
berries, tea, grapes 
and wine. 
↑ Adiponectin, IL-10, 
iNOS mRNA in MetS without 
dyslipidaemia 
 
↓ SBP 
 
↔ IL-6, IL-8, TNF-α, SOD mRNA, GPx 
mRNA, ox-LDL, 8-isoprostanes 
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Broncel et al. 
(2010) 
Randomised, 
Parallel, Single-
Blinded 
N=47 (15 men, 32 
female); age 42-65 years 
N=22 healthy controls 
(BMI 24.15 kg.m-2) 
N=25 MetS patients 
(BMI 31.05 kg.m-2) 
8 weeks 
INT: 100 mg Chokeberry 
Extract three times daily. 
CON: Normal diet (no 
capsules supplied) 
INT: NR 
 
CON: 0 mg 
NR 
 
↓ SBP, DBP, Endothelin-1, TC, LDL, 
TG, TBARS, Catalase 
 
↑ HDL, SOD, GPx, Fibrinogen 
 
↔ BM, WC, CRP 
 
 
 
Gurrola-Díaz et 
al. (2010) 
 
Randomised, 
Parallel, Placebo 
Controlled, 
Single-Blinded 
 
N=124 (42 males,  
82 female); 
age 49 years 
N=73 healthy controls 
N=51 MetS patients 
(INT 1: n=27) 
(INT 2: n=26) 
(INT 3: n=20) 
 
4 weeks 
INT 1: MetS on 100 
mg.day-1 Hibiscus 
sabdariffa extract powder 
INT 2: MetS on 
preventative diet 
INT 3: Preventative Diet + 
100 mg.day-1 Hibiscus 
 
CON: Non-MetS 
individuals + 100 mg.day-1 
Hibiscus 
 
 
INT 1 and 3: 
19.24 mg 
 
CON: 19.24 mg 
 
Diet individually 
adjusted for each 
subject in INT 2, 
providing 30% 
energy from fat 
(~7% of saturated 
fat), 55% from 
carbohydrates, and 
15% from protein, 
with ~200 mg 
cholesterol/day. 
Fibre content ranged 
from 20 to 30 g. 
 
INT 1: ↓ TC, TG:HDL, glucose, LDL 
↑ HDL 
↔ SBP, DBP, TG, VLDL 
 
INT 2: ↑ HDL 
↔ SBP, DBP, LDL, VLDL, glucose, 
TC, TG 
 
INT 3: ↓ TG, VLDL, glucose, SBP, DBP 
↑ HDL 
↔ TC 
 
CON: ↓ TG 
↔ TC, TG, HDL, LDL, VLDL, glucose, 
SBP, DBP 
 
Jeong et al. 
(2014) 
Randomised, 
Parallel, Placebo 
Controlled, 
Double-Blinded 
 
 
N=73 (36 males,  
37 females) 
INT: N=38; 
age 58 years 
(BMI 26.3 kg.m-2) 
CON: N=35; 
age 60 years 
(BMI 25.1 kg.m-2) 
 
 
 
 
12 weeks 
INT: 750 mg.day-1 Black 
raspberry extract 
CON: 750 mg.day-1 placebo 
powder 
INT: 26 mg 
 
CON: 0 mg 
NR 
 
 
↓ TC, TC:HDL, IL-6, TNF-α 
 
↑ brachial FMD, adiponectin 
 
↔ TG, HDL, LDL, apoA1, apoB, CRP, 
sVCAM-1, sICAM-1 
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Augmentation Index (AIx); Apolipoprotein A1 (apoA1); Apolipoprotein B (apoB); Body Fat Percent (%BF); Body Mass (BM); Body Mass Index (BMI); C-reactive protein (CRP); Control (CON); Diastolic Blood 
Pressure (DBP); Flow-mediated Dilatation (FMD); Glutathione Peroxidase (GPx); Glycated Haemoglobin (HbA1c); Heart Rate (HR); High-density Lipoprotein (HDL); Hydroxynonenal (HNE); Homeostatic Model 
Assessment of Insulin Resistance (HOMA-IR); Interleukin (IL); Inducible Nitric Oxide (iNOS); Intervention (INT); Lipopolysaccharide (LPS); Low-density Lipoprotein (LDL); Malondialdehyde (MDA); Metabolic 
Syndrome (MetS); Nitric Oxide (NOx); Oxidised LDL (ox-LDL); Superoxide Dismutase (SOD); Soluble Intercellular Cell Adhesion Molecule (sICAM); Soluble Vascular Cell Adhesion Molecule (sVCAM); Systolic 
Blood Pressure (SBP); Total Anti-oxidant Capacity (TAC); Thiobarbituric Acid Reactive Substances (TBARS); Total Cholesterol (TC); Triglycerides (TG); Tumour Necrosis Factor alpha (TNF-α); Vascular Cell 
Adhesion Molecule (VCAM); Very Low-density Lipoprotein (VLDL); Waist Circumference (WC). 
 
Jeong et al. 
(2016) 
Randomised, 
Parallel, Placebo 
Controlled, 
Double-Blinded 
N=50 (23 males,  
27 females) 
INT: N=25; 
age 55 years 
(BMI 24.7 kg.m-2) 
CON: N=25; 
age 61 years 
(BMI 25.9 kg.m-2) 
12 weeks 
INT: 750 mg.day-1  
black raspberry extract 
CON: 750 mg.day-1 placebo 
powder 
 
INT: 26 mg 
 
CON: 0 mg 
 
All participants were 
instructed to follow 
a diet based on 
‘‘Dietary 
Approaches to Stop 
Hypertension’’ 
(DASH) diet for 
controlling MetS. 
Also avoid any berry 
species. 
 
↑ Adiponectin 
 
↓ AIx, IL-6 and TNF-α 
 
↔ SBP, DBP, central SBP, HR, CRP, 
sVCAM-1, sICAM-1 
 
Sikora et al. 
(2012) 
Randomised, 
Parallel, 
Controlled, 
Single-Blinded 
N=52 (42-65 years) 
INT: N=38; MetS 
CON: N=14; Healthy 
 
8 weeks 
INT: 100 mg three times 
daily of chokeberry extract 
CON: No treatment 
 
 
INT: 60 mg 
 
CON: 0 mg 
Low fat diet. 30% 
calories from fat. 
Avoid products with 
chokeberry. 
↓ TC, TG, LDL, platelet aggregation and 
coagulation 
 
↔ WC, HDL 
Whole Food 
Puupponen-Pimiä 
et al. (2013) 
 
Randomised, 
Parallel, 
Double-Blinded 
 
N=32 (13 males,  
19 females) 
INT: N=20 
age 52 years 
(BMI 31.8 kg.m-2) 
CON: N=12 
age 50 years 
(BMI 32.9 kg.m-2) 
8 weeks 
INT: Berry Mix 
100 g strawberry puree,  
100 g frozen raspberries 
and 100 g frozen 
cloudberries 
CON: Normal diet (no 
berries supplied) 
 
INT: 70.7 mg 
 
CON: 0 mg 
 
Berry consumption 
substituted evenly 
with the other 
carbohydrates in 
habitual diet for 
berry mix group. 
 
 
↑ Leptin 
 
↔ SBP, DBP, TC, LDL, HDL, resistin, 
8-isoprostane 
 
Kolehmainen et 
al. (2012) 
 
Randomised, 
Parallel, Placebo 
Controlled, 
Single-Blinded 
 
N=27 (8 males,  
19 females) 
INT: N=15 
age 53 years 
(BMI 31.4 kg.m-2) 
CON: N=12 
age 50 years 
(BMI 32.9 kg.m-2) 
 
 
8 weeks 
INT: 200 g bilberry puree, 
40 g dried bilberries 
(Equivalent to 400 g fresh 
bilberries) 
CON: Normal diet 
(80 g.day-1 berry 
consumption allowed) 
INT: 1381 mg 
 
CON: NR 
 
 
Berry consumption 
substituted evenly 
with the other 
carbohydrates in 
habitual diet for 
bilberry group. 
Avoid all other berry 
product 
↓ IL-12, Inflammation score 
(combination of CRP, IL-6, IL-12 and 
LPS) 
 
↔ BM, WC, %BF, SBP, DBP, glucose, 
insulin, insulin sensitivity, TC, TG, 
HDL, LDL, apoA1, apoB, IL-6, CRP, 
adiponectin, leptin, LPS 
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Overall, it is possible to discern trends from the studies above. Anthropometric changes in body 
mass and waist circumference were not significantly improved with any anthocyanin 
intervention. This may be due to short supplementation length and/or parallel research design 
where responses were compared in separate individuals, thus succumbing to inter-individual 
variance in genetics and behavioural patterns (habitual diet and physical activity). SBP 
improved in more studies than DBP, however BP responses remained unchanged in most 
studies. Of note, BP improvements were only observed in participants with elevated baseline 
levels.  
Glucose levels remained unchanged in 6/7 studies, likely due to healthy baseline values and/or 
provision of high daily anthocyanin dosages. Metabolism of the sugar moieties from 
anthocyanins may have contributed to elevating glucose; masking any bioactive effects of 
phytochemicals (Faria et al., 2009). This may explain parallel glycaemic and insulinaemic 
responses in the three studies to measure these markers, as daily anthocyanin dosages were the 
three highest of all studies. 
In accordance with Wallace, Slavin and Frankenfeld (2016) and Yang et al. (2017), 
anthocyanin supplementation improved total cholesterol and LDL, but not other aspects of the 
lipid profile (triglycerides, HDL, VLDL and apolipoproteins). Improvements manifested only 
in individuals who were dyslipidaemic at baseline (Vendrame et al., 2016; Wallace, Slavin and 
Frankenfeld, 2016). 
Improvements in cardio-metabolic markers are thought to be due to the anti-inflammatory and 
anti-oxidative properties of anthocyanins (Vendrame et al., 2016). In the MetS population, 4/9 
studies improved inflammatory biomarkers and 6/8 studies improved oxidative stress 
biomarkers. The wide inter-individual variability in inflammatory markers may have limited 
the anti-inflammatory effect of anthocyanin supplementation and the ability to observe 
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differences against the control group. However, 3 of 5 studies did report upregulation of the 
anti-inflammatory adipocytokine, adiponectin (Tsuda, 2008), despite no changes in systemic 
pro-inflammatory markers (CRP and cytokines). Subsequently, anthocyanin-rich interventions 
in 7/9 studies, altered inflammatory milieu towards an anti-inflammatory state in individuals 
with MetS. Hence, a strong effect of anthocyanin-rich interventions on endothelial function 
markers was observed; where 9/11 studies improved. The anti-oxidant potential of 
anthocyanins was evidenced by a clear trend towards reductions in oxidative stress biomarkers. 
Given that inflammation and oxidative stress contribute to the underlying pathophysiology of 
MetS, anthocyanin-rich foodstuffs are a promising intervention for this population based on 
the evidence above. 
2.2.5.2.2.1.1. Influence of Anthocyanin Supplementation Strategy 
Previous reviews of anthocyanin-rich interventions on cardio-metabolic markers have 
mentioned the inability to determine the effective form (matrix), dosages and duration of 
supplementation, due to high variability between research designs, a lack of dose-response 
studies and standardised clinical biomarkers (Basu and Lyons, 2012; Reis et al., 2016). This 
variability is highlighted in Table 2.8; however, some trends are discernible, which may 
influence the design of future clinical trials with MetS populations. 
As previously mentioned in section 2.1.4.1, the form of supplementation influences the 
bioavailability of anthocyanins and other phytochemicals (Bohn, 2014). Accordingly,         
Table 2.8 indicated greater benefits with capsules over liquids and whole foods for SBP and 
lipid profile, despite on average fewer total anthocyanins being provided with capsules over 
the duration of supplementation. This is the first time such a trend has been noted in any 
population with supplementation of anthocyanin-rich sources. A possible reason may be due 
to the targeted release of anthocyanins afforded by the capsule shell; augmenting 
bioavailability and enabling anthocyanins to exert their bioactive functions more effectively. 
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Equally, the lack of effect from whole foods may be due to poor bioavailability despite 
consumption of high daily doses. Liquid supplements had no effect on glycaemic, insulinaemic 
and some lipid profile variables, possibly due to the high sugar content inducing a glycaemic 
stress that outweighed the benefits of the phytochemicals (Vendrame et al., 2016). However, 
total cholesterol and LDL were reduced with liquid supplements as they normally possess the 
highest anti-oxidant content of any matrix (Basu and Lyons, 2012). The most common trend 
with liquid supplements was its consistent reduction of oxidative stress and subsequent 
improvement in endothelial function.  
Each food source has a unique anthocyanin profile producing different phenolic acid 
metabolites (Fang, 2015). Analysis of the type of food and its effect on particular biomarkers 
revealed some trends. Blueberries and bilberries containing delphinidin were unable to 
significantly modulate body mass, waist circumference or the lipid profile, however endothelial 
function was improved with blueberries (Vendrame et al., 2016). Moreover, foods rich in 
delphinidin have been purported to have positive metabolic effects (Overall et al., 2017), 
however only hibiscus extract was found to lower plasma glucose concentration. Malvidin-
based anthocyanins exert positive cardiovascular effects (Overall et al., 2017), which complies 
with improvements in SBP and endothelial function from grape interventions. Pelargonidin has 
been shown to decrease lipid accumulation (Belwal et al., 2017), explaining the reduction of 
total cholesterol and LDL with strawberries. The radical scavenging and inhibitory lipid 
peroxidation effects of cyanidin and pelargonidin (Tsuda et al., 1996) likely explain the 
reduction in oxidative stress with cranberries, chokeberries and strawberries. Consequently, the 
improvements in endothelial function with cranberries, chokeberries, strawberries, tart cherries 
and black raspberries may be attributed to the anti-oxidant activity of these anthocyanidins. 
Furthermore, hypolipidaemic effects of cyanidin-rich extracts (Valcheva-Kuzmanova et al., 
2007) may explain subsequent improvements in endothelial function and BP with chokeberries. 
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Significant anti-inflammatory effects were observed with foods containing mainly cyanidin 
and peonidin glycosides, such as black raspberries and bilberries; induced by their phenolic 
acid metabolites PCA and VA (Fang, 2015). Furthermore, cyanidin and peonidin glycosides 
can be metabolically transformed to each other by methylation and demethylation (Fang, 
2014), thus further contributing to PCA and VA production. 
Differences in supplement strategies (dosage and duration) between studies make deciphering 
trends difficult (Reis et al., 2016; Wallace, Slavin and Frankenfeld, 2016), particularly without 
dose-response data. Studies providing <100 mg.day-1 anthocyanins, improved SBP more than 
>100 mg.day-1 dosages. Prolonged supplementation beyond 8 weeks was ineffective on BP. A 
trend for reducing total cholesterol and LDL was observed for anthocyanin dosages                
<154 mg.day-1. Lipid profile alterations tended to be influenced more by the presence or 
absence of dyslipidaemia at baseline. Pro-inflammatory and oxidative stress markers were 
inclined to greater reductions at anthocyanin dosages between 26-35 mg.day-1 and                  
≥154 mg.day-1, respectively. Lastly, dosage seemed not to affect endothelial function, however 
prolonged supplementation corresponded to greater improvements.  
Humans consume anthocyanins commonly from their diet (Wallace, Slavin and Frankenfeld, 
2016), thus dietary restrictions in human trials require examination to provide ecologically 
valid recommendations. Anthocyanin bioactivity is influenced by its interactions with fibre, 
lipids, complex carbohydrates and other anti-oxidants (Yang et al., 2017). Surprisingly, only 
one study maintained usual diet resulting in reduced lipid peroxidation and greater adiponectin 
(Simão et al., 2013). This design is the most ecologically valid, thus more data is required when 
mimicking normal daily-living conditions to accurately assess the effect of anthocyanin-rich 
interventions. 
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Bohn (2014) mentioned polyphenol bioavailability may be augmented when various 
polyphenols are consumed together since they synergistically facilitate uptake, absorption and 
distribution pathways. Perhaps this may explain non-significant improvements for BP, glucose, 
insulin, triglycerides and HDL with polyphenol and berry restricted diets. Furthermore, 
improvements in total cholesterol, LDL, inflammation and endothelial function may be a 
consequence of other polyphenols consumed from the habitual diet. Endothelial function and 
BP effects from black raspberry anthocyanins were likely masked by the incorporation of the 
DASH diet in addition to berry restriction (Jeong et al., 2016). Total cholesterol, oxidative 
stress and endothelial function tended to improve with polyphenol-restricted diets indicating 
an effect primarily of anthocyanins in humans with MetS. Low fat diets were found to improve 
the lipid profile, primarily total cholesterol and LDL. The studies to substitute dietary 
carbohydrates with berries both provided whole food anthocyanin-rich interventions. These 
interventions were ineffective on all biomarkers, except inflammation and oxidative stress, 
potentially due to the fibre content of whole foods which has been shown to attenuate 
polyphenol bioavailability (Bohn, 2014). 
2.2.5.2.2.2. Summary of Effects of Anthocyanins on MetS 
Overall, there is sufficient evidence to suggest anthocyanin-rich interventions may help 
ameliorate Metabolic Syndrome in this population. Specifically, anthocyanin-rich 
interventions in a human MetS population improved biomarkers central to MetS 
pathophysiology namely, total cholesterol, LDL, inflammation, oxidative stress and 
endothelial function. Other biomarkers displayed more equivocal findings, due to differences 
in study design, high baseline inter-individual variability of biomarkers and habitual diet; 
potentially masking any benefits of the anthocyanin-rich interventions. 
A recurring theme from Table 2.8 indicated individuals benefitted more from anthocyanin-rich 
interventions if they had developed MetS features, leading to abnormal baseline values. The 
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efficacy of polyphenol interventions in individuals at risk of developing MetS compared to 
those with MetS remains unknown (Cherniack, 2011). 
In relation to practical implications, depending on the biomarkers requiring improvement 
consideration of the matrix used is recommended. More studies are required to judge the most 
effective form of supplementation for improving cardio-metabolic, inflammatory and oxidative 
biomarkers in humans with MetS. Future studies are also required with purified anthocyanins 
compared against whole foods, to determine whether dietary interactions with anthocyanins 
influence their bioactivity. This would also enable ecologically valid assessments of whether a 
whole food anthocyanin-rich diet is more beneficial for individuals with MetS, compared to an 
anthocyanin supplemented diet. 
Despite these interventions possessing a high anthocyanin content, the synergistic influence of 
other polyphenols, micronutrients and/or fibre on the health-promoting responses should be 
considered. Consequently, these interventions may be incorporated as part of a healthy, varied 
diet and not a magic-bullet solution for ameliorating complications in humans with MetS. 
Finally, the question is posited, can anthocyanin-rich tart cherries improve biomarkers 
associated with MetS? Johnson et al. (2017) reported tart cherry juice improved markers of 
endothelial function (ox-LDL and sVCAM-1) and tended to lower total cholesterol after 12 
weeks consumption compared to a placebo drink, in individuals with MetS (section 2.1.6.5.2). 
Despite this solitary study in humans (Johnson et al., 2017), observations from in vitro 
(Seeram, 2001; Keane et al., 2016b; Kirakosyan et al., 2018) and rodent (Seymour et al., 2008, 
2009) studies suggest tart cherries are an intervention with great promise for preventing and 
ameliorating MetS and its complications. Further research examining responses to tart cherries 
in humans with MetS is clearly warranted and will be addressed as part of this thesis.  
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Part 2.3. Application of Caenorhabditis elegans for Human Health 
The final section encompasses a brief review and commentary of Caenorhabditis elegans and 
its use as a model organism to understand the responses and mechanisms of action through 
which dietary interventions, particularly MTCJ, act and how they may be applied to human 
health. The literature reviewed here informs the original research conducted in chapter 7. 
2.3.1. Introduction to Caenorhabditis elegans 
In 1965, Sydney Brenner was the first to exploit the soil nematode Caenorhabditis elegans as 
a model organism (Brenner, 1974); for which his work on genetic regulation of organ 
development and programmed cell death in C. elegans won him, Robert Horvitz and John 
Sulston the Nobel Prize for Physiology or Medicine in 2002 (Dijkstra, 2002). 
The nematode worm, C. elegans, has a short life-cycle with the egg-to-egg cycle lasting 3-4 
days (Figures 2.12 and 2.13) at 20°C. The egg-laying adult is 1.3-1.5 mm long and has a 
lifespan of 2-3 weeks under suitable living conditions (Markaki and Tavernarakis, 2010). Adult 
hermaphrodites have 959 somatic cells, forming different organs and tissues including muscle, 
hypodermis (skin), intestine, reproductive organs, glands, and a nervous system containing 302 
neurons (Kaletta and Hengartner, 2006) (Figure 2.14). Adults exist predominately as self-
fertilising hermaphrodites each capable of producing ~300 genetically identical offspring, 
although male worms appear at a rate of <0.2% in the population (Corsi, Wightman and 
Chalfie, 2015). The body of C. elegans is transparent making it is easy to track cells, observe 
internal organs and follow biological processes such as fat metabolism with fluorescent dyes 
and reporters (Kaletta and Hengartner, 2006).  
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Figure 2.12. Life cycle of C. elegans at 22°C. Numbers along the arrows represent hours (h) 
necessary to transition from one stage to the next. Stressful conditions include lack of food, 
high population density and environmental conditions (thermal, hypoxic, osmotic and 
oxidative stress). 
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Figure 2.13. C. elegans at different developmental stages as viewed under microscope. Tracks 
in the plate indicate where animals have travelled on the bacterial lawn. Image courtesy of Dr 
Samantha Hughes. 
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Figure 2.14. (A) C. elegans as viewed through a high-power microscope. The head is on the 
left, with the intentional cells clearly visible towards the tail, some oocytes can be seen. Scale 
bar is 100 µm. Image courtesy of Dr Samantha Hughes. (B) Stylised image of the C. elegans 
basic anatomy. The pharynx (shown in green) is the head of the animal. The worm is a self-
fertilising hermaphrodite, with both male (blue) and female (grey) reproductive organs. The 
intestine runs the length of the animal, in pink (Altun and Hall, 2009). 
 
There is strong, evolutionary conservation of molecular and cellular pathways between              
C. elegans and mammals (Shaye and Greenwald, 2011; Kim et al., 2018); 12 out of 17 known 
signal transduction pathways are conserved in both humans and C. elegans (Leung et al., 2008). 
The human and C. elegans genomes have significant homology, approximately 80% of human 
genes have orthologues in C. elegans (Kaletta and Hengartner, 2006) and 40% of genes known 
to be associated with human disease also have orthologues in C. elegans (Corsi, Wightman and 
Chalfie, 2015). The C. elegans genome has been fully sequenced and mapped, containing 
~20,000 coding genes and ~25,000 non-coding genes (Howe et al., 2016). Moreover, at least 
83% of the C. elegans proteome has human homologues (Lai et al., 2000). 
There are several other advantages to those listed above which endorse the use of C. elegans 
as a model of human disease. C. elegans can be grown easily and cheaply in a controlled, low 
A 
B 
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maintenance environment on a diet of Escherichia coli (Kaletta and Hengartner, 2006). Due to 
its rapid life-cycle and prolific reproductive rates, high-throughput screening of interventions 
(such as drugs, chemicals or nutrients) can be observed in multiple generations of animals, 
using different disease models (Markaki and Tavernarakis, 2010). Furthermore, its small size 
facilitates high-throughput analysis as assays can be performed with ~100 animals per well of 
a 96-well plate (Kaletta and Hengartner, 2006). Lastly, it is a cost-effective model to conduct 
molecular and cellular research relating to human diseases as high-throughput experiments can 
be performed quickly (Kaletta and Hengartner, 2006) in accordance with the 3R rule 
(replacement, refinement and reduction) of conducting humane animal research (Russell and 
Burch, 1959).  
As the genome has been fully sequenced and mapped, genome manipulation in C. elegans is 
relatively simple and is amenable to unbiased forward and reverse genetic screens (Markaki 
and Tavernarakis, 2010). Gene function can be simply and quickly knocked down by the 
process of RNA interference (RNAi) (Corsi, Wightman and Chalfie, 2015). Furthermore, 
mutant strains that either overexpress a gene or inhibit gene function can be efficiently 
generated and the resulting phenotypes identified (Markaki and Tavernarakis, 2010). 
Subsequently, many phenotypes modelling human disease are available, which facilitates the 
understanding of pathways and molecular mechanisms that underpin human diseases (Corsi, 
Wightman and Chalfie, 2015). Consequently, it is possible to use the C. elegans model to 
design effective mechanism-based therapies against human disease (Silverman et al., 2010). 
Thus, the ability to develop therapies which specifically target the source of disease 
pathogenesis results in more efficient and effective prevention or treatment. Moreover, the 
efficacy of prophylactic and therapeutic interventions can be rapidly assessed for their ability 
to confer health benefits in a live model. 
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2.3.2. C. elegans as a Model for Human Disease 
C. elegans provides a unique model to assess the genetic and phenotypic basis of human disease 
in vivo (Silverman et al., 2010). Additional advantages over an in vitro model include the study 
at a multicellular, whole-organism level compared to that of tissue culture which focuses on a 
single cell; detection of organism-level end points (feeding, reproduction, lifespan and motility) 
(Leung et al., 2008) and monitoring of behavioural responses. Importantly, dissection of both 
in vivo targeted and non-targeted responses from an intervention can be observed. Together, 
this allows a more informed mechanistic understanding of disease when applied to humans 
(Silverman et al., 2010). Mammalian animal models offer better understanding and is the 
superior preclinical model for therapeutic interventions. However, such models are complex, 
labour-intensive and expensive to isolate mechanisms of action (Kaletta and Hengartner, 2006). 
Indeed, C. elegans is an ideal model for bridging the gap between in vitro assays and 
mammalian animal models (Markaki and Tavernarakis, 2010). 
Worms are a standard model system for a wide-range of research; and are used as a model of 
various human diseases including cancer (Kyriakakis, Markaki and Tavernarakis, 2015), 
diabetes (Moreno-Arriola et al., 2014), obesity (Zheng and Greenway, 2012) and neurological 
diseases (Calahorro and Ruiz-Rubio, 2011). Many notable discoveries relating to basic biology 
and medicine were first made in C. elegans, such as the cell death abnormality pathway 
involved in apoptosis (Ellis and Horvitz, 1986). C. elegans is particularly useful as a model for 
assessing responses and mechanisms pertaining to lifespan (Markaki and Tavernarakis, 2010), 
ageing (Tissenbaum, 2015), obesity (Elle et al., 2008), diabetes (Markaki and Tavernarakis, 
2010), and calorie restriction (Lakowski and Hekimi, 1998). 
As eluded to in section 2.2.5.2.1, calorie restriction has been practiced for centuries to improve 
cardio-metabolic health and prolong longevity (Masoro, 2000). Positive preliminary results 
have been presented from studies incorporating CR in microorganism (yeast) (Lin et al., 2004) 
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and animal models (Heilbronn and Ravussin, 2003). Lee et al. (2006) reported extended 
lifespan and improved resistance to oxidative stress amongst adult C. elegans worms that were 
totally deprived of food. Two possible mechanisms through which CR may increase lifespan 
in C. elegans include a slower metabolic rate and reduced insulin signalling (Walker et al., 
2005). The latter as demonstrated in C. elegans, is purported to be inherently linked with 
nutrient-sensing pathways that mediate CR, such as target of rapamycin (TOR), MAPK and 
AMPK (Narasimhan, Yen and Tissenbaum, 2009; Templeman and Murphy, 2018). CR 
regulates glucose metabolism and insulin signalling, thus reducing the risk of developing 
cardio-metabolic disease and mediating lifespan extension (Walker et al., 2005). Therefore, 
since nematodes and mammals have common responses to glucose homeostasis and insulin 
signalling with CR, results could potentially be applied to humans (Partridge, 2010). 
C. elegans is a useful tool for understanding the interactions between nutrients and cardio-
metabolic diseases as key evolutionary pathways involving energy homeostasis are conserved 
between worms and mammals (Hashmi et al., 2013). Understanding the effects of nutrients on 
the insulin signalling pathway is important for dissecting molecular mechanisms associated 
with diabetes, obesity and ultimately lifespan (Ashrafi et al., 2003). C. elegans has an insulin-
like signalling (ILS) pathway that regulates glycogenesis, lipogenesis, lipid homeostasis, lipid 
storage and lifespan (Markaki and Tavernarakis, 2010). RNAi knockdown of acetyl-coenzyme 
A carboxylase (ACC), fatty-acid synthase (FAS) and fatty-acid desaturase (SCD, fat-7) 
orthologues in C. elegans were found to reduce body fat (Ashrafi et al., 2003), mimicking 
responses observed in calorie restricted mice (Bruss et al., 2009). daf-2 (mammalian insulin 
receptor homologue) mutants with reduced insulin signalling have been observed to 
accumulate high amounts of body fat (Ashrafi et al., 2003). Moreover, RNAi knockdown of 
daf-16 (forkhead box O orthologue, FOXO) restored insulin signalling, thus accelerated ageing 
and reduced body fat to wild-type levels (Ashrafi et al., 2003). Interestingly, inactivation of the 
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ILS pathway and subsequent activation of DAF-16 in C. elegans (Figure 2.15), leads to a 
metabolic shift from glucose to lipid oxidation and is associated with increased longevity (van 
Heemst, 2010). Similarly, as mentioned in section 2.2.5.2.1.2 under conditions of limited 
cellular energy status during CR in humans, AMPK is activated prompting PGC-1α activation 
through direct phosphorylation, which predisposes PGC-1α to deacetylation by SIRT-1 (Canto 
and Auwerx, 2011). Subsequently, insulin signalling is reduced, and substrate metabolism 
shifts in favour of lipid oxidation (Apfeld et al., 2004). In C. elegans, sir-2.1 (SIRT-1 
orthologue) (Tissenbaum and Guarente, 2001), aak-2 (AMPK orthologue) and daf-
16/FOXO function simultaneously to mediate lifespan extension (Apfeld et al., 2004).  
In addition to a switch towards lipid oxidation, greater DAF-16 activity upregulates anti-
oxidant enzyme (catalase and manganese superoxide dismutase) synthesis and prevents the 
manifestation of oxidative stress and NF-κB mediated inflammation (van Heemst, 2010). 
Therefore, normal lipid storage and metabolism has become tightly coupled to suppression of 
oxidative stress and inflammation (van Heemst, 2010). Furthermore, FOXO activation through 
reduced ILS may extend lifespan via the anti-oxidative effects of PGC-1α activation, 
responsible for mitochondrial biogenesis and shifting substrate utilisation towards fat from 
carbohydrate (van Heemst, 2010). CR has been associated with greater mitochondrial number 
and thus more efficient mitochondrial activity, utilising less oxygen, producing less ROS and 
eventually extending lifespan (van Heemst, 2010). Similarly, the anti-oxidative, anti-
inflammatory and CRM properties of MTC may operate through the ILS pathway to increase 
lifespan. 
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Figure 2.15. Schematic representation of regulation of FOXO activity (Hesp, Smant and 
Kammenga, 2015). Insulin-like signalling leads to PI(3)K activation, which induces Akt to 
inhibit FOXO by phosphorylation. The human tumour suppressor PTEN inhibits Akt activity, 
possibly by phosphorylation of PIP3 (not shown). When cells are under oxidative stress, JNK 
activity increases, while AMPK is activated by high AMP/ATP ratios. Both kinases activate 
FOXO by phosphorylation. When FOXO is active, it relocates to the nucleus and promotes the 
expression of genes that promote longevity. C. elegans homologues of mammalian proteins are 
shown in italics. 
Overall, the evolutionary conserved ILS pathway in C. elegans is central to the relationship 
between metabolism, calorie restriction and longevity. DAF-16/FOXO repression accelerates 
ageing, reduces body fat but does not extend lifespan (Silverman et al., 2010). This indicates 
the daf-2/daf-16 pathway to be involved in extending lifespan through expression of genes 
related to oxidative stress, inflammation and substrate utilisation (Elle et al., 2008). Analysis 
of the molecular responses to the ILS pathway in C. elegans provides a model to elucidate 
mechanisms of action of dietary interventions against human diseases such as diabetes and 
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obesity. Hence, the study conducted in chapter 7 assessed responses to MTC within the insulin 
signalling pathway. 
2.3.3. Dietary Interventions on Lifespan and Cardio-Metabolic Responses in C. elegans 
Given the complexity of cellular and molecular interactions in humans, understanding the 
mechanisms of action in response to dietary interventions is very difficult. Comparatively, the 
C. elegans model is simpler and smaller yet evolutionarily conserved with high genetic 
homology to humans, therefore suitable for understanding the mechanisms of action in 
response to dietary interventions. 
Metabolic Syndrome is underpinned by insulin resistance and thus improvements in insulin 
sensitivity would delay or prevent the development of cardio-metabolic disease in humans. 
Understandably, the insulin signalling pathway is key to modulating insulin sensitivity, where 
cross-talk between insulin signalling and PPAR pathways mediates improved insulin 
sensitivity through regulating lipid metabolism in humans (Leonardini et al., 2009). nhr-49 is 
considered to be a functional homologue of mammalian PPARα in C. elegans (Elle et al., 
2008). nhr-49 is a central regulator of lipid and glucose metabolism gene transcription in 
response to low nutritional status as found during CR (van Gilst et al., 2005; Elle et al., 2008). 
2.3.3.1. Polyphenols as Calorie Restriction Mimetics 
Polyphenols including resveratrol, EGCG (epigallocatechin-3-gallate), curcumin, quercetin 
and anthocyanins, have been identified as potential calorie restriction mimetics (CRMs) 
(Madeo et al., 2014; Willcox and Willcox, 2014). Of these, resveratrol, found in grape skins, 
has demonstrated the greatest effect as a CRM by activating SIRT-1 (Li, Daniel and Tollefsbol, 
2011). Likewise, activation of SIR-2.1 protein by resveratrol in C. elegans was found to extend 
lifespan, thus mimicking CR pathways (Wood et al., 2004). Zhang et al. (2009) demonstrated 
EGCG to significantly extend longevity in C. elegans under stressful conditions through 
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upregulation of daf-16, sod-3 (human superoxide dismutase-3 orthologue, SOD3), and skn-1 
(human Nrf2 orthologue, NFE2L2), all associated with anti-oxidant and anti-inflammatory 
functions. Moreover, the PPAR pathway involved in mediating the benefits of CR has been 
shown to be activated by polyphenols in C. elegans (Sun et al., 2016; Machado et al., 2018). 
Polyphenols from Yerba Maté (Ilex paraguariensis) were shown to reduce fat storage and 
stimulate fatty acid oxidation through increased ATGL-1 and NHR-49 activity in C. elegans 
(Machado et al., 2018). Increased hosl-1 (hormone-sensitive lipase orthologue, LIPE) 
expression was also found in worms after exposure to polyphenols from Yerba Maté and 
cranberries, explaining reduced fat accumulation due to activation of NHR-49 and SBP-1 
pathways which increase β-oxidation and regulate fat/sterol synthesis, respectively (Sun et al., 
2016; Machado et al., 2018).  
The C. elegans model has been used to determine the mechanistic relationship between 
polyphenolic supplementation, cardio-metabolic function and longevity. Viswanathan et al. 
(2005) observed that lifespan extension in the presence of resveratrol was independent of       
daf-16/FOXO. Likewise, blueberry extract, particularly proanthocyanidins, extended lifespan 
through the p38 MAPK signalling cascade and not via sir-2.1 or ILS pathway (Wilson et al., 
2006). Thus, upregulation of SKN-1 via p38 MAPK signalling may explain lifespan extension 
through greater oxidative stress resistance (Pang et al., 2014). Furthermore, Grünz et al. (2012) 
showed flavanols induced DAF-16 nuclear exclusion, thus suggesting that lifespan extension 
was independent of daf-16/FOXO. In contrast, nuclear localisation of DAF-16 with the 
polyphenol myricetin elicited lifespan extension (Büchter et al., 2013). Guha et al. (2013) also 
suggested lifespan extension was mediated through daf-16/FOXO, as shown with cranberry 
extract. Cocoa flavanols (Martorell et al., 2011) and purple wheat anthocyanins (Chen et al., 
2013) increased oxidative stress resistance and extended lifespan through sir-2.1 and DAF-16 
in C. elegans. This is in agreement with murine models where anthocyanin-rich blueberry 
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(Seymour et al., 2011) and Montmorency tart cherry (Seymour et al., 2008, 2009) extracts were 
shown to increase PPARα and PPARγ activity and PPARα, PPARγ and PGC-1α mRNA 
expression at the muscle and adipose tissue levels thus reversing MetS phenotype. This 
highlights the action of polyphenols on the PPAR pathway to modulate lipid and glucose 
metabolism since activation of the ILS pathway initiates phosphorylation and thus nuclear 
exclusion of FOXO, subsequently removing repression of PPARγ activity. 
Interestingly, the findings above may indicate that structural differences in polyphenols 
influence the pathway through which lifespan extension occurs (Grünz et al., 2012). 
Ultimately, lifespan extension through improved cardio-metabolic function has repeatedly 
been observed with polyphenols in C. elegans through mimicking similar changes in signalling 
pathways induced by CR. 
2.3.4. Significance for MTC Research – Could MTC concentrate be the elixir of life? 
There is an inherent lack of understanding relating to mechanisms of action in the field of 
polyphenols and health, which extends to MTC interventions. The ability to delineate 
mechanisms allows the development of mechanism-based therapies against diseases. This 
chapter has briefly discussed molecular mechanisms of action pertaining to cardio-metabolic 
function and lifespan extension with polyphenols in C. elegans. As this thesis emphasises the 
effect of MTC on cardio-metabolic function, a study was conducted in C. elegans to determine 
whether dilutions of MTC concentrate induced comparable responses and operated through 
similar pathways as other polyphenols (Chapter 7).  
The simple anatomy, physiological traits, similarity to humans (at the genetic, molecular and 
tissue level) together with the ease of genome manipulation, demonstrates how C. elegans is a 
convenient yet powerful model to research the innate biological responses to dietary 
interventions and dissect the molecular pathways through which they operate. As eluded to 
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previously, the C. elegans model has several distinct advantages which enables cost- and time-
effective high-throughput screening of interventions and subsequent phenotypic traits. Most 
importantly, using unbiased forward and reverse genetic screening the C. elegans model allows 
the identification of mechanisms of action related to prophylactic and therapeutic interventions 
against human disease (Silverman et al., 2010). Subsequently, this enhances understanding of 
human disease processes and enables the formation of mechanism-based interventional 
strategies to effectively mitigate disease development and progression (Silverman et al., 2010). 
Literature has shown a beneficial effect of polyphenols in dietary interventions on cardio-
metabolic function, longevity and the pathways through which these occur in C. elegans 
(Viswanathan et al., 2005; Wilson et al., 2006; Martorell et al., 2011; Chen et al., 2013; Guha 
et al., 2013; Sun et al., 2016; Machado et al., 2018). Hence, related to this section a similar 
study was performed with MTC as this had not been done previously (Chapter 7). This study 
specifically observed development, lifespan and fat content responses to various dilutions of 
MTC concentrate in the worms. Then, using developmental delay at a certain MTC dilution as 
a read-out, a targeted small-scale RNAi screen of genes associated with lipid and glucose 
metabolism was performed. From this, specific genes were identified which were key in 
regulating the MTC response. Furthermore, the lifespan assay enabled determination of 
whether MTC could operate as a CRM. The molecular effects of MTC consumption on cardio-
metabolic function have previously been examined in a rodent model (Seymour et al., 2008, 
2009), as discussed in section 2.1.6.5.2. However, C. elegans was chosen for this thesis as it 
enabled targeted genetic screening. Mechanisms elucidated from the study in chapter 7 may 
be translated to humans and thus this study serves to potentially inform future clinical research 
with MTC in human participants. 
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2.4. Aims and Hypotheses 
The literature review has identified numerous areas where further research is required to 
determine the efficacy of Montmorency tart cherries on cardio-metabolic health parameters, in 
healthy and MetS human populations. Subsequently, these gaps are addressed in the following 
experimental chapters. 
2.4.1. Aims 
2.4.1.1. General Aim 
The overarching aim of the series of studies that comprise of this thesis was to establish whether 
Montmorency tart cherry (Prunus cerasus L.) supplementation with and without FATMAX 
exercise could improve biomarkers associated with cardio-metabolic health.  
2.4.1.2. Specific Aims 
The four experimental chapters within this thesis addressed four separate research objectives: 
i. Assess the effects of Montmorency tart cherry juice supplementation and individualised 
FATMAX exercise on cardio-metabolic biomarkers in healthy humans. 
ii. Determine the effects of a single, acute bolus of Montmorency tart cherry juice and 
capsules on acute cardio-metabolic responses in humans with MetS. Furthermore, 
identify whether capsules are more efficacious than juice at improving cardio-metabolic 
function. Lastly, establish whether a dose-response effect is observed with consumption 
of Montmorency tart cherry juice. 
iii. Examine acute and prolonged cardio-metabolic responses to short-term, continuous 
supplementation of Montmorency tart cherry juice in humans with MetS. Also, 
ascertain whether 6 days prior loading of Montmorency tart cherry juice can enhance 
acute cardio-metabolic function compared to a single, acute bolus. 
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iv. Elucidate the molecular mechanisms of action through which Montmorency tart 
cherries influence cardio-metabolic function, using a C. elegans model. 
2.4.2. Hypotheses 
Hypotheses relating to the overall thesis are outlined below. Specific hypotheses pertaining to 
individual studies are presented in their respective chapters. 
H1: Montmorency tart cherry supplementation will significantly improve resting cardio-
metabolic biomarkers compared to the placebo-controlled condition, in healthy and MetS 
human populations. 
H2: Montmorency tart cherry supplementation with FATMAX exercise will improve cardio-
metabolic biomarkers compared to the placebo-controlled condition, in a healthy human 
cohort. 
H3: A single, acute bolus of Montmorency tart cherry juice and capsules will improve acute 
cardio-metabolic biomarkers compared to the placebo-controlled condition, in humans with 
MetS. 
H4: Short-term, continuous supplementation of Montmorency tart cherry juice will improve 
cardio-metabolic biomarkers compared to the placebo-controlled condition, in humans with 
MetS. 
H5: Montmorency tart cherry acts as a calorie restriction mimetic and exerts its beneficial 
cardio-metabolic responses through evolutionary conserved mechanisms related to calorie 
restriction, in C. elegans. 
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This chapter outlines common methodological procedures that were used and serves to function 
as a reference for experimental chapters presented later in this thesis. Specific methodologies 
pertaining to studies can be found in the relevant chapters. 
3.1. Participant Recruitment 
Chapters 4-6 recruited male and female human participants aged between 18-65 years using 
convenience sampling. Chapter 4 recruited healthy participants (section 4.2.1), chapters 5 
(section 5.2.1.1 and 5.2.2.1) and 6 (section 6.2.1) recruited participants with Metabolic 
Syndrome. 
All participants were recruited through methods including posters, email and word of mouth 
from the target populations previously described. Ethical approval for each study was gained 
prior to recruitment and all participants were aware of the risks and benefits of participating in 
studies. Prior to inclusion in studies, participants were also made aware of the dietary and 
exercise restrictions associated with the studies. Before research commenced, all participants 
provided written informed consent, completed health screen questionnaires and underwent a 
screening procedure to determine suitability for inclusion in each study. All studies (Chapters 
4-6) were conducted in accordance with the Declaration of Helsinki (2013). 
3.2. Dietary and Exercise Guidelines 
Participants were provided with specific dietary and exercise guidelines to adhere to for each 
study. All participants arrived at the laboratory between 7–10 am, after an overnight fast of a 
minimum of 10 hours, to account for circadian variation as previously shown by Bell et al. 
(2014b) after MTC supplementation in humans. Participants were instructed to cease 
consumption of any other supplementation two weeks before and during the course of each 
study. 
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Participants were instructed to maintain their habitual polyphenol intake, particularly 
anthocyanins, as opposed to complete restriction throughout the study. This was to ensure that 
the polyphenols provided by MTC supplementation were supplementary to the existing 
habitual polyphenol intake of each participant, rather than replacing the habitual provisions 
which would occur by enforcing a total restriction of polyphenol-rich (particularly 
anthocyanin) dietary sources. Another reason for maintaining habitual polyphenol 
consumption was to assess the effects of MTC supplementation on outcome variables in 
conditions representing normal daily activity, therefore upholding ecological validity (Meyer, 
Gäßler and Kindermann, 2007). 
Total energy, macronutrient and polyphenol intake of participants’ ‘Western’ habitual diet was 
assessed through food diaries. This was to assess compliance of replicating dietary intake for 
the 3 days prior to each testing session (Alkhatib et al., 2015; Nordby et al., 2015; Roberts et 
al., 2015). Instructions on completing food diaries and information regarding portion sizes were 
provided. Participants were instructed to record all dietary items consumed during two 
weekdays and a weekend day of the same week in order to analyse habitual diet (Stull et al., 
2010, 2015; Chai et al., 2018). Fluids or food were not provided during testing sessions in 
chapters 5 and 6, but participants were able to drink water ad libitum, where volume of 
consumption was monitored during the first session and repeated in subsequent sessions 
(Keane et al., 2016b). Participants also refrained from consuming water 3 hours prior to arrival 
at the laboratory to limit variations in body composition analysis. 
Food diaries were analysed using dietary analysis software (Dietplan 7.0, Forestfield Software, 
UK), to monitor adherence of total energy, macronutrient and polyphenol intake compared to 
the habitual diet and the 3-day period before testing sessions. If dietary items were not found 
in the database software, manual entry of nutrient composition of the item was conducted. 
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3.3. Supplementation 
The series of studies presented in this thesis used various forms of MTC supplementation. For 
details on composition of placebo, refer to the methodology section of relevant chapters. 
GraphPad software (GraphPad, QuickCalcs, San Diego, California, USA) was used to 
randomise supplementation order in chapters 4-6. 
Chapter 4 (section 4.2.1.1) supplemented Montmorency Tart Cherry Juice (MTCJ), composed 
of a commercially available MTC concentrate (30 mL) (Montmorency Tart Cherry 
Concentrate, Cherry Active, Active Edge Ltd, Hanworth, UK) mixed with 100 mL water and 
a placebo drink, twice daily for 20 days. In chapter 5, part A (section 5.2.1.2.3), participants 
were acutely supplemented with a single dose of MTCJ (30 mL concentrate with 100 mL 
water), 10 MTC capsules (Montmorency Tart Cherry Capsules, Cherry Active, Active Edge 
Ltd, Hanwell, UK) and a placebo drink. During chapter 5, part B (section 5.2.2.2.1), 
participants were also supplemented a single, acute dose of double concentrated MTCJ (60 mL 
concentrate with 100 mL water). Chapter 6 (section 6.2.2.3) supplemented MTCJ (30 mL 
concentrate with 100 mL water) and a placebo drink for 7 consecutive days. Participants 
consumed each dose within 3 minutes of commencing ingestion of the supplement. 
Each 30 mL serving of MTC concentrate provided a total anthocyanin content of 270 mg           
(9 mg.mL-1) (Howatson et al., 2012) and juice from approximately 90-110 whole 
Montmorency tart cherries; whilst 1 capsule was made from approximately 10 whole 
Montmorency tart cherries. 
The total anti-oxidant status of 30 mL MTCJ and 60 mL MTCJ was found to be 2.32 ± 0.03 
and 2.51 ± 0.02 mmol.L-1, respectively.  
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3.4. Testing Protocol 
All testing sessions in chapters 4-6 were conducted in a temperature-controlled laboratory 
maintained between 21-24ºC, 38-45% relative humidity (dry-bulb) and 99.8-102.4 kPa 
atmospheric pressure (AWS888N, Oregon Scientific, USA). Testing protocols are described 
further in their relevant chapters. 
3.5. Measures and Equipment  
3.5.1. Anthropometrics 
Stature (m) was measured on a stadiometer (Seca 217 Stadiometer, Seca, Hamburg, Germany) 
to the nearest 1 mm with subjects standing without shoes, heels and back touching the 
stadiometer, head in the Frankfort horizontal plane and after holding a maximal inhalation. 
Body mass (kg) (Seca 799, Seca, UK) was measured on a flat, uncarpeted surface with as 
minimal clothing as possible ensuring repeated measurements were performed with the same 
clothing. Based on stature and body mass data, body mass index (BMI) was calculated using 
the formula of Keys et al. (1972).  
Waist circumference (cm) was measured at the end of normal expiration between the top of the 
iliac crest and the lower (10th) costal (Stewart and Marfell-Jones, 2011) using a handheld 
ergonomic tape measure (Seca 201, Seca, Hamburg, Germany). 
3.5.2. Body Composition 
Segmental body composition analysis (Body Composition Analyser BC-418, Tanita, Japan) 
was performed in all studies according to manufacturer’s specifications. The principle of the 
analyser was based on bioelectrical impedance, therefore only measurements with total body 
water between 50-70% of total body mass were considered for analysis. Prior to measurement, 
all participants were required to fulfil criteria per manufacturer’s recommendations, in addition 
to the dietary and exercise guidelines outlined for each study. These included abstentions from 
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caffeine and alcohol ingestion 24 hours before measurement and urination before 
measurement. To ensure validity and reliability, all measurements were conducted at the same 
time of day to avoid circadian variation influencing results. Values for fat mass, fat free mass 
(FFM) and body fat percentage (whole body and trunk) were monitored. 
A previous study using the Tanita BC-418 analyser reported a high correlation, no significant 
mean bias and narrow limits of agreement for body fat percentage measurements between the 
analyser and Dual-Energy X-ray Absorptiometry (Pietrobelli et al., 2004), suggesting the 
analyser is a valid tool for measuring body fat percentage. Additionally, a test-retest CV of 
1.4% was obtained for body fat percentage by Kelly and Metcalfe (2012). 
Intraclass Correlation Coefficient (ICC) estimates and their 95% confidence intervals were 
calculated using SPSS v22 (IBM, Chicago, USA) based on a single-measures (type), absolute 
agreement (definition), two-way mixed-effects model for within- and between-day test-retest 
reliability. ICC was chosen as it is a common statistical test for test-retest reliability which 
accounts for the correlation and agreement between measurements (Koo and Li, 2016). ICC 
values were measured on a scale between 0 and 1, and classified as poor (0.00 – 0.50), moderate 
(0.50 – 0.75), good (0.75 – 0.90) and excellent (0.90 – 1.00) (Koo and Li, 2016). 
Test-retest reliability of the analyser for fat mass, FFM and body fat percentage (whole body 
and trunk) were assessed from a sample of 5 healthy participants (age 28 ± 7 years; body mass 
74.9 ± 14 kg; stature 1.77 ± 0.47 m), as previously conducted by Pietrobelli et al. (2004). 
Participants were not on any weight loss or weight gain regimen during this period. The within-
day intra-individual reliability for the same variables was determined by measuring each 
participant on 10 occasions within 1 hour (Pietrobelli et al., 2004). Between-day intra-
individual reliability was calculated by taking three measurements per day on three different 
days each separated by 10 days to mimic the study design of chapter 4. All variables 
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demonstrated good to excellent reliability according to 95% confidence intervals for within-
day and between-day reliability (Table 3.1). 
Table 3.1. Within-day and between-day mean, standard deviation, range, ICC and Coefficient 
of Variation (%) for body composition variables measured with bioelectrical impedance body 
composition analyser. 
FFM (Fat Free Mass) 
3.5.3. Cardiovascular Function 
3.5.3.1. Cardiac Haemodynamics 
Beat-to-beat resting cardiac haemodynamic parameters including heart rate (HR), cardiac 
output (CO), stroke volume (SV), mean arterial pressure (MAP) and total peripheral resistance 
(TPR) were measured non-invasively (Finometer MIDI Model-2, Finapres Medical Systems 
BV, Amsterdam, The Netherlands), using the arterial volume clamp method (Penaz, 1985). An 
appropriately sized finger-cuff was applied around the middle phalanx of the middle finger of 
the hand and a height correction unit was subsequently fixed to the finger-cuff. All 
measurements were obtained in the seated position. To avoid data selection, recordings were 
averaged over 10 consecutive beats with the lowest values for each parameter taken for 
statistical analysis (Cook et al., 2017a). 
 
 Mean ± SD (Range)  ICC (95% CI) CV (95% CI) 
 Within-Day Between-Day Within-Day Between-Day Within-Day Between-Day 
Fat Mass 
(kg) 
12.1 ± 0.2 
(11.7 – 12.4) 
11.8 ± 0.3 
(11.1 – 12.1) 
0.93 
(0.88 – 0.97) 
0.90 
(0.88 – 0.91) 
2 
(1 – 4) 
3 
(2 – 7) 
FFM (kg) 
58.6 ± 0.2 
(58.3 – 58.8) 
57.5 ± 0.2 
(57.1 – 57.9) 
0.97 
(0.89 – 0.99) 
0.92 
(0.88 – 0.96) 
1 
(0 – 3) 
3 
(1 – 6) 
Whole-body  
Fat (%) 
17.2 ± 0.4 
(16.7 – 17.6) 
17.0 ± 0.5 
(16.7 – 17.4) 
0.91 
(0.89 – 0.94) 
0.92 
(0.84 – 0.97) 
2  
(1 – 5) 
3 
(2 – 5) 
Trunk Fat 
(%) 
21.0 ± 0.7 
(20.3 – 22.1) 
20.8 ± 0.9 
(19.9 – 21.3) 
0.89 
(0.87 – 0.94) 
0.88 
(0.86 – 0.93) 
3 
(1 – 6)   
4 
(2 – 8) 
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3.5.3.2. Blood Pressure 
Brachial BP was measured using an automated sphygmomanometer (Omron MX3, Omron, 
Japan) in chapters 4-6. Four measurements were recorded in an upright seated position, on the 
arm not used for venepuncture, with an average of the final three being taken as BP (Cook et 
al., 2015). The cuff was placed around the upper arm, 2-3 cm above the antecubital fossa, by 
the same researcher each time. The first reading was not included due to the defence mechanism 
(a rise in BP as a consequence of increased anxiety which diminishes with subsequent 
measurements) affecting results (Naismith and Braschi, 2003). Prior to the first measurement, 
participants rested for 10 minutes, with 2 minutes rest between subsequent measurements 
(Rosenkilde et al., 2010). 
3.5.3.3. Pulse Wave Analysis 
Pulse wave analysis (PWA) was used to monitor arterial stiffness non-invasively using 
applanation tonometry (SphygmoCor, ScanMed Medical, UK) as there is a strong association 
between PWA and cardiovascular disease incidents, independent of traditional risk factors 
(Choi et al., 2007; Keane et al., 2016b). A high-sensitivity tonometer was placed over the radial 
artery at the wrist, which was slightly extended and rested on a pillow (Doupis et al., 2016). 
Aortic (central) systolic and diastolic BP, pulse pressure (PP), augmentation pressure (AP), 
augmentation index (AIx), corrected augmentation index at heart rate 75 bpm (AIx at HR75) 
and subendocardial viability ratio (SEVR) were determined by the software using generalised 
transfer functions. Gallagher, Adji and O’Rourke (2004) and Pauca, O’Rourke and Kon (2001) 
have previously validated these functions at rest. High reproducibility of AIx determined from 
PWA, using SphygmoCor, has been shown in various populations suggesting suitability of use 
in clinical interventional studies (Wilkinson et al., 1998). Recordings with a quality-index 
≥80% only, as suggested by the manufacturer, were selected for statistical analysis.  
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3.5.3.4. Cardiac Haemodynamics, PWA and Brachial Blood Pressure Reliability 
Waldron et al. (2017) found intra-trial measurements of cardiac haemodynamic parameters 
were reliable at rest in healthy, normotensive, males, using the Finapres system; although 
stroke volume was associated with larger errors. However, in individuals with MetS, intraclass 
correlation coefficients (ICC) were used to assess test-retest reliability of resting cardiac 
haemodynamic (Finapres), PWA (SphygmoCor) and brachial BP parameters during pilot 
testing, prior to initiating the second study (Chapter 5). ICC estimates and their 95% 
confidence intervals were calculated, using SPSS v22.0 (IBM, Chicago, USA), based on a 
single-measures (type), absolute agreement (definition), two-way mixed-effects model for 
intra-trial and inter-trial test-retest reliability. ICC was chosen as it is a common statistical test 
for test-retest reliability, which accounts for the correlation and agreement between 
measurements (Koo and Li, 2016). Five participants with MetS (age 45 ± 10 years, body mass 
89.9 ± 12.1 kg, stature 1.72 ± 0.51 m) participated in the pilot testing where intra-trial (7 
repeated measurements during the same testing session, corresponding to the 7 time points) 
and inter-trial (one measurement obtained on three different days, each separated by 2 weeks, 
corresponding to the 3 conditions) reliability was determined in the same format as the protocol 
used in chapter 5. Interpretation was based on ICC classifications outlined in section 3.5.2. 
Intra-trial reliability for AP, SV and TPR demonstrated moderate to excellent reliability, all 
other variables in Table 3.2 demonstrated good to excellent reliability according to 95% 
confidence intervals. Inter-trial reliability for aortic SBP, aortic DBP, SEVR, HR, brachial SBP 
and brachial DBP demonstrated good to excellent reliability according to 95% confidence 
intervals. All other variables in Table 3.2 demonstrated moderate to excellent reliability. 
Consequently, based on this data and similar research design, it was deemed suitable to 
measure cardiac haemodynamic and PWA parameters in individuals with MetS for chapter 6.  
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Table 3.2. Intra-trial and inter-trial mean, standard deviation, range, ICC and Coefficient of 
Variation (%) for resting PWA (SphygmoCor), cardiac haemodynamic (Finapres) and brachial 
blood pressure parameters measured during pilot testing. 
 Mean ± SD (Range)  ICC (95% CI) CV (95% CI) 
 Intra-Trial Inter-Trial Intra-Trial Inter-Trial Intra-Trial Inter-Trial 
Aortic SBP 
(mmHg) 
125 ± 10 
(113 – 144) 
122 ± 13 
(110 – 140) 
0.90 
(0.81 – 0.96) 
0.88 
(0.86 – 0.91) 
8 
(5 – 14) 
11 
(7 – 17) 
Aortic DBP 
(mmHg) 
83 ± 4 
(69 – 93) 
83 ± 7 
(69 – 95) 
0.96 
(0.86 – 0.98) 
0.91 
(0.88 – 0.97) 
5 
(2 – 7) 
9 
(3 – 11) 
Augmentation 
Pressure 
(mmHg) 
 
12 ± 1 
(7 – 18) 
 
15 ± 1 
(12 – 17) 
0.92 
(0.66 – 0.98) 
0.92 
(0.72 – 0.98) 
8  
(4 – 12) 
7 
(4 – 10) 
AIx (%) 
28 ± 2 
(21 – 38) 
36 ± 3 
(26 – 38) 
0.93 
(0.77 – 0.94) 
0.86 
(0.57 – 0.96) 
7 
(5 – 9)   
10 
(4 – 12) 
AIx at HR75 (%) 
26 ± 2 
(20 – 33) 
24 ± 2 
(21 – 30) 
0.96 
(0.85 – 0.99) 
0.91 
(0.69 – 0.97) 
7 
(4 – 9) 
8 
(2 – 11) 
SEVR (%) 
193 ± 20 
(166 – 219) 
184 ± 30 
(157 – 217) 
0.88 
(0.78 – 0.93) 
0.84 
(0.80 – 0.90) 
10 
(7 – 14) 
16 
(8 – 20) 
       
Cardiac Output 
(L.min-1) 
6.62 ± 0.51 
(5.81 – 7.23) 
7.14 ± 0.62 
(6.24 – 7.84) 
0.93 
(0.78 – 0.98) 
0.85 
(0.52 – 0.96) 
8 
(3 – 11) 
9 
(6 – 13) 
Stroke Volume 
(mL) 
106 ± 12 
(98 – 110) 
108 ± 13 
(101 – 124) 
0.88 
(0.60 – 0.97) 
0.81 
(0.56 – 0.95) 
11 
(5 – 16) 
12 
(7 – 19) 
MAP 
(mmHg) 
93 ± 6 
(89 – 98) 
109 ± 7 
(98 – 115) 
0.94 
(0.79 – 0.96)  
0.91 
(0.70 – 0.91) 
6 
(2 – 9) 
6 
(5 – 15) 
Heart Rate 
(beats.min-1) 
62 ± 3 
(60 – 67) 
66 ± 3 
(64 – 70) 
0.92 
(0.84 – 0.93) 
0.92 
(0.84 – 0.97) 
5 
(4 – 10) 
5 
(2 – 12) 
TPR 
(mmHg·min-1·L) 
1.44 ± 0.11 
(1.05 – 1.49) 
1.42 ± 0.13 
(1.31 – 1.55)  
0.87  
(0.52 – 0.97) 
0.84 
(0.53 – 0.92) 
7 
(3 – 13) 
9 
(4 – 15) 
       
Brachial SBP 
(mmHg) 
130 ± 12 
(125 – 149) 
132 ± 13 
(122 – 148) 
0.92  
(0.83 – 0.97) 
0.87  
(0.80 – 0.94) 
9 
(4 – 12) 
10 
(6 – 12) 
Brachial DBP 
(mmHg) 
72 ± 5 
(66 – 77) 
72 ± 6 
(68 – 78) 
0.94  
(0.85 – 0.98) 
0.89 
(0.85 – 0.95) 
7 
(4 – 10) 
8 
(2 – 11) 
AIx (Augmentation Index); DBP (Diastolic Blood Pressure); MAP (Mean Arterial Pressure); SBP (Systolic 
Blood Pressure); SEVR (Subendocardial Viability Ratio); TPR (Total Peripheral Resistance). 
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3.5.4. Indirect Calorimetry 
Through indirect calorimetry, breath-by-breath measurements of V̇O2 consumption and V̇CO2 
production during pulmonary gas exchange were used to determine whole-body energy 
expenditure, fat oxidation rate, carbohydrate oxidation rate and RER at rest and during 
exercise. The contribution of protein to total energy expenditure at rest and during exercise was 
considered negligible (Jeukendrup and Wallis, 2005). 
Resting metabolic rate (RMR) was assessed in chapters 4-6, to determine resting energy 
expenditure, substrate oxidation rates and RER. Determination of RMR was conducted in a 
temperature-controlled annexe of the main laboratory to ensure a thermoneutral environment. 
This was to prevent results being affected by inducing a thermoregulatory effect on heat 
generation (Henry, 2005). Participants arrived at the laboratory according to the dietary and 
exercise restrictions outlined for each study. RMR was measured based on an open-circuit 
indirect calorimetry system (GEM Nutrition Ltd, Cheshire, UK). Prior to use, the unit was 
calibrated against a mixture of gases with known concentrations (1.1% CO2, 21% O2). 
Participants lay supine for 30 minutes with data averaged for the final 20 minutes only, to 
achieve steady-state and account for any initial short-term variances in respiration (Kelly et al., 
2013). A ventilated hood was placed over the head with a flexible plastic seal around the neck 
and shoulders to prevent air inside and outside the hood from mixing excessively. Participants 
were instructed to remain silent and lay as still as possible, whilst music was played to prevent 
sleeping. Values for V̇O2 (L.min-1), V̇CO2 (L.min-1), RER and EE (kcal.day-1) were obtained 
every minute during the half hour period.  
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Resting EE was determined by application of the Weir equation (Weir, 1949) below. 
Energy Expenditure (kcal.day-1) = [(3.94 * V̇O2) + (1.106 * V̇CO2)] * 1.44  (1) 
Equations 2 and 3 outlined by Frayn (1983), were used to determine fat oxidation and 
carbohydrate oxidation rates at rest. 
Fat Oxidation Rate (g.min-1) = (1.67 * V̇O2) – (1.67 * V̇CO2)    (2) 
Carbohydrate Oxidation Rate (g.min-1) = (4.55 * V̇CO2) – (3.21 * V̇O2)   (3) 
RER or respiratory quotient (RQ) can be used as an alternative indirect indicator of substrate 
oxidation based on stoichiometry. The oxidation of 1 mol of glucose requires 134 L of O2 and 
produces 134 L of CO2 and therefore an RQ of 1 (134 L / 134 L = 1), representing 
predominately carbohydrate oxidation. Equally, an RQ of 0.7 suggests primarily oxidation of 
fat as 1 mol of palmitic acid requires 515 L of O2 and produces 358 L of CO2 (358 L / 515 L = 
0.7) (Jeukendrup and Wallis, 2005). 
RER (or RQ) = V̇CO2 / V̇O2     (4) 
Intraclass Correlation Coefficient (ICC) estimates and their 95% confidence intervals were 
calculated using SPSS v22 (IBM, Chicago, USA) based on a single-measures (type), absolute 
agreement (definition), two-way mixed-effects model for within- and between-day test-retest 
reliability. ICC was chosen as it is a common statistical test for test-retest reliability which 
accounts for the correlation and agreement between measurements (Koo and Li, 2016). ICC 
values were measured on a scale between 0 and 1, and classified as poor (0.00 – 0.50), moderate 
(0.50 – 0.75), good (0.75 – 0.90) and excellent (0.90 – 1.00) (Koo and Li, 2016). 
RMR reliability was measured using the same people as reliability testing for body composition 
with healthy participants. Within-day intra-individual reliability was not measured as 
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participants were only measured once a day during the testing protocol. Between-day intra-
individual reliability was taken by taking a measurement on three different days each separated 
by 10 days to mimic the study design of chapter 4. 
Between-day ICC and Coefficient of Variation (%) for RMR measurements, showed good to 
excellent reliability in healthy individuals (Table 3.3). ICC values were measured on a scale 
between 0 and 1, and classified as poor (0.00 – 0.50), moderate (0.50 – 0.75),                               
good (0.75 – 0.90) and excellent (0.90 – 1.00) (Koo and Li, 2016). 
Table 3.3. Mean, standard deviation, range, ICC and Coefficient of Variation (%) for RMR 
variables measured with an open-circuit indirect calorimetry system. 
EE (Energy Expenditure); RER (Respiratory Exchange Ratio); V̇CO2 (Volume of Carbon Dioxide Production); 
V̇O2 (Volume of Oxygen Uptake). 
Within-day, intra-individual reliability was measured in the fasted state in individuals with 
MetS (using the same participants as those for cardiac haemodynamic/PWA reliability testing), 
but not using the same design as chapter 5, as most measurements during testing were taken 
in the post-prandial state. Hence, measurements were taken twice separated by one hour (to 
mimic the length between measurements during the testing protocol). 
Between-day, intra-individual reliability was measured by obtaining a measurement on three 
different days each separated by 14 days (washout) to mimic the study design of chapter 5.  
 Mean ± SD (Range) ICC (95% CI) CV (95% CI) 
EE (kcal.day-1) 
1776 ± 218  
(1507 – 2053) 
0.89 
(0.86 – 0.92) 
12 
(6 – 16) 
RER (AU) 
 0.84 ± 0.08 
(0.77 – 0.88) 
0.94 
(0.92 – 0.96) 
10 
(6 – 12) 
V̇O2 (L.min-1) 
264 ± 30 
(190 – 365) 
0.91 
(0.87 – 0.91) 
11 
(7 – 15) 
V̇CO2 (L.min-1) 
220 ± 20 
(164 – 318) 
0.95 
(0.91 – 0.97) 
9 
(6 – 13) 
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Within-day and between-day ICC and Coefficient of Variation (%) for RMR measurements, 
showed good to excellent reliability in MetS individuals (Table 3.4). ICC values were measured 
on a scale between 0 and 1, and classified as poor (0.00 – 0.50), moderate (0.50 – 0.75),          
good (0.75 – 0.90) and excellent (0.90 – 1.00) (Koo and Li, 2016). As the data showed good to 
excellent reliability, it was deemed suitable to take RMR measurements in chapter 6 also. 
Table 3.4. Within-day and between-day mean, standard deviation, range, ICC and Coefficient 
of Variation (%) for RMR variables measured with an open-circuit indirect calorimetry system. 
EE (Energy Expenditure); RER (Respiratory Exchange Ratio); V̇CO2 (Volume of Carbon Dioxide Production); 
V̇O2 (Volume of Oxygen Uptake). 
 
3.6. Blood Sampling and Analysis 
3.6.1. Blood Sampling 
Venous blood was sampled using the venepuncture butterfly method (BD Vacutainer Safety-
Lok Blood Collection Set 21G with Luer Adapter, Becton Dickinson and Co., Oxford, UK) in 
chapters 4-6. Whole blood (8-12 mL), sampled from veins located in the antecubital fossa 
region, was collected into either ethylenediaminetetraacetic acid (EDTA), lithium heparin or 
serum separator tubes (Vacutainer, Becton Dickinson and Co., Oxford, UK). The serum 
separator tube was left to stand for a minimum of 30 minutes at room temperature (Tuck et al., 
2009), then all tubes were centrifuged for 10 minutes at 4000 rev.min-1 (Sorvall ST 8R, Thermo 
 Mean ± SD (Range)  ICC (95% CI) CV (95% CI) 
 Within-Day Between-Day Within-Day Between-Day Within-Day Between-Day 
EE (kcal.day-1) 
1742 ± 236 
(1531 – 2497) 
1992 ± 230 
(1534 – 2224) 
0.93 
(0.90 – 0.96) 
0.91 
(0.89 – 0.93) 
11 
(8 – 15) 
12 
(6 – 13) 
RER (AU) 
0.85 ± 0.05 
(0.82 – 0.90) 
0.86 ± 0.09 
(0.84 – 0.91) 
0.95 
(0.91– 0.97) 
0.93 
(0.90 – 0.94) 
6 
(3 – 8) 
10 
(8 – 13) 
V̇O2 (L.min-1) 
247 ± 28 
(190 – 336) 
246 ± 31 
(176 – 350) 
0.91 
(0.89 – 0.94) 
0.88 
(0.86 – 0.91) 
11 
(7 – 16) 
13 
(6 – 15) 
V̇CO2 (L.min-1) 
291 ± 18 
(177 – 301) 
286 ± 23 
(166 – 322) 
0.94 
(0.87 – 0.94) 
0.93 
(0.86 – 0.93) 
6 
(4 – 9)   
8 
(4 – 10) 
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Fisher Scientific, USA). Serum and plasma supernatants were aliquoted into cryogenic vials  
(2 mL Cryogenic Vials, Fisherbrand, Leicestershire, UK) and stored in a freezer (MDF-U53V, 
VIP Series, Sanyo, Japan) at -80ºC for later analysis. 
3.6.2. Glucose 
Glucose concentrations were determined through reaction of glucose oxidase with glucose to 
form hydrogen peroxide and gluconic acid. The amount of hydrogen peroxide released 
indicated glucose concentration via amperometric hydrogen peroxide determination. 
Immediately after centrifugation, serum samples were assessed for glucose (range 0.5-50 
mmol.L-1, CV ≤1.5%) (Biosen C-Line, EKF Diagnostics, Cardiff, UK) in duplicates, by 
pipetting 10 µL of sample into a pre-filled reaction cup (Safe-Lock Mixing Cup, EKF 
Diagnostics, Cardiff, UK) containing 500 µL of haemolysing solution. Each reaction cup was 
then vortexed for 5 seconds before being analysed. For purposes of enhanced accuracy, serum 
was chosen over plasma and whole blood as serum lacks erythrocytes, leukocytes and clotting 
factors such as fibrinogen. Furthermore, metabolite concentrations are higher in serum than 
plasma thus less prone to background noise affecting accuracy, with glucose tending to be more 
accurate by 5% in sera (Ladenson et al., 1974; Yu et al., 2011). 
3.6.3. General Assay Methodology 
Prior to analysis, serum samples were allowed to thaw and were then vortexed (Whirlimixer, 
Fisherbrand, Leicestershire, UK). Serum samples were directly analysed for ACE (angiotensin-
I-converting enzyme), HDL, insulin, TAS, total cholesterol and triglycerides. Indirect 
calculation of LDL was performed after determination of the other lipid metabolites using the 
formula suggested by Ahmadi et al. (2008) in chapter 4, and by the Friedewald, Levy and 
Fredrickson (1972) formula outlined below in chapters 5-6. The use of the Friedewald formula 
(Equation 5) in chapter 5-6 was based on data showing a strong, significant correlation 
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between predicted LDL concentrations and direct LDL measurement in individuals with MetS 
(Knopfholz et al., 2014). 
LDL (mmol.L-1) = (Total Cholesterol) - (HDL) - (
Triglycerides
2.2
)   (5) 
A semi-automated spectrophotometer (RX monza, Randox Laboratories Ltd, Antrim, UK) was 
used to measure the absorbency of the sample at a specific wavelength and temperature relevant 
to each assay (TAS, triglycerides, total cholesterol and HDL only). A two-point calibration of 
the spectrophotometer was conducted for each assay using a reagent blank and a standard to 
generate a calibration curve, against which total anti-oxidants, triglycerides, total cholesterol 
and HDL within samples were compared. 
All samples were measured in duplicates, with intra-assay CV determined by analysing all 
serum samples. Each test run was assessed for validity and test-retest reliability prior to 
determination of biomarkers in serum samples by analysing quality control samples (analytical 
variance), relevant to each assay, 10 times. With regards to lipid metabolites, samples 
exhibiting pathological (Lipid Control Level 3 LE2663, Randox Laboratories Ltd, Antrim, UK) 
and borderline (Lipid Control Level 2 LE2662, Randox Laboratories Ltd, Antrim, UK) values 
were determined to provide improved reliability and accuracy of results. The overall assay CV 
was determined from values obtained from each duplicate across all time points for all 
participants. 
All directly assayed biomarkers were determined colorimetrically, where the colour change 
induced by the relevant indicator for each assay correlated linearly to the concentration of the 
target metabolite within serum, according to Beer-Lambert’s law (Swinehart, 1962). Lipid 
assays were associated with a positive linear correlation, where a greater concentration of the 
target metabolite was related to a greater concentration of the indicator thus intensifying the 
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pink colour produced (Figure 3.1). According to the manufacturer’s guidelines, all samples 
were assessed within 3 months of blood sampling for lipid metabolites.  
Figure 3.1. Example of colour change from clear (left) to pink (right) for lipid assays. 
 
3.6.4. Triglycerides Assay 
Serum triglycerides (Triglycerides TR210, Randox Laboratories Ltd, Antrim, UK) were 
determined after enzymatic hydrolysis with lipases, where values were corrected for free 
glycerol by subtracting 0.11 mmol.L-1 (Stinshoff et al., 1977), according to the manufacturer’s 
guidelines. The assay standard curve (Figure 3.2) and principle are shown below. 
    lipases 
Triglycerides   +   H2O          glycerol +      fatty acids 
           Glycerol kinase 
Glycerol      +       ATP          glycerol-3-phosphate    +    ADP 
 
          Glycerol-3-phosphate oxidase  
Glycerol-3-phosphate   +    O2        dihydroxyacetone-phosphate  +   H2O2 
 
              peroxidase 
2H2O2  +  4-aminophenazone  + 4-chlorophenol       quinoneimine +  HCl  +  4H2O 
 
Thawed samples (5 µL) were reacted with enzyme reagent (500 µL) and then incubated in a 
dry heating block (Rx Monza Heat Block DB-10C, Randox Laboratories Ltd, Antrim, UK) for 
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5 minutes at 37ºC. Samples were then analysed in the spectrophotometer at 37ºC and a 
wavelength of 546 nm. Analytical variance based on quality control levels 2 and 3 CV were 
5.18% and 6.22%, respectively, suggesting the spectrophotometer and assay were reliable. All 
quality control values were within the quality control low (level 2: 0.92 – 1.39 mmol.L-1) and 
high (level 3: 2.52 – 4.48 mmol.L-1) concentration ranges, suggesting the spectrophotometer 
and the assay were also valid. Assay accuracy, sensitivity and linearity were 95.35%,              
0.26 mmol.L-1 and 13.23 mmol.L-1, respectively, falling within the range of measurement for 
experimental samples obtained in chapters 4-6. Intra- and inter-assay precision for level 2 
quality control was 2.90% and 5.32%, respectively, and 2.48% and 3.82%, respectively for 
level 3 quality control. All lipid biomarkers were analysed within 3 months of blood sampling. 
Figure 3.2. Representative two-point standard curve calibration used to determine triglyceride 
concentrations from serum samples. 
 
3.6.5. Total Cholesterol Assay 
Total cholesterol (Cholesterol CH200, Randox Laboratories Ltd, Antrim, UK) was determined 
from serum samples after enzymatic hydrolysis and oxidation. The formation of the indicator 
quinoneimine from hydrogen peroxide and 4-aminoantipyrine in the presence of phenol and 
peroxidase induced a colour change linearly correlating to the concentration of cholesterol 
within the sample. The assay standard curve (Figure 3.3) and principle are shown below. 
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    Cholesterol esterase 
Cholesterol ester  +  H2O         Cholesterol     +   Fatty Acids 
 
    Cholesterol oxidase 
Cholesterol  +      O2       Cholestene-3-one +     H2O2  
 
        peroxidase 
2H2O2    +   phenol   +   4-aminoantipyrine         quinoneimine      +      4H2O 
 
Similar to triglycerides, samples (5 µL) were reacted with 500 µL of reagent, containing 
peroxidase, phenol, cholesterol esterase, cholesterol oxidase and 4-aminoantipyrine, then 
incubated at 37ºC for 5 minutes. Absorbency of the sample was then analysed in the 
spectrophotometer at 25ºC and a wavelength of 510 nm. The spectrophotometer and assay were 
valid as values for quality control samples were within the low (level 2: 3.31 – 4.29 mmol.L-1) 
and high (level 3: 5.14 – 6.68 mmol.L-1) concentration ranges. Analytical variance for quality 
control level 2 (CV – 5.92%) and level 3 (CV – 6.29%) suggested the spectrophotometer and 
assay were reliable. Assay accuracy, sensitivity and linearity were 92.08%, 0.35 mmol.L-1 and 
17 mmol.L-1, respectively, falling within the range of measurement for experimental samples 
obtained in chapters 4-6. Intra- and inter-assay precision for level 2 quality control was 2.74% 
and 3.92%, respectively, and 1.23% and 4.64%, respectively, for level 3 quality control. 
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Figure 3.3. Representative two-point standard curve used to ascertain total cholesterol 
concentrations in serum samples. 
 
3.6.6. HDL Assay 
According to manufacturer’s guidelines, in order to isolate HDL from other lipid metabolites 
(LDL and chylomicrons) in serum, samples were pre-treated with a buffer containing 
phosphotungstic acid and magnesium chloride. Samples were then centrifuged at 12000 
rev.min-1 for 2 minutes (Hyspin 16K, Anachem, Luton, UK) to leave a supernatant which was 
then assessed using the same procedure as total cholesterol (section 3.6.5). Values obtained 
when assessing assay validity were within the low (level 2: 1.35 – 1.83 mmol.L-1) and high 
(level 3: 2.57 – 3.49 mmol.L-1) concentration ranges, suggesting the spectrophotometer and the 
assay were valid. Quality control levels 2 and 3 CV were 3.93% and 2.53%, respectively 
suggesting the spectrophotometer and assay were also reliable. Assay accuracy, sensitivity and 
linearity were 95.41%, 0.07 mmol.L-1 and 23.70 mmol.L-1, respectively, falling within the 
range of measurement for experimental samples obtained in chapters 4-6. The high (level 2) 
and low (level 3) concentration quality controls, intra- and inter-assay precision were reported 
as 10.5% and 10.2% (level 2), respectively, and 8.8% and 11.7% (level 3), respectively. An 
example of the assay standard curve (Figure 3.4) is shown below. 
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Figure 3.4. Representative two-point calibration standard curve used to determine HDL 
concentrations in serum samples. 
 
3.6.7. Total Cholesterol:HDL Ratio 
Ratios between total cholesterol and HDL (TC:HDL) were calculated by dividing total 
cholesterol values by their corresponding HDL values for each time point measured in 
chapters 4-6, to determine atherogenic (Castelli) index (Millán et al., 2009). TC:HDL has been 
shown to be a better predictive indicator of cardiovascular risk than either parameter in 
isolation (Millán et al., 2009). Furthermore, TC:HDL is also a good predictor of the degree of 
benefit from lipid-lowering treatments (Millán et al., 2009).   
3.6.8. Insulin Assay 
Serum insulin samples were measured in duplicates using a human 96-well insulin enzyme-
linked immunosorbent assay (ELISA) (Insulin Human ELISA KAQ1251, Invitrogen, Thermo 
Fisher Scientific, USA), with a common sample measured on each plate for determining inter-
plate CV. Ready-made standards (concentrations: 0.0, 4.9, 14.0, 42.0, 98.0, 172.0 µIU) were 
reconstituted with 2 mL distilled water for the 0.0 standard and with 1 mL for all other 
standards, in order to generate a six-point standard curve. The ELISA was based on the 
‘sandwich immunoassay’ principle where 50 µL of standards/controls/samples were added to 
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wells pre-coated with anti-insulin capture antibodies to enable selective binding for insulin. 
Following this, 50 µL anti-insulin horseradish peroxidase (HRP) conjugate was added to each 
well to bind to capture antibodies and form an antibody-antigen complex. To ensure complete 
binding, the plate was incubated for 30 minutes at room temperature and then washed with 
wash buffer solution to remove unbound antibodies. Chromogen substrate 
(tetramethylbenzidine, TMB), was added (100 µL) to each well within 15 minutes following 
the washing step and then the plate was incubated in the dark for 15 minutes. A detectable 
colour change from colourless to blue ensued upon addition of chromogen substrate due to 
conversion by HRP (Figure 3.5). After incubation, the reaction was stopped with the addition 
of 100 µL stop solution resulting in a second colour change from blue to yellow (Figure 3.5).  
 
Figure 3.5. Representation of colour change from colourless (left) to blue (middle) upon 
addition of chromogen substrate, and colour change from blue (middle) to yellow (right) upon 
addition of stop solution. 
 
The plate was then immediately read on a plate reader (Multiskan™ FC Microplate 
Photometer, Thermo Scientific, USA) at 450 nm to obtain absorbances of each well and insulin 
concentrations (pmol.L-1) were then calculated using the standard curve according to Beer-
Chapter 3. General Methodology 
121 
 
Lambert’s law. A four-parameter algorithm standard curve was generated (Figure 3.6) using 
standard curve fitting software (SigmaPlot, Systat Software Inc, San Jose, USA), where values 
were converted from µIU.mL-1 to pmol.L-1 by multiplying by 6.945 (Bos et al., 2010). The kit 
inter-assay using normal and high quality controls and intra-assay precision, range and 
sensitivity were 8.1% (normal quality control) and 9.0% (high quality control), 5.4%,          
35.42-1736.25 pmol.L-1 and 1.18 pmol.L-1, respectively. Intra-plate precision was 8.8% 
(normal quality control) and 9.6% (high quality control) and 7.69%, respectively. 
Figure 3.6. Representative four-parameter algorithm standard curve generated using standard 
curve fitting software to determine insulin concentrations in pmol.L-1. 
3.6.8.1. Insulin Resistance and Sensitivity Indexes 
In chapters 5-6, Homeostatic Model Assessment (HOMA) was used to estimate fasting steady-
state pancreatic β-cell function (HOMA2-β), insulin resistance (HOMA2-IR index) and insulin 
sensitivity (HOMA2-%S) through the HOMA2 model (HOMA2-IR, available from 
https://www.dtu.ox.ac.uk/homacalculator/) (Levy, Matthews and Hermans, 1998). Equations 
6, 7 and 8 outline the determination of these variables (Matthews et al., 1985). The HOMA 
model estimates insulin sensitivity and pancreatic β-cell function based on fasting glucose and 
insulin concentrations (Wallace, Levy and Matthews, 2004). The relationship between these 
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concentrations reflects the effect of hepatic glucose production and insulin secretion; 
maintained by a feedback loop between the liver and β-cells (Wallace, Levy and Matthews, 
2004). 
HOMA2-β (%) = 
(20 * Fasting Insulin (μIU.mL-1))
(Fasting Glucose (mmol.L-1)-3.5)
 * 100   (6) 
HOMA2-%S (%) = (
1
HOMA2-IR
) * 100      (7) 
HOMA2-IR =
 [Fasting Glucose (mmol.L-1) * Fasting Insulin (μIU.mL-1)]
22.5
   (8) 
As recommended by Wallace, Levy and Matthews (2004), HOMA2-%S was calculated to 
assist in the correct interpretation of HOMA2-β. Classifications where HOMA2-β = 100% and 
HOMA2-IR = 1 indicate normal pancreatic β-cell function and lack of insulin resistance in 
healthy individuals (Wallace, Levy and Matthews, 2004). A value lower than the threshold for 
HOMA2-β indicates dysfunctional pancreatic β-cell function and a value greater than the 
threshold for HOMA2-IR indicates increased insulin resistance.  
Statistically significant, strong, positive correlations of HOMA2-%S and HOMA2-β against 
other insulin sensitivity and β-cell function assessment methods have been observed in various 
populations, as summarised by Wallace, Levy and Matthews (2004). Additionally, strong, 
positive correlations have been detected in healthy participants and those with hypertension 
and T2D between HOMA2-IR and the hyperinsulinaemic-euglycaemic clamp method 
(Wallace, Levy and Matthews, 2004; Sarafidis et al., 2007), suggesting suitability of using the 
HOMA2 model to determine pancreatic β-cell function and insulin resistance. Consequently, 
the HOMA2 model has also been utilised in various studies examining responses in humans 
with MetS (Vittone et al., 2007; Saadi et al., 2008; Yeap et al., 2010; Beltrán-Debón et al., 
2015).
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Effects of Montmorency Tart Cherry Juice 
Supplementation and FATMAX Exercise on Fat 
Oxidation and Cardio-Metabolic Markers in 
Healthy Humans 
 
Publication arising from this Chapter (Appendix 10): Desai, T., Bottoms, L. and Roberts, 
M. (2018). The effects of Montmorency tart cherry juice supplementation and FATMAX 
exercise on fat oxidation rates and cardio-metabolic markers in healthy humans. European 
Journal of Applied Physiology, 118 (12), pp. 2523-2539. 
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4.1. Introduction 
Cardiovascular disease, T2D and associated diseases combined are the leading health burden 
and cause of mortality worldwide (Danaei et al., 2014), therefore the necessity for an 
intervention is paramount. Dietary interventions to improve cardio-metabolic health are highly 
sought after as they pose less risk than pharmacological drugs (Vendrame et al., 2016). 
Substantial evidence now exists demonstrating the relationship between high consumption of 
vegetables and fruits, improvements in disease symptoms and the reduced risk of disease 
development (Li et al., 2017). However, concerns remain over the feasibility of maintaining a 
high fruit and vegetable intake over a prolonged time period, therefore daily dietary 
supplementation containing health-promoting phytonutrients is appealing. Subsequently, the 
present study supplemented small volumes of highly concentrated MTCJ, to boost 
consumption of phytonutrients and thus provide sufficient amounts at physiologically relevant 
concentrations in a more practical and efficient method (Zheng et al., 2017).  
Tart cherries and thus tart cherry juice possess a high phytochemical content particularly rich 
in anthocyanins, flavonols and phenolic acids (Seymour et al., 2009; Kirakosyan et al., 2010). 
These phytochemicals are thought to contribute to effectively combating oxidative stress, 
inflammation and repairing muscle damage post-exercise (Bell et al., 2014c; Bell et al., 2015). 
In rodents, tart cherries modulated peroxisome proliferator-activated receptor (PPAR) 
signalling pathways, thus percentage fat mass, hyperinsulinaemia, hyperlipidaemia and 
inflammation were all reduced (Seymour et al., 2008, 2009). Observations in humans have 
been more equivocal, with tart cherry supplementation showing no effect on blood pressure 
and blood-based cardio-metabolic markers in healthy participants (Lynn et al., 2014). More 
favourable findings have been reported in studies (Ataie‐Jafari et al., 2008; Martin et al., 2010; 
Keane et al., 2016bc) examining ‘at risk’ or diseased populations, indicating amelioration of 
cardio-metabolic function with tart cherry juice. 
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Skeletal muscle is a critical organ involved in lipid metabolism and dysfunction of cellular and 
molecular cascades which are implicated in the manifestation of CVD, insulin resistance, 
inflammation and oxidative stress (Stump et al., 2006). During sub-maximal exercise at 
FATMAX intensity, skeletal muscle primarily oxidises lipids (Romijn et al., 1993). In healthy 
participants, Robinson et al. (2015) demonstrated a significant positive correlation between 
MFO and both 24-hour fat oxidation and insulin sensitivity. As eluded to in section 2.2.5.1.2 
findings suggest FATMAX exercise encourages enhancements in fat oxidation rate leading to 
improved body composition, total cholesterol and insulin sensitivity (Brun, Romain and 
Mercier, 2011). Consequently, the purpose of specifically incorporating aerobic FATMAX 
exercise in the present study were twofold. Firstly, an individualised approach to achieve 
maximal fat oxidation rates during moderate-intensity exercise has been suggested as the best 
method to reduce HbA1c, insulin-dependent glucose, fat mass and total cholesterol (Brun, 
Romain and Mercier, 2011). Secondly, it is an appropriate methodological test to measure the 
effects of an intervention on fat oxidation rates during exercise and when combined with a 
potential CRM, such as MTCJ, may induce additional improvements on cardio-metabolic 
pathways and therefore overall health (Besnier et al., 2015). 
Rationale for the present study was based on previous work demonstrating the benefits of 
anthocyanin-rich blackcurrants (Cook et al., 2015, 2017b) and green tea polyphenols (Venables 
et al., 2008) on fat oxidation rates during exercise. Also, the positive results regarding the 
effects of tart cherry supplementation against cardio-metabolic dysfunction in rodents 
(Seymour et al., 2008, 2009) and humans (Ataie‐Jafari et al., 2008; Martin et al., 2010; Keane 
et al., 2016bc). However, to date, no research has explored the cardio-metabolic responses to 
tart cherry supplementation and exercise in tandem, thus healthy participants were recruited to 
assess for any adverse effects prior to investigating responses in clinical populations. 
Subsequently, this study set out to examine the physiological responses of MTCJ 
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supplementation with FATMAX exercise on fat oxidation rates, body composition and cardio-
metabolic markers in healthy participants. It was hypothesised that MTCJ supplementation 
would augment fat oxidation rates at rest and during exercise, thus proving more efficacious at 
improving body composition, functional and in sera cardio-metabolic markers than previous 
research conducted with tart (Martin et al., 2010; Lynn et al., 2014) and sweet (Kelley et al., 
2006) cherry supplementation at rest in healthy participants. 
4.2. Methods 
4.2.1. Participants 
Eleven (7 males and 4 females) healthy, recreationally active (≥150 minutes moderate-intensity 
aerobic exercise per week), participants (mean ± SD; age 30 ± 10 years, stature 1.76 ± 0.09 m, 
body mass 76.4 ± 13.2 kg, BMI 24.43 ± 3.23 kg.m-2, V̇O2peak 35.87 ± 4.78 mL.kg-1.min-1) 
volunteered for the study. All participants were non-smokers, BMI <30, injury-free and not 
diagnosed with any cardio-metabolic or renal diseases at the time of testing but had a family 
history of cardio-metabolic disease. Participants were instructed to cease consumption of any 
other supplementation two weeks before and for the duration of the study. All participants 
provided written informed consent to participate in the study and completed health screen 
questionnaires before the study commenced. Ethical approval was obtained from the University 
of Hertfordshire Health and Human Sciences Ethics Committee. The study was registered as a 
clinical trial on clinicaltrials.gov (NCT02999256). 
As this was the first study to examine fat oxidation with cherries, it was difficult to confidently 
predict a sample size using power analysis. Previous studies that had researched the effects of 
fat oxidation (Cook et al., 2015; Roberts et al., 2015) or cherry supplementation (Bowtell et 
al., 2011; Bell et al., 2014bc) had a total sample size between 10-16 participants.  
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4.2.2. Procedures 
4.2.2.1. Research Design 
This study utilised a single-blind (blinded to participant), placebo-controlled, randomised, 
crossover design, where each participant acted as their own control. Participants were required 
to complete two conditions over 10 weeks, differing only in supplementation, Montmorency 
tart cherry juice (MTCJ) and placebo (PLA). Participants were randomised to start 
consumption of either MTCJ or PLA first, followed by a 14-day washout period (Howatson et 
al., 2012; Cook et al., 2015; Keane et al., 2016b) and then consumption of the reverse 
supplement to the first condition.  
Both conditions were identical in terms of design and testing procedures and comprised of 5 
sessions each, with sessions lasting approximately 2.5 hours. A timeline for testing sessions 
and the supplementation period is shown in Figure 4.1. 
Baseline measurements were obtained during the first FATMAX/V̇O2max session in the first 
condition. Other than blood sampling and the type of exercise itself, all other testing procedures 
pre- and post-exercise were identical across each session. Blood sampling was conducted pre- 
and post-exercise in order to ascertain the acute differences induced by one-hour sub-maximal 
FATMAX exercise; and pre-, mid- and post-supplementation to assess the longer-term effects 
of supplementation on cardio-metabolic biomarkers, within and between conditions.
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Figure 4.1. Schematic of testing protocol for each condition (MTCJ and PLA).  
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4.2.2.2. Dietary and Exercise Guidelines 
Participants were instructed to maintain their habitual polyphenol intake, particularly 
anthocyanins, as opposed to complete restriction throughout the study. Refer to section 3.2 for 
further details on dietary guidelines employed in this study. 
Croci et al. (2014) recommended macronutrient dietary control greater than 48 hours before 
exercise to reduce day-to-day intra-individual variability in fat oxidation. Pilot testing 
demonstrated less variability with 72-hour dietary control (CV – 9.88%) for MFO during the 
one-hour sub-maximal exercise at FATMAX, compared to 48-hour dietary control                   
(CV – 13.93%). Participants were therefore asked to replicate their 3-day food and drink 
consumption before each testing session (Alkhatib et al., 2015; Nordby et al., 2015; Roberts et 
al., 2015). A standardised menu for the final 24-hours, of the 3-day period, was provided to 
each participant based on their habitual diet. This was based on findings from Roberts et al. 
(2015), who reported greater adherence to a diet standardised 24-hours prior to exercise and 
notably, less variance in fat oxidation compared to dietary control of only the evening meal 
before exercise. Standardisation of macronutrients was set at 15% protein, 55% carbohydrate 
and 30% fat of energy intake (Melanson et al., 2002; Ben Ounis et al., 2009). As subjects tend 
to underreport dietary consumption with food diaries, an extra 20% (Mertz et al., 1991; Black 
et al., 1993) of the 3-day average for habitual energy intake was added to the standardised 
menu. Standardisation was performed to ensure that all participants attended exercise testing 
sessions in a similar state of energy balance and fuel repletion (Horton et al., 1998; Jeacocke 
and Burke, 2010). All participants reported 100% adherence when food diaries were assessed 
for percentage contributions of macronutrients to total energy intake, total polyphenols and 
anthocyanins. Analysis of habitual diets indicated daily consumption of 1593 mg and 57 mg 
for total polyphenols and anthocyanins, respectively; more than double the general population 
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intake for anthocyanins (23 mg) (Zamora-Ros et al., 2011) but less than the total polyphenol 
consumption in the UK (1675 mg) (Zamora-Ros et al., 2016).  
4.2.2.3. Supplementation 
The supplementation period lasted 20 days, similar to Roberts et al. (2015), where participants 
ceased consumption following the 20th day and during the washout period. The experimental 
condition included supplementation with MTCJ whilst the control involved supplementation 
of an energy matched placebo (Table 4.1). The MTCJ was made with 30 mL Montmorency 
tart cherry concentrate (Cherry Active, Active Edge Ltd, Hanworth, UK) and 100 mL water. 
Placebo composition consisted of 30 mL commercially available fruit-flavoured cordial 
(Cherries and Berries, Morrisons, Bradford, UK), with anthocyanins used only for colouring 
and negligible anti-oxidant content, mixed with 100 mL water. In order to match the placebo 
for energy, taste and visual appearance, a flavourless carbohydrate (Maltodextrin, My Protein 
Ltd, Northwich, UK), citric acid (100% Pure Citric Acid, VB and Sons, UK) and black food 
colouring (Morrisons, Bradford, UK) were added, respectively. Participants consumed two   
130 mL servings per day, once in the morning immediately before breakfast, then again in the 
evening before dinner (Bell et al., 2014b; Bell et al., 2016). Due to fasting restrictions on testing 
days, participants delayed consumption of the morning serving until lunchtime. Refer to   
section 3.3 for more information on supplementation. 
In order to optimise compliance to supplementation, participants were given enough 
supplements to last 5 days, after which they returned to the laboratory with any unconsumed 
juice before being given further supplements to last another 5 days. This was repeated a total 
of four times to fulfil the 20-day supplementation period. 
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Table 4.1. Nutritional information of Montmorency tart cherry concentrate and placebo 
supplements. 
 Montmorency tart cherry 
concentrate (per 30 mL) 
Placebo (per 130 mL) 
Energy (kcal) 102 102 
Carbohydrate (g) 24.50 25.35 
of which sugars (g) 17.90 25.32 
Protein (g) 1.10 0.03 
Fat (g) 0 0 
of which saturates (g) 0 0 
Fibre (g) 2.60 Trace 
Total Anthocyanins (mg) 270 0 
 
4.2.3. Testing Protocol 
During all testing sessions, stature, body mass and waist circumference were measured initially, 
immediately followed by segmental body composition analysis (sections 3.5.1 and 3.5.2). 
After 10 minutes rest, resting HR (Polar T31c and FT1, Polar Electro Oy, Finland) and BP 
(section 3.5.3.2) were obtained followed by RMR (section 3.5.4). Pre-exercise blood sampling 
was then performed followed by post-exercise blood sampling during the one-hour                  
sub-maximal sessions only. HR and BP were measured after post-exercise blood sampling, 
approximately 5-8 minutes after the cessation of exercise (Figures 4.2A and 4.2B).  
 
 
 
 
Chapter 4. MTCJ and FATMAX Exercise on Cardio-Metabolic Markers in Healthy Humans 
132 
 
Figure 4.2. Schematic of testing procedure (A) during FATMAX and V̇O2max testing sessions 
and (B) during 1-hour sub-maximal exercise at individually determined FATMAX testing 
sessions.  
4.2.3.1. FATMAX and V̇O2max Protocol 
During the first and fourth testing sessions of each condition, participants conducted FATMAX 
and V̇O2max tests. An incremental 3-minute step protocol was chosen to determine FATMAX. 
This was based on data obtained during pilot testing where two FATMAX protocols were 
A) 
B) 
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compared and reliability of the protocols assessed. The first protocol required participants to 
cycle at 70 rev.min-1 at an initial intensity of 30 W with increments of 15 W every 2 minutes. 
The second protocol increased by 10 W every 3 minutes with initial wattage and cadence the 
same as the first protocol. Both protocols were repeated twice separated by one week, with   
72-hours dietary standardisation. Limits of agreement (LoA) and CV for MFO and FATMAX 
(%V̇O2peak) for both tests indicated better reliability for the latter protocol (Appendix 1). 
The FATMAX test required participants to cycle on an electromagnetically braked cycle 
ergometer (Excalibur, Lode, Groningen, The Netherlands) at 70 rev.min-1. Fore/aft position, 
saddle and handlebar height on the cycle ergometer were recorded for each participant, during 
the first exercise session and replicated for all other sessions thereafter. Participants started at 
an intensity of 30 W and the cycle was programmed to increase wattage by 10 W every                 
3 minutes. The FATMAX test was terminated once RER was greater than 1 for a continuous 
period of 30 seconds (Croci et al., 2014). This protocol was adapted from previous studies 
(Achten, Gleeson and Jeukendrup, 2002; Alkhatib, 2014), in order to design an appropriate test 
which reflected the determination of FATMAX and MFO as accurately as possible, for the 
participant cohort recruited in this study. In alignment with Alkhatib et al. (2014), smaller        
10 W increments were chosen to better determine FATMAX based on assessment of a wide 
range of exercise intensities (Venables, Achten and Jeukendrup, 2005; Purge, Lehismets and 
Jürimäe, 2015). 
The V̇O2max test was performed 15 minutes following the FATMAX test to prevent the 
depletion of muscle glycogen, which occurs during the V̇O2max test, affecting substrate 
oxidation in the FATMAX test. Due to the low-intensity nature of the FATMAX test, 15 
minutes provided sufficient recovery time before the V̇O2max test and minimised subject 
burden as participants did not have to attend a separate session for determination of V̇O2max. 
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The protocol for determination of V̇O2max consisted of cycling at 70-80 rev.min-1, at an initial 
intensity of 100 W with wattage increasing by 20 W every minute until volitional exhaustion. 
The test was terminated according to BASES Sport and Exercise Physiology testing guidelines 
(Winter et al., 2007). 
HR and differentiated (overall and legs) ratings of perceived exertion (RPE) on a 6-20 scale 
(Borg, 1973) were recorded 15 seconds before the end of each stage for FATMAX and V̇O2max 
tests. RPE was recorded during all exercise sessions at 1, 3- and 5-minutes intervals during the 
V̇O2max, FATMAX and 1-hour sub-maximal sessions, respectively. 
4.2.3.1.1. FATMAX Analysis 
FATMAX was determined through visual inspection of the fat oxidation curve generated from 
the FATMAX sub-maximal test. The corresponding intensity at the peak of this curve was 
deemed to be FATMAX and was implemented during the one-hour sub-maximal sessions. This 
intensity was also confirmed by identifying the highest fat oxidation rate for the final minute 
of each stage calculated from a 15 second rolling average of each 3-minute stage. The second 
V̇O2max and FATMAX tests were used to assess changes in training status (MacRae and 
Mefferd, 2006) and any differences in FATMAX which may have occurred due to the previous 
exercise sessions and supplementation. FATMAX was adjusted to the new exercise intensity 
for the post-supplementation one-hour sub-maximal exercise if the change in FATMAX 
(expressed in terms of %V̇O2max) was greater than a pre-determined threshold (CV between 
both FATMAX determination tests >6%). The rationale behind this was to set an operational 
standard against which comparisons could be made to determine whether FATMAX changed 
after 16 days of supplementation. The threshold was established based on data collected during 
pilot testing, where the CV of FATMAX between two FATMAX sub-maximal determination 
tests (3 minutes stage protocol) were calculated. This ensured that the change in exercise 
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intensity represented a genuine physiological shift in FATMAX, as opposed to differences in 
FATMAX occurring due to equipment variance.  
4.2.4. Measures and Equipment 
4.2.4.1. Respiratory Gas Analysis 
Real-time breath-by-breath gaseous exchange data (Metalyzer 3B, Cortex Biophysik, Leipzig, 
Germany) was recorded during all exercise tests. This method enabled the quantification of 
V̇O2 (L.min-1), V̇CO2 (L.min-1) and RER. Consequently, indirect calorimetry was used to 
calculate EE (kcal.min-1) and substrate oxidation rates (g.min-1) using stoichiometric equations 
specifically developed for exercise at intensities between 40-50% V̇O2peak, as shown below  
(Jeukendrup and Wallis, 2005). 
Fat Oxidation Rate (g.min-1) = [(1.695 ∙ V̇O2) - (1.701 ∙V̇CO2)]  (1) 
CHO Oxidation Rate (g.min-1) = [(4.344 ∙ V̇CO2) - (3.061∙ V̇O2)]  (2) 
Energy Expenditure (kcal.min-1) = [(0.575 ∙ V̇CO2) - (4.435 ∙ V̇O2)]  (3) 
RER was determined from the ratio of CO2 produced relative to O2 consumed as shown in 
Equation 4.  
RER = V̇CO2 / V̇O2      (4) 
Prior to exercise, mask (V Mask, Hand Rudolph, USA) and hairnet (Hans Rudolph, USA) sizes 
were determined and maintained for each participant throughout the study. The automated gas 
analyser was calibrated using a three-point calibration procedure as per manufacturer’s 
instructions. First, barometric pressure was analysed followed by calibration of the analyser 
against a mixture of gases with known concentrations (5% CO2, 17% O2). Finally, the volume 
transducer in the analyser was calibrated with a 3-litre calibration syringe (Series 5530, Hans 
Rudolph, USA). 
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Exported data was analysed only from the final 50 minutes of all one-hour sub-maximal tests 
to ensure participants reached steady-state. Data was averaged for every 15 second period 
during the entire 50 minutes of exercise. To ensure energy and substrate oxidation rates were 
reliable, data during the final minute of each stage was averaged for the FATMAX test as this 
was the period where steady-state was most likely to be achieved (Bordenave et al., 2007). 
4.2.4.2. Blood Sampling and Analysis 
Refer to section 3.6.1 for details on blood sampling procedures. 
Blood samples were obtained from 10 participants, as one subject was uncomfortable with the 
venepuncture method. 
4.2.4.2.1. Plasma Volume Change 
Whole blood from EDTA or lithium heparin tubes, was analysed for haemoglobin and 
haematocrit to calculate plasma volume change (PVC).  Assay results were corrected for PVC 
as a result of exercise-induced changes in haemoconcentration (Allgrove et al., 2011) by the 
equation shown below: 
Corrected Assay Results = %PVC * Measured Post-Exercise Assay Value 
PVC was determined using the method and equations of Dill and Costill (1974) by means of 
comparing the pre- and post-exercise haemoglobin and haematocrit values. 
BVA = BVB * (HbB / HbA)  (5) 
CVA = BVA * HctA   (6) 
PVA = BVA - CVA   (7) 
∆PV (%) = 100 * (PVA-PVB) / PVB  (8) 
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Where BV denotes blood volume, CV (cell volume), Hb (haemoglobin), Hct (haematocrit), 
PV (plasma volume) and ∆PV, % (percentage change in plasma volume). Subscripts of B and 
A denote pre-exercise and post-exercise values, respectively whilst pre-exercise BV was 
assumed to be 100. 
Haemoglobin was analysed, via a modified azidemethemoglobin reaction, by pipetting 10µL 
of whole blood into a microcuvette (HemoCue Hb 201 Microcuvettes, Sweden) which was 
then placed into a reader (HemoCue Hb 201+, Sweden). Haematocrit was analysed by pipetting 
60 µL of whole blood into micro haematocrit tubes (Hawksley, UK) after which one end was 
sealed with Cristaseal wax (Hawksley, UK). Tubes were then placed into a centrifuge 
(Haematospin 1300, Hawksley, UK) and spun at 1300 rev.min-1 for 3 minutes. Tubes were 
placed on a slide reader (Micro Haematocrit Tube Reader, Hawksley, UK) and percentage 
packed cell volume was subsequently determined. 
4.2.4.2.2. Glucose 
Refer to general methodology section 3.6.2 for details on performing glucose analysis. 
Overall intra-individual and inter-individual CV were 1.41% and 10.64%, respectively. 
4.2.4.2.3. Total Anti-oxidant Status Assay 
Total anti-oxidant capacity within serum samples, tart cherry concentrate and tart cherry juice 
(concentrate diluted with water), was assessed using the total anti-oxidant status colorimetric 
assay (Total Anti-oxidant Status NX2332, Randox Laboratories Ltd, Antrim, UK). The assay 
was based on the Trolox Equivalent Anti-oxidant Capacity (TEAC) method, according to the 
manufacturer’s guidelines. Briefly, ABTS® (2,2’-Azino-di-[3-ethylbenzthiazoline 
sulphonate]) was incubated with metmyoglobin (chromogen) and hydrogen peroxide to 
generate the radical cation ABTS®+ and the appearance of a stable blue-green colour. 
Repression of the colour change (Figure 4.3), due to inhibition of ABTS®+ by anti-oxidants, 
was proportional to the concentration of anti-oxidants within the sample, indicating a negative 
linear correlation (Figure 4.4). The assay principle is shown below.  
Chapter 4. MTCJ and FATMAX Exercise on Cardio-Metabolic Markers in Healthy Humans 
138 
 
HX-FeIII   +  H2O2      X–[FeIV = 0]      + H2O 
ABTS®     +  X–[FeIV = 0]      ABTS®+     +    HX-FeIII    
HX-FeIII : Metmyoglobin 
X–[FeIV = 0] : Ferrylmyoglobin 
H2O2 : Hydrogen Peroxide 
H2O : Water  
 
 
 
 
 
Figure 4.3. Example of colour change from stable blue-green colour (left) to clear (right), due 
to inhibition of ABTS®+ by anti-oxidants. 
Figure 4.4. Representative two-point standard curve used for determining TAS concentrations 
in serum samples. 
Absorbency of the samples was measured at 37ºC and a wavelength of 600 nm. According to 
the manufacturer’s guidelines, all samples were assessed within 14 days of blood sampling. 
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Analytical variance was determined by analysing quality control (Total Anti-oxidant Status 
Control NX2331, Randox Laboratories Ltd, Antrim, UK) samples ten times. All quality control 
values were within the quality control range for TAS (1.26 – 1.88 mmol.L-1), suggesting the 
spectrophotometer and the assay were valid and reliable; analytical variance was found to be 
6.71%. The accuracy of the assay was 94.27% when comparing the ten quality control samples 
to the expected quality control concentration. Assay linearity was reported to be 2.5 mmol.L-1, 
thus all experimental samples were within the upper detection limit of the assay. 
Intra-assay variation for serum samples and MTCJ was determined by repeatedly analysing the 
same samples ten times. Overall intra-assay and MTCJ CV were 3.49% and 1.26%, 
respectively. Intra-individual variability for pre- and post-exercise serum samples were found 
to be 2.94% and 5.12%, respectively for this phase. Pre- and post-exercise inter-individual 
CV’s were 4.72% and 5.56%, respectively. 
4.2.4.2.4. Triglycerides Assay 
Refer to general methodology section 3.6.4 for details on performing triglyceride analysis. 
Overall intra-assay CV was 4.96% and serum pre- and post-exercise inter-individual CV were 
7.91% and 11.50%, respectively. Pre- and post-exercise intra-individual CV’s were 2.21% and 
5.47%, respectively. 
4.2.4.2.5. Total Cholesterol Assay 
Refer to general methodology section 3.6.5 for details on performing total cholesterol analysis. 
Intra-individual CV was 1.77% for pre-exercise serum samples, 3.66% for post-exercise 
samples and 1.99% for overall intra-assay CV. Pre- and post-exercise inter-individual CV were 
4.96% and 6.16%, respectively. 
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4.2.4.2.6. HDL Assay 
Refer to general methodology section 3.6.6 for details on performing HDL analysis. 
Overall intra-assay CV was 4.66% and serum pre- and post-exercise intra-individual CV were 
1.17% and 1.76%, respectively. Pre- and post-exercise inter-individual CV were 4.03% and 
4.15%, respectively.  
4.2.4.2.7. Total Cholesterol:HDL Ratio 
Refer to general methodology section 3.6.7 for details on calculating TC:HDL ratio. 
4.2.4.2.8. LDL 
Indirect calculation of LDL was conducted using the formula outlined in Equation 9 (Ahmadi 
et al., 2008): 
LDL (mmol.L-1) = (
Total Cholesterol
1.19
) + (
Triglycerides
0.81
) - (
HDL
1.1
) - 0.98   (9) 
4.2.5. Data Analysis 
Statistical analysis was performed using SPSS v22.0 (IBM, Chicago, USA) where data are 
reported as mean ± standard deviation (±SD). Data normality was checked using a Shapiro-
Wilk test, upon violation of the normality assumption, analysis of variance (ANOVA) was still 
conducted as the model is sufficiently robust to detect statistically significant differences 
between means, in terms of type 1 error (Blanca et al., 2017). Greenhouse-Geisser correction 
was applied upon violation of Mauchly’s test of sphericity for ANOVAs (P < 0.05). Statistical 
significance was set at P < 0.05. A within-group 3-way, 2 x 3 x 2 (condition x supplementation 
x exercise), repeated-measures ANOVA with post-hoc Bonferroni’s adjustment, measured 
differences of body mass, BMI, HR, BP, glucose, TAS, triglycerides, total cholesterol, HDL 
and TC:HDL. Waist circumference, body composition and resting EE, RER, fat and 
carbohydrate (CHO) oxidation were analysed using a 2-way, 2 x 3 (condition x 
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supplementation) repeated-measures ANOVA design with post-hoc Bonferroni’s adjustment. 
A paired-samples t-test was used to identify differences between individual data points within 
conditions and between conditions for the corresponding time point. 
Parameters measured during the FATMAX and V̇O2max tests, including MFO and power 
output at FATMAX, FATMAX (%V̇O2peak), RER at FATMAX, percentage of maximal HR 
(%HRmax) at FATMAX and V̇O2peak, were analysed using a 2 x 2 (condition x time) repeated-
measures ANOVA. A paired samples t-test was used to identify differences between conditions 
for the first and second FATMAX tests. 
Variables measured during the one-hour sub-maximal exercise at FATMAX including, RER, 
HR, RPE (overall), RPE (legs), EE, CHO oxidation, fat oxidation and percentage contribution 
of fat and CHO to total EE, were analysed using a 2 x 3 (condition x time) repeated-measures 
ANOVA, when averaged for the final 50 minutes.  
Partial Eta-Squared ( 2partial ) was used to report effect sizes for ANOVA where effects were 
classified as small (0.01-0.08), moderate (0.09-0.25) and large (>0.25) (Cohen, 1988). Cohen’s 
d effect size was used for paired-samples t-test where effects were classified as no effect            
(0-0.1), small (0.2-0.4), moderate (0.5-0.7) and high (≥0.8) (Cohen, 1988). 
Test-retest reliability was measured using Bland-Altman plots (Bland and Altman, 1986) for 
MFO and %V̇O2peak, during FATMAX tests and one-hour sub-maximal tests conducted in pilot 
testing. Reliability of MFO and %V̇O2peak measured during FATMAX tests and one-hour sub-
maximal tests was performed in the same 11 participants recruited in this study. LoA between 
the tests were calculated by plotting differences between corresponding measurements against 
the mean of the measurements. Reference lines for the mean difference ±1.96 SD are shown 
on the plots. LoA for the FATMAX test represented by MFO and %V̇O2peak were                        
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0.03 [-0.13 – 0.20] g.min-1 and -0.49 [-5.91 – 4.93] %V̇O2peak, respectively, indicating high 
reliability of the test (Appendix 2). During the one-hour sub-maximal exercise, LoA for MFO 
and %V̇O2peak were -0.01 [-0.11 – 0.09] g.min-1 and 0.45 [-2.93 – 3.83] %V̇O2peak, respectively, 
suggesting high agreement and reliability for the FATMAX intensity during prolonged 
exercise (Appendix 2). Additionally, agreement of fat oxidation rates during the one-hour sub-
maximal test and the FATMAX determination protocol was assessed. Fat oxidation rates 
averaged for the final 50 minutes of the one-hour sub-maximal exercise test and mean fat 
oxidation rates obtained during the final minute of the stage eliciting MFO in the FATMAX 
determination test were compared (Appendix 2). The narrow limits of agreement                      
(0.00 [-0.09 – 0.09] g.min-1) indicated a low degree of variation, therefore suggesting that the 
one-hour sub-maximal exercise at FATMAX demonstrated good agreement with fat oxidation 
rates for the final minute of the intensity eliciting FATMAX (Appendix 3).  
In order to determine whether independent variables could explain the variance observed for 
MFO, bivariate correlations were conducted between MFO values obtained during the final 
minute of the stage corresponding to FATMAX at baseline and independent variables affecting 
FATMAX, including age, anthropometrics, body composition, dietary intake and V̇O2peak. No 
significant correlations (P > 0.05) were found for any independent variables, thus regression 
analysis was not performed. 
4.3. Results 
4.3.1. Exercise Results 
4.3.1.1. One-hour Sub-Maximal Cycling Tests 
No significant interactions or main effects for condition and time (P > 0.05) were observed for 
mean EE, percentage contributions of fat and CHO to EE, V̇O2, V̇CO2, HR, overall RPE, legs 
RPE and serum glucose during one-hour cycling at individual FATMAX; suggesting exercise 
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intensities and physiological responses were similar between conditions over the 
supplementation period (Table 4.2). 
Table 4.2. Mean ± SD values of final 50 min for variables measured during one-hour sub-
maximal exercise at individual FATMAX throughout the study duration for PLA and MTCJ. 
AU (Arbitrary Units); CHO (Carbohydrate); EE (Energy Expenditure); HR (Heart Rate); MTCJ (Montmorency 
Tart Cherry Juice); PLA (Placebo); RER (Respiratory Exchange Ratio); RPE (Ratings of Perceived Exertion); 
V̇CO2 (Volume of Carbon Dioxide Production); V̇O2 (Volume of Oxygen Uptake). 
Mean fat oxidation rates during the final 50 minutes of the one-hour cycling exercise at 
individual FATMAX were not significantly different between conditions                                  
(PLA: 0.25 ± 0.10 g.min-1 and MTCJ: 0.26 ± 0.09 g.min-1;
 F(1, 10) = 0.35; P = 0.567,               
2
partial  = 0.034), time (Pre-Supplementation: 0.25 ± 0.09 g.min
-1, Mid-Supplementation:     
 Pre-Supplementation Mid-Supplementation Post-Supplementation 
CHO Oxidation 
(g.min-1) 
 
PLA 0.85 ± 0.33 0.84 ± 0.27 0.89 ± 0.25 
MTCJ 0.98 ± 0.25 0.88 ± 0.29 0.99 ± 0.19 
EE  
(kcal.min-1) 
 
PLA 1.09 ± 0.24 1.10 ± 0.24 1.19 ± 0.29 
MTCJ 1.19 ± 0.22 1.18 ± 0.26 1.20 ± 0.20 
Contribution of 
Fat to EE (%) 
 
PLA 22.49 ± 17.11 23.33 ± 8.03 21.67 ± 10.34 
MTCJ  19.88 ± 8.03 24.06 ± 10.96 20.51 ± 7.37  
Contribution of 
CHO to EE (%) 
PLA 77.51 ± 17.11  76.67 ± 8.03 78.33 ± 10.34 
MTCJ 80.12 ± 8.03  75.94 ± 10.96 79.49 ± 7.37 
V̇O2  
(L.min-1) 
  
PLA 1.16 ± 0.26 1.16 ± 0.25 1.18 ± 0.31 
MTCJ 1.25 ± 0.23 1.25 ± 0.28 1.26 ± 0.21 
V̇CO2  
(L.min-1) 
 
PLA 1.00 ± 0.25 1.00 ± 0.24 1.03 ± 0.25 
MTCJ 1.10 ± 0.21 1.08 ± 0.24 1.12 ± 0.18 
RER 
(AU) 
 
PLA 0.87 ± 0.05 0.87 ± 0.03 0.88 ± 0.04 
MTCJ 0.88 ± 0.03 0.87 ± 0.04 0.89 ± 0.03 
HR  
(beats.min-1) 
 
PLA 114 ± 17 112 ± 18 113 ± 17 
MTCJ 116 ± 9 116 ± 14 115 ± 15 
RPE (Overall) 
(AU) 
 
PLA 10 ± 2 10 ± 1 10 ± 2 
MTCJ 11 ± 2 10 ± 2 11 ± 1 
RPE (Legs) 
(AU) 
 
PLA 10 ± 2 10 ± 2 11 ± 1 
MTCJ 11 ± 2 11 ± 2 11 ± 1 
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0.27 ± 0.08 g.min-1, Post-Supplementation: 0.25 ± 0.11 g.min-1;
 F(2, 20) = 1.22; P = 0.318,  
2
partial  = 0.108) or interaction between condition and time (F(2, 20) = 0.273; P = 0.764,         
2
partial  = 0.027) (Figure 4.5). 
 
Figure 4.5. Mean (±SD) fat oxidation rates measured during final 50 minutes exercise at 
individual FATMAX for PLA and MTCJ. 
There were also no main effects (P > 0.05) for condition, time or interaction for mean CHO 
oxidation rates. A significant main effect for time (Pre-Supplementation: 0.88 ± 0.04,            
Mid-Supplementation: 0.87 ± 0.04, Post-Supplementation: 0.89 ± 0.04;
 F(2, 20) = 4.14;                    
P = 0.031, 2partial  = 0.293) was detected for mean RER but not between conditions or the 
interaction (P > 0.05). Post-hoc analysis identified a trend towards significance between mid-
supplementation and post-supplementation (P = 0.070). 
4.3.1.2. FATMAX and V̇O2max Determination Tests 
No significant differences between conditions (PLA: 0.26 ± 0.05 g.min-1 and                          
MTCJ: 0.23 ± 0.04 g.min-1;
 F(1, 10) = 2.79; P = 0.126, 
2
partial  = 0.22) or time                                   
0.000
0.025
0.050
0.075
0.100
0.125
0.150
0.175
0.200
0.225
0.250
0.275
0.300
0.325
0.350
0.375
0.400
Pre-Supplementation Mid-Supplementation Post-Supplementation
F
a
t 
O
x
id
a
ti
o
n
 R
a
te
 (
g
.m
in
-1
)
Measurement Time Points
PLA
MTCJ
Chapter 4. MTCJ and FATMAX Exercise on Cardio-Metabolic Markers in Healthy Humans 
145 
 
(Test 1: 0.25 ± 0.08 g.min-1 and Test 2: 0.25 ± 0.10 g.min-1; F(1,10) = 0.06; P = 0.807,             
2
partial = 0.01) were found for MFO during the FATMAX determination tests. A tendency     
(t(10) = 2.210; P = 0.052, d = 0.59) towards significance was observed between conditions for 
MFO during the second FATMAX test (PLA: 0.28 ± 0.12 g.min-1 and                                         
MTCJ: 0.22 ± 0.08 g.min-1). 
No main effects (P > 0.05) for condition, time or interaction were detected for FATMAX 
(%V̇O2peak) (Test 1 – PLA: 42.77 ± 8.69% and MTCJ: 45.94 ± 9.28%, Test 2 – PLA:               
45.28 ± 12.07% and MTCJ: 47.91 ± 11.52%), MFO (Test 1 – PLA: 0.25 ± 0.08 g.min-1 and 
MTCJ: 0.24 ± 0.08 g.min-1, Test 2 – PLA: 0.28 ± 0.12 g.min-1 and MTCJ:                                         
0.22 ± 0.08 g.min-1), RER at FATMAX (Test 1 – PLA: 0.87 ± 0.04 and MTCJ: 0.88 ± 0.04, 
Test 2 – PLA: 0.87 ± 0.03 and MTCJ: 0.90 ± 0.03), %HRmax at FATMAX (Test 1 – PLA:        
60 ± 10% and MTCJ: 63 ± 7%, Test 2 – PLA: 60 ± 10% and MTCJ: 63 ± 8%), power output 
at FATMAX (Test 1 – PLA: 66 ± 20 W and MTCJ: 72 ± 18 W, Test 2 – PLA: 70 ± 19 W and 
MTCJ: 78 ± 18 W) and V̇O2peak (Test 1 – PLA: 36.10 ± 5.17 mL.kg-1.min-1 and                        
MTCJ: 36.33 ± 5.34 mL.kg-1.min-1, Test 2 – PLA: 37.07 ± 5.77 mL.kg-1.min-1 and MTCJ:  
36.94 ± 5.89 mL.kg-1.min-1). Values tended to be greater with MTCJ (F(1,10) = 3.65; P = 0.085, 
2
partial = 0.27) for RER at FATMAX, particularly during the second test (0.90 ± 0.03) 
compared to the first test (0.88 ± 0.04) (t(10) = -2.040; P = 0.068, d = 0.63). RER at FATMAX 
was significantly greater (t(10) = -2.770; P = 0.020, d = 1.10) during the second test with MTCJ 
(0.90 ± 0.03) compared to PLA (0.87 ± 0.03). 
Paired-samples t-test between conditions did not outline significant differences (t(10) = -2.040; 
P = 0.256, d = 0.63) for the shift in wattage for FATMAX; 3 participants increased wattage 
with PLA whilst 4 participants increased with MTCJ. Thus, the shift in wattage between 
conditions was considered negligible and not a limitation of the research. 
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4.3.2. Anthropometric and Functional Variables 
No interactions or main effects for condition and time were detected for anthropometric 
measurements in Table 4.3 (P > 0.05).  However, there was a tendency towards significantly 
lower percentage body fat (t(10) = 1.887; P = 0.080, d = 0.05) and fat mass (t(10) = 1.903;                  
P = 0.081, d = 0.05) values pre- to post-supplementation with PLA compared to no difference 
with MTCJ for percentage body fat (t(10) = -0.841; P = 0.420, d = 0.02) and fat mass                    
(t(10) = -1.386; P = 0.196,  d = 0.04). 
No interactions or main effects for condition, time and exercise (P > 0.05) were obtained for 
functional variables presented in Table 4.3, apart from a main effect of exercise for HR       
(F(1,10) = 25.493; P < 0.001, 
2
partial = 0.718), as expected. 
The change in resting EE from the mid- to post-supplementation trial was significantly different 
between conditions (t(10) = -2.602; P = 0.026, d = 0.86) suggesting different responses during 
days 10-20 of supplementation. A tendency towards significance was detected with MTCJ 
where resting CHO oxidation increased from mid- to post-supplementation but not with PLA 
(t(10) = -2.213; P = 0.051, d = 0.77).  
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Table 4.3. Mean ± SD for anthropometric, body composition and resting functional variables obtained pre- and/or post-exercise in both conditions at 
baseline and during pre-, mid- and post-supplementation trials. 
 
 
 Pre-Supplementation Mid-Supplementation Post-Supplementation 
 Pre-Exercise Post-Exercise Pre-Exercise Post-Exercise Pre-Exercise Post-Exercise 
Body Mass (kg) 
PLA 75.75 ± 13.38 75.37 ± 13.30 75.84 ± 13.33 75.44 ± 13.24 75.48 ± 13.60 75.08 ± 13.70 
MTCJ 75.83 ± 13.36 75.47 ± 13.42 75.94 ± 14.15 75.55 ± 14.25 76.05 ± 13.81 75.70 ± 13.85 
          
BMI (kg.m2) 
PLA 24.48 ± 3.30 24.39 ± 3.30 24.54 ± 3.29 24.41 ± 3.29 24.39 ± 3.33 24.28 ± 3.38 
MTCJ 24.53 ± 3.29 24.41 ± 3.29 24.57 ± 3.61 24.41 ± 3.61 24.60 ± 3.48 24.51 ± 3.49 
        
Waist Circumference 
(cm) 
PLA 77.50 ± 11.30  77.30 ± 11.90  78.00 ± 11.30  
MTCJ 75.50 ± 10.80  76.10 ± 11.50  76.60 ± 12.30  
        
Fat Mass  
(kg) 
PLA 16.43 ± 8.21  15.96 ± 8.46  16.05 ± 7.97  
MTCJ 15.95 ± 7.91  16.04 ± 8.60  16.24 ± 8.34  
        
Fat Free Mass  
(kg) 
PLA 58.75 ± 13.01  59.57 ± 13.00  59.15 ± 13.08  
MTCJ 55.76 ± 20.27  59.64 ± 13.45  54.05 ± 18.72  
        
Whole-body Fat  
(%) 
PLA 21.91 ± 10.48  21.14 ± 10.45  21.37 ± 10.05  
MTCJ 20.41 ± 10.05  21.23 ± 10.50  21.47 ± 10.43  
        
Trunk Fat  
(%) 
PLA 22.58 ± 9.66  21.53 ± 9.59  21.98 ± 9.37  
MTCJ 21.85 ± 9.29  21.65 ± 9.58  21.95 ± 9.70  
         
Resting HR  
(beats.min-1) 
PLA 65 ± 8 74 ± 12 62 ± 6 79 ± 16 65 ± 6 80 ± 10^ 
MTCJ 65 ± 11 73 ± 8 65 ± 9 72 ± 11 64 ± 7 76 ± 7 
         
SBP (mmHg) 
PLA 117 ± 16 115 ± 10 115 ± 13 121 ± 18 116 ± 11 114 ± 12 
MTCJ 118 ± 12 121 ± 13 119 ± 11 117 ± 12 117 ± 12 116 ± 12 
         
DBP (mmHg) 
PLA 73 ± 10 73 ± 7 72 ± 10 75 ± 9 72 ± 8 72 ± 10 
MTCJ 74 ± 10 75 ± 10 72 ± 9 75 ± 8 72 ± 10 74 ± 7 
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AU (Arbitrary Units); BMI (Body Mass Index); CHO (Carbohydrate); DBP (Diastolic Blood Pressure); EE (Energy Expenditure); HR (Heart Rate); MTCJ (Montmorency Tart 
Cherry Juice); PLA (Placebo); RER (Respiratory Exchange Ratio); SBP (Systolic Blood Pressure). 
 
 
 
 
  
 
 
      
Resting RER (AU) 
PLA 0.83 ± 0.03  0.84 ± 0.03  0.84 ± 0.04  
MTCJ 0.84 ± 0.03  0.83 ± 0.03  0.84 ± 0.04  
         
Resting EE  
(kcal.day-1) 
PLA 1718 ± 274  1865 ± 291  1745 ± 279  
MTCJ 1823 ± 233  1825 ± 294  1924 ± 375  
        
Resting Fat Oxidation 
(g.min-1) 
PLA 0.08 ± 0.03  0.07 ± 0.02  0.07 ± 0.03  
MTCJ 0.07 ± 0.02  0.08 ± 0.03  0.08 ± 0.02  
         
Resting CHO 
Oxidation (g.min-1) 
PLA 0.14 ± 0.03  0.15 ± 0.05  0.15 ± 0.06  
MTCJ 0.16 ± 0.05  0.14 ± 0.05  0.17 ± 0.06  
Chapter 4. MTCJ and FATMAX Exercise on Cardio-Metabolic Markers in Healthy Humans 
149 
 
4.3.3. Glucose and TAS Biomarkers 
No significant interactions or main effects for condition, time and exercise were detected for 
glucose (P > 0.05). 
A main effect for time (F(2, 18) = 11.137; P = 0.001, 
2
partial  = 0.55) and a significant interaction 
(F(1, 9) = 19.122; P = 0.002, 
2
partial  = 0.68) between condition and exercise were detected for 
TAS (Figure 4.6). Post-hoc analysis revealed significantly lower concentrations post-
supplementation compared to mid-supplementation. There was also a tendency towards 
significance for the interaction between time and exercise (F(2, 18) = 3.466; P = 0.053,            
2
partial  = 0.28).  
Pre-exercise TAS with MTCJ was significantly lower post-supplementation (1.18 ± 0.02 
mmol.L-1; 98.92% of baseline) compared to mid-supplementation (1.33 ± 0.05 mmol.L-1; 
111.93% of baseline) by 11.45%. In comparison, values were statistically similar with PLA 
(t(9) = 1.464; P = 0.177, d = 0.47) (Table 4.4). There was a tendency towards significance        
(t(9) = -1.998; P = 0.077, d = 0.71) for the difference between pre-supplementation (1.17 ± 0.03 
mmol.L-1; 101.26% of baseline) and mid-supplementation (1.33 ± 0.05 mmol.L-1; 111.93% of 
baseline) values prior to exercise with MTCJ, but not for PLA (t(9) = -0.556; P = 0.585,                  
d = 0.24). After the onset of supplementation, the change in TAS during one-hour FATMAX 
exercise was significantly different (t(19) = 2.291; P = 0.034, d = 0.64), where an average 
increase of 1.75% was seen with MTCJ and a decrease of 5.17% with PLA. 
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Figure 4.6. Mean (±SD) TAS concentrations presented at all measured time points for PLA 
and MTCJ. *Denotes significant difference between corresponding time point during post-
supplementation for MTCJ. 
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AU (Arbitrary Units); LDL (Low-density Lipoprotein); MTCJ (Montmorency Tart Cherry Juice); PLA (Placebo); TAS (Total Anti-oxidant Status); TC:HDL (Total Cholesterol 
to HDL Ratio) 
 
 
 
 
Table 4.4.  Mean ± SD for all blood-based biomarkers measured for PLA and MTCJ during pre-, mid-, post-supplementation, before and after 1-hour FATMAX 
exercise. 
 
 Pre-Supplementation Mid-Supplementation Post-Supplementation 
Baseline Pre-Exercise Post-Exercise Pre-Exercise Post-Exercise Pre-Exercise Post-Exercise 
Glucose  
(mmol.L-1) 
PLA 
5.19 ± 0.71 
5.15 ± 0.56 5.47 ± 0.77 5.01 ± 0.57 5.33 ± 0.70 5.13 ± 0.86 5.52 ± 0.65 
MTCJ 5.22 ± 0.86 5.33 ± 0.52 5.21 ± 0.73 5.39 ± 0.56 5.07 ± 0.68 5.24 ± 0.82 
         
Triglycerides 
(mmol.L-1) 
PLA 
0.5 ± 0.3 
0.5 ± 0.0 0.5 ± 0.0 0.7 ± 0.1 0.7 ± 0.1 0.5 ± 0.0 0.6 ± 0.0 
MTCJ 0.6 ± 0.0 0.6 ± 0.1 0.6 ± 0.1 0.6 ± 0.1 0.7 ± 0.0 0.6 ± 0.0 
         
Total Cholesterol 
(mmol.L-1) 
PLA 
3.77 ± 0.67 
3.25 ± 0.03 3.20 ± 0.10 2.96 ± 0.11 2.74 ± 0.16 3.29 ± 0.05 3.17 ± 0.06 
MTCJ 3.11 ± 0.06 3.01 ± 0.05 2.94 ± 0.20 2.75 ± 0.21 3.40 ± 0.07 2.94 ± 0.20 
         
LDL (mmol.L-1) 
PLA 
1.48 ± 0.83 
1.30 ± 0.08 1.23 ± 0.13 0.92 ± 0.13 0.63 ± 0.20 1.35 ± 0.07 1.31 ± 0.16 
MTCJ 1.09 ± 0.12 1.00 ± 0.13 0.79 ± 0.32 0.66 ± 0.23 1.43 ± 0.12 1.28 ± 0.14 
         
TC:HDL (AU) 
PLA 
2.28 ± 0.16 
1.98 ± 0.08 1.93 ± 0.09 1.83 ± 0.06 1.61 ± 0.18 2.06 ± 0.06 1.98 ± 0.15 
MTCJ 2.00 ± 0.14 1.85 ± 0.12 1.69 ± 0.21 1.54 ± 0.12 2.21 ± 0.09 2.05 ± 0.13 
         
Haemoglobin  
(g.L-1) 
PLA 
143 ± 15 
142 ± 14 142 ± 15 143 ± 17 143 ± 14 139 ± 16 145 ± 15 
MTCJ 144 ± 16 146 ± 17 146 ± 17 148 ± 18 142 ± 16 144 ± 13 
         
Haematocrit (%) 
PLA 
44 ± 1 
44 ± 1 44 ± 1 45 ± 1 45 ± 1 44 ± 1 45 ± 1 
MTCJ 45 ± 1 45 ± 1 46 ± 1 46 ± 1 44 ± 1 45 ± 1 
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4.3.4. Lipid Biomarkers 
No significant interactions or main effects for condition, time and exercise were detected for 
triglycerides and LDL (P > 0.05). 
A main effect for time only was found for HDL (F(1.3, 11.703)  = 7.098; P = 0.016, 
2
partial  = 0.441). 
Post-hoc analysis showed post-supplementation concentrations were significantly lower than 
mid-supplementation (P < 0.001) (Figure 4.7). As with TAS, a significant (t(9) = 3.123;                 
P = 0.012, d = 0.68) reduction in pre-exercise HDL concentrations was observed from mid-
supplementation (1.84 ± 0.47 mmol.L-1; 114.48% of baseline) to post-supplementation          
(1.56 ± 0.34 mmol.L-1; 98.62% of baseline) with MTCJ whereas no difference was found for 
PLA (t(9) = 0.719; P = 0.490, d = 0.15) (Table 4.4). 
Mean post-exercise values for total cholesterol (main effect for exercise: F(1, 9) = 8.951;                
P = 0.015, 2partial  = 0.5) and TC:HDL ratio (main effect for exercise: F(1, 9) = 8.951; P = 0.015, 
2
partial  = 0.5) were significantly lower than pre-exercise values. In addition, both total 
cholesterol (F(1.23, 11.154) = 6.092; P = 0.026, 
2
partial  = 0.404) and TC:HDL (F(2, 18) = 10.995;        
P = 0.001, 2partial  = 0.55) demonstrated main effects for time, however no main effect for 
condition, or significant interactions were detected (P > 0.05). 
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Figure 4.7. Mean (±SD) HDL concentrations presented at all measured time points for PLA 
and MTCJ. *Denotes significant difference between corresponding time point during post-
supplementation for MTCJ. 
 
4.4. Discussion 
This was the first study in any population to combine exercise and tart cherry supplementation 
whilst examining cardio-metabolic biomarkers. The main findings of this study were that 20 
days of MTCJ supplementation did not significantly increase fat oxidation rates at rest or 
during FATMAX exercise, nor did it alter waist circumference, body composition or cardio-
metabolic biomarkers compared to the placebo condition. 
4.4.1. Metabolic Responses 
The present study did not find statistically significant differences between conditions for RER, 
EE, fat and CHO oxidation rates, contrasting previously reported results regarding the effect 
of dietary anthocyanin supplementation on substrate metabolism with exercise. Cook et al. 
(2015) observed a 16% increase in fat oxidation with 7 days encapsulated, anthocyanin-rich, 
New Zealand blackcurrant extract (NZBE) supplementation compared to placebo during 
cycling exercise at 65% V̇O2max. Crucially, Cook et al. (2015) instructed participants to 
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consume one NZBE capsule, containing 105 mg anthocyanins, 2 hours prior to commencing 
exercise thus coinciding peak bioavailability and concentrations of anthocyanins, secondary 
metabolites and phase II conjugates in plasma and target tissues with the time of measurement 
of substrate oxidation rates during exercise. Muscle oxygenation responses to Montmorency 
tart cherry capsule consumption were improved with similar time-dependent supplementation 
strategies, whereby short-term (7 days) and acute (60 minutes) loading was provided to 
coincide anthocyanin pharmacokinetics with measurement of physiological responses 
(Morgan, Barton and Bowtell, 2019). RER during 10 minutes of steady-state exercise at ~65% 
V̇O2peak was not different after consuming Montmorency tart cherry capsules (Morgan, Barton 
and Bowtell, 2019), however the short exercise timeframe likely negated the ability to observe 
significantly lower RER. This provides evidence that fat oxidation and other physiological 
parameters can be improved with short-term (7 days) and acute (2 hours before exercise) 
supplementation of dietary anthocyanins. Highlighting the importance of timing of 
consumption to maximise bioavailability and concentrations in plasma and target tissues. 
Subsequently, the inclusion of an overnight fast may explain why Montmorency tart cherry 
anthocyanins and its metabolites were not able to significantly augment fat oxidation rates.  
Differences in fat oxidation responses to NZBE anthocyanin supplementation may be 
explained by the different types of anthocyanins present compared to MTCJ. The main 
anthocyanins in NZBE (35-50% delphinidin-3-rutinoside and 5-20% delphinidin-3-glucoside) 
are derived from the anthocyanidin, delphinidin (Cook et al., 2017b), whereas cyanidin based 
anthocyanins (cyanidin-3-glucosylrutinoside and cyanidin-3-rutinoside) comprise 93% of the 
total anthocyanin content in Montmorency tart cherries (Kirakosyan et al., 2009). It has been 
previously reported that delphinidin based anthocyanins provide more effective cardio-
metabolic protection than cyanidin based anthocyanins (Overall et al., 2017). Additionally, 
cyanidin is less stable in the gastrointestinal environment, although it is not dependent on gut 
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bacteria for metabolism or absorption whereas delphinidin is dependent on gut bacteria 
(Overall et al., 2017). Healthy individuals are expected to have greater diversity and 
concentrations of ‘good’ gut bacteria, acting to increase the bioavailability of anthocyanins and 
their metabolites (Hidalgo et al., 2012; Fernandes et al., 2014). Since gut bacteria do not 
modulate cyanidin based anthocyanin metabolism and absorption, it is not surprising that 
cardio-metabolic markers or fat oxidation rates were not improved in the healthy participants 
from this study. 
It is feasible that consumption of a fruit extract (NZBE) in capsule form would not influence 
substrate oxidation rates as much as supplements in juice form (MTCJ) when ingested 
immediately before exercise, given the likely differences in macronutrient content and 
metabolism such as anthocyanin degradation and absorption rates. Perhaps this explains why 
Cook et al. (2015) were able to observe greater fat oxidation with NZBE. Cook et al. (2015) 
reported NZBE anthocyanins contributed 30.70% of fat to total EE during exercise, whilst 
MTCJ peaked during the mid-supplementation test at 24.06% and averaged 21.48% throughout 
the present study. Similar results were reported with the placebo, with the most likely 
explanation being the high carbohydrate content of the MTCJ and placebo drinks, compared to 
the capsules provided in the NZBE study which were completely devoid of carbohydrate. The 
significant increase in resting EE was facilitated by upregulation of CHO oxidation, signifying 
that the higher CHO content of MTCJ did induce greater glycolytic flux from days 10-20 of 
supplementation. This provides an explanation for the lower MFO rates and percentage 
contributions of fat to total EE in the present study compared to Cook et al. (2015). MTCJ 
contained fructose and glucose, thus the significant elevation in CHO oxidation at rest with 
MTCJ during the final 10 days of supplementation may be due to fructose accumulation. In 
support of these findings, co-ingestion of glucose and fructose, as opposed to either alone, has 
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been shown to significantly increase CHO oxidation rates in healthy participants (Jentjens and 
Jeukendrup, 2005). 
4.4.2. Anti-oxidant Responses 
The tendency towards significance for the 13.35% increase in TAS from pre-supplementation 
to mid-supplementation with MTCJ, may explain the tendency for greater fat oxidation with 
MTCJ during one-hour FATMAX exercise between these time points. The increase in oxygen 
flux and therefore generation of ROS during exercise (Radak et al., 2013), as a by-product of 
fatty acid oxidation at FATMAX, may have been mitigated by MTCJ anti-oxidants. These anti-
oxidants may have retarded mitophagy and preserved mitochondrial function, thus enabling 
the continuation of fat oxidation (Montgomery and Turner, 2014). The 12.76% decrease in 
TAS from mid-supplementation to post-supplementation prior to exercise suggests TAS does 
not increase linearly with further ingestion of MTCJ after 10 days but returns to baseline. As 
far as the author is aware, this is the first study to demonstrate such an effect. Consequently, 
this may have contributed to the different responses observed between conditions for HDL and 
resting EE during days 10-20 of supplementation. Endogenously derived anti-oxidants are the 
primary contributors to the anti-oxidant balance; thus supplementation of exogenous anti-
oxidants may inhibit synthesis of endogenous anti-oxidants in order to maintain a homeostatic 
balance (Poljsak, Šuput and Milisav, 2013). Thus, it is plausible that the synthesis of 
endogenous anti-oxidants was reduced during the final 10 days of exogenous anti-oxidant 
supplementation with MTCJ resulting in a net reduction of TAS. A potential increase in 
oxidative stress from mid- to post-supplementation may have contributed to inefficient 
oxidative metabolism and thus greater resting EE (Frisard and Ravussin, 2006). These findings 
are supported by Timmers et al. (2011) who reported significantly lower basal EE due to 
improved mitochondrial function and therefore metabolic efficiency after 30 days resveratrol 
supplementation, a potent anti-oxidant, in humans that were obese but otherwise healthy. 
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Furthermore, the reduced synthesis/uptake of anti-oxidants may be a defensive mechanism 
against an excessively elevated anti-oxidant balance which may affect hormetic responses. 
Such is the complexity of the interactions of free radicals, pro-oxidant species, anti-oxidants 
and the cellular mechanisms involved, that no one reason is liable to be responsible for this 
potential anti-oxidant effect. 
4.4.3. Lipid Responses 
In relation to lipid responses, it is reasoned a lack of cardio-metabolic dysregulation does not 
provide sufficient scope for a cherry intervention to further regulate cardio-metabolic function 
at rest (Kelley et al., 2006, 2013; Ataie‐Jafari et al., 2008; Martin et al., 2010). Despite the 
addition of an exercise intervention, a similar reasoning can be applied to the present study, 
given the healthy baseline lipid concentrations presented by the participants in this study. This 
observation is further supported by rodents susceptible to dyslipidaemia responding 
significantly better to cherry consumption than those without dyslipidaemia (Seymour et al., 
2008, 2009; Wu et al., 2014). The initial physiological status of participants seems to influence 
the efficacy of cherry interventions. 
It is apparent accumulation of anthocyanins and their metabolites with long-term 
supplementation likely did not occur in the present study. This is likely due to the poor 
bioavailability, intestinal absorption and rapid elimination rates of anthocyanins (Manach et 
al., 2004). Alternatively, it may be that the anthocyanin and secondary metabolite 
concentrations reached a ceiling level below a physiologically relevant threshold (Krga et al., 
2016), to affect serum lipids, thus explaining pre-exercise HDL responses to MTCJ 
consumption. A biphasic response was observed where a non-significant, yet clinically 
relevant, increase in HDL from pre- to mid-supplementation was followed by a significant 
decline from mid- to post-supplementation with MTCJ but not PLA. Based on data from 
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epidemiological studies with middle-age and high-risk subjects, suggesting an increase of 
0.026 mmol.L-1 could reduce the risk of coronary heart disease by 2% in males (Gordon et al., 
1989), the change in HDL from pre- to mid-supplementation may result in a risk reduction of 
12% with MTCJ. However, this finding should be interpreted with caution as the translation 
across to healthy subjects of both sexes and the lack of statistical and clinically significant 
improvements for other lipid profile markers with MTCJ, renders the increase in HDL less 
important. The decline from mid- to post-supplementation suggests that administering cherry 
interventions longer than 10 days does not maintain elevated HDL concentrations, but rather a 
return to baseline as supported by findings from Kelley et al. (2006), Ataie‐Jafari et al. (2008), 
Martin et al. (2010) and Lynn et al. (2014).   
Finally, limitations associated with this study include the overnight fast dietary restriction put 
in place to reduce intra- and inter-individual variability, but at the expense of upholding 
ecological validity. Secondly, previous research which demonstrated improvements in body 
mass, fat mass and metabolic function required participants to exercise at FATMAX 2-4 times 
per week for 2-12 months (Brun, Romain and Mercier, 2011). Thus, MTC phytochemicals 
were not able to compound upon any cellular and molecular adaptations promoting fat 
oxidation which may have occurred with FATMAX training. Thirdly, the small sample size 
did not assist the ability to find significant differences with MTCJ as post-hoc power analysis 
suggested the study was underpowered (1-β = 0.18; α = 0.05; n = 11) for detecting a significant 
interaction between condition and time (pre-, mid-, post-supplementation) for fat oxidation 
during one-hour sub-maximal exercise. Additionally, due to the differences in viscosity of the 
placebo and MTCJ, 9/11 participants correctly identified which supplement they were provided 
when asked at the end of the study. Consequently, this may have contributed to the lack of 
significance between conditions as participants could manipulate their activity during the 
study. This highlights a limitation of juice concentrate as a form of supplementation and 
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perhaps alternative forms such as capsules are preferable to uphold anonymity between 
conditions. 
Future work should attempt to elucidate the cellular and molecular mechanisms, in humans to 
provide a basis upon which theories explaining the obtained responses can be either accepted 
or refuted. This would provide crucial information by which supplementation strategies can be 
altered to maximise the efficacy of MTCJ. Based on Cook's et al. (2015) findings, it would be 
appropriate to suggest that any effect of anthocyanin supplementation on fat oxidation is short-
term and provides a rationale to acutely supplement MTC in future studies. The augmentation 
of fat oxidation with acute supplementation may then contribute to mitigating the development 
of cardio-metabolic symptoms in clinical populations such as those with MetS. 
4.5. Conclusion 
This was the first study to examine the effect of cherry supplementation on fat oxidation rates 
at rest and during exercise. Findings showed that MTCJ did not significantly increase fat 
oxidation rates at rest or during FATMAX exercise. Additionally, secondary cardio-metabolic 
markers were also not significantly different with MTCJ supplementation, indicating this 
intervention does not act as a CRM in healthy participants. Consequently, it is unnecessary for 
healthy participants to supplement MTCJ to improve cardio-metabolic biomarkers. Previous 
studies to report a significant response to cherry supplementation in animal (Seymour et al., 
2008, 2009; Wu et al., 2014) and human (Ataie‐Jafari et al., 2008; Martin et al., 2010; Keane 
et al., 2016bc) studies occurred when initial values were abnormal, thus further research is 
warranted in clinical populations, including MetS.  
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5.1. Introduction 
Substantial literature exists (Basu et al., 2009, 2011; Basu et al., 2010; Basu and Lyons, 2012; 
Stull et al., 2015; Amiot, Riva and Vinet, 2016; Vendrame et al., 2016), as shown in section 
2.2.5.2.2.1, that highlights consumption of anthocyanin-rich dietary interventions are 
beneficial for mitigating symptoms associated with MetS, despite findings from chapter 4. 
Montmorency tart cherries (MTC) may be one such intervention not only rich in anthocyanins, 
but also other phenolics resulting in being one of the most potent dietary anti-oxidant 
interventions when consumed in habitual portion sizes (Ou et al., 2012). The anti-oxidative 
properties of MTC may only be beneficial in the presence of a pro-oxidant balance, therefore 
as oxidative stress is typical in humans with MetS (Chiva-Blanch and Badimon, 2017), the 
anti-oxidant hypothesis may be a potential mechanism by which MTC may improve MetS 
symptoms. This study proceeded to explore the potential beneficial effects of MTC on cardio-
metabolic function by addressing some of the issues encountered in chapter 4. Specifically, 
recruitment of participants with MetS possessing some cardio-metabolic dysfunction rather 
than healthy participants. Secondly, acute administration of supplements to coincide with the 
pharmacokinetics of MTC phytochemicals as previously conducted by Keane et al. (2016ab). 
Based on findings from Keane et al. (2016b) this study acutely administered Montmorency 
Tart Cherry Capsules (MTCC), for the first time in a clinical health study, and Montmorency 
Tart Cherry Juice (MTCJ) and assessed responses on blood-based and functional cardio-
metabolic markers. Lastly, to determine whether the high carbohydrate content present in 
MTCJ affects glycaemic, insulinaemic and lipaemic metabolism, by comparing responses to 
the lower carbohydrate MTCC supplements for the first time.  
As mentioned in section 2.2.4, MetS encompasses a cluster of cardio-metabolic conditions 
including insulin resistance, central adiposity, dyslipidaemia and pre-hypertension (Kaur, 
2014). The presence of three or more of these symptoms combined, augments the incidence of 
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chronic diseases such as CVD by 2-fold and T2D by 5-fold (Falkner and Cossrow, 2014). 
Ultimately, this highlights the strong association between MetS and higher rates of both 
cardiovascular and total mortality (Falkner and Cossrow, 2014). 
Despite the difficulty in measuring MetS prevalence rates, it is accepted that global rates are 
on the rise (O’Neill and O’Driscoll, 2015). In the UK, current indications suggest 
approximately 25% of the population >20 years of age have MetS (Scuteri et al., 2015), 
equating to ~12 million individuals. In the United States [~35% MetS prevalence rate (Aguilar 
et al., 2015)], low fruit and vegetable intake accounted for 15.1% of all diet-related cardio-
metabolic deaths (Micha et al., 2017). Therefore, fruit and vegetables rich in polyphenols, 
especially anthocyanins, are attractive interventions against cardio-metabolic disease risk 
factors (Vendrame et al., 2016) such as insulin resistance (Muraki et al., 2013), dyslipidaemia 
(Liu et al., 2016), hypertension (Del Rio et al., 2013) and central adiposity (Bertoia et al., 
2016); as supported by epidemiological evidence (Arts and Hollman, 2005; Wallace, 2011; 
Cassidy et al., 2013). 
Given the promising evidence provided above, the present study set out to determine whether 
acute administration of MTC could improve cardio-metabolic function in individuals with 
MetS. To the authors knowledge, no study has been conducted assessing the responses of 
humans with MetS to MTC supplementation, however individual aspects of the MetS cluster 
have been explored in pathological populations. Keane et al. (2016b) showed significant 
reductions in systolic blood pressure (SBP) after acute ingestion of MTCJ in early-hypertensive 
males. Additionally, Martin et al. (2010, 2011) demonstrated significant reductions in serum 
triglycerides, triglyceride/HDL ratio and VLDL concentrations after 4 weeks tart cherry juice 
supplementation (230 mL.day-1) in participants with central adiposity and dyslipidaemia. 
Moreover, Ataie-Jafari et al. (2008) reported 6 weeks concentrated sour cherry juice 
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supplementation improved HbA1c, in females with T2D, along with total cholesterol and LDL 
in those participants with hyperlipidaemia.  
As previously eluded to in section 2.1.6.2, the anthocyanin pharmacokinetics after consuming 
whole Montmorency tart cherries (Seymour et al., 2014) followed the general pattern and time-
course of anthocyanin metabolism (Kay, Mazza and Holub, 2005); parent anthocyanin 
concentrations in plasma peaked 2-4 hours post-ingestion and excretion rates in urine peaked 
6-8 hours post-ingestion. The pharmacokinetics of anthocyanins and metabolites derived from 
powdered freeze-dried MTC are currently unknown when administered in encapsulated form, 
but it is anticipated that their bioavailability may be enhanced. Hydroxypropyl methylcellulose 
(HPMC) is a material used to form the shell of capsules, and both in vitro (Glube, Moos and 
Duchateau, 2013) and in vivo (Lown et al., 2017) studies have demonstrated disintegration of 
HPMC 30 minutes post-ingestion in the presence of intestinal fluid. This material has 
previously been shown to delay the release of green tea catechins (Glube, Moos and Duchateau, 
2013) and mulberry extract anthocyanins (Lown et al., 2017) which consequently delayed 
glucose and insulin responses until 30 minutes after ingestion, coinciding with the 
disintegration and dissolution of the capsule shell (Lown et al., 2017). Capsules as a delivery 
vehicle of phytochemicals to target tissues via systemic circulation are useful as they are 
programmed to selectively degrade once in the gastrointestinal tract, therefore potentially 
maximising bioavailability (Oidtmann et al., 2012). This is achieved due to protection of 
phytochemicals by the exterior capsule shell against factors known to influence their 
stability such as pH, temperature, light, enzymes (particularly in saliva) and sugars (Robert 
and Fredes, 2015). It has been previously eluded to in chapter 2, that phytochemical, 
particularly anthocyanin bioavailability is notoriously poor (Kay, 2006). Subsequently, MTCC 
was provided to assess whether encapsulation, and thus protection of MTC phytochemicals 
from premature degradation, potentially maximises bioavailability and therefore their 
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beneficial effects on cardio-metabolic function. Finally, anthocyanin research on their anti-
oxidant effect suggests that lower concentrations, based on the concept of hormesis, are more 
effective at inducing cellular, molecular and thus functional changes to improve health 
(Wallace, 2011). The delivery of a lower dose in this study (30 mL MTCJ) also has practical 
and financial benefits to consumers. 
Based around the pharmacokinetics of MTC phytochemicals, this study aimed to explore the 
short-term responses to acute supplementation of MTCJ and MTCC on cardiac 
haemodynamics, arterial stiffness by pulse wave analysis (PWA), substrate metabolism and 
various blood-based cardio-metabolic biomarkers in humans with MetS. Given that these 
subjects present at least three or more risk factors resulting in a holistic state of cardio-
metabolic dysregulation, it was hypothesised that the MTC interventions would have positive 
responses on various diagnostic cardio-metabolic markers, in particular glucose, lipids and 
SBP based on previous human studies with tart cherry supplementation (Keane et al. 2016b; 
Martin et al., 2010; Ataie-Jafari et al., 2008). Furthermore, it was hypothesised that MTCC 
would be more effective than MTCJ or placebo in mediating these benefits, as MTCC would 
induce less glycaemic, insulinaemic and lipaemic stress, and bioavailability of phytochemicals 
was anticipated to be superior. 
Pharmacokinetic studies comparing 30 and 60 mL MTC concentrate consumption in healthy 
humans (Bell et al., 2014b; Keane et al., 2016a), suggested a physiological dose-response 
effect of circulating parent anthocyanins and secondary phenolic acid metabolites. Hence,    
Part B of this study aimed to compare whether a dose-response effect would be observed on 
cardio-metabolic biomarkers in individuals with MetS. The rationale for this arm of the study 
was based on previous literature reporting beneficial cardiovascular responses to an acute         
60 mL dose of MTC concentrate (Keane et al., 2016bc). It was hypothesised that a dose-
response effect would be observed for cardio-metabolic biomarkers in individuals with MetS. 
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5.2. Methods 
5.2.1. Part A 
5.2.1.1. Participants  
Eleven (6 males and 5 females) participants with Metabolic Syndrome (MetS) (Tables 5.1 and 
5.2) volunteered for this pilot study. All participants were screened for MetS prior to formal 
inclusion onto the study according to the harmonised criteria outlined by Alberti et al. (2009), 
where 3 of the 5 qualifying criteria [Waist Circumference: ethnicity and sex specific criteria; 
Fasting Triglycerides: ≥1.69 mmol.L-1; Fasting High-Density Lipoprotein: <1.03 mmol.L-1 
(men), <1.29 mmol.L-1 (women); Blood Pressure: ≥130 mmHg SBP or ≥85 mmHg DBP; 
Fasting Glucose: ≥5.6 mmol.L-1] had to be met. Recruitment (Figure 5.1) was conducted via 
word of mouth, flyers and email advertisements. Participants were excluded from the study if 
they did not meet the criteria for MetS at screening, were smokers, pregnant, heavy alcohol 
consumers (>14 units per week), current or previous diagnosis of chronic disease 
(gastrointestinal, cardiovascular, hepatic or renal), or were on statins, hyperlipidaemic, anti-
hypertensive, anti-diabetic, anti-inflammatory or steroidal medication. Verbal and written 
information was provided to all participants regarding the study purpose and procedures. 
Ethical approval was obtained from the University of Hertfordshire Health, Science, 
Engineering and Technology Ethics Committee and informed consent was provided by all 
participants prior to enrolment. This study was registered as a clinical trial on clinicaltrials.gov 
(NCT03615885). 
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AU (Arbitrary Units); BMI (Body Mass Index); HOMA2-IR (Homeostatic Model Assessment of Insulin 
Resistance); HOMA2-β (Homeostatic Model Assessment of pancreatic β-cell function); HOMA2-%S 
(Homeostatic Model Assessment of Insulin Sensitivity). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5.1. Selected baseline characteristics obtained during screening (n = 11). 
Characteristics Mean ± SD 
Age (years) 49 ± 12 
Stature (m) 1.72 ± 0.11 
Body Mass (kg) 99.5 ± 20.5 
BMI (kg.m-2) 33 ± 5 
Whole-body Fat (%) 38 ± 10 
Trunk Fat (%) 34 ± 13 
Fat Mass (kg) 41 ± 17 
Fat Free Mass (kg) 58 ± 15 
Fasting Total Cholesterol (mmol.L-1) 3.83 ± 0.91 
Fasting Insulin (pmol.L-1) 115.67 ± 73.75 
HOMA2-IR (AU) 2.2 ± 1.4 
HOMA2-β (%) 132.5 ± 52.9 
HOMA2-%S (%) 60.4 ± 27.3 
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Table 5.2. Individual baseline characteristics of MetS criteria obtained during screening (n = 11). 
DBP (Diastolic Blood Pressure); HDL (High-density Lipoprotein); SBP (Systolic Blood Pressure). 
 
 
 
 
 
 
 
  Participant 
Characteristics Mean ± SD 1 2 3 4 5 6 7 8 9 10 11 
Waist 
Circumference 
(cm) 
106.0 ± 13.4 102.2* 133* 93 90.8 119* 119* 95 104.1* 94 112* 104* 
Fasting Glucose 
(mmol.L-1) 
5.63 ± 0.76 6.20* 5.33 6.72* 4.48 5.93 6.50* 6.21* 5.12 5.78 4.85 4.79 
Fasting 
Triglycerides 
(mmol.L-1) 
1.9 ± 0.5 1.9* 2.0* 2.6* 1.7* 0.9 1.5 2.6* 2.1* 2.0* 2.1* 1.5 
Fasting HDL 
(mmol.L-1) 
1.23 ± 0.36 2.23 1.25 1.22* 0.94* 1.23* 0.83* 1.19* 1.30 1.06* 1.28* 1.01* 
SBP (mmHg) 132 ± 9 122 146* 130* 130* 136* 143* 129 132* 142* 120 126 
DBP (mmHg) 80 ± 9 67 90* 86* 87* 79 91* 72 72 88* 67 85* 
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Figure 5.1. CONSORT flow diagram of the participants recruited, screened, tested, analysed 
and excluded during the course of the study. 
 
Assessed for eligibility (n = 43) 
Excluded (n = 30) 
   Not meeting inclusion criteria (n = 27) 
   Declined to participate (n = 3) 
Analysed (n = 11) 
 
Allocated to Placebo intervention (n=5) 
 Received allocated intervention (n=5) 
 Not received allocated intervention (n=0) 
Allocation 
1 
Analysis 
Randomised (n = 13) 
Enrolment 
Allocated to MTCJ intervention (n=4) 
 Received allocated intervention (n=4) 
 Not received allocated intervention (n=0) 
Allocated to MTCC intervention (n=4) 
 Received allocated intervention (n=4) 
 Did not receive allocated intervention (n=0) 
Allocation 
2 
Allocation 
3 
Allocated to Placebo intervention (n=4) 
 Received allocated intervention (n=3) 
 Not received allocated intervention (n=1) 
(Participant dropped out for personal reasons) 
Allocated to MTCC intervention (n=5) 
 Received allocated intervention (n=4) 
 Did not receive allocated intervention (n=1) 
(Participant dropped out for personal reasons) 
 
Allocated to Placebo intervention (n=4) 
 Received allocated intervention (n=4) 
 Not received allocated intervention (n=0) 
Allocated to MTCJ intervention (n=4) 
 Received allocated intervention (n=4) 
 Not received allocated intervention (n=0) 
Allocated to MTCC intervention (n=3) 
 Received allocated intervention (n=3) 
 Did not receive allocated intervention (n=0) 
Allocated to MTCJ intervention (n=4) 
 Received allocated intervention (n=4) 
 Not received allocated intervention (n=0) 
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5.2.1.2. Procedures 
5.2.1.2.1. Research Design 
A single-blind (blinded to participant), placebo-controlled, randomised, crossover design was 
utilised; each participant acted as their own control. During the 6-week study duration, all 
participants completed 3 testing sessions during which one of three [placebo (PLA) or MTCJ 
or MTCC] different supplements were provided each time. As in chapter 4, a 14-day washout 
period (Keane et al., 2016b; Cook et al., 2015; Howatson et al., 2012) was incorporated 
between testing sessions and between the screening and first testing sessions.  
Testing sessions lasted 6 hours and were identical in terms of design and testing procedures. 
Schematics of the overall study design and specific procedures during a testing session are 
depicted in Figure 5.2. Baseline anthropometric (stature, body mass, waist circumference, body 
fat percentage) and functional (PWA, cardiac haemodynamics, RMR) measurements were 
obtained prior to consumption of the supplement. Functional measurements were recorded at 
30 minutes, 1, 2, 3, 4- and 5-hours post-bolus. Blood sampling was performed at baseline, 1, 
3- and 5-hours post-bolus only.  
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Figure 5.2. (A) Schematic representation of the overall study design. (B) Schematic 
representation of the specific procedures during each testing session. 
 
 
 
 
 
A) 
B) 
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5.2.1.2.2. Dietary Guidelines 
Refer to general methodology section 3.2 for further details on dietary guidelines employed in 
this study. 
All participants complied with dietary guidelines upon analysis for percentage contributions of 
macronutrients to total energy intake [(protein 16 ± 23%), (CHO 45 ± 56%), (fat 39 ± 38%)], 
total polyphenols (70 ± 83 mg) and anthocyanins (26 ± 22 mg). 
5.2.1.2.3. Supplementation 
This study acutely administered three different supplements including a placebo which acted 
as the control condition and two experimental conditions, MTCJ and MTCC. The placebo was 
composed of 30 mL commercially available fruit-flavoured cordial (Cherries and Berries, 
Morrisons, Bradford, UK) mixed with 100 mL water. The placebo drink was also matched 
against MTCJ for energy content, taste and visual appearance by adding a flavourless 
carbohydrate (Maltodextrin, My Protein Ltd, Northwich, UK), citric acid (100% Pure Citric 
Acid, VB and Sons, UK), red and black food colouring (Morrisons, Bradford, UK), 
respectively. MTCJ consisted of 30 mL Montmorency tart cherry concentrate (Cherry Active, 
Active Edge Ltd, Hanworth, UK) and 100 mL water. To match the anthocyanin content of 
MTCJ, participants consumed 10 Montmorency tart cherry capsules (Cherry Active Capsules, 
Active Edge, Ltd, Hanworth, UK) with 130 mL water. Each capsule contained 435 mg of 
freeze-dried Montmorency tart cherry skin powder, with Table 5.3 detailing nutritional 
analysis. Based on the ease of distinguishing between PLA and MTCJ in chapter 4, further 
anonymity of the supplementation was ensured in chapter 5 by blinding the participants to the 
source of anthocyanins. This was achieved by explaining that an ‘anthocyanin-rich 
supplement’ would be provided rather than disclosing Montmorency tart cherries as the 
specific source. Further anonymity was placed by indicating to participants placebo capsules 
may be provided. Only 2/11 participants correctly identified the interventions provided 
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(intervention or placebo) and none identified the intervention as ‘cherry’ or ‘containing 
cherries’ (either sweet or tart). Refer to section 3.3 for more information on supplementation. 
Table 5.3. Nutritional information of each supplement provided. 
 Montmorency tart 
cherry concentrate  
(per 30 mL) 
Montmorency tart 
cherry capsules  
(per capsule – 435 mg) 
Placebo  
(per 130 mL) 
Energy (kcal) 102 1.3 102 
Carbohydrate (g) 24.5 0.3 25.35 
of which sugars (g) 17.9 0.1 25.32 
Protein (g) 1.1 Trace 0.03 
Fat (g) 0 Trace 0 
of which saturates (g) 0 0 0 
Fibre (g) 2.6 Trace Trace 
Salt (g) 0 Trace 0 
Total Anthocyanins 
(mg) 
270 27 0 
 
5.2.1.2.4. Measures and Equipment 
5.2.1.2.4.1. Anthropometrics 
Refer to general methodology section 3.5.1 for details on procedures of measuring stature, body 
mass and waist circumference.  
Refer to general methodology section 3.5.2 for details on procedures of measuring segmental 
body composition. 
5.2.1.2.4.2. Cardiac Haemodynamics 
Refer to general methodology section 3.5.3.1 for details on procedures for obtaining cardiac 
haemodynamic measurements. 
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5.2.1.2.4.3. Blood Pressure 
Refer to general methodology section 3.5.3.2 for details on procedures for obtaining blood 
pressure measurements. 
5.2.1.2.4.4. Pulse Wave Analysis 
Refer to general methodology section 3.5.3.3 for details on procedures for obtaining PWA 
measurements. 
5.2.1.2.4.5. Resting Metabolic Rate 
Refer to general methodology section 3.5.4 for details on procedures for obtaining RMR 
measurements. 
In addition to values for RER and EE (kcal.day-1), resting fat and carbohydrate oxidations rates 
were also calculated at all time points. 
5.2.1.2.5. Blood Sampling and Analysis 
5.2.1.2.5.1. Blood Sampling 
Refer to general methodology section 3.6.1 for details on blood sampling procedures.  
Due to logistical difficulties, blood sampling through cannulation was not possible, therefore 
venous blood was sampled through 4 individual venepunctures (one at each time point: pre-
bolus and 1, 3, 5-hours post-bolus). A total of 5 mL venous blood was collected into serum-
separation tubes for each sample.   
Pilot work was initially conducted to calculate PVC from haemoglobin and haematocrit 
obtained from whole blood sampled into EDTA tubes. Due to the resting nature of the study 
and replicating total water consumption for each session, there was no change (P > 0.05) in 
plasma volume between time points (pre-bolus and 1, 3, 5-hours post-bolus) and sessions, thus 
biomarker concentrations in assays were not corrected for PVC. In support of this, Keane et al. 
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(2016b) sufficiently controlled PVC through replicating water consumption and thus did not 
correct biomarker concentrations for PVC during their 8-hour protocol. 
5.2.1.2.5.2. Glucose 
Refer to general methodology section 3.6.2 for details on performing glucose analysis. 
Overall intra-individual and inter-individual CV were 1.93% and 13.43%, respectively. 
5.2.1.2.5.3. Insulin and Insulin Resistance and Sensitivity Indexes 
Refer to general methodology section 3.6.8 for details on performing insulin analysis. 
Inter- and intra-plate CV were 9.1% and 7.8%, respectively. 
Refer to general methodology section 3.6.8.1 for details on insulin resistance and sensitivity 
analysis. 
5.2.1.2.5.4. Triglycerides 
Refer to general methodology section 3.6.4 for details on performing triglyceride analysis. 
Overall intra-individual and inter-individual CV were 2.33% and 5.94%, respectively. 
5.2.1.2.5.5. Total Cholesterol 
Refer to general methodology section 3.6.5 for details on performing total cholesterol analysis. 
Overall intra-individual and inter-individual CV were 4.45% and 5.63%, respectively. 
5.2.1.2.5.6. HDL 
Refer to general methodology section 3.6.6 for details on performing HDL analysis. 
Overall intra-individual and inter-individual CV were 3.63% and 6.12%, respectively. 
5.2.1.2.5.7. Total Cholesterol:HDL Ratio 
Refer to general methodology section 3.6.7 for details on performing TC:HDL analysis. 
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5.2.1.2.5.8. LDL 
LDL was determined indirectly using the Friedewald formula (Friedewald, Levy and 
Fredrickson, 1972). 
5.2.1.3. Data Analysis 
Statistical analysis was performed using SPSS v22.0 (IBM, Chicago, USA) where data are 
reported as mean ± standard deviation (±SD). Data normality was checked using a Shapiro-
Wilk test. Greenhouse-Geisser correction was applied upon violation of Mauchly’s test of 
sphericity for ANOVAs (P < 0.05). Statistical significance was set at P < 0.05. Due to this 
being a pilot study and the lack of prior data on the effects of MTC products in humans with 
MetS from which to conduct power calculations, a minimum sample size of 10 was established 
(Udani et al., 2011). 
To account for day-to-day physiological variances at pre-bolus between conditions for each 
variable, data was analysed as change from pre-bolus for each time point measured post-bolus. 
This enabled a fair assessment of the post-bolus responses to each condition from pre-bolus 
across all variables. The pre-bolus time point was not included as a covariate, as one-way 
ANOVA analysis indicated no significant differences between conditions (P > 0.05) for all 
variables at the pre-bolus time point, hence two-way repeated-measures ANOVA was 
performed.  
A within-group two-way, 3 x 6, condition (PLA vs MTCC vs MTCJ) x time (30 minutes, 1, 2, 
3, 4- and 5-hours post-bolus), repeated-measures ANOVA design with post-hoc Bonferroni 
adjustment, measured differences for SBP, DBP, RMR, cardiac haemodynamic and PWA 
parameters on change from pre-bolus values for each condition. 
Blood-based biomarkers were analysed using the same model but with a 3 x 3, condition (PLA 
vs MTCJ vs MTCC) by time (1, 3- and 5-hours post-bolus) design on change from pre-bolus 
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values for each condition. A paired-samples t-test was used to identify differences between 
individual data points within conditions and between conditions for the corresponding time 
point.  
Partial Eta-Squared (
2
partial ) was used to report effect sizes for ANOVA where effects were 
classified as small (0.01-0.08), moderate (0.09-0.25) and large (>0.25) (Cohen, 1998). Cohen’s 
d effect size was used for paired-samples t-test and post-hoc interaction comparisons where 
effects were classified as no effect (0-0.1), small (0.2-0.4), moderate (0.5-0.7) and high (≥0.8) 
(Cohen, 1998). 
Bivariate correlations were performed between SBP and PWA parameters on change from pre-
bolus data for each time point measured post-bolus. Coefficients were classified as                 
weak (0.1-0.2), moderate (0.3-0.5), strong (>0.5) (Cohen, 1988).  
5.2.2. Part B 
5.2.2.1. Participants 
Six (4 male and 2 female) participants with MetS (Tables 5.4 and 5.5) from the original cohort 
in Part A volunteered for this additional arm of the study. 
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AU (Arbitrary Units); BMI (Body Mass Index); HOMA2-IR (Homeostatic Model Assessment of Insulin 
Resistance); HOMA-β (Homeostatic Model Assessment of pancreatic β-cell function); HOMA2-%S 
(Homeostatic Model Assessment of Insulin Sensitivity). 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5.4. Baseline characteristics obtained during screening of all participants (n = 6). 
Characteristics Mean ± SD 
Age (years) 53 ± 13 
Stature (m) 1.76 ± 0.13 
Body Mass (kg) 106.4 ± 25.0 
BMI (kg.m-2) 34 ± 6 
Whole-body Fat (%) 33 ± 7 
Trunk Fat (%) 31 ± 12 
Fat Mass (kg) 40 ± 14 
Fat Free Mass (kg) 57 ± 16 
Fasting Total Cholesterol (mmol.L-1) 3.86 ± 0.33 
Fasting Insulin (pmol.L-1) 104.50 ± 20.04 
HOMA2-IR (AU) 2.0 ± 1.1 
HOMA2-β (%) 106.1 ± 41.1 
HOMA2-%S (%) 64.6 ± 35.2 
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Table 5.5. Individual baseline characteristics of MetS criteria obtained during screening (n = 6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
DBP (Diastolic Blood Pressure); HDL (High-density Lipoprotein); SBP (Systolic Blood Pressure). 
  Participant 
Characteristics Mean ± SD 1 2 3 4 5 6 
Waist Circumference 
(cm) 
109.6 ± 13.9 102.2* 133* 119* 95 104.1* 104* 
Fasting Glucose 
(mmol.L-1) 
5.69 ± 0.70 6.20* 5.33 6.50* 6.21* 5.12 4.79 
Fasting Triglycerides 
(mmol.L-1) 
1.9 ± 0.4 1.9* 2.0* 1.5 2.6* 2.1* 1.5 
Fasting HDL 
(mmol.L-1) 
1.30 ± 0.49 2.23 1.25 0.83* 1.19* 1.30 1.01* 
SBP (mmHg) 133 ± 10 122 146* 143* 129 132* 126 
DBP (mmHg) 80 ± 10 67 90* 91* 72 72 85* 
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5.2.2.2. Procedures 
The same procedures as in Part A were used during this arm, except for the supplement 
provided. Additionally, due to an equipment malfunction, RMR was not measured in this arm. 
5.2.2.2.1. Supplementation 
This arm acutely administered MTCJ composed of 60 mL MTC concentrate (Cherry Active, 
Active Edge Ltd, Hanworth, UK) and 100 mL water (MTCJ60) (refer to Table 5.6 for 
nutritional information comparing MTCJ60 to PLA, MTCC and MTCJ). As in Part A, 
anonymity was achieved by explaining to participants that a placebo or ‘anthocyanin-rich 
supplement’ would be provided; Montmorency tart cherries as the specific source was not 
disclosed. Further anonymity was placed by indicating to participants placebo capsules may be 
provided. Only 1/6 participants correctly distinguished between placebo and the interventions 
provided. 
Table 5.6. Nutritional information of 60 mL Montmorency tart cherry concentrate against other 
supplements previously provided. 
 MTC 
concentrate  
(per 60 mL) 
MTC 
concentrate  
(per 30 mL) 
MTC capsules  
(per capsule – 435 
mg) 
Placebo  
(per 130 mL) 
Energy (kcal) 204 102 1.3 102 
Carbohydrate (g) 49 24.5 0.3 25.35 
of which sugars (g) 35.8 17.9 0.1 25.32 
Protein (g) 2.2 1.1 Trace 0.03 
Fat (g) 0 0 Trace 0 
of which saturates (g) 0 0 0 0 
Fibre (g) 5.2 2.6 Trace Trace 
Salt (g) 0 0 Trace 0 
Total Anthocyanins 
(mg) 
540 270 27 0 
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5.2.2.3. Data Analysis 
The same statistical tests were performed as in section 5.2.1.3, with slight differences due to 
study design.  
As in Part A, to account for day-to-day physiological variances at pre-bolus between conditions 
for each variable, data was analysed as change from pre-bolus for each time point measured 
post-bolus. 
A within-group two-way, 4 x 6, condition (PLA vs MTCC vs MTCJ vs MTCJ60) x time (30 
minutes, 1, 2, 3, 4- and 5-hours post-bolus), repeated-measures ANOVA design with post-hoc 
Bonferroni adjustment, measured differences of SBP, DBP, RMR, cardiac haemodynamic and 
PWA parameters.  
Blood-based biomarkers were analysed using the same model but with a 4 x 3, condition (PLA 
vs MTCJ vs MTCC vs MTCJ60) by time (1, 3- and 5-hours post-bolus) design on change from 
pre-bolus values for each condition. A paired-samples t-test was used to identify differences 
between individual data points within conditions and between conditions for the corresponding 
time point.  
Bivariate correlations were performed between SBP and PWA parameters on change from pre-
bolus data for each time point measured post-bolus. Coefficients were classified as                 
weak (0.1-0.2), moderate (0.3-0.5), strong (>0.5) (Cohen, 1988).  
Statistical analysis was only conducted on data obtained from the same six participants enrolled 
in Parts A and B. Given the small sample size in this arm, individual physiological responses 
were compared between interventions in addition to the aforementioned statistical analysis. 
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5.3. Results  
The present study measured variables relevant to MetS, and as the defining aspect is insulin 
resistance, serum insulin and glucose were regarded as primary endpoints. Other variables 
focused on the other two main aspects of MetS, cardiovascular dysfunction and 
lipidaemia. Raw data for all variables from Part A are provided in Appendix 4. 
5.3.1. Part A 
5.3.1.1. Blood Biomarkers 
Analysis of change from pre-bolus responses for serum insulin (Figure 5.3) showed a 
significant main effect for condition (F(2, 20) = 3.653; P = 0.044, 
2
partial  = 0.27), time            
(F(1.07, 10.67) = 13.411; P < 0.001, 
2
partial  = 0.57) and interaction (F(4, 40) = 5.837; P = 0.001, 
2
partial  = 0.37). Post-hoc comparisons on the interaction indicated PLA (60.84 ± 54.34 
pmol.L-1) increased significantly more for the change from pre-bolus to 1-hour post-bolus 
compared to MTCC (-9.86 ± 22.78 pmol.L-1) (P = 0.016, d = 1.70). A significantly different 
response was also observed for the change from pre-bolus to 3-hours post-bolus between PLA 
(-8.99 ± 39.53 pmol.L-1) and MTCJ (-48.80 ± 50.01 pmol.L-1) (P = 0.028, d = 0.88). Post-hoc 
analysis on the main effect for condition showed PLA (12.01 ± 41.60 pmol.L-1) increased 
significantly more (P = 0.039) than MTCJ (-18.01 ± 44.31 pmol.L-1). The change from 1-hour 
to 3-hours post-bolus was significant between PLA and MTCC (t(10) = -2.295; P = 0.045,             
d = 0.85) and between MTCJ and MTCC (t(10) = 3.361; P = 0.007, d = 1.06). The mean post-
bolus change was lower in 9/11 participants with MTCC compared to PLA. 
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Figure 5.3. Response curves for the mean (±SD) change in insulin concentrations from pre-
bolus values to time points post-bolus for each condition. *Denotes significant difference 
between PLA and MTCC at 1-hour time point. ^Denotes significant difference between PLA 
and MTCJ at 3-hour time point. $Denotes significant difference for change in insulin from 1-3 
hours post-bolus between PLA and MTCJ against MTCC. Statistical analysis performed by a 
two-way, RM-ANOVA with post-hoc Bonferroni adjustment (P < 0.05). 
 
A tendency towards significance was observed for the interaction (F(4, 40) = 2.112; P = 0.097, 
2
partial  = 0.17) for LDL (Table 5.7). Statistical analysis for total cholesterol                           
(F(1.159, 11.587) = 6.470; P = 0.023, 
2
partial  = 0.39), indicated a main effect for time only, with 
post-hoc identifying differences between 1-hour (P = 0.039, d = 0.62) and 3-hours (P < 0.001, 
d = 0.44) compared to 5-hours post-bolus (Table 5.7). No significant interaction and main 
effects for condition or time were detected for glucose, triglycerides, HDL or TC:HDL                
(P > 0.05) (Table 5.7).  
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Table 5.7. Mean ± SD change from pre-bolus values to post-bolus time points for selected blood-
based biomarkers per treatment condition. 
  Post-bolus Time Points 
  1 hr 3 hr 5 hr 
Glucose 
(mmol.L-1) 
PLA 0.35 ± 1.67 -0.58 ± 0.85 -0.63 ± 0.67 
MTCC -0.11 ± 0.36 -0.22 ± 0.58 -0.28 ± 0.77 
MTCJ -0.22 ± 0.68 -0.79 ± 0.95 -0.72 ± 1.22 
Triglycerides 
(mmol.L-1) 
PLA 0.1 ± 0.2 0.1 ± 0.4 0.2 ± 0.4 
MTCC -0.1 ± 0.2 -0.1 ± 0.4 -0.1 ± 0.3 
MTCJ -0.1 ± 0.3 0.0 ± 0.2 0.1 ± 0.4 
Total 
Cholesterol*$ 
(mmol.L-1) 
PLA 0.04 ± 0.28 0.16 ± 0.47 0.29 ± 0.40 
MTCC -0.16 ± 0.51 -0.16 ± 0.59 0.15 ± 0.64 
MTCJ -0.05 ± 0.25 -0.03 ± 0.18 0.13 ± 0.21 
HDL (mmol.L-1) 
PLA -0.12 ± 0.19 -0.10 ± 0.16 -0.18 ± 0.19 
MTCC -0.05 ± 0.16 -0.04 ± 0.10 -0.03 ± 0.17 
MTCJ -0.07 ± 0.12 0.01 ± 0.11 -0.09 ± 0.17 
TC:HDL (AU) 
PLA 0.27 ± 0.39 0.31 ± 0.54 0.70 ± 0.64 
MTCC 0.30 ± 0.72 0.07± 0.55 0.39 ± 0.64 
MTCJ 0.19 ± 0.43 -0.04 ± 0.40 0.42 ± 0.62 
LDL (mmol.L-1) 
PLA 0.25 ± 0.49 0.36 ± 0.59 0.70 ± 0.56 
MTCC 0.03 ± 0.71 -0.07 ± 0.85 0.06 ± 0.66 
MTCJ 0.08 ± 0.52 0.12 ± 0.33 0.24 ± 0.66 
AU (Arbitrary Units); HDL (High-density Lipoprotein); MTCC (Montmorency Tart Cherry Capsules); MTCJ 
(Montmorency Tart Cherry Juice); PLA (Placebo); TC (Total Cholesterol). *Denotes significant main effect for 
time with post-hoc identifying differences between 1-hour and 5-hours post-bolus. $Denotes significant main 
effect for time with post-hoc identifying differences between 3-hours and 5-hours post-bolus. 
5.3.1.2. Cardiac Haemodynamics 
No significant main effects for condition, time or the condition by time interaction were 
detected for SBP, DBP, MAP, SV, CO and TPR (P > 0.05) (Table 5.8). However, individual 
responses for the change from pre-bolus to 2-hours post-bolus showed only 3/11 participants 
with lower SBP after consuming PLA, while 6/11 participants had lower SBP after ingesting 
MTCC and 10/11 with MTCJ. The mean change between PLA (3 ± 7 mmHg) and MTCJ            
(-8 ± 6 mmHg) at 2-hours post-bolus was -11 mmHg (Figure 5.4). 
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HR responses revealed a significant interaction effect (F(10, 100) = 5.301; P < 0.001,              
2
partial  = 0.35). Post-hoc analysis displayed a tendency towards significance for HR at             
30 minutes post-bolus between PLA (-1 ± 3 beats.min-1) and MTCC (-5 ± 5 beats.min-1)                   
(P = 0.080, d = 0.27), where all 11 participants responded with lower HR at 30 minutes post-
bolus compared to pre-bolus with MTCC, whereas only 6 of 11 participants responded the 
same way with PLA. 
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Table 5.8.  Mean ± SD change from pre-bolus values to post-bolus time points for selected cardiac haemodynamic and PWA parameters per 
treatment condition. 
   Post-bolus Time Points 
  30 mins 1 hr 2 hr 3 hr 4 hr 5 hr 
Brachial DBP 
(mmHg) 
PLA 3 ± 4 5 ± 7 5 ± 5 8 ± 8 5 ± 7 4 ± 6 
MTCC 1 ± 9 4 ± 10 2 ± 10 0 ± 6 1 ± 9 3 ± 8 
MTCJ 3 ± 6 6 ± 4 3 ± 4 7 ± 6 6 ± 8 6 ± 5 
MAP  
(mmHg) 
PLA 1 ± 5 5 ± 7 5 ± 7 7 ± 9 5 ± 9 5 ± 9 
MTCC 3 ± 11 6 ± 10 2 ± 10 2 ± 6 1 ± 9 5 ± 8 
MTCJ 2 ± 3 2 ± 6 -4 ± 5 4 ± 7 4 ± 8 -2 ± 12 
Cardiac Output 
(L.min-1) 
PLA 0.11 ± 0.96 -0.02 ± 1.57 -0.31 ± 1.32 -0.58 ± 1.03 -0.53 ± 1.64 -0.35 ± 1.44 
MTCC -0.10 ± 0.68 -0.24 ± 0.99 -0.13 ± 1.15 0.03 ± 1.06 -0.31 ± 1.48 -0.21 ± 1.37 
MTCJ -0.33 ± 1.80 -0.46 ± 1.46 -0.04 ± 1.98 -0.34 ± 1.94 -0.62 ± 1.50 -0.61 ± 1.56 
Stroke Volume 
(mL) 
PLA 1 ± 15 -1 ± 19 -1 ± 15 -5 ± 19 -5 ± 24 2 ± 24 
MTCC 6 ± 11 -1 ± 17 4 ± 8 8 ± 13 1 ± 18 3 ± 20 
MTCJ 1 ± 27 -4 ± 19 1 ± 27 -4 ± 30 1 ± 24 2 ± 23 
TPR 
(mmHg·min-1·L) 
PLA 0.00 ± 0.21 0.15 ± 0.37 0.14 ± 0.31 0.26 ± 0.46 0.16 ± 0.27 0.09 ± 0.26 
MTCC 0.01 ± 0.17 0.09 ± 0.28 0.02 ± 0.37 0.08 ± 0.32 0.09 ± 0.39 0.12 ± 0.34 
MTCJ 0.08 ± 0.33 0.07 ± 0.27 -0.03 ± 0.38 0.10 ± 0.34 0.10 ± 0.28 0.11 ± 0.35 
        
HR  
(beats.min-1) 
PLA -1 ± 3 -3 ± 4 -5 ± 7 -5 ± 7 -7 ± 8 -7 ± 7 
MTCC -5 ± 5 -4 ± 5 -4 ± 7 -6 ± 7 -5 ± 10 -4 ± 10 
MTCJ 0 ± 5 -1 ± 5 -5 ± 6 -7 ± 5 -7 ± 4 -8 ± 6 
Aortic SBP 
(mmHg) 
PLA 1 ± 7 3 ± 8 4 ± 9 2 ± 11 4 ± 8 5 ± 5 
MTCC 2 ± 5 4 ± 9 4 ± 14 2 ± 10 2 ± 8 4 ± 6 
MTCJ -1 ± 8 -1 ± 8 -2 ± 7 1 ± 4 2 ± 7 3 ± 7 
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AIx at HR75 (Augmentation Index at Heart Rate 75 bpm); DBP (Diastolic Blood Pressure); HR (Heart Rate); MAP (Mean Arterial Pressure); mmHg (millimetres of Mercury); 
mmHg (millimetres of Mercury); MTCC (Montmorency Tart Cherry Capsules); MTCJ (Montmorency Tart Cherry Juice); PLA (Placebo); SEVR (Subendocardial Viability 
Ratio); TPR (Total Peripheral Resistance) *Denotes significant main effect for time with post-hoc identifying differences between 1-hour and 3-hours post-bolus. ^Denotes 
significant main effect for time with post-hoc identifying differences between 1-hour and 5-hours post-bolus. $Denotes significant main effect for time with post-hoc identifying 
differences between 3-hours and 5-hours post-bolus. 
Aortic DBP 
(mmHg) 
PLA 0 ± 6 0 ± 7 3 ± 14 3 ± 5 4 ± 7 2 ± 7 
MTCC 5 ± 6 3 ± 5 4 ± 8 0 ± 8 3 ± 7 6 ± 7 
MTCJ -2 ± 6 -2 ± 6 2 ± 4 1 ± 8 1 ± 7 1 ± 4 
Pulse Pressure  
(mmHg) 
PLA 1 ± 8 3 ± 8 1 ± 9 -1 ± 8 0 ± 6 3 ± 5 
MTCC -3 ± 7 1 ± 9 0 ± 7 2 ± 5 -1 ± 6 -2 ± 7 
MTCJ 1 ± 6 1 ± 5 -4 ± 4 0 ± 8 1 ± 6 2 ± 5 
AIx at HR75*^$  
(%) 
PLA 0 ± 4 -1 ± 3 2 ± 5 2 ± 5 3 ± 5 5 ± 5 
MTCC 0 ± 6 -1 ± 6 -2 ± 6 0 ± 5 2 ± 6 3 ± 7 
MTCJ 0 ± 4 -1 ± 7 -2 ± 7 -2 ± 7 0 ± 8 2 ± 7 
SEVR (%) 
PLA -1 ± 33 11 ± 20 15 ± 27 10 ± 21 16 ± 26 3 ± 21 
MTCC 15 ± 23 9 ± 16 17 ± 21 16 ± 22 19 ± 24 9 ± 22 
MTCJ 6 ± 26 8 ± 22 31 ± 32 24 ± 31 21 ± 31 12 ± 20 
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Figure 5.4. Mean (±SD) SBP, augmentation pressure (AP) and augmentation index (AIx) 
response curves from respective pre-bolus time points for each condition. 
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5.3.1.3. Pulse Wave Analysis 
A main effect for time (F(5, 50) = 7.84; P < 0.001, 
2
partial  = 0.44) only was observed for the 
change in AP from pre-bolus. Post-hoc analysis identified the change in AP was lower at both 
1-hour (P = 0.026, d = 0.63) and 2-hours post-bolus (P = 0.041, d = 0.81) against 5-hours post-
bolus. However, individual responses showed 7/11 participants responded with lower AP at   
2-hours post-bolus with MTCJ, compared to 2/11 participants with PLA (Figure 5.4). 
Similarly, only a main effect for time (F(5, 50) = 10.090; P < 0.001, 
2
partial  = 0.50) was observed 
for the change in AIx from pre-bolus. Post-hoc analysis showed AIx to be significantly higher 
at 5-hours post-bolus than all other post-bolus time points (P < 0.05), except 4-hours post-
bolus. Individual responses showed 9/11 participants reduced arterial stiffness at this time point 
compared to pre-bolus with MTCJ, while only 2/11 responded in this manner with PLA (Figure 
5.4). There were no significant correlations between SBP and AIx (ρ = 0.105; P = 0.401) or 
AP (ρ = 0.145; P = 0.247) at 2-hours post-bolus for MTCJ. 
No significant main effects for condition, time or interaction were detected for aortic SBP, 
aortic DBP, and pulse pressure (P > 0.05). A main effect for time was detected for AIx at HR75 
(F(5, 50) = 7.747; P < 0.001, 
2
partial  = 0.44) and SEVR (F(5, 50) = 3.903; P = 0.005,                   
2
partial  = 0.28) (Table 5.8). Post-hoc analysis identified the change in AP was lower at             
30-minutes (P = 0.037, d = 0.64), 1-hour (P = 0.001, d = 0.38) and 2-hours post-bolus                  
(P = 0.001, d = 0.67) compared to 5-hours post-bolus. 
5.3.1.4. Resting Metabolic Rate 
Resting EE and RER did not show main effects for condition, time or interaction (P > 0.05) 
(Appendix 4). No main effects for condition or interaction (P > 0.05) were seen, however 
significant main effects for time were observed for resting fat (F(5, 50) = 18.096; P < 0.001, 
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2
partial  = 0.64) and carbohydrate oxidation (F(5, 50) = 16.750; P < 0.001, 
2
partial  = 0.63).            
Fat and carbohydrate oxidation were found to be lower at all time points compared to                 
30-minutes post-bolus (P < 0.05). 
5.3.2. Part B 
5.3.2.1. Blood Biomarkers 
Analysis of change from pre-bolus responses for serum insulin (Figure 5.5) showed a 
significant main effect for time (F(1.091, 5.454) = 18.99; P = 0.006, 
2
partial  = 0.79) and interaction 
(F(6, 30) = 4.046; P = 0.004, 
2
partial  = 0.45). The difference between 1-hour to 3-hours post-
bolus with change from pre-bolus data was significant between MTCC and MTCJ (t(5) = 3.361; 
P = 0.020, d = 1.34) and between MTCC and MTCJ60 (t(5) = 3.909; P = 0.011, d = 1.76). 
Analysis of individual responses for mean post-bolus changes from pre-bolus suggested a 
greater reduction in insulin concentrations in 4/6 individuals with MTCJ60 compared to MTCJ. 
Additionally, individual responses showed a greater reduction in insulin concentrations in 4/6 
individuals with MTCJ60 compared to PLA. 
Figure 5.5. Response curves for the mean (±SD) change in insulin concentrations from pre-
bolus values to time points post-bolus for each condition. ^Denotes significant difference 
between 1-hour time point. *Denotes significant difference for change in insulin from 1-3 hours 
post-bolus between MTCC and MTCJ. $Denotes significant difference for change in insulin 
from 1-3 hours post-bolus between MTCC and MTCJ60. 
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Change from pre-bolus responses for serum glucose concentrations did not show any 
significant main effects for condition, time or interaction (P > 0.05). Change from pre-bolus to 
post-bolus values for selected glycaemic, insulinaemic and lipid variables are presented in 
Table 5.9. 
Table 5.9. Mean ± SD change from pre-bolus values to post-bolus time points for selected blood-
based biomarkers per treatment condition. 
  Post-bolus Time Points 
  1 hr 3 hr 5 hr 
Glucose 
(mmol.L-1) 
PLA 0.75 ± 2.23 -0.60 ± 0.87 -0.49 ± 0.56 
MTCC -0.22 ± 0.37 -0.44 ± 0.56 -0.49 ± 0.41 
MTCJ 0.08 ± 0.49 -0.39 ± 0.62 -0.35 ± 1.10 
MTCJ60 0.24 ± 0.74 -0.50 ± 0.48 -0.43 ± 0.68 
Triglycerides 
(mmol.L-1) 
PLA 0.1 ± 0.2 0.1 ± 0.3 0.1 ± 0.4 
MTCC 0.1 ± 0.2 0.1 ± 0.2 0.0 ± 0.3 
MTCJ -0.1 ± 0.2 0.1 ± 0.2 0.2 ± 0.3 
MTCJ60 0.1 ± 0.3 0.3 ± 0.6 0.3 ± 0.6 
HDL  
(mmol.L-1) 
PLA -0.16 ± 0.25 -0.16 ± 0.17 -0.24 ± 0.19 
MTCC -0.05 ± 0.17 -0.03 ± 0.06 0.04 ± 0.17 
MTCJ -0.04 ± 0.11 0.00 ± 0.14 -0.05 ± 0.17 
MTCJ60 -0.01 ± 0.09 0.04 ± 0.08 0.01 ± 0.17 
LDL^  
(mmol.L-1) 
 
PLA 0.23 ± 0.63 0.41 ± 0.56 0.63 ± 0.44 
MTCC 0.31 ± 0.47 0.34 ± 0.41 0.31 ± 0.34 
MTCJ -0.11 ± 0.33 0.24 ± 0.30 0.33 ± 0.43 
MTCJ60 -0.12 ± 0.47 -0.01 ± 0.74 0.27 ± 0.99 
TC:HDL*  
(AU) 
PLA 0.23 ± 0.50 0.43 ± 0.67 0.85 ± 0.61 
MTCC 0.33 ± 0.82 0.20 ± 0.46 0.38 ± 0.77 
MTCJ -0.01 ± 0.27 -0.07 ± 0.53 0.30 ± 0.48 
MTCJ60 -0.24 ± 0.26 -0.41 ± 0.44 -0.14 ± 0.52 
AU (Arbitrary Units); HDL (High-density Lipoprotein); MTCC (Montmorency Tart Cherry Capsules); MTCJ 
(Montmorency Tart Cherry Juice – 30 mL dose); MTCJ60 (Montmorency Tart Cherry Juice – 60 mL dose); PLA 
(Placebo); TC (Total Cholesterol). *Denotes significant main effect for time with post-hoc identifying differences 
between 3-hours and 5-hours post-bolus. ^Denotes significant main effect for time with post-hoc identifying 
differences between 1-hour and 3-hours against 5-hours post-bolus. 
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No significant interaction or main effects for condition or time were detected for total 
cholesterol, triglycerides and HDL (P > 0.05) (Table 5.9). Individual responses demonstrated 
a reduction in total cholesterol for all 6 individuals with MTCJ60 compared to MTCJ when 
analysing mean post-bolus change from pre-bolus data (Figure 5.6). Mean post-bolus change 
from pre-bolus showed 5/6 individuals responded with higher concentrations of HDL after 
MTCJ60 consumption compared to PLA. Furthermore, 4/6 individuals responded with higher 
HDL concentrations after MTCJ60 supplementation compared to MTCJ, while no change was 
seen in 1 individual. 
Figure 5.6. Mean (±SD) change in total cholesterol concentrations from pre-bolus for all 
conditions. 
No main effects for condition or interaction were observed (P > 0.05) for TC:HDL ratio (Table 
5.9), however individual responses showed mean post-bolus change from pre-dose improved 
in all 6 individuals with MTCJ60 compared to MTCJ, and in 5/6 individuals with MTCJ60 
compared to PLA.  
No significant main effects for condition or interaction were found for LDL (P > 0.05)        
(Table 5.9). 
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5.3.2.2. Cardiac Haemodynamics 
A significant interaction effect was observed for the change in SBP (F(15, 75) = 1.842; P = 0.044, 
2
partial  = 0.27) with post-hoc comparisons identifying a tendency (P = 0.088) towards 
significance between PLA (4 ± 8 mmHg) and MTCJ (-11 ± 6 mmHg) at 2-hours post-bolus 
(Figure 5.7). No other main effects for time or condition were detected with SBP (P > 0.05). 
Examination of individual responses showed 4/6 participants had lower SBP with MTCJ 
compared to MTCJ60 when averaging change from pre-bolus across all post-bolus time points. 
Statistical analysis did not detect any main effects for condition, time or interaction for DBP, 
MAP, TPR, CO and SV (P > 0.05) (Table 5.10). Heart rate responses only demonstrated a 
significant main effect for time (F(5, 25) = 13.274; P < 0.001, 
2
partial  = 0.73), with 30-minutes 
post-bolus decreasing more than 3-hours post-bolus (P = 0.037, d = 0.75). Additionally, heart 
rate at 1-hour post-bolus reduced significantly more than 2-hours (P = 0.006, d = 0.31),              
3-hours (P = 0.022, d = 0.57) and 4-hours post-bolus (P = 0.036, d = 0.57). 
Figure 5.7. Mean (±SD) change in SBP from pre-bolus for all conditions. 
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Table 5.10.  Mean ± SD change from pre-bolus values to post-bolus time points for selected cardiac haemodynamic parameters per treatment 
condition. 
   Post-bolus Time Points 
  30 mins 1 hr 2 hr 3 hr 4 hr 5 hr 
Brachial DBP 
(mmHg) 
PLA 4 ± 5 6 ± 8 6 ± 7 8 ± 10 4 ± 8 6 ± 7 
MTCC -3 ± 9 0 ± 10 -2 ± 6 -2 ± 6 0 ± 10 0 ± 4 
MTCJ 3 ± 5 6 ± 4 3 ± 4 8 ± 6 6 ± 6 3 ± 6 
MTCJ60 0 ± 5 0 ± 7 2 ± 7 1 ± 9 6 ± 6 4 ± 9 
MAP  
(mmHg) 
PLA 3 ± 5 9 ± 6 6 ± 7 9 ± 11 6 ± 10 8 ± 10 
MTCC -2 ± 11 3 ± 9 -3 ± 7 1 ± 7 1 ± 9 3 ± 5 
MTCJ 1 ± 2 2 ± 4 -4 ± 4 5 ± 4 2 ± 8 -4 ± 13 
MTC60 -1 ± 5 -1 ± 8 0 ± 8 1 ± 9 4 ± 10 4 ± 9 
Resting HR  
 (beats.min-1) 
 
PLA 
 
-2 ± 4 
 
-3 ± 4 
 
-5 ± 4 
 
-7 ± 6 
 
-7 ± 7 
 
-7 ± 6 
MTCC -6 ± 7 -4 ± 6 -6 ± 8 -8 ± 7 -6 ± 9 -7 ± 7 
MTCJ -1 ± 5 -3 ± 6 -7 ± 7 -8 ± 6 -8 ± 5 -10 ± 5 
MTCJ60 -1 ± 3 0 ± 5 -4 ± 2 -5 ± 4 -6 ± 7 -4 ± 4 
 
 
Cardiac Output 
(L.min-1) 
PLA -0.35 ± 0.91 -0.13 ± 2.17 -0.55 ± 1.61 -0.42 ± 0.67 -0.76 ± 0.84 -1.19 ± 0.80 
MTCC -0.22 ± 0.44 0.12 ± 1.07 0.26 ± 0.48 0.06 ± 0.91 -0.13 ± 1.16 0.06 ± 0.72 
MTCJ -0.30 ± 1.66 -0.48 ± 1.82 -0.43 ± 1.52 -0.32 ± 1.62 -0.53 ± 1.40 -0.65 ± 1.44 
MTCJ60 0.31 ± 2.47 0.62 ± 3.05 -0.56 ± 2.53 -1.22 ± 2.28 -1.08 ± 2.04 0.01 ± 3.23 
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DBP (Diastolic Blood Pressure); HR (Heart Rate); MAP (Mean Arterial Pressure); mmHg (millimetres of Mercury); MTCC (Montmorency Tart Cherry Capsules); MTCJ 
(Montmorency Tart Cherry Juice); MTCJ60 (Montmorency Tart Cherry Juice 60 mL); PLA (Placebo); TPR (Total Peripheral Resistance). 
 
 
 
 
 
 
 
 
 
 
Stroke Volume 
(mL) 
PLA -5 ± 17 -9 ± 22 -6 ± 17 -1 ± 22 -9 ± 18 -11 ± 20 
MTCC 4 ± 7 4 ± 21 9 ± 4 12 ± 15 6 ± 17 13 ± 13 
MTCJ -3 ± 19 -4 ± 23 2 ± 24 -13 ± 27 4 ± 23 3 ± 25 
MTCJ60 8 ± 28 11 ± 31 -1 ± 28 -6 ± 17 -6 ± 26 12 ± 23 
TPR  
(mmHg·min-1·L) 
PLA 0.00 ± 0.21 0.15 ± 0.37 0.14 ± 0.31 0.26 ± 0.46 0.16 ± 0.27 0.09 ± 0.26 
MTCC 0.01 ± 0.17 0.09 ± 0.28 0.02 ± 0.37 0.08 ± 0.32 0.09 ± 0.39 0.12 ± 0.34 
MTCJ 0.08 ± 0.33 0.07 ± 0.27 -0.03 ± 0.38 0.10 ± 0.34 0.10 ± 0.28 0.11 ± 0.35 
MTCJ60 -0.19 ± 0.26 -0.13 ± 0.34 0.01 ± 0.26 0.04 ± 0.28 0.11 ± 0.26 -0.06 ± 0.38 
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5.3.2.3. Pulse Wave Analysis 
No main effects were found for aortic SBP (P > 0.05) (Table 5.11). However, 5/6 individuals 
responded with lower aortic SBP after MTCJ60 consumption compared to PLA when assessing 
mean post-bolus change from pre-bolus. 
Pulse pressure showed a tendency towards significance for the interaction main effect            
(F(15, 75) = 1.690; P = 0.071, 
2
partial  = 0.25) (Table 5.11). Individual responses highlighting all 
6 participants had narrower mean post-bolus pulse pressure with MTCJ60 compared to PLA at 
30 minutes post-bolus. Moreover, individual responses showed 4/6 participants with narrower 
mean post-bolus pulse pressure at 4-hours post-bolus with MTCJ compared to PLA. 
Similar to pulse pressure, individual responses for AIx suggested 4/6 participants had more 
compliant arteries with MTCJ60 compared to PLA when analysing mean post-bolus change 
from pre-bolus. A significant interaction effect (F(15, 75) = 1.943; P = 0.032, 
2
partial  = 0.28) 
was observed with AIx (Table 5.11); with differences showing MTCJ (3 ± 11%) to increase 
more than MTCJ60 (-2 ± 6%) at 30 minutes post-bolus (P = 0.015, d = 0.57). 
A main effect for time was found for AP (F(5, 25) = 5.994; P = 0.001, 
2
partial  = 0.55), although 
individual responses indicated all 6 participants responded with lower AP with MTCJ 
compared to PLA at 2-hours post-bolus (Table 5.11). Finally, a main effect of time was 
observed for SEVR (F(5, 25) = 3.947; P = 0.009, 
2
partial  = 0.44). No other main effects for 
condition or interaction were found (P > 0.05) (Table 5.11). Post-hoc analyses were unable to 
detect differences for the main effect for time with AP and SEVR.
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Table 5.11.  Mean ± SD change from pre-bolus values to post-bolus time points for selected PWA parameters per condition. 
   Post-bolus Time Points 
  30 mins 1 hr 2 hr 3 hr 4 hr 5 hr 
Aortic SBP 
(mmHg) 
PLA 6 ± 4 6 ± 9 8 ± 7 9 ± 8 9 ± 5 8 ± 3 
MTCC 1 ± 6 6 ± 11 5 ± 17 1 ± 11 1 ± 9 3 ± 6 
MTCJ 1 ± 9 -1 ± 10 -5 ± 7 1 ± 3 2 ± 9 4 ± 9 
MTCJ60 -1 ± 4 -3 ± 7 1 ± 6 3 ± 7 4 ± 7 2 ± 8 
Aortic DBP  
(mmHg) 
PLA 12 ± 13 10 ± 12 14 ± 12 12 ± 16 11 ± 10 11 ± 12 
MTCC 1 ± 3 1 ± 8 -4 ± 8 -1 ± 6 3 ± 8 -3 ± 6 
MTCJ -3 ± 6 -5 ± 5 1 ± 4 2 ± 9 -2 ± 6 2 ± 5 
MTC60 -1 ± 5 0 ± 8 1 ± 8 1 ± 9 4 ± 10 3 ± 9 
Pulse Pressure 
(AU) 
 
PLA 
 
6 ± 7 
 
-4 ± 8 
 
-6 ± 11 
 
-3 ± 5 
 
-2 ± 5 
 
-3 ± 7 
MTCC 0 ± 7 5 ± 8 1 ± 5 0 ± 3 -2 ± 8 0 ± 9 
MTCJ -2 ± 7 -6 ± 5 -4 ± 4 -1 ± 6 0 ± 4 2 ± 2 
MTCJ60 -2 ± 6 -3 ± 7 0 ± 7 2 ± 8 0 ± 5 -1 ± 4 
AIx at HR75 
(%) 
PLA 1 ± 4 0 ± 4 5 ± 5 4 ± 5 5 ± 6 6 ± 5 
MTCC -3 ± 7 -2 ± 5 -2 ± 8 1 ± 6 2 ± 7 3 ± 9 
MTCJ 2 ± 4 1 ± 9 -3 ± 7 -2 ± 8 2 ± 8 5 ± 8 
MTCJ60 -1 ± 5 -1 ± 9 2 ± 9 2 ± 8 3 ± 10 4 ± 11 
AIx (%) 
PLA 2 ± 4 2 ± 5 6 ± 6 5 ± 7 7 ± 8 6 ± 6 
MTCC 0 ± 8 2 ± 8 1 ± 6 3 ± 7 5 ± 9 6 ± 9 
MTCJ 3 ± 5 3 ± 11 -2 ± 8 -1 ± 7 6 ± 9 7 ± 8 
MTCJ60 -2 ± 6 -2 ± 8 -1 ± 10 3 ± 9 4 ± 10 4 ± 11 
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AIx at HR75 (Augmentation  Index at Heart Rate 75 bpm); Diastolic Blood Pressure (DBP); mmHg (millimetres of Mercury); MTCC (Montmorency Tart Cherry Capsules); 
MTCJ (Montmorency Tart Cherry Juice); MTCJ60 (Montmorency Tart Cherry Juice 60 mL); PLA (Placebo); Systolic Blood Pressure (SBP); Subendocardial Viability Ratio 
(SEVR). 
 
 
 
 
 
 
 
 
 
 
 
Augmentation 
Pressure 
(mmHg) 
PLA 2 ± 2 2 ± 5 3 ± 5 5 ± 5 5 ± 4 6 ± 4 
MTCC 1 ± 4 3 ± 5 2 ± 4 2 ± 3 3 ± 4 5 ± 6 
MTCJ 2 ± 4 0 ± 5 -2 ± 3 1 ± 6 2 ± 6 5 ± 4 
MTCJ60 -1 ± 3 -1 ± 3 3 ± 3 2 ± 2 3 ± 2 2 ± 4 
SEVR (%) 
PLA -6 ± 43 8 ± 25 13 ± 32 10 ± 18 15 ± 28 1 ± 21 
MTCC 13 ± 28 4 ± 20 17 ± 22 15 ± 23 13 ± 23 11 ± 28 
MTCJ 10 ± 32 14 ± 27 41 ± 40 30 ± 41 20 ± 32 21 ± 10 
MTCJ60 -7 ± 9 -2 ± 26 8 ± 17 8 ± 23 -5 ± 31 -5 ± 16 
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5.4. Discussion 
Cardio-metabolic responses to MTC had not previously been examined in humans with MetS, 
thus providing an aim for this study. Since the inception of the present study, Johnson et al. 
(2017) published an abstract outlining the effects of chronic supplementation of MTCJ on 
cardiac haemodynamics, arterial stiffness and blood-based cardio-metabolic biomarkers in 
humans with MetS. However, the present study examined the cardio-metabolic responses of 
humans with MetS to an acute bolus of MTCC, 30 and 60 mL MTCJ in a randomised, placebo-
controlled trial, thus adding further novelty of this research. 
The hypotheses were partially accepted as the key findings demonstrated significantly lower 
post-prandial responses to insulin with MTCJ compared to PLA, and a blunted insulin response 
with MTCC compared to PLA, 1-hour post-bolus. In accordance with previous research (Keane 
et al., 2016b), individual responses showed SBP to be lower with MTCJ compared to PLA,    
2-hours post-bolus. Individual responses also showed MTCJ60 consumption increased HDL. 
Finally, responses between MTCC and MTCJ were not statistically different, thus refuting the 
hypothesis that MTCC may be superior than MTCJ; although physiological differences were 
apparent at particular time points for certain markers. 
5.4.1. Metabolic Responses 
Findings from the present research showed the mean post-bolus change for insulin was 
significantly lower with MTCJ (-18.02 ± 44.31 pmol.L-1) than PLA (12.01 ± 41.60 pmol.L-1), 
and significantly lower than PLA at 3-hours post-bolus. Also, insulin responses between PLA 
and MTCC were physiologically different where the mean change from pre-bolus across all 
post-bolus time points increased with PLA but decreased by 20.61 pmol.L-1 with MTCC. 
However, a caveat of these findings is that they were likely influenced by the high carbohydrate 
content (99.88% of which sugars) in the placebo, where maltodextrin was added to match the 
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energy content of the placebo to MTCJ. Consequently, this provoked a contrived response with 
the placebo on insulin, making comparisons against MTCC and MTCJ difficult. Nevertheless, 
as this was the first study to assess acute glycaemic and insulinaemic tolerability to MTCC and 
MTCJ consumption, it is possible to discern novel findings. A blunted insulin response 
throughout the 5-hour post-bolus period with MTCC was observed, as the 10 capsules ingested 
contained only 1 gram of carbohydrate. Additionally, in alignment with MTC 
pharmacokinetics (Keane et al., 2016b), absolute insulin concentrations at 3-hours post-bolus 
were similar between MTCC (77.42 ± 3.04 pmol.L-1) and MTCJ (76.53 ± 8.95 pmol.L-1). This 
highlights the role of MTCJ phytochemicals in reducing insulin to a similar concentration as 
MTCC, despite differences in glycaemic load. Remarkably, data from Part B also showed 
similar absolute insulin concentrations for MTCC (76.74 ± 41.39 pmol.L-1), MTCJ               
(70.15 ± 39.28 pmol.L-1) and MTCJ60 (82.97 ± 14.21 pmol.L-1) at 3-hours post-bolus. This 
indicates the absence of a dose-response effect with MTC phytochemicals but also a boundary 
level at which insulin concentrations could be reduced to. Interestingly, the similar 
concentrations suggest no difference between the delivery of MTC phytochemicals in capsule 
or juice form, indicating no enhancement of phytochemical bioavailability with capsules. 
However, MTC interventions effectively blunted insulin responses when parent anthocyanin 
and secondary metabolite plasma concentrations were likely at their greatest. 
The high glucose load in the placebo elicited a significantly higher insulin secretion response 
1-hour post-bolus compared to MTCC. Additionally, MTC anthocyanins may have inhibited 
glucose absorption across the apical membrane of enterocytes into systemic circulation via 
suppression of SGLT-1 (Alzaid, 2013). Furthermore, findings from Part B would support the 
mechanism that saturation of anthocyanins and secondary metabolites at a threshold (Wallace, 
Slavin and Frankenfeld, 2016) around 270 mg, limited uptake and subsequently SGLT-1 
activity. This likely explains the similar glucose concentrations between MTCJ and MTCJ60, 
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despite MTCJ60 possessing double the total carbohydrate and sugar content. Likewise, 
insulinaemic and glycaemic responses to 7 days of New Zealand blackcurrant powder (NZBP) 
supplementation suggested a 14.3% reduction in fasting insulin compared to control (Willems 
et al., 2017). Crucially, the authors measured fasting insulin, 1-hour post-consumption of the 
final bolus, implying an acute effect of NZBP on insulin. Willems et al. (2017) ascribed the 
decline in insulin to improved insulin sensitivity. A similar mechanism may be cited to explain 
MTCJ and MTCC responses, given baseline HOMA2-IR (2.2 ± 1.4) and HOMA2-%S          
(60.4 ± 27.3%) values indicated insulin resistance (Queiroz et al., 2009) and low insulin 
sensitivity, respectively. Lower insulin combined with normal glucose concentrations may 
suggest MTCJ and MTCC improved insulin sensitivity (Willems et al., 2017). Such as response 
may subsequently prevent pancreatic β-cell glucotoxicity (Amiot, Riva and Vinet, 2016), thus 
reducing the burden on β-cells by averting excess insulin secretion (Alvarado et al., 2016). The 
direction of the insulinaemic response provides evidence that MTCC may be a more tolerable 
intervention for individuals with dysfunctional glycaemic control and insulin resistance, such 
as type 2 diabetics. Moreover, it is possible that short-term improvements in insulin control 
with MTC interventions, may develop into long-term adaptations with consistent use.  
5.4.2. Cardiovascular Responses 
The most noteworthy cardiovascular response was the reduction in SBP at 2-hours post-bolus 
with MTCJ compared to PLA, in both Parts A and B. This finding was consistent with previous 
literature assessing SBP with cherry interventions (Kent et al., 2015a; Keane et al., 2016bc; 
Chai et al., 2018). Keane et al. (2016bc) observed significantly lower SBP with MTCJ 
compared to PLA for the first 3-hours after ingestion, with peak reductions of 7 mmHg at          
2-hours post-bolus (Keane et al., 2016b) and 6 mmHg at 1-hour post-bolus (Keane et al., 
2016c). Similarly, the present study observed the greatest reduction in SBP (-8 mmHg) also at 
2-hours post-bolus, suggesting MTCJ modulates SBP at this time point as it likely coincides 
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with parent anthocyanin and metabolite pharmacokinetics (Keane et al., 2016b). Likewise, 
sweet cherry juice also had its greatest effect on SBP (-5.50 mmHg) 2-hours post-prandially, 
in old and young adults (Kent et al., 2015b), with the authors attributing the improvement to 
the parent anthocyanins but not phenolic metabolites, as peak metabolite concentrations did 
not coincide with the time course of the observed effect. Interestingly, modulation of SBP with 
MTCC did not occur, despite administration of the same total anthocyanin content. Based on 
Keane et al. (2016b) explaining PCA and VA from MTCJ, likely exerted the dampened SBP 
response, it may be that these metabolites were not present at physiologically relevant 
concentrations within systemic circulation with MTCC, potentially due to the variable 
mechanics of capsule shell disintegration impeding anthocyanin metabolism. Since data from 
Part B seems not to indicate a dose-response effect for SBP, it is less surprising that the mean 
reduction in SBP across the 5-hour post-bolus period was greater in 4 of 6 individuals with 
MTCJ than MTCJ60. 
Hypertension and isolated systolic hypertension increase CVD risk (Feresin et al., 2017); 
however, mean SBP reductions of at least 5-6 mmHg over 5 years has been linked with a lower 
risk of coronary heart disease and stroke by 20-25% and 35-40%, respectively (Collins et al., 
1990). Bundy et al. (2017) also reported a reduction in SBP >5 mmHg was clinically relevant 
and associated with lower CVD/mortality risk. Thus, the magnitude of change with MTCJ 
indicates clinically relevant reductions in SBP; mean difference between MTCJ and PLA at   
2-hours post-bolus of -11 mmHg. Consequently, this emphasises the highly potent hypotensive 
properties of MTCJ and the effect of a lower MTCJ dosage compared to Keane et al. (2016b). 
This finding is of high importance as approved anti-hypertensive drugs, with associated 
harmful side effects, lower SBP by a comparable magnitude (Bramlage and Hasford, 2009) as 
MTCJ, which currently has no known side effects. A limitation of examining acute cardio-
metabolic responses is low ecological validity and biological significance of the results 
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(Rodriguez-Mateos et al., 2013). However, long-term studies supplementing tart (Keane et al., 
2016c) and sweet (Kent et al., 2015a) cherries have also been shown to lower SBP, although 
only in subjects presenting elevated baseline SBP. 
The present study demonstrated individual responses for arterial stiffness were improved only 
at 2-hours post-bolus with MTCJ compared to PLA. However, pulse pressure, AP and TPR as 
indicators of vascular stiffness were not significantly improved with MTCJ. Furthermore, AIx 
or AP were not significantly correlated to SBP at 2-hours post-bolus with MTCJ; modulation 
of arterial stiffness does not explain the reduction in SBP at that time point. These findings 
align with previous research pertaining to supplementation of MTCJ on arterial stiffness (Lynn 
et al., 2014; Keane et al., 2016b; Johnson et al., 2017). The rapid effect of AIx and AP 
improvement with MTCJ60 may be explained by its pharmacokinetics, where Keane et al. 
(2016a) showed significantly greater serum PCA and VA concentrations 1-hour post-bolus of 
60 mL MTCJ compared to PLA.  
A chemical mechanism involving NO and/or ACE inhibition may explain BP responses. Keane 
et al. (2016b) were unable to demonstrate augmented plasma nitrate/nitrite concentrations after 
60 mL MTCJ consumption, rendering NO-mediated vasodilation less likely. Conversely, 
Kirakosyan et al. (2018) demonstrated MTC extract to inhibit ACE, potentially explaining 
reductions in SBP (MTCJ), aortic SBP and narrower pulse pressure (both with MTCJ60) from 
the present study; future work should assess ACE inhibition in humans. However, concomitant 
stimulation of eNOS and ACE inhibition should not be ruled out. Aortic SBP can be used for 
assessing the effectiveness of anti-hypertensive treatments with respect to cardiovascular risk 
factors (McEniery et al., 2014), supporting MTCJ60 as a potentially safe, yet effective anti-
hypertensive intervention.  
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MTCC induced vasodilation may have facilitated greater venous return thus explaining HR, 
SV and CO responses at 30 minutes post-bolus. A similar mechanism was provided by Cook 
et al. (2017a) in response to acute, encapsulated NZBE supplementation. The observed 
response with MTCC was remarkable, as disintegration of the capsule shell requires 30 minutes 
(Lown et al., 2017), indicating an immediate response after dissolution. Subsequently, 
provision of MTC in liquid form (MTCJ) may facilitate faster absorption of phytochemicals 
(McGhie and Walton, 2007; Bohn, 2014) than MTCC. However, the lack of response with 
MTCJ would suggest either extensive degradation by salivary amylase (Kamonpatana, 2012) 
and/or a delayed uptake of secondary metabolites and phase II conjugates (Fernandes et al., 
2014). This delayed uptake of metabolites may be the rate-limiting step. 
In agreement with responses observed in participants with MetS during the present 
investigation, Johnson et al. (2017) reported 12 weeks MTCJ consumption tended to lower 
total cholesterol but had no significant effect on other lipids. Despite non-significant statistical 
differences, individual responses in Part B of the present study showed all 6 participants had 
lower mean post-bolus total cholesterol concentrations after 60 mL MTCJ consumption 
compared to 30 mL MTCJ. This suggests total cholesterol may be more sensitive to 
improvement at higher phytochemical concentrations. 
5.4.3. Limitations and Future Work 
As with all research, certain limitations are apparent. Firstly, the artificial effect of the placebo 
on glycaemic and insulinaemic responses influenced the data and nullified comparisons against 
MTC interventions. This was an oversight on the part of the researcher, despite the initial 
intention to calorie match the placebo against MTCJ. Subsequent studies should match the 
placebo for relative percentages of macronutrients to total energy or utilise a water placebo if 
aiming to evaluate the intervention as a whole, including detrimental effects of juices such as 
sugars (Peluso and Palmery, 2014).  
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Secondly, as this was a pilot investigation the sample size was small limiting conclusions. 
However, this pilot investigation served its purpose in indicating null responses and potential 
benefits of MTCC, MTCJ and MTCJ60 consumption on cardio-metabolic markers in 
participants with MetS. This preliminary data serves to inform the design of future clinical 
trials with larger sample sizes to determine whether there is any clinically relevant benefit of 
MTC consumption.  
Third, the phytochemical pharmacokinetics of MTCC was and remains unknown. Thus, there 
is a necessity to address this gap to enable better understanding of the data from this study and 
future work incorporating MTCC. Additionally, any advantageous responses observed with 
MTC interventions may be due to a residual synergistic effect of habitually consumed 
polyphenols, as this study aimed to uphold ecological validity by permitting habitual 
polyphenol intake. The beneficial responses observed with MTCJ and MTCJ60 compared to 
MTCC and PLA, may be a consequence of other nutrients, such as fibre which was shown to 
reduce SBP, total cholesterol and post-prandial glucose and insulin (Hodgson, 2004); aligning 
with findings from the present study. Although much attention has been given to the beneficial 
effects of anthocyanins and their metabolites, the synergistic influence of other phytonutrients 
within MTC require consideration.  
Finally, acute cardio-metabolic responses were monitored during this study, however to 
enhance ecological validity and clinical relevance, data from longer-term responses in humans 
with MetS is required. 
5.5. Conclusion 
This research is the first to present data that acute administration of MTC interventions in 
capsule and juice form can modulate certain cardio-metabolic markers in humans with MetS. 
Further evidence is provided that MTCJ is an effective, low-risk intervention for lowering SBP 
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in various populations and should be considered for individuals with isolated systolic 
hypertension. Future work should consider monitoring 24-hour ambulatory BP responses to 
MTCJ. Chapter 4 indicated a limited effect of MTCJ in healthy humans, therefore pathological 
populations should be studied. Despite recruiting humans with MetS in this study, the effects 
of MTC seemed to only apply to certain variables which were abnormal at baseline. The 
physiological responses to each MTC intervention differed depending on the cardio-metabolic 
marker examined, although there were no statistical differences between MTCC and MTCJ. A 
dose-response effect was not apparent, however individual responses suggested MTCJ60 may 
reduce atherosclerotic and cardiovascular risk. Consequently, recommendations for which 
MTC intervention is most suitable should be based on the cardio-metabolic marker that requires 
most attention, with consideration of the individuals’ overall cardio-metabolic health. 
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6.1. Introduction 
In keeping with the themes of this thesis, the present chapter examined the effects of 7 days 
continuous MTCJ supplementation in humans with MetS. Chapter 5 highlighted for the first 
time that MTC interventions may exert beneficial effects on certain cardio-metabolic markers 
in humans with MetS. In acknowledgement of some of the limitations within chapter 5, this 
chapter aimed to assess cardio-metabolic function and potential mechanisms more conclusively 
in order to further understanding of these responses in this particular population.  
The prevention of CVD and T2D would be a major step in retarding the current exponential 
rise in global prevalence and incidence rates (World Health Organisation, 2017; Cho et al., 
2018). MetS augments the incidence of CVD by 2-fold and T2D by 5-fold (Falkner and 
Cossrow, 2014). Dietary interventions to prevent and mitigate MetS are sought after as they 
can conveniently be implemented into an individual’s lifestyle. Anthocyanins, a sub-class of 
polyphenols, and their metabolites possess potent anti-oxidative and anti-inflammatory 
properties and have been shown to improve MetS symptoms (Zhu et al., 2018). Furthermore, 
section 2.2.5.2.2.1 highlighted improvements in cardio-metabolic function after consumption 
of anthocyanin-rich interventions in humans with MetS. 
Montmorency tart cherries are rich in phytochemicals including anthocyanins, however their 
bioefficacy may be attributed to downstream metabolites and synergisms with other nutrients 
within MTC, which may also induce health benefits (Keane et al., 2016abc; Kirakosyan et al., 
2018). Insulin resistance is key to the underlying pathophysiology of MetS and anthocyanin-
mediated improvements in insulin and glucose metabolism (Belwal et al., 2017) can ameliorate 
many of its associated symptoms (Tsuda, 2008). Willems et al. (2017) reported 7 days 
continuous consumption of anthocyanin-rich NZBP likely increased insulin sensitivity in 
healthy individuals. Furthermore, chapter 5 suggested the MTC interventions may have 
elicited improvements in insulin sensitivity and thus pancreatic β-cell function based on 
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glycaemic and insulinaemic responses observed amongst participants with MetS. Thus, to test 
this hypothesis the present study assessed surrogate markers of insulin sensitivity, insulin 
resistance and pancreatic β-cell function after short-term, continuous MTCJ supplementation.  
Chapters 4 and 5 discussed provision of small anti-oxidant dosages, based on the concept of 
hormesis, may be more effective at inducing cellular, molecular and thus functional changes to 
improve health; as supported by Wallace (2011) and Wallace, Slavin and Frankenfeld (2016). 
Greater improvements of functional and blood-based cardio-metabolic biomarkers previously 
measured in chapter 5 may be induced after multiple days’ supplementation of a low anti-
oxidant dosage. Thus, a 30 mL dose of MTC concentrate (270 mg anthocyanins) was provided 
for 7 days, as chapter 5 did not indicate any further improvements in cardio-metabolic function 
with 60 mL MTC concentrate or MTCC. Additionally, the lower dosage is thought to retain 
more anthocyanins and secondary metabolites in systemic circulation for longer; maximising 
their bioactive properties (Seymour et al., 2014). Lastly, the lower dosage is more economically 
viable for consumers, making this research more ecologically valid.  
Centred around chapter 5, cardio-metabolic responses were also observed after an acute bolus 
of MTCJ, on the 7th day of supplementation, when bioavailability of MTC phytochemicals are 
thought to be greatest. Subsequently, this may explain the clinically-relevant reduction in SBP 
at 2-hours post-consumption of tart (Keane et al., 2016b) and sweet (Kent et al., 2015b) cherry 
juice, due to the pharmacokinetic profile of their anthocyanins and secondary metabolites. A 
caveat of recommending MTCJ as an intervention for managing hypertension is that greater 
clinical evidence is required which can be applied to normal daily-living conditions. This can 
be achieved through 24-hour ambulatory blood pressure monitoring (ABPM), instead of the 
lab-based BP measurements obtained by previous studies involving cherry interventions 
(Ataie-Jafari et al., 2008; Kelley et al., 2013; Lynn et al., 2014; Kent et al., 2015ab; Keane et 
al., 2016bc; Johnson et al., 2017; Chai et al., 2018), which can be affected by phenomena such 
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as white coat syndrome (Hodgkinson et al., 2011). Moreover, 24-hour ABPM is deemed to be 
the reference standard for accurate assessment of cardiovascular risk in adults (Hodgkinson et 
al., 2011; Hermida et al., 2015). Hence, this study measured 24-hour ABPM before and after 
7 days of MTCJ supplementation, as Stote et al. (2017) demonstrated a trend towards reduced 
SBP after 7 days blueberry juice supplementation. Furthermore, chapter 5 corroborated 
findings from previous literature of sweet (Kent et al., 2015ab) and tart (Keane et al., 2016a; 
Keane et al., 2016b; Chai et al., 2018) cherries’ anti-hypertensive properties, specifically in 
participants with MetS; however, the mechanism of action has yet to be elucidated. Keane et 
al. (2016b) were unable to demonstrate increased NO bioavailability, whilst Lynn et al. (2014), 
Keane et al. (2016b) and data from chapter 5 did not indicate significant modulation of arterial 
stiffness with MTCJ. Therefore, an alternative mechanism involving ACE inhibition was 
hypothesised in the present study, since Kirakosyan et al. (2018) observed 88.7% ACE 
inhibition in vitro with MTC extract.  
The present study aimed to expand upon Johnson's et al. (2017) study by examining cardio-
metabolic responses after short-term (7 days), continuous MTCJ supplementation and acute 
responses to a single-bolus, in humans with MetS. The study also aimed to provide data using 
clinically-relevant methodologies and explain mechanisms of action for observed responses 
with MTCJ. It was hypothesised that MTCJ would improve glycaemic and insulinaemic 
function through increasing insulin sensitivity. Moreover, MTCJ would maintain reductions in 
SBP 2-hours post-consumption and lower 24-hour SBP after 7 days supplementation, through 
ACE inhibition. Lastly, 6 days prior loading of MTCJ would improve acute cardio-metabolic 
responses more than a single, acute bolus. 
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6.2. Methods 
6.2.1. Participants 
Twelve (6 males and 6 females) participants with Metabolic Syndrome (Tables 6.1 and 6.2) 
volunteered for this pilot study. All participants were screened for MetS prior to formal 
inclusion onto the study according to the harmonised criteria outlined by Alberti et al. (2009), 
where 3 of the 5 qualifying criteria [Waist Circumference: ethnicity and sex specific criteria; 
Fasting Triglycerides: ≥1.69 mmol.L-1; Fasting High-Density Lipoprotein: <1.03 mmol.L-1 
(men), <1.29 mmol.L-1 (women); Blood Pressure: ≥130 mmHg SBP or ≥85 mmHg DBP; 
Fasting Glucose: ≥5.6 mmol.L-1] had to be met. Ethical approval was obtained from the 
University of Hertfordshire Health, Science, Engineering and Technology Ethics Committee 
and informed consent was provided by all participants prior to enrolment. This study was 
registered as a clinical trial on clinicaltrials.gov (NCT03619941). 
Refer to chapter 5, section 5.2.1.1, for further details regarding recruitment (Figure 6.1) and 
exclusion criteria.  
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AU (Arbitrary Units); BMI (Body Mass Index); HOMA2-IR (Homeostatic Model Assessment of Insulin 
Resistance); HOMA2-β (Homeostatic Model Assessment of pancreatic β-cell function); HOMA2-%S 
(Homeostatic Model Assessment of Insulin Sensitivity). 
 
 
 
Table 6.1. Selected baseline characteristics obtained during screening (n = 12). 
Characteristics Mean ± SD 
Age (years) 50 ± 10 
Stature (m) 1.73 ± 0.12 
Body Mass (kg) 94.1 ± 23.1 
BMI (kg.m-2) 31 ± 7 
Whole-body Fat (%) 39 ± 11 
Trunk Fat (%) 32 ± 10 
Fat Mass (kg) 41 ± 17 
Fat Free Mass (kg) 55 ± 17 
Fasting Total Cholesterol (mmol.L-1) 4.17 ± 1.21 
24-hour SBP (mmHg) 128 ± 10 
24-hour DBP (mmHg) 77 ± 8 
Fasting Insulin (pmol.L-1) 118.99 ± 68.14 
HOMA2-IR (AU) 2.2 ± 1.4 
HOMA2-β (%) 137.9 ± 49.5 
HOMA2-%S (%) 63.2 ± 40.5 
ACE (pg.mL-1) 8627 ± 8702 
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Table 6.2. Individual baseline characteristics of MetS criteria obtained during screening (n = 12). 
DBP (Diastolic Blood Pressure); HDL (High-density Lipoprotein); SBP (Systolic Blood Pressure). 
 
 
 
 
 
 
  Participant 
Characteristics Mean ± SD 1 2 3 4 5 6 7 8 9 10 11 12 
Waist 
Circumference 
(cm) 
101.0 ± 19.3 102* 125* 80* 85 125.4* 119* 88* 82* 74.5 100* 104* 127* 
Fasting Glucose 
(mmol.L-1) 
5.32 ± 1.04 6.15* 4.89 5.42 4.20 6.90* 6.38* 3.94 4.90 3.95 5.04 5.26 6.08* 
Fasting 
Triglycerides 
(mmol.L-1) 
1.6 ± 0.3 1.7* 2.0* 1.2 1.8* 2.2* 1.3 1.7* 1.9* 1.8* 1.7* 1.1 1.3 
Fasting HDL 
(mmol.L-1) 
1.41 ± 0.32 1.95 1.32 1.38 1.69 1.09 1.31 1.19* 1.58 1.88 1.52 1.01* 1.01* 
SBP (mmHg) 135 ± 16 122 131* 131* 158* 149* 161* 104 131* 136* 135* 131* 125 
DBP (mmHg) 77 ± 8 66 75 88* 91* 85* 70 75 70 85* 79 69 76 
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Figure 6.1. CONSORT flow diagram of the participants recruited, screened, tested, analysed 
and excluded during the course of the study. 
 
 
Assessed for eligibility (n = 39) 
Excluded (n = 24) 
   Not meeting inclusion criteria (n = 23) 
   Declined to participate (n = 1) 
Analysed (n = 12) 
 
Allocated to Placebo intervention (n = 8) 
 Received allocated intervention (n = 7) 
 Not received allocated intervention (n = 1) 
(Participant dropped out for personal reasons) 
 
Allocation 
1 
Analysis 
Randomised (n = 15) 
Enrolment 
Allocated to MTCJ intervention (n = 7) 
 Received allocated intervention (n = 7) 
 Not received allocated intervention (n = 0) 
Allocation 
2 
Allocated to Placebo intervention (n = 7) 
 Received allocated intervention (n = 6) 
 Not received allocated intervention (n = 1) 
(Participant dropped out for personal reasons) 
Allocated to MTCJ intervention (n = 7) 
 Received allocated intervention (n = 6) 
 Not received allocated intervention (n = 1) 
(Participant dropped out for personal reasons) 
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6.2.2. Procedures 
6.2.2.1. Research Design 
A single-blind (blinded to participant), placebo-controlled, randomised, crossover design was 
utilised; each participant acted as their own control. During the 6-week study duration, 
participants completed both testing sessions during which placebo (PLA) or Montmorency Tart 
Cherry Juice (MTCJ) supplements were consumed for a continuous period of 7 days. As in 
chapters 4 and 5, a 14-day washout period (Howatson et al., 2012; Cook et al., 2015; Keane 
et al., 2016b) was incorporated prior to crossover to the opposing condition.  
Participants attended 4 testing sessions in total, in the laboratory. Schematics of the overall 
study design and specific procedures during a testing session are depicted in Figure 6.2. The 
first testing session lasted 1 hour; baseline anthropometric (stature, body mass, waist 
circumference, percentage body fat), functional (PWA, cardiac haemodynamics, RMR) and 
fasting blood-based biomarkers were measured. Participants were then provided with 
supplements to consume over the next 6 days at home, with the final dose on the 7th day being 
consumed in the laboratory during testing session two. Testing session two lasted 6 hours; 
anthropometric, functional and fasting blood-based biomarkers were measured prior to 
consumption of the supplement (6 days post-supplementation), after which functional 
measurements were recorded at 30 minutes, 1, 2, 3, 4- and 5-hours post-bolus. Blood sampling 
was performed at pre-bolus, 1, 3- and 5-hours post-bolus only. Testing session three was the 
same as session one, however participants were provided with the opposing supplement to 
which they consumed between sessions one and two. Lastly, session four was identical to 
session two. 
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Figure 6.2. (A) Schematic representation of the overall study design. (B) Schematic 
representation of the specific procedures during each testing session. ‘Suppl.’ denotes 
supplementation.  
 
A) 
B) 
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6.2.2.2. Dietary Guidelines 
Refer to general methodology section 3.2 for further details on dietary guidelines employed 
in this study. 
All participants complied with dietary guidelines upon analysis for percentage contributions of 
macronutrients to total energy intake [(protein 14 ± 22%), (CHO 48 ± 40%), (fat 38 ± 41%)], 
total polyphenols (62 ± 70 mg) and anthocyanins (20 ± 17 mg). 
6.2.2.3. Supplementation 
This study acutely administered two different supplements including a placebo which acted as 
the control condition and one experimental condition, MTCJ. MTCJ consisted of 30 mL 
Montmorency tart cherry concentrate (Cherry Active, Active Edge Ltd, Hanworth, UK) and 
100 mL water. It was identified that MTC concentrate contained glucose (55.73% of total 
sugars) and fructose (44.27% of total sugars). The placebo was composed of 30 mL 
commercially available fruit-flavoured cordial (Cherries and Berries, Morrisons, Bradford, 
UK) mixed with 100 mL water. The placebo drink was matched against MTCJ for percentage 
contribution of carbohydrate to total energy and contribution of sugars to total carbohydrate, 
energy content, taste and visual appearance by adding dextrose (My Protein Ltd, Northwich, 
UK), fructose (Fruit Sugar, Morrisons, Bradford, UK), cornflour (Morrisons, Bradford, UK), 
citric acid (100% Pure Citric Acid, VB and Sons, UK), red and black food colouring 
(Morrisons, Bradford, UK). Nutritional analysis of both beverages is detailed in Table 6.3. 
Anonymity of the supplementation was ensured by blinding the participants to the source of 
anthocyanins. This was achieved by explaining that an ‘anthocyanin-rich supplement’ would 
be provided rather than disclosing Montmorency tart cherries as the specific source. Only 2/12 
participants correctly distinguished the supplements provided (intervention or placebo) and 
none identified the intervention as ‘cherry’ or ‘containing cherries (either sweet or tart)’. Refer 
to section 3.3 for more information on supplementation. 
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Table 6.3. Nutritional information of each supplement provided. 
 
 
 
 
 
 
 
 
 
6.2.2.4. Measures and Equipment 
6.2.2.4.1. Anthropometrics 
Refer to general methodology section 3.5.1 for details on procedures of measuring stature, body 
mass and waist circumference.  
Refer to general methodology section 3.5.2 for details on procedures of measuring segmental 
body composition. 
6.2.2.4.2. Cardiac Haemodynamics 
Refer to general methodology section 3.5.3.1 for details on procedures for obtaining cardiac 
haemodynamic measurements. 
6.2.2.4.3. Blood Pressure 
Refer to general methodology section 3.5.3.2 for details on procedures for obtaining blood 
pressure measurements. 
 Montmorency tart 
cherry concentrate  
(per 30 mL) 
Placebo  
(per 130 mL) 
Energy (kcal) 102 102 
Carbohydrate (g) 24.5 25 
of which sugars (g) 17.9 18 
Glucose (g) 9.98 10.03 
Fructose (g) 7.92 7.97 
Protein (g) 1.1 0.5 
Fat (g) 0 0 
of which saturates (g) 0 0 
Fibre (g) 2.6 Trace 
Total Anthocyanins (mg) 270 0 
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6.2.2.4.4. 24-hour Ambulatory Blood Pressure 
In addition to clinic blood pressure measurements in the laboratory using an automated 
sphygmomanometer, 24-hour ambulatory blood pressure monitoring (ABPM) (Meditech 
ABPM-04, Meditech, Hungary) was also conducted through an oscillometric method. Barna, 
Keszei and Dunai (1998), have clinically validated the use of ABPM-04 monitors against 
British Hypertension Society guidelines. Moreover, ABPM-04 monitors have been used in 
interventional studies in participants with MetS (Johnston et al., 2010). ABPM provides a more 
accurate representation of blood pressure as measurements are obtained under normal daily-
living conditions, negating white coat syndrome; and mean pressures are taken from multiple 
readings over a 24-hour period, thus ABPM has become the reference standard for measuring 
BP non-invasively and diagnosing hypertension (Hodgkinson et al., 2011). 
Participants underwent a familiarisation period of wearing the ABPM device prior to data 
collection. A day before and after the 7 day supplementation period, participants were fitted 
with a 24-hour ABPM on the non-dominant arm (Drawz, Abdalla and Rahman, 2012). The 
ABPM was programmed (CardioVisions Software 1.15.2, Meditech, Hungary) to take readings 
every 30 minutes during the day (07:00-22:00) and every hour during the night (22:00-07:00) 
(Gupta et al., 2008; Stull et al., 2015). Participants were encouraged to follow their normal 
daily living pattern but maintain similar activities during each day of 24-hour ABPM 
measurement, and were advised to keep still and relax their arm whenever the monitor recorded 
measurements (Igwe et al., 2017). A minimum of 14 day-time readings and 7 night-time 
readings were considered for a valid 24-hour ABPM (O’Brien et al., 2003). Dietary 
consumption during 24-hour ABPM measurements coincided with the enforced 3-day dietary 
guidelines, thus participants were instructed to keep the same dietary intake on all 4 days of 
measurement. 
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The following data was obtained from the ABPM monitor: mean 24-hour, day-time and night-
time SBP, DBP, MAP and PP (Fagard et al., 2008). The difference between mean day and 
night SBP, DBP, MAP and PP was also calculated. 
6.2.2.4.5. Pulse Wave Analysis 
Refer to general methodology section 3.5.3.3 for details on procedures for obtaining PWA 
measurements. 
6.2.2.4.6. Resting Metabolic Rate 
Refer to general methodology section 3.5.4 for details on procedures for obtaining RMR 
measurements. 
In addition to values for RER and EE (kcal.day-1), resting fat and carbohydrate oxidations rates 
were also calculated at all time points. 
6.2.2.5. Blood Sampling and Analysis 
6.2.2.5.1. Blood Sampling 
Refer to general methodology section 3.6.1 for details on general blood sampling procedures.  
Refer to chapter 5, section 5.2.1.2.5.1 for specific details regarding blood sampling within this 
study. 
6.2.2.5.2. Glucose 
Refer to general methodology section 3.6.2 for details on performing glucose analysis. 
Overall intra-individual and inter-individual CV were 2.13% and 10.05%, respectively. 
6.2.2.5.3. Insulin and Insulin Resistance and Sensitivity Indexes 
Refer to general methodology section 3.6.8 for details on performing insulin analysis. 
Inter- and intra-plate CV were 6.1% and 5.5%, respectively. 
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Refer to general methodology section 3.6.8.1 for details on insulin resistance and sensitivity 
analysis. 
6.2.2.5.4. Triglycerides 
Refer to general methodology section 3.6.4 for details on performing triglyceride analysis. 
Overall intra-individual and inter-individual CV were 2.94% and 5.45%, respectively. 
6.2.2.5.5. Total Cholesterol 
Refer to general methodology section 3.6.5 for details on performing total cholesterol analysis. 
Overall intra-individual and inter-individual CV were 4.45% and 5.63%, respectively. 
6.2.2.5.6. HDL 
Refer to general methodology section 3.6.6 for details on performing HDL analysis. 
Overall intra-individual and inter-individual CV were 4.22% and 5.04%, respectively. 
6.2.2.5.7. Total Cholesterol:HDL Ratio 
Refer to general methodology section 3.6.7 for details on performing TC:HDL analysis. 
6.2.2.5.8. LDL 
LDL was determined indirectly using the Friedewald formula (Friedewald, Levy and 
Fredrickson, 1972). 
6.2.2.5.9. Angiotensin-I-Converting Enzyme Assay 
Human ACE (CD 143) (peptidyl-dipeptidase A, EC 3.4.15.1) protein concentrations were 
measured according to manufacturer’s guidelines, from serum samples in duplicates using a 
96-well ELISA [Human ACE ELISA (CD 143) ab119577, Abcam, Cambridge, UK]; based on 
the ‘sandwich immunoassay’ principle. 
An ACE specific mouse monoclonal antibody was pre-coated onto 96-well plates. A 7-point 
standard curve (Figure 6.3) was generated after serial dilution of lyophilised recombinant 
human ACE standard (50000 pg.mL-1). Following serial dilution, 100 µL of standards (50000, 
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25000, 12500, 6250, 3125, 1562.5, 781.25 pg.mL-1 and blank control containing no protein) 
and serum samples were then added to wells and incubated for 90 minutes at 37ºC (Combi-
H12 Hybridisation Incubator, FINEPCR, South Korea). A biotinylated detection polyclonal 
antibody from goat, specific for ACE was then added (100 µL) to each well and incubated for 
60 minutes at 37ºC, followed by washing with phosphate buffered saline buffer (0.01 M,          
pH 7.4). Secondary enzyme-linked antibody, Avidin-Biotin-Peroxidase Complex (100 µL), 
was added to each well and incubated for 30 minutes at 37ºC, unbound conjugates were then 
washed away with phosphate buffered saline buffer. The colour developing agent, TMB, was 
then added (90 µL) to visualise the HRP enzymatic reaction and the plate incubated for 20 
minutes at 37ºC in the dark. Catalysis of TMB by HRP produced a blue colour product. After 
incubation, acidic stop solution (100 µL) was added to each well, producing an immediate 
colour change from blue to yellow. The plate was then immediately read on a plate reader 
(Multiskan™ FC Microplate Photometer, Thermo Scientific, USA) at 450 nm to obtain 
absorbances of each well. ACE concentrations (pg.mL-1) were then calculated using the 
standard curve according to Beer-Lambert’s law. The intensity of yellow colouration was 
directly proportional to the amount of human ACE protein in the sample. 
A linear standard curve was generated (Figure 6.3) using standard curve fitting software 
(SigmaPlot, Systat Software Inc, San Jose, USA). The kit inter-assay using a quality control 
and intra-assay precision, range and sensitivity were 2.1% (quality control), 7.5%,                   
780-50000 pg.mL-1 and <5 pg.mL-1, respectively. Inter- and intra-plate precision were 12.3% 
and 9.2%, respectively. A common sample measured on each plate was used for determining 
inter-plate CV.  
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Figure 6.3. Representative seven-point standard curve used to determine ACE concentrations 
from serum samples. 
6.2.3. Data Analysis 
Statistical analysis was performed using SPSS v22.0 (IBM, Chicago, USA) where data are 
reported as mean ± standard deviation (±SD). Data normality was checked using a Shapiro-
Wilk test. Greenhouse-Geisser correction was applied upon violation of Mauchly’s test of 
sphericity for ANOVAs (P < 0.05). Statistical significance was set at P < 0.05. Based on data 
from chapter 5 for the interaction effect between condition (PLA and MTCJ) and time for 
serum insulin, a priori power (α = 0.05; 1-β = 0.8) analysis indicated a sample size of 8 would 
be sufficient to detect a significant difference pre-post 6 days supplementation for serum 
insulin. Therefore, a minimum of 12 participants were recruited assuming a 20% dropout rate 
(Nogueira et al., 2012). 
A within-group two-way, 2 x 2, condition (PLA vs MTCJ) x time (Pre-Load and Post-Load), 
repeated-measures ANOVA design with post-hoc Bonferroni adjustment, measured 
differences for all blood-based biomarkers, cardiac haemodynamic, PWA, RMR and 24-hour 
BP parameters.  
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To account for day-to-day physiological variances at pre-bolus between conditions for each 
variable, data was analysed as change from pre-bolus for each time point measured post-bolus 
during testing sessions 2 and 4. This enabled a fair assessment of the post-bolus responses to 
each condition, from pre-bolus across all variables. The pre-bolus time point was not included 
as a covariate, as one-way ANOVA analysis indicated no significant differences (P > 0.05) 
between conditions for all variables at the pre-bolus time point, hence two-way repeated-
measures ANOVA was performed.  A within-group two-way, 2 x 6, condition (PLA vs MTCJ) 
x time (30 minutes, 1, 2, 3, 4- and 5-hours post-bolus), repeated-measures ANOVA design with 
post-hoc Bonferroni adjustment, measured differences of cardiac haemodynamic, PWA and 
RMR parameters on change from pre-bolus values. Blood-based biomarkers were analysed 
using the same model but with a 2 x 3, condition (PLA vs MTCJ) by time (1, 3- and 5-hours 
post-bolus) design on change from pre-bolus values for each condition.  
Comparisons between acute responses observed after MTCJ consumption in chapters 5 and 6 
were conducted to determine any differential effects after 6 days of prior loading (chapter 6) 
compared to a single, acute bolus (chapter 5). A 2 x 3, supplementation strategy (acute v             
6 days loading) by time (1, 3- and 5-hours post-bolus) mixed-model ANOVA was performed 
on change from pre-bolus data for all blood-based variables except ACE. The same model was 
used for all cardiac haemodynamic, PWA and RMR parameters but with a 2 x 6, 
supplementation strategy (acute v 6 days loading) by time (30 minutes, 1, 2, 3, 4- and 5-hours 
post-bolus) design. 
Partial Eta-Squared (
2
partial ) was used to report effect sizes for ANOVA where effects were 
classified as small (0.01-0.08), moderate (0.09-0.25) and large (>0.25) (Cohen, 1998). Cohen’s 
d effect size was used for paired-samples t-test and post-hoc interaction comparisons where 
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effects were classified as no effect (0-0.1), small (0.2-0.4), moderate (0.5-0.7) and high (≥0.8) 
(Cohen, 1998).  
Bivariate correlations were performed to check for relationships between ACE and all cardiac 
haemodynamic, PWA and 24-hour BP parameters on change from pre- to post-
supplementation data for PLA and MTCJ. Bivariate correlations were also performed between 
the aforementioned variables on change from pre-bolus data for each post-bolus time point. 
Coefficients were classified as weak (0.1-0.2), moderate (0.3-0.5), strong (>0.5) (Cohen, 1988).  
6.3. Results 
Based on results from chapter 5, serum insulin was regarded as the primary endpoint for the 
present study. HOMA2-IR, acute SBP and 24-hour SBP were regarded as secondary variables. 
Tertiary endpoints focused on other aspects of MetS including hyperlipidaemia, 
hyperglycaemia and cardiovascular dysfunction. 
Post-hoc power analysis indicated sufficient power (1-β = 0.99; α = 0.05; n = 12) to detect a 
significant main effect for the interaction between condition and time (pre-post 6 days 
supplementation) for insulin, HOMA2-IR and 24-hour SBP. Acute SBP also demonstrated 
sufficient power (1-β = 0.86; α = 0.05; n = 12) to detect a significant interaction effect. 
6.3.1. Blood Biomarkers 
6.3.1.1. Glucose 
Responses to glucose pre and post 6 days supplementation (Figure 6.4) demonstrated a 
significant interaction effect (F(1, 11) = 5.534; P = 0.038, 
2
partial  = 0.34) and main effect for 
time (F(1, 11) = 8.077; P = 0.016, 
2
partial  = 0.42) only. Post-hoc indicated a significant difference 
between PLA and MTCJ at pre-supplementation time point (P = 0.023, d = 2.85). Fasting 
glucose was significantly (t(11) = 3.506; P = 0.005, d = 0.56) lower 6 days after supplementation 
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(5.40 ± 0.95 mmol.L-1) compared to pre-supplementation (5.90 ± 0.86 mmol.L-1) with MTCJ. 
Individual responses showed 10/12 individuals with lower fasting glucose after 6 days 
supplementation of MTCJ compared to PLA. 
Mixed-model ANOVA demonstrated a tendency for the main effect of supplementation 
strategy (F(1, 21) = 4.289; P = 0.051, 
2
partial  = 0.17), where a single acute bolus induced a larger 
reduction in glucose from pre-bolus compared to 6 days prior loading. Individual responses 
showed 8/11 participants with lower glucose concentrations for the mean post-bolus change 
from baseline after a single bolus of MTCJ. In comparison, 4/12 participants responded in this 
manner after 6 days consumption of MTCJ. Moreover, at 1-hour post-bolus glucose 
concentrations after 6 days MTCJ consumption increased in 11/12 participants, compared to 
4/11 participants after acute MTCJ supplementation (Figure 6.5).
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Figure 6.4. (A) Glucose, (B) Insulin, (C) HOMA2-IR and (D) HOMA2-%S responses before and after supplementation of PLA and MTCJ. Bar 
graphs depict mean (±SD) group values for each condition, pre and post 6 days supplementation. Lines depict individual responses for all 12 
participants. *Denotes significant difference between conditions at respective time point. ^Denotes significant difference between pre- and post-
supplementation time points for MTCJ. Statistical analysis performed by a two-way, RM-ANOVA with post-hoc Bonferroni adjustment                    
(P < 0.05). 
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Figure 6.5. Mean (±SD) change from pre-bolus responses for glucose after MTCJ 
supplementation with 6 days prior loading compared to a single, acute bolus.  
 
6.3.1.2. Insulin 
Insulin responses to 6 days supplementation (Figure 6.4) only showed a significant interaction 
effect (F(1, 11) = 7.293; P = 0.021, 
2
partial  = 0.40). Pairwise comparisons indicated a significant 
difference between PLA and MTCJ at pre-supplementation time point (P = 0.049, d = 0.41). 
However, physiological responses showed after 6 days the mean change pre- to post-
supplementation was 27.05 ± 42.42 pmol.L-1 with PLA and -12.42 ± 30.50 pmol.L-1 with 
MTCJ. Moreover, individual responses showed 10/12 individuals with lower fasting insulin 
after 6 days supplementation of MTCJ compared to PLA, indicating a tendency for lower 
fasting insulin after MTCJ consumption compared to PLA. 
Similar to glucose, serum insulin only demonstrated a main effect of time (F(2, 22) = 16.828;      
P < 0.001, 
2
partial  = 0.61) on change from pre-bolus data (Table 6.4). Post-hoc showed insulin 
to be significantly higher at 1-hour post-bolus compared to both 3-hours (P = 0.005, d = 1.27) 
and 5-hours post-bolus (P = 0.004, d = 1.34). Insulin responses were not significantly different 
between MTCJ supplementation strategies or the strategy by time interaction (mixed-model 
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ANOVA) (P > 0.05), however there was a main effect for time (F(2, 21) = 26.151; P < 0.001, 
2
partial  = 0.56) (Appendix 8). Post-hoc showed insulin to be significantly higher at 1-hour 
post-bolus compared to both 3-hours (P < 0.001, d = 1.56) and 5-hours post-bolus (P < 0.001,            
d = 1.42). 
Table 6.4. Mean ± SD change from pre-bolus values to post-bolus time points for selected blood-
based biomarkers per treatment condition. 
  Post-bolus Time Points 
  1 hr 3 hr 5 hr 
Glucose* 
(mmol.L-1) 
PLA 0.47 ± 0.96 -0.09 ± 0.60 0.12 ± 0.66 
MTCJ 0.48 ± 0.36 -0.27 ± 0.51 -0.25 ± 0.55 
     
Insulin*  
(pmol.L-1) 
PLA 9.70 ± 44.24 -32.34 ± 37.38 -38.82 ± 41.38 
MTCJ 27.26 ± 42.20 -28.53 ± 29.30 -32.20 ± 32.60 
     
Triglycerides* 
(mmol.L-1) 
PLA 0.2 ± 0.2 0.3 ± 0.3 0.4 ± 0.4 
MTCJ 0.0 ± 0.2 0.2 ± 0.1 0.3 ± 0.2 
     
HDL 
(mmol.L-1) 
PLA 0.00 ± 0.05 -0.02 ± 0.08 -0.03 ± 0.08 
MTCJ -0.01 ± 0.05 0.00 ± 0.04 -0.04 ± 0.07 
     
LDL 
(mmol.L-1) 
PLA 0.34 ± 0.41 0.50 ± 0.53 0.65 ± 0.53 
MTCJ 0.06 ± 0.49 0.20 ± 0.29 0.12 ± 0.39 
     
TC:HDL 
(AU) 
PLA -0.01 ± 0.10 0.13 ± 0.35 0.17 ± 0.44 
MTCJ 0.08 ± 0.40 -0.06 ± 0.28 -0.07 ± 0.44 
     
ACE  
(pg.mL-1) 
PLA 447 ± 4048 581 ± 1801 376 ± 1776 
MTCJ 420 ± 1929 332 ± 2325 22 ± 3250 
ACE (Angiotensin-I-converting Enzyme); AU (Arbitrary Units); HDL (High-density Lipoprotein); HOMA2-IR 
(Homeostatic Model Assessment of Insulin Resistance); HOMA2-β (Homeostatic Model Assessment of 
pancreatic β-cell function); HOMA2-%S (Homeostatic Model Assessment of Insulin Sensitivity); LDL (Low-
density Lipoprotein); MTCJ (Montmorency Tart Cherry Juice); PLA (Placebo); TC (Total Cholesterol). *Denotes 
significant main effect for time with post-hoc identifying differences between 1-hour and both 3-hours and              
5-hours post-bolus. 
 
6.3.1.3. HOMA2 
As with insulin, HOMA2-IR (F(1, 11) = 8.115; P = 0.016, 
2
partial  = 0.43) and HOMA2-%S    
(F(1, 11) = 6.332; P = 0.029, 
2
partial  = 0.37) demonstrated a significant interaction after 6 days 
supplementation (Figure 6.4), with pairwise comparisons showing a significant difference 
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between PLA and MTCJ at pre-supplementation time point for HOMA2-IR (P = 0.039,               
d = 0.43). Individual responses for HOMA2-IR showed insulin resistance increased in 10/12 
participants with PLA, whereas insulin resistance was reduced in 8/12 participants after 6 days 
MTCJ consumption. Moreover, HOMA2-%S showed 9/12 participants increased insulin 
sensitivity with 6 days continuous MTCJ consumption; 2/12 increased with PLA. 
A main effect for time (F(1, 11) = 7.720; P = 0.018, 
2
partial  = 0.41) only was observed for 
HOMA2-β with pre-post 6 days supplementation data (Table 6.5). Post-hoc analysis 
highlighted greater pancreatic β-cell function post-supplementation compared to pre-
supplementation (P = 0.018, d = 0.37). No significant main effects were found on change from 
pre-bolus data for HOMA2-β (P > 0.05). 
Table 6.5. Mean ± SD responses for selected blood-based biomarkers before and after 6 days 
supplementation of PLA and MTCJ. 
  
Pre-Supplementation Post-Supplementation 
HOMA2-β* 
(%) 
PLA 131 ± 43 152 ± 49 
MTCJ 132 ± 53 148 ± 56 
Triglycerides 
(mmol.L-1) 
PLA 1.2 ± 0.1 1.3 ± 0.1 
MTCJ 1.4 ± 0.1 1.3 ± 0.1 
ACE 
(pg.mL-1) 
PLA 8706 ± 8748 9334 ± 10363 
MTCJ 10161 ± 11474 9127 ± 10915 
ACE (Angiotensin-converting Enzyme); HOMA2-β (Homeostatic Model Assessment of pancreatic β-cell 
function); MTCJ (Montmorency Tart Cherry Juice); PLA (Placebo). *Denotes significant main effect for time. 
 
6.3.1.4. Lipids 
Reponses to total cholesterol after 6 days supplementation showed significant main effects for 
time (F(1, 11) = 5.097; P = 0.045, 
2
partial  = 0.32) and interaction (F(1, 11) = 5.700; P = 0.036, 
2
partial  = 0.34) (Figure 6.6). Post-hoc identified a significant difference between PLA and 
MTCJ at pre-supplementation (P = 0.030, d = 2.14). Total cholesterol was significantly         
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(t(11) = 3.724; P = 0.003, d = 0.39) lower 6 days after supplementation (4.1 ± 1.0 mmol.L
-1) 
compared to pre-supplementation (4.5 ± 1.0 mmol.L-1) with MTCJ. 
A significant interaction effect was observed for HDL (F(1, 11) = 5.212; P = 0.043,                 
2
partial  = 0.32) and LDL (F(1, 11) = 7.004; P = 0.023, 
2
partial  = 0.39) after 6 days 
supplementation (Figure 6.6). A significant difference between PLA and MTCJ was found at 
post-supplementation time point for HDL (P = 0.049, d = 0.42), while pre-supplementation 
was significantly different for LDL (P = 0.031, d = 0.42). LDL was significantly (t(11) = 3.681; 
P = 0.004, d = 0.21) lower 6 days after supplementation (2.71 ± 1.62 mmol.L-1) compared to 
pre-supplementation (3.07 ± 1.69 mmol.L-1) with MTCJ. 
Individual responses showed 6/12 participants increased HDL concentrations after 6 days 
MTCJ supplementation, whereas 2/12 increased with PLA. Moreover, 10/12 participants 
reduced LDL concentrations after MTCJ supplementation, compared to 5/12 with PLA. 
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Figure 6.6. (A) Total cholesterol, (B) HDL, (C) LDL and (D) TC:HDL responses before and after supplementation of PLA and MTCJ. Bar graphs 
depict mean (±SD) group values for each condition, pre and post 6 days supplementation. Lines depict individual responses for all 12 participants. 
*Denotes significant difference between conditions at pre-supplementation time point. ^Denotes significant difference between conditions at post-
supplementation time point. $Denotes significant difference between pre- and post-supplementation time points for MTCJ. Statistical analysis 
performed by a two-way, RM-ANOVA with post-hoc Bonferroni adjustment (P < 0.05). 
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A main effect for condition (F(1, 11) = 5.328; P = 0.041, 
2
partial  = 0.33) showed total cholesterol 
concentrations increased significantly more with PLA than MTCJ for the mean change from 
pre-bolus (Figure 6.7). Individual responses for the change from pre-bolus showed 10/12 
participants with lower total cholesterol concentrations at 3-hours post-bolus after MTCJ 
consumption compared to PLA. Similarly, 7/12 participants responded with lower total 
cholesterol concentrations 5-hours post-bolus with MTCJ compared to PLA.  
Figure 6.7. Mean (±SD) change in total cholesterol from pre-bolus for PLA and MTCJ. 
Change from pre-bolus data indicated a significant main effect of condition (F(1, 11) = 5.874;    
P = 0.034, 
2
partial  = 0.35) and time (F(2, 22) = 4.110; P = 0.030, 
2
partial  = 0.27) for LDL, with 
higher LDL concentrations at pre-supplementation compared to post-supplementation                
(P = 0.034, d = 0.08) (Table 6.4). No main effects for condition, time or interaction were found 
for HDL or TC:HDL ratio with change from pre-bolus data (P > 0.05) (Table 6.4). 
Mixed-model analysis showed the change from pre-bolus at 5-hours post-bolus tended to be 
significantly different (main interaction effect: F(2, 42) = 2.592; P = 0.087, 
2
partial  = 0.11), with 
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total cholesterol concentrations increasing after a single acute MTCJ bolus, whereas a decrease 
was observed after 6 days prior loading (Appendix 8). Individual responses showed 9/11 
participants to have higher total cholesterol concentrations than baseline at 5-hours post-bolus 
after consumption of a single, acute bolus of MTCJ, compared to 5/11 participants after 6 days 
prior loading. 
A main effect of time only was found for HDL with mixed-model analysis between acute and 
6 days prior loading strategies (F(2, 21) = 4.117; P = 0.023, 
2
partial  = 0.16) (Appendix 8).        
Post-hoc comparisons showed HDL concentrations were significantly lower at 5-hours post-
bolus compared to 3-hours post-bolus (P = 0.037, d = 0.70). No main effects for mixed-model 
analysis were found with LDL (P > 0.05) (Appendix 8). 
After 6 days supplementation, an interaction effect was observed for TC:HDL (F(1, 11) = 13.681; 
P = 0.004, 
2
partial  = 0.55) (Figure 6.6). Post-hoc comparisons showed PLA to be significantly 
higher than MTCJ at pre-supplementation time point (P = 0.011, d = 2.67). TC:HDL ratio was 
significantly (t(11) = 2.690; P = 0.021, d = 0.30) lower 6 days after supplementation                  
(3.47 ± 1.28 mmol.L-1) compared to pre-supplementation (3.11 ± 1.13 mmol.L-1) with MTCJ. 
Mixed-model analysis did not indicate any main effects for supplementation strategy, time or 
the interaction for TC:HDL (P > 0.05) (Appendix 8). 
No significant interaction or main effects for condition and time were observed for triglycerides 
with pre-post 6 days supplementation data (P > 0.05) (Table 6.5). However, change from pre-
bolus data showed a main effect of time (F(2, 22) = 11.649; P < 0.001, 
2
partial  = 0.51) and a 
tendency for a significant interaction (F(2, 22) = 3.148; P = 0.063, 
2
partial  = 0.22) (Table 6.4). 
Post-hoc comparisons for the main effect of time showed triglyceride concentrations increased 
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more at 3-hours (P = 0.020, d = 1.50) and 5-hours post-bolus (P = 0.010, d = 2.50) compared 
to 1-hour post-bolus. 
A main effect for time only was found with mixed-model analysis for triglycerides                    
(F(2, 21) = 5.901; P = 0.006, 
2
partial  = 0.22) (Appendix 8). Post-hoc analysis showed 
triglyceride concentrations increased more at 3-hours post-bolus compared to 1-hour post-
bolus (P = 0.012, d = 0.91). Individual responses showed all 12 participants to have higher 
triglyceride concentrations than baseline at 3-hours post-bolus after 6 days prior loading of 
MTCJ, whereas only 7/11 participants responded in this manner after a single, acute bolus. 
6.3.1.5. ACE 
ACE did not show any main effects for condition, time or interaction with pre-post 6 days 
supplementation data (Table 6.5) or change from pre-bolus data (Table 6.4) (P > 0.05). 
6.3.2. Cardiac Haemodynamics 
No main effects for condition, time or interaction were detected for SBP, DBP, MAP, HR, SV, 
CO and TPR (P > 0.05) for pre-post 6 days supplementation data (Appendix 6). Despite there 
being no main effects for condition or time, a tendency towards significance was detected for 
the interaction (F(5, 55) = 2.128; P = 0.076, 
2
partial  = 0.16) with SBP. Individual responses for 
the change from pre-bolus to 2-hours post-bolus showed 4/12 participants decreased SBP with 
PLA (4 ± 13 mmHg), while 10/12 participants reduced with MTCJ (-7 ± 10 mmHg)           
(Figure 6.8). 
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Figure 6.8. Mean (±SD) change in SBP from pre-bolus for PLA and MTCJ.  
 
Mixed-model analysis indicated only a main effect for time with SBP (F(5, 21) = 5.469;                   
P < 0.001, 
2
partial  = 0.21), DBP (F(5, 21) = 3.026; P = 0.014, 
2
partial  = 0.13), MAP                      
(F(5, 21) = 3.802; P = 0.003, 
2
partial  = 0.15) and HR (F(5, 21) = 27.038; P < 0.001,                   
2
partial  = 0.56) (Appendix 9). 
There were no main effects for condition, time or interaction on change from pre-bolus data 
with DBP, MAP, CO and TPR (P > 0.05) (Appendix 6). Responses to CO, SV and TPR did 
not indicate significant differences for the main effect of supplementation strategy, time or 
interaction with mixed-model analysis (P < 0.05) (Appendix 9). 
6.3.3. Pulse Wave Analysis 
No significant main effects for condition, time or interaction were detected for aortic SBP, 
aortic DBP, AP, pulse pressure, AIx, AIx at HR75 and SEVR (P > 0.05) for pre-post 6 days 
supplementation data (Appendix 6). 
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No main effects for condition, time or interaction (P > 0.05) were found for aortic SBP. 
However, individual responses for the change from pre-bolus to 2-hours post-bolus showed 
4/12 participants decreased aortic SBP with PLA (3 ± 9 mmHg), while 9/12 participants 
responded with lower aortic SBP after consuming MTCJ (-4 ± 8 mmHg) (Figure 6.9). 
Figure 6.9. Mean (±SD) change in aortic SBP from pre-bolus for PLA and MTCJ.  
Main effects for time with mixed-model analyses were found for AIx (F(5, 21) = 5.885;                    
P < 0.001, 
2
partial  = 0.22), AP (F(5, 21) = 8.238; P < 0.001, 
2
partial  = 0.28) and SEVR                
(F(5, 21) = 6.363; P = 0.001, 
2
partial  = 0.23) (Appendix 9). 
There were no main effects for condition, time or interaction on change from pre-bolus data 
with aortic DBP and pulse pressure (P > 0.05) (Appendix 6). No main effects of 
supplementation strategy, time or interaction with mixed-model analysis were found for aortic 
DBP, pulse pressure or AIx at HR75 (P > 0.05) (Appendix 9). 
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6.3.4. Resting Metabolic Rate 
No significant main effects for condition, time or the condition by time interaction were 
detected for resting energy expenditure after 6 days MTCJ consumption (P > 0.05). 
Significant interaction effects were found for resting RER (F(1, 11) = 10.045; P = 0.009,      
2
partial  = 0.48), fat oxidation rate (F(1, 11) = 9.394; P = 0.011, 
2
partial  = 0.46) and carbohydrate 
oxidation rate (F(1, 11) = 5.644; P = 0.037, 
2
partial  = 0.34) between PLA and MTCJ after 6 days 
supplementation (Figure 6.10). Post-hoc identified a significant difference between conditions 
at pre-supplementation time point for fat (P = 0.024, d = 0.68) and carbohydrate (P = 0.027,  
d = 0.81) oxidation rates. RER was significantly (t(11) = 2.823; P = 0.017, d = 0.70) lower          
6 days after supplementation (0.83 ± 0.04) compared to pre-supplementation (0.86 ± 0.04) with 
MTCJ. 
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Figure 6.10. (A) Resting RER, (B) Carbohydrate Oxidation and (C) Fat Oxidation responses before and after supplementation of PLA and MTCJ. 
Bar graphs depict mean (±SD) group values for each condition, pre and post 6 days supplementation. Lines depict individual responses for all 12 
participants. *Denotes significant difference between conditions at pre-supplementation time point. ^Denotes significant difference between pre- 
and post-supplementation time points for MTCJ. Statistical analysis performed by a two-way, RM-ANOVA with post-hoc Bonferroni adjustment 
(P < 0.05). 
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A significant main effect for time only was observed for resting energy expenditure                  
(F(5, 55) = 2.788; P = 0.026, 
2
partial  = 0.20), RER (F(5, 55) = 43.536; P < 0.001, 
2
partial  = 0.80), 
fat (F(5, 55) = 14.183; P < 0.001, 
2
partial  = 0.56) and carbohydrate (F(5, 55) = 15.936; P < 0.001, 
2
partial  = 0.59) oxidation on change from pre-bolus data (Appendix 7). 
Mixed-model analyses for resting RER (F(5, 21) = 37.794; P < 0.001, 
2
partial  = 0.64), fat         
(F(5, 21) = 17.798; P < 0.001, 
2
partial  = 0.46) and carbohydrate (F(5, 21) = 20.075; P < 0.001, 
2
partial  = 0.49) oxidation indicated significant main effects for time and supplementation 
strategy only (Appendix 9). No significant main effects for supplementation strategy, time or 
interaction were found for resting energy expenditure (P > 0.05) (Appendix 9). 
6.3.5. 24-hour ABPM 
A significant interaction (F(1, 11) = 9.941; P = 0.016, 
2
partial  = 0.59) and main effect for 
condition (F(1, 11) = 7.916; P = 0.026, 
2
partial  = 0.53) was observed for mean 24-hour SBP 
after 7 days of supplementation (Figure 6.11). A significant difference between PLA and MTCJ 
was identified with post-hoc analysis at the post-supplementation time point (P = 0.024,              
d = 0.44). Individual responses showed 11/12 participants reduced 24-hour SBP after 7 days 
MTCJ supplementation, compared to 2/12 with PLA. 
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Figure 6.11. (A) Mean 24-hour SBP, (B) Mean 24-hour DBP and (C) Mean 24-hour MAP responses before and after supplementation of PLA and 
MTCJ. Bar graphs depict mean (±SD) group values for each condition, pre and post 7 days supplementation. Lines depict individual responses for 
all 12 participants. ^Denotes significant difference between conditions at pre-supplementation time point. *Denotes significant difference between 
conditions at post-supplementation time point. Statistical analysis performed by a two-way, RM-ANOVA with post-hoc Bonferroni adjustment  
(P < 0.05). 
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Likewise, mean 24-hour DBP only showed significant main effects for condition                       
(F(1, 11) = 12.321; P = 0.010, 
2
partial  = 0.64) and interaction (F(1, 11) = 12.789; P = 0.009, 
2
partial  = 0.65) (Figure 6.11). At pre-supplementation (P = 0.049, d = 0.14) and post-
supplementation (P = 0.008, d = 0.66) time points, post-hoc comparisons demonstrated a 
significant difference between PLA and MTCJ. Individual responses showed 10/12 
participants reduced mean 24-hour DBP after 7 days MTCJ supplementation, compared to 2/12 
with PLA. 
A significant interaction (F(1, 11) = 6.236; P = 0.041, 
2
partial  = 0.47) and tendency towards 
significance for the main effect of condition (F(1, 11) = 5.122; P = 0.058, 
2
partial  = 0.42) was 
detected for mean 24-hour MAP (Figure 6.11). Post-hoc analysis indicated PLA was 
significantly higher than MTCJ at the post-supplementation time point (P = 0.010, d = 0.58). 
Individual responses showed 9/12 participants reduced mean 24-hour MAP after 7 days MTCJ 
supplementation, compared to 1/12 with PLA. 
A tendency towards a significant interaction effect (F(1, 11) = 3.995; P = 0.086, 
2
partial  = 0.36) 
was found for mean 24-hour pulse pressure. No main effects for time or condition were detected 
(P > 0.05).  
Mean day-time SBP demonstrated a tendency towards significance for the interaction              
(F(1, 11) = 4.499; P = 0.072, 
2
partial  = 0.39) and a significant main effect for condition only 
(F(1, 11) = 6.507; P = 0.038, 
2
partial  = 0.48) (Table 6.6). Three of 12 participants were found to 
have lower mean day-time SBP with PLA after 7 days supplementation, whilst 11/12 
participants  were found to have lower mean day-time SBP with MTCJ. 
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Significant main interaction (F(1, 11) = 5.725; P = 0.048, 
2
partial  = 0.45) and condition             
(F(1, 11) = 5.876; P = 0.046, 
2
partial  = 0.46) effects were observed for mean day-time DBP 
(Table 6.6). Pairwise comparisons for the interaction effect showed significantly higher mean 
day-time DBP with PLA compared to MTCJ at post-supplementation time point (P = 0.020,  
d = 0.67). Individual responses showed 8/12 participants had lower mean day-time DBP after 
7 days MTCJ supplementation, compared to 2/12 with PLA. 
There were no significant main effects for condition, time or interaction with mean day-time 
MAP (P > 0.05) (Table 6.6). A main effect for time was observed for mean day-time pulse 
pressure (F(1, 11) = 13.661; P = 0.008, 
2
partial  = 0.66), with post-hoc showing pre-
supplementation to be higher than post-supplementation (P = 0.008, d = 0.42) (Table 6.6). 
Analysis on night-time SBP, DBP, MAP and pulse pressure demonstrated no significant main 
effects for condition, time or interaction (P > 0.05) (Table 6.6). 
The day-night difference for SBP (F(1, 11) = 7.355; P = 0.030, 
2
partial  = 0.51) and pulse pressure 
(F(1, 11) = 7.199; P = 0.031, 
2
partial  = 0.51) only showed a significant main effect for condition, 
where PLA was larger than MTCJ (Table 6.6). Day-night differences for DBP and MAP 
indicated no significant main effects for condition, time or interaction (P > 0.05) (Table 6.6). 
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Table 6.6. Mean ± SD day-time, night-time and day-night differences from 24-
hour ABPM responses before and after 7 days supplementation of PLA and MTCJ. 
  
Pre-Supplementation Post-Supplementation 
Day SBP* 
(mmHg) 
PLA 132 ± 8 133 ± 8 
MTCJ 132 ± 9 127 ± 11 
Day DBP$ 
(mmHg) 
PLA 79 ± 7 81 ± 7^ 
MTCJ 79 ± 6 76 ± 6 
Day MAP 
(mmHg) 
PLA 92 ± 8 97 ± 7 
MTCJ 92 ± 10 94 ± 7 
 
Day PP§ 
(mmHg) 
 
PLA 
 
53 ± 6 
 
51 ± 5 
MTCJ 53 ± 5 50 ± 8 
Night SBP 
(mmHg) 
PLA 113 ± 13 117 ± 7 
MTCJ 117 ± 12 117 ± 13 
Night DBP 
(mmHg) 
PLA 68 ± 9 69 ± 8 
MTCJ 69 ± 10 68 ± 8 
Night MAP 
(mmHg) 
PLA 82 ± 11 85 ± 7 
MTCJ 81 ± 14 84 ± 11 
Night PP 
(mmHg) 
PLA 46 ± 8 48 ± 5 
MTCJ 48 ± 7 49 ± 7 
D/N SBP* 
(mmHg) 
PLA 19 ± 12 16 ± 6 
MTCJ 15 ± 10 10 ± 8 
D/N DBP 
(mmHg) 
PLA 11 ± 8 12 ± 8 
MTCJ 10 ± 9 9 ± 7 
D/N MAP 
(mmHg) 
PLA 10 ± 8 13 ± 7 
MTCJ 11 ± 11 10 ± 9 
D/N PP* 
(mmHg) 
PLA 7 ± 7 4 ± 4 
MTCJ 5 ± 5 1 ± 3 
DBP (Diastolic Blood Pressure); D/N (Day/Night Difference); MAP (Mean Arterial Pressure); mmHg 
(millimetres of Mercury); MTCJ (Montmorency Tart Cherry Juice); PLA (Placebo); PP (Pulse Pressure); SBP 
(Systolic Blood Pressure). *Denotes significant main effect for condition. §Denotes significant main effect for 
time. $Denotes significant main effect for interaction. ^Denotes significant difference between conditions at 
corresponding time point. 
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6.3.6. ACE Correlations 
Bivariate correlations did not reveal any significant relationships between ACE and cardiac 
haemodynamic, PWA or 24-hour BP parameters with change from pre- to post-
supplementation data (P > 0.05) or change from pre-bolus data for either PLA or MTCJ             
(P > 0.05). 
6.4. Discussion 
In succession to the research carried out in chapter 5, this study aimed to examine blood-based 
and functional cardio-metabolic responses to an acute bolus of MTCJ but also to short-term 
continuous (7 days) MTCJ supplementation in a human, MetS population. The present study 
was the first to assess 24-hour ABPM responses and measure ACE concentrations ex vivo, to 
explain cardiovascular responses to cherry (sweet or tart) consumption, in a human trial. The 
hypotheses of the study were partially accepted as individual responses suggested a tendency 
for potential improvements in the underlying pathophysiology of MetS, insulin resistance and 
sensitivity, after 6 days MTCJ consumption compared to PLA. Findings also indicated a 
significant reduction in glucose, total cholesterol and LDL concentrations with concomitant 
lower resting RER values after 6 days MTCJ consumption compared to PLA. Of great clinical 
relevance, MTCJ significantly improved 24-hour BP after 7 days consumption compared to 
PLA. However, the present study was unable to confirm the hypothesis that ACE inhibition 
was responsible for the anti-hypertensive effect of MTCJ. Lastly, individual responses 
indicated 6 days prior loading of MTCJ to improve total cholesterol concentrations, compared 
to a single, acute bolus; although RER and glucose individual responses were improved with a 
single, acute bolus, suggesting the hypothesis was partially accepted. 
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6.4.1. Metabolic Responses 
Reductions in glucose concentrations after 6 days of MTCJ supplementation were observed 
suggesting improved glycaemic function. As there was a tendency for lower fasting insulin 
concentrations with concomitant normal fasting glucose concentrations, this may be suggestive 
of improved insulin sensitivity as mentioned by Willems et al. (2017), after 6 days 
supplementation of MTCJ compared to PLA. However, HOMA2-%S was not found to be 
higher after 6 days MTCJ intake, although 9/12 participants did report a physiological increase 
in HOMA2-%S. Hence, with a larger sample size these findings may corroborate the 
physiological theory postulated in chapter 5, that MTCJ may confer improvements in insulin 
sensitivity. Willems et al. (2017) demonstrated a reduction in fasting insulin by 14.3% after 7 
days consumption of NZBP and attributed this to heightened insulin sensitivity. Similarly, 
fasting insulin was reduced by 9.3% after 6 days consumption of MTCJ and reduced by 14% 
when comparing against placebo. Individual responses suggested insulin resistance tended to 
be improved after 6 days intake of MTCJ (HOMA2-IR change: -0.27 ± 0.56) compared to PLA 
(HOMA2-IR change: 0.48 ± 0.78), likewise Willems et al. (2017) indicated 7 days 
anthocyanin-rich NZBP consumption tended to improve insulin resistance. Together, these 
findings highlight short-term continuous supplementation of cyanidin- (MTC) and delphinidin-
rich (NZBP) interventions may have the capacity to improve insulin sensitivity/resistance in 
healthy (Willems et al., 2017) and MetS populations. However, larger datasets are required to 
justify these initial observations. Moreover, it remains to be seen how long any beneficial 
effects last, and whether intermittent supplementation for 6-7 days over a longer duration may 
be a more physiologically effective, ecologically valid and economically viable 
supplementation strategy. 
Stote et al. (2017) were unable to show significant reductions in glucose, insulin and insulin 
sensitivity after 7 days blueberry juice consumption due to normal baseline values. It was noted 
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that glucose, insulin and HOMA2-IR were significantly higher with MTCJ than PLA at pre-
supplementation in the present study due to the high day-to-day inter-individual variance of 
individuals with MetS. Thus, higher baseline values may have facilitated improvements in 
these markers based on individual responses compared to Stote et al. (2017) over 7 days. 
Notably, analysis indicated no supplementation order effect for these markers. 
Given that tart cherry concentrate is naturally high in sugar, accumulation of glucose and 
fructose likely contributed to raised glucose concentrations at 1-hour post-bolus, by                    
0.7 mmol.L-1, with 6 days prior loading of MTCJ compared to a single, acute bolus. Chai et al. 
(2018) also showed a similar glucose response after 12 weeks MTCJ supplementation. Yet, 
Ataie‐Jafari et al. (2008) reported reduced HbA1c after 6 weeks tart cherry concentrate 
consumption, and an 8% reduction in fasting glucose. Similarly, the present study showed 
MTCJ significantly reduced fasting glucose by 9% after 6 days consumption, highlighting the 
potential efficacy of tart cherry lowering hyperglycaemia in insulin resistant subjects. 
However, a caveat of such a finding is that chronic consumption of dietary sources rich in 
glucose and fructose facilitates extensive apical GLUT-2 recruitment (Fernandes et al., 2015); 
enhancing post-prandial glycaemic stress (Alzaid et al., 2013). The accumulation of fructose 
and subsequent alterations in gut bacteria (Payne, Chassard and Lacroix, 2012) may also 
explain the individual response data where triglyceride concentrations (Schaefer, Gleason and 
Dansinger, 2009) were greater at 3-hours post-bolus after 6 days prior loading of MTCJ, 
compared to the single bolus. Likewise, Chai et al. (2018) reported significantly higher 
triglyceride concentrations with prolonged MTCJ consumption. Mechanistically, the probable 
improvements in insulin sensitivity (HOMA2-%S) with MTCJ may have been through 
receptor-interactions, specifically increased insulin-receptor substrate 1 phosphorylation 
prompting glucose uptake through increased GLUT-4 translocation (Belwal et al., 2017). 
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The significant reduction in RER after 6 days MTCJ supplementation, may be explained by 
the tendency for heightened insulin sensitivity; also suggested by Solverson et al. (2018) after 
7 days blackberry feeding. The interaction between insulin sensitivity and fat oxidation may 
be mediated by anthocyanin-induced AMPK activation (Solverson et al., 2018). MTC has been 
shown to activate PPAR transcription factors, downstream of AMPK, in rodent (Seymour et 
al., 2008, 2009) and nematode (Chapter 7) models. Therefore, activation of PPARα and     
PGC-1α may account for preferential oxidation of fat as a substrate, while PPARγ agonism 
may explain the tendencies for insulin sensitising effects of MTCJ in the present study. This 
finding supports the hypothesis first proposed in chapter 4 that MTC may act as a CRM. 
As fasting glucose and insulin responses were complementary of each other, the change after 
6 days indicates MTCJ may normalise glucoregulatory control (Belwal et al., 2017), in a 
population with early insulin resistance (baseline HOMA2-IR: 2.2 ± 1.4). The significance of 
which may be highlighted when considering insulin resistance is the underlying cause of 
impaired cardio-metabolic function in humans with MetS. 
6.4.2. Lipid Responses 
This study suggests MTCJ may improve aspects of the lipid profile in individuals with MetS. 
The significant reduction in total cholesterol found in the present study agrees with findings 
from Ataie‐Jafari et al. (2008), but similar responses were not observed in other studies 
providing tart cherries (Martin et al., 2010; Chai et al., 2018), although a trend for lower 
concentrations was observed in MetS adults (Johnson et al., 2017). The reduction in total 
cholesterol with MTCJ may be explained by lower LDL fractions after 6 days supplementation. 
Similarly, reductions in LDL were reported by Ataie‐Jafari et al. (2008) and Chai et al. (2018) 
in subjects with elevated baseline LDL after tart cherry juice consumption; aligning with 
findings from other human trials supplementing anthocyanin-rich interventions that 
hyperlipidaemia is a prerequisite to observe improvements (Wallace, Slavin and Frankenfeld, 
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2016). Clinically, LDL responses after 6 days MTCJ consumption may correspond to an 8% 
relative risk reduction of major vascular events (Silverman et al., 2016).  
Chapter 5 postulated a prolonged dampening effect due to accumulation, and likely greater 
retention, of MTC phytochemicals in tissues and systemic circulation. This may explain the 
individual responses where total cholesterol concentrations were lower at 5-hours post-bolus, 
after 6 days prior loading. This suggests total cholesterol was amenable to change in the 
presence of greater tart cherry anthocyanin and secondary metabolite concentrations, as 
supported by findings from Ataie‐Jafari et al. (2008) (720 mg.day-1 anthocyanins for 6 weeks), 
individual responses with 60 mL MTCJ consumption in chapter 5 and 12 weeks MTCJ 
consumption in humans with MetS (Johnson et al., 2017). 
The present study is the first to report significantly greater HDL concentrations after cherry 
consumption compared to a control condition, however this result was more an effect of 
reductions in HDL with placebo. Moreover, the change after 6 days MTCJ consumption was 
not significant as baseline HDL was normal, agreeing with previous studies supplementing tart 
cherries (Ataie‐Jafari et al., 2008; Martin et al., 2010; Lynn et al., 2014; Johnson et al., 2017; 
Chai et al., 2018) and chapters 4 and 5. 
Bing sweet cherry consumption had no effect on TC:HDL ratio in healthy adults (Kelley et al., 
2006). In the present study, TC:HDL ratio was found to be lower after 6 days consumption of 
MTCJ and individual responses showed 10/12 participants with lower TC:HDL ratios after 
MTCJ supplementation compared to 1/12 participants with placebo. Furthermore, TC:HDL 
ratio was shown to be a good predictor of cardiovascular risk reduction when assessing 
interventions (Millán et al., 2009), thus improvements in TC:HDL after 6 days MTCJ 
consumption highlight its clinical efficacy against cardiovascular events.  
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Lastly, changes in the lipid profile induced by MTCJ after 6 days indicate a state of lower 
atherogenic and cardiovascular risk, aligning with findings in patients with MetS after MTCJ 
consumption (Johnson et al., 2017), and potentially explaining the improved 24-hour ABPM 
responses in the current study. 
6.4.3. Cardiovascular Responses 
The efficacy of sweet and tart cherry interventions on improving blood pressure, particularly 
SBP, had been demonstrated numerous times in various populations (Ataie‐Jafari et al., 2008; 
Kent et al., 2015ab; Keane et al., 2016bc), including MetS as shown in chapter 5. However, 
these studies used lab-based measurements which is clinically inferior to 24-hour ABPM 
(Hermida et al., 2011; Hodgkinson et al., 2011). Therefore, the present study was the first to 
demonstrate reductions in mean 24-hour SBP, DBP and MAP after cherry supplementation in 
any population. Cocoa flavanols were also found to reduce day-time DBP, mean 24-hour SBP 
and DBP in participants with features of MetS (Grassi et al., 2008). 
A clinically significant reduction in mean 24-hour SBP was observed after 7 days MTCJ 
consumption (-5 mmHg); which would be associated with prevention of all-cause and 
cardiovascular mortality by 20% (Banegas et al., 2018). This finding adds greater clinical and 
biological relevance to the individual responses reported for acute SBP reductions in the 
present study, chapter 5 and by Keane et al. (2016b) after an acute, single-bolus of MTCJ. In 
this study, a reduction of 11 mmHg was observed after 6 days MTCJ consumption compared 
to PLA for acute SBP at 2-hours post-bolus. Comparative reductions of 8 mmHg were seen 
with 7 days blueberry juice consumption compared to PLA in individuals with pre- and stage 
1 hypertension (Stote et al., 2017), highlighting the efficacy of 6-7 days consumption of 
anthocyanin-rich juices (~270-314 mg.day-1 total anthocyanins). As in chapter 5, the 
magnitude of acute SBP reduction with MTCJ was comparable to approved anti-hypertensive 
drugs associated with harmful side effects (Bramlage and Hasford, 2009). Moreover, the             
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2 mmHg reduction in mean 24-hour DBP after 7 days MTCJ consumption would be associated 
with a risk reduction of CHD and stroke by 6 and 15%, respectively (Cook et al., 1995). This 
response was facilitated by significant day-time DBP reductions with MTCJ, which has been 
shown to be a significant predictor of CVD, CHD and stroke (Fagard et al., 2008).  
Despite supplementing a similar daily anthocyanin dosage as the present study (270 mg.day-1), 
Stull et al. (2015) reported no effect on 24-hour BP after consuming anthocyanin-rich         
(290.3 mg.day-1 anthocyanins) blueberry smoothie for 6 weeks compared to PLA, in 
individuals with MetS. This finding supports the short-term, low-dose anti-oxidant hypothesis. 
The pharmacokinetics of PCA and VA may explain the acute lab-based SBP reductions with 
MTCJ compared to PLA, 2-hours post-bolus, based on individual responses. The hypotensive 
effects of VA may also explain the 24-hour ABPM responses to MTCJ consumption as VA is 
structurally similar to apocynin, a vasodilatory drug (Rodriguez-Mateos et al., 2013; Igwe et 
al., 2017). Lab-based DBP responses were similar to observations reported by other MTCJ 
supplementation studies (Lynn et al., 2014; Johnson et al., 2017; Chai et al., 2018), including 
chapter 5. Differences between lab-based and 24-hour ABPM may be due to the provision of 
an additional bolus of MTCJ prior to ABPM and/or greater variability in measurement of lab-
based BP monitoring compared to 24-hour ABPM, due to phenomena such as white coat 
syndrome (Drawz, Abdalla and Rahman, 2012; O’Brien et al., 2013). 
In comparison to Keane et al. (2016b) (-7 mmHg) and chapter 5 (-11 mmHg), the magnitude 
of acute, lab-based SBP reduction in the present study (-11 mmHg) was similar after 2-hours 
compared to placebo. Thus, indicating no additional benefit of 6 days prior loading of MTCJ 
in individuals with MetS exhibiting early-hypertension at baseline. This suggests an elevated 
baseline SBP and the attainment of a physiologically relevant threshold of phytochemicals are 
required to elicit a reduction in SBP; beyond which further reductions are not observed. 
Individual responses indicated lower aortic SBP 2-hours post-bolus of MTCJ compared to 
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PLA. A similar mechanism may be cited as the brachial SBP response at 2-hours post-bolus, 
through PCA and VA mediated endothelium-dependent vasodilation. Additionally, the 
brachial and aortic SBP responses concur with a cross-sectional study highlighting 
significantly lower brachial and aortic SBP with higher habitual anthocyanin intakes (Jennings 
et al., 2012). 
Aviram and Dornfeld (2001) demonstrated reductions in SBP were correlated with 
significantly lower ACE activity after 2 weeks pomegranate juice consumption. Furthermore, 
Kirakosyan et al. (2018) demonstrated 88.7% ACE inhibition in vitro, with MTC extract 
applied in physiologically relevant concentrations. However, in the present study, as no 
correlations were observed between serum ACE concentrations and changes in cardiovascular 
parameters, ACE inhibition may not explain the hypotensive effects of MTCJ; potentially 
because PCA and VA are weak ACE inhibitors (Hidalgo et al., 2012). Moreover, the present 
study would have benefitted from assessment of ACE activity rather than ACE protein 
concentrations, to explain the hypotensive mechanism of MTCJ. Yet, individual responses 
showed 8/12 participants had lower ACE concentrations 6 days after MTCJ consumption 
compared to 4/12 with PLA. Overall, ACE inhibition may still explain the hypotensive effects 
of MTCJ, however future research should incorporate more rigorous methodologies to 
elucidate mechanisms. 
6.4.4. Strengths, Limitations and Future Work 
Despite the prospective nature of the study, a limitation would be the small sample size on 
which conclusions are based, therefore larger clinical trials are required assessing individuals 
with MetS, but also other clinical populations. Due to financial constraints surrogate indices of 
pancreatic β-cell function, insulin resistance and sensitivity were used. Future work should 
consider using tolerance tests or hyperinsulinaemic-euglycaemic clamps (Stull, 2016) to assess 
the efficacy of MTCJ on post-prandial responses, which provides more ecologically valid 
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conclusions. However, the present study addressed the artificial placebo effect encountered in 
chapter 5 by using an energy and carbohydrate matched placebo to assess the impact of the 
phytochemicals in MTCJ. 
A key strength of the study was the use of 24-hour ABPM as a clinically relevant measure of 
assessing the effect of MTCJ on blood pressure and subsequently cardiovascular risk. Another 
strength was the use of a dietary supplement made of a whole food; upholding ecological 
validity due to the simplicity of incorporating such an intervention into habitual diets. Further 
understanding of the efficacy of purified anthocyanins alone compared to a whole dietary 
supplement on cardio-metabolic markers is required, to inform dietary and clinical practice. 
Lastly, although not objectively measured, participants did not report any adverse effects from 
MTCJ consumption indicating a degree of tolerance; a major benefit over pharmacological 
interventions.  
6.5. Conclusion  
The present study has provided novel findings and revealed for the first time the ability of an 
MTC intervention (specifically juice) to significantly improve 24-hour BP, fasting glucose, 
total cholesterol and TC:HDL ratio, and also lower resting RER compared to a control in any 
human population. LDL concentrations were also found to be lower in individuals with MetS 
for the first time, after 6 days consumption of MTCJ compared to PLA. Moreover, individual 
responses also indicated tendencies for improvements in fasting insulin, insulin resistance and 
insulin sensitivity after consuming MTC, for the first time in any human population. Together, 
these responses demonstrated clinically relevant improvements on aspects of cardio-metabolic 
function, emphasising the potential efficacy of MTCJ in preventing further cardio-metabolic 
dysregulation in an ‘at risk’ population. An overarching theme from the comparison between 
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supplementation strategies with MTCJ on acute cardio-metabolic responses, demonstrated 6 
days prior loading had a limited beneficial impact compared to a single, acute bolus. 
This research was unable to confirm ACE inhibition as a mechanism of the hypotensive 
properties of MTCJ, thus further work is required to elucidate mechanisms for BP responses, 
but also other cardio-metabolic improvements shown here. It remains to be seen how long the 
reductions in 24-hour BP last with MTCJ, however with further research MTCJ could perhaps 
replace or be used as an adjuvant to anti-hypertensive drugs in the future. Nevertheless, the 
evidence presented is promising for individuals with elevated cardiovascular risk particularly, 
pre-hypertension. 
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The study presented within this chapter was conducted in collaboration with Dr. Samantha 
Hughes and colleagues at the HAN BioCentre, HAN University of Applied Sciences, 
Nijmegen, The Netherlands. Contributions towards this study are highlighted on page xi. 
7.1. Abstract 
Montmorency Tart Cherries, MTC, (Prunus cerasus L.) possess a high anthocyanin content as 
well as one of the highest oxygen radical absorbance capacities of fruits at common habitual 
portion sizes. MTC have been shown to contribute to reducing plasma lipids, plasma glucose 
and fat mass in rats and strikingly, similar effects are observed in humans. However, there is a 
paucity of research examining the molecular mechanisms by which such MTC effects are 
induced. Here, we show that when exposed to MTC, Caenorhabditis elegans display a 
significant extension to lifespan, and these worms are healthier. Using RNA interference, it is 
possible to silence genes involved in fat metabolism and provide insight into the molecular 
pathways through which MTC acts. We have identified that MTC functions via the PPAR 
signalling pathway, specifically nhr-49 and daf-22. Our data provides encouraging evidence 
that MTC may be operating as a calorie restriction mimetic via metabolic pathways. 
7.2. Introduction 
Globally, approximately 1.75 billion people have MetS, a cluster of cardio-metabolic criteria 
including obesity, hyperglycaemia, dyslipidaemia and elevated blood pressure (Holubková et 
al., 2012). MetS is often a precursor to type 2 diabetes and cardiovascular disease, which 
together place a significant burden on health services and are the leading causes of reduced 
lifespan and increased morbidity worldwide (O’Neill et al., 2016). Given the social challenges 
faced by the prevalence of MetS, obesity, cardiovascular disease and diabetes, non-
pharmacological interventions are desperately needed to safely prevent and mitigate the 
development of these diseases.  
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Recently, there has been renewed interest into diets supplemented with “functional foods” 
particularly rich in polyphenols for health and exercise benefits, namely beetroot juice (Ferreira 
and Behnke, 2010), purple sweet potatoes (Liu et al., 2010), blueberries (Wilson et al., 2006; 
McAnulty et al., 2011), pomegranate juice (Trombold et al., 2011), green tea (Jówko et al., 
2011) and cherries (Traustadottir et al., 2009; Bell et al., 2014b). Ensuring a diet rich in such 
foods results in significant health benefits to humans, specifically related to their anti-oxidative, 
anti-inflammatory, anti-obesity and anti-cancer properties (Ghosh, 2005; Wu et al., 2006; 
Seymour et al., 2009). Montmorency Tart Cherries (Prunus cerasus L.), MTC, possess a high 
anthocyanin content and has one of the highest oxygen radical absorbance capacities of fruits 
consumed at common habitual portion sizes (Ou et al., 2012). The health benefit of MTC is 
likely due to the presence of polyphenols, mainly anthocyanins, which are commonly found in 
the skin of the fruit and are responsible for its dark red pigmentation (Khoo et al., 2017). 
Human studies have established that MTC has anti-inflammatory (Bell et al., 2014b), anti-
oxidative (Bell et al., 2014b), anti-hypertensive (Keane et al., 2016b) and anti-hyperuricaemic 
(Bell et al., 2014b) properties. Correspondingly, rats fed MTC displayed significantly improved 
lipid profiles and reduced fat mass, hyperinsulinaemia and hyperglycaemia compared to control 
animals (Seymour et al., 2008, 2009). Additionally, tart cherries have been shown to have an 
anti-diabetic effect in diabetic rats, via the reduction of plasma glucose (Tahsini and Heydari, 
2012). Together, although this is promising evidence that MTC can thwart MetS development, 
there is a paucity of research examining mechanisms of action by which these effects are 
induced. Previous studies investigating the mechanisms underpinning MTC used animal models 
and showed that MTC induced gene expression of PPARα/γ and downregulated both IL-6 and 
TNF-α (Seymour et al., 2008, 2009), all major pathways involved in fat metabolism and insulin 
signalling. It is likely that the phytochemicals in MTC may alter the transcription of other genes 
involved in the response to oxidative stress (Kirakosyan et al., 2018), but these have yet to be 
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fully elucidated. It is therefore obvious that a detailed understanding of the effect of MTC on 
these, and other, pathways that lead to positive health effects is lacking.  
Caenorhabditis elegans is a powerful model organism to study the molecular pathways that 
underpin human disease (Markaki and Tavernarakis, 2010; Shaye and Greenwald, 2011).          
C. elegans is a small, transparent nematode worm with a short life span of just 4 weeks, a large 
brood size of 250 genetically identical offspring and simple anatomy. Strikingly, the nematode 
has many well-studied molecular networks and tissue systems that are also found in vertebrates, 
including intestine, skin (cuticle) and a nervous (autonomic and somatic) system. The worm 
has been fully sequenced and mapped (Hillier et al., 2005), with 80% of human genes 
possessing homologues in C. elegans (Kaletta and Hengartner, 2006). In addition, feeding 
behaviour, nutritional uptake and fat metabolism are conserved between C. elegans and humans 
(Hashmi et al., 2013). Lastly, C. elegans is extremely powerful in terms of technical 
methodology, such as RNA interference (RNAi) (Ashrafi et al., 2003; Kamath and Ahringer, 
2003; Rual et al., 2004), and together with easy access to a vast number of genetic mutants, 
facilitates molecular pathway dissemination. Taken together, these factors emphasise the 
translational relevance of this model species and its potential to predict effects in higher animals 
and inform clinical nutrition practice in humans. 
This study examined the response of C. elegans to various dilutions of MTC concentrate that 
relate to the recommended dilution for human consumption. Due to the significant genetic 
homology between nematodes and humans, it is possible to silence genes involved in fat 
metabolism in nematodes and observe the effect in the presence and absence of MTC. Such 
single gene knockdown provides insight into the molecular pathways by which MTC is able to 
exert its health promoting effects.  
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7.3. Materials and Methods 
7.3.1. Strains and Maintenance of Worms 
Strains were derived from the wild type N2 Bristol strain and maintained at 20°C, as described 
previously (Brenner, 1974). C. elegans were maintained on Nematode Growth Media (NGM) 
agar prepared according to standard protocols (Brenner, 1974) and plates seeded with OP50    
E. coli as a bacterial food source. 
To synchronise worm populations, gravid worms were washed from plates with M9 buffer 
(Brenner, 1974) and dissolved using alkaline hypochlorite solution (4 mL 5% sodium 
hypochlorite, 1 mL 4M sodium hydroxide, 5 mL dH2O) to obtain the eggs. Hypochlorite 
solution was removed by washing the eggs three times with M9 buffer. Eggs were left to hatch 
overnight at 15°C in M9 buffer in the absence of a food source, giving rise to a population of 
synchronised L1 larvae which could then be placed directly onto NGM to develop to L4 stage 
at a similar rate. 
7.3.2. MTC concentrate seeded NGM  
Montmorency tart cherry concentrate (Cherry Active, Active Edge Ltd, Hanwell, UK) has a 
recommended human consumption of 30 mL MTC concentrate mixed with 240 mL water, 
daily. This is equivalent to a daily dose of 125 µL.mL-1. 
MTC was added directly to the cooled molten NGM prior to pouring plates. The final 
concentrations of MTCJ in the NGM plates were 16.7 µL.mL-1, 66.7 µL.mL-1, 83.3 µL.mL-1, 
116.77 µL.mL-1 and 150 µL.mL-1 in NGM. The pH of all preparations was checked, 
substituting water for NGM. For each MTC spiked water sample, there was no change in pH 
compared to the control. 
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7.3.3. RNA interference 
RNA interference experiments were performed using standard protocols (Ashrafi et al., 2003; 
Kamath and Ahringer, 2003). NGM for RNAi was supplemented with 116.7 µL.mL-1 of 
MTCJ in NGM, similar to the recommended daily human dose, or 116.7 µL.mL-1 distilled 
water as the control.  
The RNAi clones were chosen based on their homology to human genes involved in different 
aspects of fat metabolism (Ashrafi et al., 2003; Shaye and Greenwald, 2011). Clones were 
obtained from the Vidal ORFeome-based RNAi library (Rual et al., 2004) and those used in 
this research are listed in Table 7.1. All nematode experiments were conducted using the N2 
strain. dsRNA was delivered by feeding to age-synchronised L1 stage animals, which were 
incubated at 20°C and phenotypes were observed 48 hours later, when control animals had 
reached the L4 stage. Control RNAi was performed using HT115 bacteria transformed with an 
empty L4440 vector.  
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Table 7.1. List of worm genes, and their human homologues, used for RNAi analysis 
Human Gene / description Worm gene name 
Isoform 1 of Hepatocyte nuclear factor 4-gamma nhr-49 
gastric triacylglycerol lipase isoform 1 lipl-1 
fatty acid desaturase 1 fat-4 
Isoform 1 of Tubby protein homologue tub-1 
fatty acid desaturase 1 fat-3 
Isoform SCPx of Non-specific lipid-transfer protein daf-22 
Elongation of very long chain fatty acids protein 3 elo-4 
One of the nematode cytochrome P450s cyp-13A11 
4-trimethylaminobutyraldehyde dehydrogenase alh-11 
Isoform HNF4-Alpha-2 of Hepatocyte nuclear factor 4-alph nhr-80 
highly similar to Krueppel-like factor 5 klf-1 
SREBP sbp-1 
Lipase member M precursor lipl-4 
Glutaminyl-peptide cyclotransferase-like protein H27A22.1 
Acyl-coenzyme A thioesterase 8 C37H5.13 
Fatty acyl-CoA reductase 1 fard-1 
Isoform 5 of Phospholipase B1, membrane-associated F09C8.1 
Acyl-coenzyme A thioesterase 8 F25E2.3 
Acyl-CoA:lysophosphatidylglycerol acyltransferase 1 acl-12 
Isoform 5 of Phospholipase B1, membrane-associated T19D7.7 
O-linked N-acetylglucosamine (O-GlcNAc)-selective N-
acetyl-beta-D-glucosaminidase (O-GlcNAcase) 
oga-1 
Acyl-coenzyme A thioesterase 8 C17C3.3 
Glycerol-3-phosphate acyltransferase 3 M79.2 
Gene involved in fat metabolism daf-7 
Neuronal acetylcholine receptor subunit alpha-7 eat-2 
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7.3.4. Lifespan Assay 
To assess lifespan, wild type N2 worms were used. Animals were reared on OP50 seeded NGM 
at 19°C following standard protocols. When gravid, animals were bleached and the resulting 
age synchronised L1 animals were placed onto seeded NGM. When animals were L4, this was 
counted as Day 0 of the survival assay. During the reproductive period, the worms were 
transferred to a new plate and observed every day for death. Animals were scored as dead if 
they failed to respond to a touch by a platinum wire. Survival curves were generated and data 
analysed using the OASIS software (Yang et al., 2011). For multiple analysis, P < 0.0055 was 
considered as significant (Bonferroni corrections).  
7.3.5. Microscopy 
To take images, worms were mounted onto 2% agarose pads in 0.1% sodium azide. Fluorescent 
imaging was carried out using a Zeiss Imager.M2 microscope and photomicrographs were 
taken using a x40 objective (Zeiss) and Zeiss Zen 2012 Blue Software. All images of animals 
were compiled using Adobe Photoshop 7.0 and backgrounds merged.  
7.3.6. Obesity Assay 
The obesity assay was adapted from Mak et al. (2006) and Ashrafi et al. (2003). A stock 
solution of Nile Red (Roth) was prepared at 0.5 mg.mL-1 in acetone and diluted in 1xPBS to    
1 µg.mL-1, both solutions were stored in the dark at 4°C. Nile Red was added to molten NGM 
(1 mL of working solution in 50 mL NGM) and when solid the plates were seeded with E. coli 
OP50. Age synchronised L1 worms were added to the plates and allowed to develop to L4, at 
which point the worms were sacrificed for microscopy. 
Images were taken using the same gain and exposure settings of animals on the same focal 
plane (around the grinder in the second pharyngeal bulb). Using ImageJ software, the 
fluorescence in a 20x20 pixel box placed at the grinder was calculated, to give a value 
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corresponding to level of staining of the Nile Red vital dye. The arbitrary values for “red” are 
equivalent to the level of Nile Red staining, which are normalised to the control worms and 
plotted. 
7.4. Results and Discussion 
7.4.1. Lifespan is increased following exposure to MTC 
Studies have shown that downregulation of the evolutionarily conserved insulin/IGF-1 
signalling pathway causes a metabolic shift away from glucose metabolism to lipid oxidation 
and is associated with longevity (van Heemst, 2010). Here, MTC was tested to see if it was able 
to extend lifespan, indicative of a positive effect on the insulin signalling pathway. Wild type 
animals that were not exposed to MTC lived for a maximum of 17 days post L4, while animals 
exposed to MTC displayed a significant increase in lifespan (Figure 7.1, Table 7.2). This 
extension to lifespan was most significant at lower MTC dilutions, 16.7 µL.mL-1 of MTC, the 
longest-lived animal was 23 days old and at 150 µL.mL-1, the maximum lifespan was 20 days 
(Figure 7.1, Table 7.2). Interestingly, the days at which 50% of the population died was only 
extended for the worms exposed to 16.7 µL.mL-1 MTC. In addition, lifespan of animals at 66.7 
and  33.3 µL.mL-1 of MTC showed a similar lifespan to those of 16.7 µL.mL-1 MTC and lifespan 
of worms exposed to 66.7 and 83.3 µL.mL-1 of MTC were comparable (data not shown). 
Together, data from this study shows there is an extension to lifespan following exposure to 
MTC, with lower dilutions more beneficial to the worms than elevated dilutions. It is possible 
that a hormetic effect of MTC is occurring, where the benefit provided by anti-oxidants in MTC, 
is to scavenge free radicals more effectively, while at higher concentrations the pro-oxidant 
nature of MTC phytochemicals reverses some health-promoting effects (Blando, Gerardi and 
Nicoletti, 2004; Konczak and Zhang, 2004). 
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Such a lifespan extension as observed here is similar to that of blueberry polyphenols, which 
were able to increase lifespan and delay ageing in C. elegans (Wilson et al., 2006). This may 
be related to the fact that despite tart cherries containing sugar, which would be expected to 
reduce lifespan, the fruit is able to reduce glycaemic stress by modulating the insulin signalling 
pathway (Seymour et al., 2009). Such a reduction in glycaemic stress may be mediated by the 
presence of MTC anthocyanins, phenolic acids and/or their secondary metabolites (Kirakosyan 
et al., 2009; Scazzocchio et al., 2011), which may reduce the concentration of ligands available 
to activate the insulin signalling cascade. 
Table 7.2. Statistical analysis of lifespan. Raw lifespan data was analysed using the OASIS 
software (Yang et al., 2011). The control animals (no MTC exposure), lived for a maximum of 
17 days, which was extended in all MTC exposed worms. Of the animals exposed to 16.7 
µL.mL-1 MTC, 50% mortality was extended from 10 to 13 days, and was the only dilution of 
MTC to show this. For each condition, over 100 animals were used, bar 150 µL.mL-1 where 80 
animals were used. For lifespan plots, see Figure 7.1.  
MTC Concentration 
Age in days at: 
Bonferroni p value 50% mortality 100% mortality 
0 µL.mL-1 10 17 - 
16.7 µL.mL-1 13 23 0.0001 
66.7 µL.mL-1 9 20 0.2358 
150 µL.mL-1 8 20 0.0001 
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Figure 7.1. Lifespan of worms was extended following exposure to MTC. Wild type worms 
lived for a maximum of 17 days post L4 (solid black lines). Animals exposed to 16.7 µL.mL-1 
displayed an extension to lifespan throughout (solid grey lines). In contrast, animals exposed 
to 66.7 µL.mL-1 (dashed black line) and 150 µL.mL-1 (dashed grey line) showed a faster death 
rate compared to the control animals but did have a slight extension to maximum lifespan. For 
each condition, over 100 animals were used, bar 150 µL.mL-1 where 80 animals were used. For 
statistical analysis, see Table 7.2.  
 
7.4.2. Exposure to High MTC Dilutions Reduces Lipid Staining 
Fat metabolism and lifespan are intertwined and likely to be directly coupled (Hansen, Flatt and 
Aguilaniu, 2013), therefore the fat content of MTC exposed animals using the vital dye, Nile 
Red was measured (Ashrafi et al., 2003; Mak et al., 2006). Strikingly, animals exposed to the 
lower doses of MTC (16.7 µL.mL-1 and 66.7 µL.mL-1) displayed a significantly increased level 
of Nile Red staining compared to controls (Figures 7.2 and 7.3). In contrast, elevated levels of 
MTC significantly reduced Nile Red staining (83.3 µL.mL-1 and 116.7 µL.mL-1). It is of interest 
to note that worms exposed to the 116.7 µL.mL-1 dilution of MTC had a developmental delay 
of 24 hours compared to all other dilutions (data not shown). 
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Long-lived daf-2 mutant C. elegans display an increase in fat accumulation compared to wild 
type animals (O'Rourke et al., 2009), suggesting that this is the cause of the increased lifespan 
observed with low dilutions of MTC. Although MTC has an elevated carbohydrate content, this 
would prompt the activation of transcription factors, such as SKN-1, that promote the 
expression of anti-oxidant or detoxification enzymes (Pang et al., 2014), thus allowing animals 
to promote longevity, as shown in blueberries (Wilson et al., 2006) (refer to section 7.3.1).  
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Figure 7.2. Representative images of worms exposed to MTC. In all cases, animals were grown 
from L1 to L4 on NGM supplemented with increasing dilutions of MTC and the vital dye Nile 
Red. At L4 stage, worms were mounted for microscopy and imaged using identical settings. 
Images were taken at the anterior of the animal, with the focal plane always on the valve of the 
grinder. (A) Control animals, (B) 16.7 µL.mL-1 MTC, (C) 66.7 µL.mL-1 MTC,                              
(D) 83.3 µL.mL-1 MTC and (E) 116.7 µL.mL-1 MTC. Anterior is to the left, ventral to the 
bottom. Scale bar is 500 µm. 
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Figure 7.3. Graph to show the relative fat staining in worms exposed to MTC. Images of worms 
exposed to MTC were analysed using ImageJ and the values of Nile Red staining are 
normalised to the control, and this value plotted. Control animals (black bars) show some Nile 
Red staining of the upper intestine. There is a significant increase in fat staining in the animals 
exposed to 16.7 µL.mL-1 and 66.7 µL.mL-1 MTC (dark grey bars) while those worms exposed 
to 83.3 µL.mL-1 and 116.7 µL.mL-1 MTC (light grey and white bars) have a significant 
reduction in fat staining. In all cases ** is P < 0.01 and n = 26.  
7.4.3. MTC Acts Through the PPAR Signalling Pathway 
Unravelling the pathways through which MTC acts, will shed light on the mechanisms by which 
MTC provide their many health benefits. As there is significant homology between the 
mechanisms of fat storage and regulation in C. elegans and mammals (Ashrafi, 2007), it is 
possible to elucidate which pathways are involved with MTC. A number of candidate genes 
were chosen based on their homology to key human fat metabolism processes.  
During the lifespan experiments, it was noticed that there was a small developmental delay in 
the time it took animals exposed to elevated MTC dilutions to reach L4 stage compared to 
controls. The majority of the genes tested showed a similar effect to the control RNAi, L4440, 
in the presence of MTC, in that all animals reached the L4 stage at approximately the same time. 
However, 7 genes (tub-1, daf-22, elo-4, sbp-1, lipl-4, H27A22.1 and eat-2) that were silenced 
in the presence of MTC showed a similar stage of development as the control in the absence of 
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MTC i.e. a reversal of the delay (Figure 7.4A). Strikingly, RNAi of nhr-49, lipl-1, fat-3, klf-1, 
F09C8.1, C17C3.3 and daf-7 caused an enhancement of the developmental delay caused by 
MTC alone (Figure 7.4B). 
Figure 7.4. RNAi knockdown affects development of animals exposed to MTC. Wild type 
animals were placed onto RNAi NGM seeded with, or without, 116.7 µL.mL-1 MTC, and after 
48 hours at 20°C the developmental progress of the animals was compared. (A) Control animals 
that are not exposed to MTC and are fed control RNAi (empty vector L4440) reach the L4 stage 
(top panel). In contrast MTC exposed worms lag 1 day behind the non-exposed animals (bottom 
panel). (B) Representative images of worms, which when genes of interest were silenced in the 
presence of MTC showed a recovery of the developmental delay. Shown are H27A22.1, sbp-1, 
lipl-4 and daf-22. (C) Representative images of animals where RNAi silencing of genes 
enhanced the developmental delay. Two genes are shown, lipl-1 and nhr-49. 
 
 
 
 
L4440
L4440 + 
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It was found that the RNAi knockdown of daf-22, the nematode homologue of human SCP2, in 
the presence of MTC reversed the developmental delay that is caused by exposure to MTC. In 
contrast, in the presence of MTC RNAi knockdown of nhr-49, the HNF4G/PPAR homologue, 
further enhanced the developmental delay compared to the control. Such an effect is intriguing, 
as both daf-22 and nhr-49 function in the PPAR signalling pathway (Burgering et al., 2004; van 
Gilst et al., 2005), which are central regulators of fat metabolism [reviewed in (Nunn, Bell and 
Barter, 2007)]. Strikingly, cyanidin-3-O-β-glucoside and its metabolite protocatechuic acid, 
also found in MTC, have been shown to activate PPARs thus providing an insulin-sensitising 
effect (Scazzocchio et al., 2011). Indeed, here we confirm that MTC influences the PPAR 
pathway (Seymour et al., 2008) and thus is likely to operate as a calorie restriction mimetic 
(Corton et al., 2004). 
It is striking that when sbp-1 (nematode homologue of SREBP-1c, Sterol regulatory element 
binding protein) is silenced in the presence of elevated MTC dilutions there is a recovery of the 
developmental delay. In contrast, there is an enhancement of the MTC induced developmental 
delay when lipl-1 (a lysosomal lipase) is knocked down. Both sbp-1 and lipl-1 have recently 
been shown to be regulated by the MAX-3 transcription factor, to modulate lipid metabolism 
in nematodes (Moreno-Arriola et al., 2017). It is likely, that these genes form part of a complex 
network modulating the response to carbohydrates (including glucose) and fat, as suggested 
previously.  
However, ultimately, regulation of longevity and lipid metabolism is complex, involving 
multiple genes and signalling pathways and how longevity and fat accumulation are uncoupled 
from diet remains elusive. 
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7.5. Conclusion 
To date, there is promising evidence that MTC can contribute to preventing MetS development, 
although there is a lack of research examining the mechanism of action by which such effects 
are induced. The data from this study provides encouraging evidence that MTC may be 
operating as a CRM via metabolic pathways and it is shown here that the nematode C. elegans 
is a useful model for dissecting pathways that correlate to humans. Together, this data 
highlights the use of C. elegans to dissect the molecular pathways through which MTC act and 
will allow for further detailed pathway dissemination. Due to the large number of genetic 
mutants available, it is possible to replicate studies in nematodes that have defects in the insulin 
signalling pathway to further understand how MTC might act to alleviate MetS symptoms. 
Indeed, such data can then be used to design and perform more targeted longitudinal clinical 
trials in humans with MetS. In addition, it is possible that genes identified in C. elegans as 
having a role in obesity or diabetes are likely to be implicated in human disease as well or, at 
the very least, provide candidates for anti-obesity and anti-diabetic drugs. 
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8.1. Thesis Overview 
Current and projected, global, prevalence and incidence rates of cardio-metabolic diseases are 
alarming. Hence, there is an urgent need to identify safe interventions to prevent the accentuation 
of this major problem. This thesis constituted a series of studies examining the efficacy of safe 
lifestyle interventions, including dietary supplementation of Montmorency tart cherry juice and 
capsules with and without FATMAX exercise, on cardio-metabolic function in healthy humans 
and those with MetS. The emphasis of the thesis was around preventing and reducing cardio-
metabolic dysfunction using these interventions in populations susceptible to greater risk of 
developing cardio-metabolic diseases. Lastly, limited research had identified mechanisms for the 
purported benefits of MTC, therefore various C. elegans models were used to identify mechanistic 
pathways through which MTC may act. 
8.1.1. Key Findings 
This thesis tested the hypotheses outlined in section 2.3.2. This thesis identified numerous novel 
findings and corroborated previously reported results through the four experimental studies 
conducted, including: 
H1: Montmorency tart cherry supplementation will significantly improve resting cardio-metabolic 
biomarkers compared to the placebo-controlled condition, in healthy and MetS human 
populations. 
i. MTC supplementation did not significantly improve cardio-metabolic markers compared 
to the placebo-controlled condition, in healthy humans. 
ii. MTC supplementation significantly improved certain cardio-metabolic markers compared 
to the placebo-controlled condition, in humans with MetS. 
Chapter 8. General Discussion 
273 
 
H2: Montmorency tart cherry supplementation with FATMAX exercise will improve cardio-
metabolic biomarkers compared to the placebo-controlled condition, in a healthy human cohort 
(Chapter 4). 
iii. Combination of 20 days MTCJ supplementation and FATMAX exercise did not augment 
fat oxidation at rest or during exercise, nor did it improve cardio-metabolic biomarkers in 
healthy humans.  
a. Continued supplementation of MTCJ beyond 10 days did not induce a concomitant 
elevation in total anti-oxidant status, rather levels returned to baseline. Hence, 
short-term anti-oxidant supplementation from MTCJ seemed to be more effective 
at improving cardio-metabolic function and suggests MTCJ may be a hormetin. 
H3: A single, acute bolus of Montmorency tart cherry juice and capsules will improve acute cardio-
metabolic biomarkers compared to the placebo-controlled condition, in humans with MetS 
(Chapter 5). 
iv. A single, acute bolus of MTCJ and MTCC acutely improved certain cardio-metabolic 
biomarkers in humans with MetS. 
a. MTCJ induced a clinically relevant reduction in SBP, 2-hours after consumption 
in individuals with MetS. The magnitude of change was comparable to 
pharmacological anti-hypertensive drugs. 
b. MTCC and MTCJ reduced insulin concentrations, 1-hour and 3-hours after 
consumption, respectively. A health benefit of MTCC consumption was shown for 
the first time in any human population. Data also indicated a potential improvement 
in insulin sensitivity mediated by MTCC and MTCJ. 
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c. Acute cardio-metabolic responses were not statistically different between acute 
MTCJ and MTCC supplementation in individuals with MetS. Physiological 
responses indicated MTCC reduced insulin more than MTCJ, 1-hour post-bolus. 
Although, MTCJ reduced SBP more than MTCC at 2-hours post-bolus. 
d. Dose-response effect was not apparent with MTCJ. However, individual responses 
suggested HDL, TC:HDL ratio and arterial stiffness were improved after 
consumption of 60 mL MTC concentrate compared to 30 mL MTC concentrate in 
humans with MetS. 
H4: Short-term, continuous supplementation of Montmorency tart cherry juice in individuals with 
MetS will improve cardio-metabolic biomarkers compared to the placebo-controlled condition 
(Chapter 6). 
v. Short-term, continuous supplementation of MTCJ improved certain cardio-metabolic 
biomarkers in individuals with MetS. 
a. Revealed for the first time an MTC intervention improved fasting glucose, total 
cholesterol, TC:HDL ratio and lowered resting RER in any human population, after 
6 days of MTCJ supplementation compared to a control group. 24-hour BP was 
improved after 7 days of MTCJ supplementation.  
b. Also, for the first time in individuals with MetS, a reduction in LDL concentrations 
was observed after consuming an MTC intervention compared to a control group. 
c. Individual responses indicated physiological tendencies for improved fasting 
insulin, insulin sensitivity and insulin resistance after 6 days of MTCJ 
supplementation compared to the placebo group, in humans with underlying insulin 
resistance (MetS). 
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d. Acute SBP following 7 days of continuous MTCJ supplementation was reduced   
2-hours post-bolus by a clinically relevant magnitude, corroborating results from 
chapter 5, Keane et al. (2016bc) and Kent et al. (2015). Moreover, individual 
responses showed a physiological reduction in aortic SBP 2-hours post-bolus, 
aligning with MTC anthocyanins and secondary metabolites pharmacokinetics. 
e. However, 6 days prior loading of MTCJ had no further beneficial effect compared 
to a single, acute bolus on acute cardio-metabolic responses. 
f. Unable to confirm ACE inhibition as a mechanism for hypotensive properties of 
MTCJ, therefore further work is required. 
H5: Montmorency tart cherry acts as a calorie restriction mimetic and exerts its beneficial cardio-
metabolic responses through evolutionary conserved mechanisms related to calorie restriction, in 
C. elegans (Chapter 7). 
vi. Exposure to various dilutions of MTC concentrate resulted in a significant extension to 
lifespan in C. elegans, and these worms were healthier. 
a. Elucidation of the molecular mechanisms of action suggested MTC operates 
through the PPAR signalling pathway, corroborating findings from Seymour et al. 
(2008, 2009). 
b. This study provided encouraging evidence that MTC may be functioning as a 
calorie restriction mimetic via metabolic pathways. 
8.1.2. Thesis Development 
The opening study (Chapter 4) in this thesis aimed to examine the effect of combining FATMAX 
exercise with MTCJ supplementation on fat oxidation rate, body composition and cardio-
metabolic biomarkers in healthy human participants. Rationale for this study was based on 
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Venables et al. (2008) and Cook et al. (2015; 2017b) demonstrating greater fat oxidation rates 
with green tea polyphenols and anthocyanin-rich blackcurrants, respectively.  
Chapter 5 addressed some of the issues encountered in chapter 4 and acted upon the null results 
obtained in the first experimental study. Specifically, recruitment of participants with MetS 
possessing some cardio-metabolic dysfunction in chapter 5, rather than healthy participants, as in 
chapter 4; as anthocyanin-rich dietary interventions have been shown to improve symptoms 
associated with MetS in this population (Basu and Lyons, 2012; Amiot, Riva and Vinet, 2016; 
Vendrame et al., 2016). Secondly, acute administration of MTCJ and MTCC to coincide with 
MTC phytochemical pharmacokinetics, as previously conducted by Keane et al. (2016b). MTCC 
was provided to determine whether cardio-metabolic function could be improved due to its lower 
carbohydrate content and potential to augment phytochemical bioavailability, compared to MTCJ. 
Lastly, to establish whether a dose-response effect on cardio-metabolic markers was apparent with 
acute MTCJ supplementation. 
Chapter 5 highlighted acute improvements in cardio-metabolic function after acute 
supplementation of MTC interventions, but no dose-response effect. Consequently, chapter 6 
supplemented 30 mL MTC concentrate for 7 days, due to superior practicality, feasibility and 
economic viability compared to MTCC and 60 mL MTC concentrate. Based on findings from 
chapter 4, Solverson et al. (2018) and Willems et al. (2017), it was reasoned short-term, low-
dose, exogenous anti-oxidant supplementation, would improve cardio-metabolic function. To 
provide greater clinical relevance, chapter 6 assessed responses after 7 days continuous, MTCJ 
supplementation. Thus, chapter 6 also enabled ascertainment of whether 6 days prior loading of 
MTCJ enhances acute cardio-metabolic function compared to a single, acute bolus. Additionally, 
chapter 6 attempted to elucidate ex vivo, a mechanism of action for the hypotensive properties of 
MTCJ observed in chapter 5 and by Keane et al. (2016bc), through ACE inhibition; based on data 
reported by Kirakosyan et al. (2018). 
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The last experimental chapter (Chapter 7), undertaken in collaboration with the HAN University 
of Applied Sciences, Nijmegen, aimed to delineate the mechanistic pathways through which MTC 
interventions may exert their cardio-metabolic effects. A model organism, Caenorhabditis 
elegans, was used to observe developmental responses after RNAi of target genes of interest 
associated with lipid and glucose metabolism. Then, in the presence and absence of various 
dilutions of MTC concentrate, responses to lifespan and fat content were observed and 
mechanisms subsequently discussed compared to development read-outs after RNAi. The lifespan 
assay showed worms exposed to lower dilutions of MTC concentrate lived significantly longer 
than those exposed to higher MTC dilutions and non-exposed worms. Paradoxically, the obesity 
assay indicated greater lipid accumulation in the longest-lived worms exposed to lower dilutions, 
compared to controls. Equally, worms exposed to higher MTC dilutions presented significantly 
less lipid accumulation. In rodents, mild calorie restriction was shown to increase fat mass (Li et 
al., 2010). A plausible explanation may be that due to lower nutrient availability, worms were 
more efficient in extracting nutrients at lower MTC dilutions. Hence metabolism of carbohydrates 
from MTC may have facilitated lipid accretion; and activated transcription factors such as         
SKN-1, that promote anti-oxidant enzyme expression (GPx and glutathione-S-transferase) and 
subsequently longevity (Sykiotis et al., 2011). Moreover, improved extraction and thus 
metabolism of MTC phytochemicals may have mediated lifespan extension. Overall, these 
findings highlighted MTC may be operating as a calorie restriction mimetic via the PPAR 
pathway, as previously shown in rodent models (Seymour et al., 2008, 2009). 
8.2. Common Concepts Throughout Thesis 
Common emerging themes arising from this series of studies support the observations made in 
response to MTC consumption. These concepts include the anti-oxidant hypothesis based on the 
action of MTC as a hormetin; the influence of baseline values on responses to MTC; the high 
carbohydrate content of MTCJ and the supplementation strategy of MTCJ. 
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8.2.1. Anti-oxidant Theorem 
A consistent finding from this series of studies has shown low-dose, short-term, anti-oxidant 
supplementation to exert beneficial effects on cardio-metabolic health. This was demonstrated in 
chapter 4 where fat oxidation responses corresponded to total anti-oxidant status which was 
elevated during the first 10 days of supplementation but returned to baseline between days 10-20. 
Chapter 6 showed provision of anti-oxidants for a short time (~7 days) was effective at improving 
aspects of cardio-metabolic function. Lastly, chapter 7 postulated a hormetic effect of MTCJ, as 
lower concentrations extended lifespan compared to higher concentrations which hastened death 
rate; potentially through increased toxicity associated with high anti-oxidant concentrations. 
Lifespan extension with low anti-oxidant concentrations support the CRM actions of MTC, and 
other dietary hormetins (Calabrese et al., 2010). It is postulated that excessive exogenous anti-
oxidant supplementation, inhibits endogenous anti-oxidant production to maintain a homeostatic 
balance (Poljsak, Šuput and Milisav, 2013). However, provision of low-dose exogenous anti-
oxidant concentrations heightens the total anti-oxidant balance but not as to induce toxic effects. 
Therefore, enhancing the defence mechanism to stressors and mediating improved health 
(Martucci et al., 2017), with MTC. In summation, this series of studies has put further scrutiny on 
the efficacy of costly, prolonged continuous supplementation trials; as low-dose, short-term, anti-
oxidant supplementation was shown to be effective. 
8.2.2. Carbohydrate Content of MTC  
This thesis and Chai et al. (2018) identified MTC concentrate to possess a high carbohydrate 
content, potentially contributing to greater glycaemic, insulinaemic and lipaemic stress. It was 
identified total carbohydrate accounted for 96% of total energy, of which 70% were sugars, in 
MTC concentrate. Glucose and fructose contributed 55.73% and 44.27% of total sugars, 
respectively. Relative to the same anthocyanin content in 30 mL MTC concentrate, MTCC 
provided approximately 8 and 18 times less total carbohydrate and sugars, respectively. Hence, 
Chapter 8. General Discussion 
279 
 
Chapter 5 used MTCC to assess acute cardio-metabolic responses to acute supplementation of an 
MTC intervention with a low carbohydrate load.  
Accumulation of fructose with prolonged consumption of MTCJ may have negated its benefits by 
exacerbating some of the deleterious effects of fructose such as hyperlipidaemia, hyperuricaemia 
and low-grade inflammation (Karim, Adams and Lalor, 2012). Hence, explaining the tendency for 
improved LDL with MTCC compared to MTCJ in chapter 5, and greater glucose and triglyceride 
concentrations after continuous MTCJ supplementation compared to a single acute bolus in 
chapter 6, as also reported by Chai et al. (2018). Chapters 4 and 6 also showed heightened 
carbohydrate oxidation, signifying MTCJ induced greater glycolytic flux after continuous MTCJ 
supplementation. 
Despite MTC concentrate possessing a high carbohydrate content, the anthocyanins, phenolic 
acids and/or their secondary metabolites may have modulated insulin signalling pathways, through 
reducing the concentration of ligands available to activate the insulin signalling cascade; as 
discussed in chapter 7 with C. elegans. Reduced ligand availability may have been mediated 
through anthocyanins inhibiting glucose absorption into systemic circulation via suppression of 
SGLT-1 (Alzaid et al., 2013), therefore lowering insulin concentrations. 
8.2.3. Influence of Baseline Values 
This series of studies and many others in literature have repeatedly shown the influence of baseline 
values on the efficacy of dietary interventions on cardio-metabolic markers. This thesis reasoned 
the lack of cardio-metabolic dysregulation, often does not provide sufficient scope for an MTC 
intervention to further regulate cardio-metabolic markers. Consequently, abnormal baseline values 
are generally required to observe an effect with MTC. This is supported by cherry (Kelley et al., 
2006; Ataie‐Jafari et al., 2008; Martin et al., 2010; Lynn et al., 2014; Chai et al., 2018) and other 
dietary anthocyanin-feeding studies in humans (Basu et al., 2009, 2010a, 2011; Stull et al., 2015; 
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Stote et al., 2017; Willems et al., 2017) and rodents (Seymour et al., 2008, 2009). 
Chapter 4 recruited healthy individuals with normal baseline cardio-metabolic values, hence 
limiting the ability of MTCJ to improve cardio-metabolic parameters and increase fat oxidation. 
Therefore, chapters 5 and 6 recruited participants with MetS possessing some cardio-metabolic 
dysregulation at baseline. Indeed, cardio-metabolic parameters abnormal at baseline were 
improved with MTC interventions. Lipid profile and lab-based BP changes were particularly 
influenced by baseline values. In chapter 4, total cholesterol, LDL and HDL were within optimal 
thresholds at baseline; therefore, no effect of the intervention was realised. Likewise, in         
chapter 6 the observed reductions for total cholesterol, LDL and TC:HDL ratio after 6 days MTCJ 
supplementation manifested as baseline values were not within their respective optimal thresholds. 
As baseline HDL was normal, the change after 6 days MTCJ consumption was not significant, 
agreeing with previous studies supplementing tart cherries (Ataie‐Jafari et al., 2008; Martin et al., 
2010; Lynn et al., 2014; Johnson et al., 2017; Chai et al., 2018) and chapters 4 and 5. Long-term 
studies supplementing anthocyanins from tart (Ataie‐Jafari et al., 2008; Chai et al., 2018) and 
sweet (Kent et al., 2015a) cherries lowered SBP, although only in subjects presenting elevated 
baseline SBP. The lab-based SBP reductions reported in chapters 5 and 6, 2-hours post-bolus of 
MTCJ were similar to Keane et al. (2016a) in males with early hypertension, emphasising the 
requirement of elevated baseline SBP. 
Given the influence of baseline values as shown above, results from chapters 5 and 6 were 
significantly affected by MetS diagnosis encompassing 5 different criteria. High baseline inter-
individual variability amongst participants with MetS was observed, thus diminishing statistical 
power to detect differences between interventions and controls (Amiot, Riva and Vinet, 2016). 
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8.2.4. Optimal Supplementation Strategy 
A major issue with identification of a recommended supplementation strategy using anthocyanin-
rich interventions for individuals with MetS, is the high variation between strategies utilised by 
previous studies, as shown in section 2.2.5.2.2.1.1. High baseline inter-individual variability 
amongst individuals with MetS along with differences in dosage, matrix, food source, duration, 
frequency and timing impede the ability to provide a general recommended strategy. 
In keeping with the findings from chapter 4, where TAS declined to baseline from days 10-20 of 
supplementation, chapter 6 supplemented MTCJ for 7 days based on results demonstrating 
improved cardio-metabolic function in anthocyanin-feeding studies (Stote et al., 2017; Willems et 
al., 2017; Solverson et al., 2018). Indeed, improvements across various cardio-metabolic markers 
were observed in chapter 6, suggesting the optimal length for MTCJ to enhance cardio-metabolic 
function may lie around 6-10 days; aligning with elevations in TAS. However, it is important to 
understand that long-term cardiovascular protection provided by nutritional interventions may not 
be realised with short-term supplementation (Fairlie-Jones et al., 2017). Hence, the null effects on 
arterial stiffness in chapters 5-6 may be due to acute/short-term supplementation, since 
atherogenesis is a long-term developmental process (Fairlie-Jones et al., 2017). 
This thesis has added to the literature by suggesting 270 mg.day-1 of anthocyanins from MTC 
interventions in juice or capsule form improves certain cardio-metabolic markers. Such a daily 
dose is significantly lower than other tart cherry studies (Ataie‐Jafari et al., 2008; Keane, et al., 
2016bc; Chai et al., 2018) showing a beneficial effect of MTC on cardio-metabolic markers, 
providing further support for the low-dose anti-oxidant theorem. Results pertaining to the 
minimum effective anthocyanin dosage required to improve cardio-metabolic function in 
individuals with MetS were equivocal (section 2.2.5.2.2.1.1), and the data presented in chapters 
5-6 has not fully clarified the issue. Section 2.2.5.2.2.1 identified components of MetS were 
improved after supplementation of different anthocyanin dosages in individuals with MetS. 
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Chapters 5-6 contrasted previous studies (Barona et al., 2012ab) reporting improved SBP with 
anthocyanin dosages <100 mg.day-1. Moreover, total cholesterol was found to be reduced with 
anthocyanin dosages ≤154 mg.day-1 (Basu et al., 2009; Basu et al., 2010b; Gurrola-Díaz et al., 
2010; Jeong et al., 2014), however chapter 5 indicated a trend towards lower total cholesterol with 
540 mg.day-1 (60 mL concentrate) and chapter 6 showed lower concentrations with              270 
mg.day-1. However, anthocyanin dosages ≥154 mg.day-1 were shown to modulate oxidative stress 
in individuals with MetS; agreeing with the elevated TAS observed after supplementing    540 
mg.day-1 (chapter 4) and aligning with the anti-oxidant theorem postulated in this thesis. Although 
statistical analysis was not performed, chapter 5 showed only 60 mL MTC concentrate improved 
HDL and TC:HDL ratio. Furthermore, chapter 5 indicated a beneficial effect of 60 mL concentrate 
(540 mg.day-1) on central arterial pressure parameters compared to 30 mL concentrate (270 
mg.day-1). Concurring with Jennings et al. (2012), that a higher consumption of anthocyanins is 
associated with reductions in aortic blood pressure. Interestingly, twice daily supplementation of 
30 mL MTC concentrate (total anthocyanins 540 mg.day-1) in chapter 4 initially elevated anti-
oxidant status but this returned to baseline after 20 days. Split dosages of cherry juice was not as 
effective at improving cardiovascular function compared to a single bolus (Kent et al., 2016b). 
Thus, a single bolus of 60 mL MTC concentrate (total anthocyanins 540 mg.day-1) was used in 
chapter 5, part B, showing positive effects on cardiovascular function. Subsequently, single 
dosages were maintained in chapter 6, albeit with 30 mL MTC concentrate to conform to the low-
dose hormetic effect. 
Chapter 4 highlighted the importance of timing when consuming anthocyanin-rich interventions. 
Based on the pharmacokinetics, maximising bioavailability of phytochemicals in plasma and target 
tissues enhances the bioefficacy of anthocyanin-rich interventions. Given the rapid metabolism 
and elimination rates of anthocyanins (Manach et al., 2005), acute supplementation may be 
necessary to observe an effect on cardio-metabolic function with anthocyanin-rich interventions. 
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This was corroborated in chapter 4 as the lack of acute MTCJ supplementation did not augment 
fat oxidation during exercise, however acute anthocyanin-rich blackcurrant supplementation          
2-hours before exercise increased fat oxidation rate (Cook et al., 2015). Coinciding peak 
bioavailability and concentrations of anthocyanins, secondary metabolites and phase II conjugates 
in plasma and target tissues, with the time of measurement of variables greatly improves the ability 
to observe an effect from anthocyanin-rich interventions. Hence, acute supplementation was 
incorporated into chapters 5-6, which corroborated observations where SBP declined 2-hours 
post-bolus of MTCJ (Keane et al., 2016bc). This improvement likely coincided with MTC 
pharmacokinetics where concentrations of plasma parent anthocyanins (cyanidin-3-
glucosylrutinoside and cyanidin-3-rutinoside) (Seymour et al., 2014) and secondary metabolites 
(PCA and VA) (Keane et al., 2016a) were significantly elevated. 
Building on the pharmacokinetics of MTC, chapter 5 directly compared different forms of MTC 
interventions on health markers for the first time, in any human population. It was postulated MTC 
capsules would increase phytochemical bioavailability, due to protection afforded by the capsule 
shell against factors known to influence phytochemical stability such as pH, temperature, light, 
enzymes (particularly in saliva) and sugars (Robert and Fredes, 2015). Acute cardio-metabolic 
responses were not different between MTCJ and MTCC, suggesting phytochemical bioavailability 
was not likely to be augmented with MTCC; however pharmacokinetic data is required to confirm 
this. Subsequently, chapter 6 implemented 30 mL MTC concentrate due to superior practicality, 
feasibility and economic viability as an intervention strategy, compared to MTCC; but also 
availability of pharmacokinetic data with MTC concentrate (Bell et al., 2014a; Keane et al., 
2016a). 
Section 2.2.5.2.2.1 reviewed the effects of various dietary sources rich in different anthocyanidin-
based anthocyanins on cardio-metabolic function. Bell et al. (2014b) identified cyanidin, malvidin 
and peonidin to be the most abundant anthocyanidins in MTC concentrate; cyanidin accounted for 
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the overwhelming majority of anthocyanins (Ou et al., 2012; Bell et al., 2014b). Cyanidin was 
reported to possess strong radical scavenging and anti-inflammatory properties, primarily due to 
its secondary metabolites PCA and VA (Fang, 2015). The findings in chapters 4-7 and Keane et 
al. (2016ab) support this notion and again align with the anti-oxidant theorem. The reduction in 
oxidative stress because of elevated anti-oxidant status, likely improved endothelial function and 
therefore explains the positive cardiovascular effects observed in chapters 5-6. Cyanidin and 
malvidin-based anthocyanins have been shown to exert improvements in endothelial function, SBP 
and lipid profile in humans with MetS (section 2.2.5.2.2.1.1), supporting results in chapters 5-6. 
This thesis has highlighted the efficacy of various manipulations of supplementation strategies 
with MTC interventions, particularly MTCJ. No obvious differences between MTC juice and 
capsules were seen, however juice seems to be most practical despite capsules appealing to 
individuals with insulin resistance due to its lower carbohydrate content. Secondly, in line with 
anti-oxidant status, 6-10 days MTCJ consumption seems to elicit the greatest cardio-metabolic 
improvements. A recommended minimum effective anthocyanin dosage was not identified, 
however 270 mg.day-1 induced diverse cardio-metabolic improvements in individuals with MetS; 
and 540 mg.day-1 indicated enhanced cardiovascular function (central haemodynamics, arterial 
stiffness and lipid profile).  
Overall, results obtained from chapters 5-6 agree with previous literature (Basu et al., 2009, 
2010a, 2011; Basu and Lyons, 2012; Stull et al., 2015; Amiot, Riva and Vinet, 2016; Vendrame et 
al., 2016) that MTC as an anthocyanin-rich dietary intervention improves symptoms associated 
with MetS. However, the synergistic action of other nutrients within MTC should not be 
disregarded as they may confer greater cardio-metabolic protection compared to the solitary action 
of anthocyanins alone. Further research is required to confirm findings from this thesis and provide 
additional novel data, by manipulating strategies in order to facilitate construction of an optimal 
supplementation regimen for humans with MetS. 
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8.2.5. Mechanisms of Action 
Analysis of mechanisms of action in anthocyanin-feeding studies is rare, therefore complete 
understanding of their effects on cardio-metabolic responses is lacking. This thesis attempted to 
decipher mechanisms of action in response to MTCJ, using human (Chapter 6) and C. elegans 
(Chapter 7) models. 
Keane et al. (2016b) were unable to confirm nitric oxide or changes in arterial stiffness as 
mediators of improved blood pressure, after acute MTCJ consumption. Similarly, chapters 5-6 
were also unable to attribute reductions in SBP after MTCJ consumption to changes in arterial 
stiffness. Moreover, chapter 6 was unable to demonstrate MTC mediated ACE inhibition to 
explain SBP responses, despite in vitro work suggesting otherwise (Kirakosyan et al., 2018). 
Seymour et al. (2008, 2009) previously used animal models to examine molecular mechanisms in 
response to MTC supplementation. Given its comparable homology to the human genome, a           
C. elegans model was used to further explain cardio-metabolic responses to MTC concentrate at 
the molecular level, in chapter 7. In two distinct phyla (Nematoda and Chordate), MTC was shown 
to operate via the PPAR signalling pathway, strongly indicating a similar mechanism in humans. 
Chapter 7 specifically identified modulation of genes in the insulin signalling cascade to be 
responsible for the metabolic benefits of MTC. Supported by literature (Belwal et al., 2017; 
Solverson et al., 2018), anthocyanin-mediated AMPK activation, upstream of PPAR, may explain 
the metabolic benefits of MTC consumption shown in humans (Chapters 5-6); future work should 
test this hypothesis. 
Clearly, more research is required, particularly in humans, to elucidate mechanisms of action 
pertaining to the cardio-metabolic benefits of MTC. Further work should examine the influence of 
MTC on gut microbiota given its close relationship with cardio-metabolic health. Lastly, this thesis 
revealed CRM properties of MTC, thus analysis of epigenetic mechanisms is warranted. 
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8.3. Clinical Relevance 
From the outset, this thesis intended to use MTC as a preventative intervention against cardio-
metabolic disease. Hence, human participants recruited in chapters 4-6 were either healthy 
(Chapter 4) or presented only borderline cardio-metabolic dysfunction (Chapters 5-6). This 
section summarises clinical applications of MTC interventions, discussed in previous chapters. 
Section 2.2 outlined the global burden of cardio-metabolic diseases, but also the efficacy and cost-
effectiveness of lifestyle interventions, including physical activity and diet, in combating this issue 
(Besnier et al., 2015). Recommendations for exercise and diet prescription in public health services 
are limited compared to pharmacological drugs (Seth, 2014; Nunan, 2016), despite literature 
showing enhanced cardio-metabolic function after combined exercise and polyphenol 
supplementation (Venables and Jeukendrup, 2008; Venables et al., 2008; Besnier et al., 2015). 
Specifically, chapter 4 showed FATMAX exercise and MTCJ consumption to induce clinically 
relevant increases in HDL concentrations after 10 days supplementation. In individuals with MetS, 
clinically relevant improvements in HDL and TC:HDL ratio were observed with acute 60 mL 
consumption (Chapter 5). Continuous 30 mL MTC concentrate consumption also improved 
TC:HDL ratio and reduced total and LDL cholesterol (Chapter 6), highlighting lower 
atherosclerotic and cardiovascular risk (Millán et al., 2009) with MTC concentrate consumption. 
Insulin resistance is thought to be central to the underlying pathophysiology of MetS, therefore 
findings presented in chapters 5-6 indicating a tendency for increased insulin sensitivity after 
MTCJ and MTCC consumption require acknowledgement. Fasting insulin was significantly 
reduced after acute consumption of MTCC, therefore may be advocated for individuals with poor 
insulin sensitivity or insulin resistance e.g. MetS, diabetics. Short-term improvements in insulin 
control may develop into long-term adaptations with consistent use. As previously identified, MTC 
has been shown to operate along the PPAR signalling pathway, therefore they may be used as a 
safer alternative to pharmacological drugs, such as thiazolidinediones, which improve insulin 
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resistance through PPAR agonism (Ingram et al., 2006).  
Furthermore, chapter 6 demonstrated 6 days MTCJ consumption tended to reduce insulin 
resistance, suggesting potential for holistic amelioration of cardio-metabolic dysfunction related 
to MetS. This was corroborated by concurrent improvements of fasting glucose, lipid profile,       
24-hour BP and resting substrate oxidation in chapter 6. However, the limitations of HOMA as a 
surrogate for measuring insulin resistance and sensitivity are recognised. Therefore, future work 
should consider using tolerance tests or hyperinsulinaemic-euglycaemic clamps (Stull, 2016) to 
assess the efficacy of MTCJ on post-prandial responses; providing more ecologically valid 
conclusions. 
Arguably, the most clinically relevant finding presented in this thesis was the significant reduction 
in 24-hour BP (Chapter 6). Previous research (Ataie‐Jafari et al., 2008; Keane et al., 2016ab; Chai 
et al., 2018) and chapters 5-6, reported clinically relevant lowering of lab-based BP after tart 
cherry juice consumption; but never with 24-hour ABPM, regarded as clinically superior than lab-
based measurements (Hermida et al., 2011; Hodgkinson et al., 2011). Chapter 6 also discussed 
that 24-hour BP responses were supported by the low-dose anti-oxidant hypothesis and indicates 
that augmentation of anti-oxidant status after 7 days MTCJ supplementation may contribute to the 
hypotensive effects. The hypotensive properties of other phytonutrients in MTCJ and habitual diet 
should be considered, since Hassellund et al. (2012) reported no effect of purified anthocyanin 
(640 mg.day-1) supplementation on 24-hour BP. The high anthocyanin dosage, designed to 
augment bioavailability, may have shifted the hormetic balance towards a pro-oxidant state, 
therefore negating anthocyanin-mediated benefits. Bioavailability may have been limited in 
Hassellund's et al. (2012) study, since other nutrients facilitate absorption of anthocyanins (Bohn, 
2014); thus explaining benefits observed with whole-food dietary supplements in chapter 6 but 
not with purified anthocyanins. 
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Lab-based reductions in SBP shown in chapters 5-6 may have been associated with a 38% and 
23% reduced risk of stroke and coronary artery disease, respectively, over a 5-year period (Collins 
et al., 1990). In chapter 6, a clinically significant reduction for mean 24-hour SBP was observed 
after 7 days MTCJ consumption (-5 mmHg); which would be associated with prevention of all-
cause and cardiovascular mortality by 20% (Banegas et al., 2018). To provide further clinical 
relevance for the hypotensive properties of MTC, future work should decipher the length of time 
24-hour BP reductions can be maintained after discontinuing supplementation.  
Remarkably, the magnitude of reduction in 24-hour and lab-based BP after MTCJ consumption 
(Chapters 5-6) was equivalent to anti-hypertensive drugs, thus practitioners should query the 
decision to primarily prescribe pharmacological medication associated with harmful side effects. 
Clinical decision-making would benefit from future research examining the safety, tolerability and 
overall interactions between MTC interventions and pharmacological drugs in humans. 
Subsequently, a clinical application of this may enable practitioners to prescribe hybrid strategies 
as an adjunctive or replacement therapy to pharmacological drugs (e.g. half dose of MTC and 
pharmacological drug, as opposed to a full dose of pharmacological drug alone), as a safer method 
of managing diseases. Moreover, diagnosis and management of hypertension are increasingly 
based on aortic rather than brachial pressures (McEniery et al., 2014). Physiological reductions of 
aortic SBP after acute 30 mL (Chapter 6) and 60 mL (Chapter 5) concentrate consumption, lends 
further support that MTCJ consumption could be a safe yet effective anti-hypertensive 
intervention. 
Ultimately, the clinically relevant results presented in this thesis suggest MTC interventions can 
be beneficial for individuals with MetS, to prevent the development of cardio-metabolic diseases 
that accentuate mortality risk. Although not within the remit of this thesis, given these positive 
results, future research should explore whether MTC interventions can reverse diagnoses in 
populations with existing cardio-metabolic diseases e.g. diabetes, atherosclerosis. 
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8.4. Strengths and Limitations 
The following section will identify and discuss overarching strengths and limitations associated 
with the studies presented in this thesis. High ecological validity is crucial to enable application of 
research into practice; therefore, the strengths and limitations inextricably relate to the degree of 
ecological validity in each study. 
Due to the pilot nature of the studies conducted within this thesis, the small sample sizes in 
chapters 4-6, compared to other dietary interventional studies (Basu et al., 2009, 2010a, 2011, 
Stull et al., 2010, 2015; Lynn et al., 2014), may be regarded as a limitation. Despite this, other 
research (Martin et al., 2010; Udani et al., 2011; Rodriguez-Mateos et al., 2013, 2016; Cook et al., 
2015; Kent et al., 2015b) has operated with similar sample sizes as those in chapters 4-6. 
Nevertheless, clinical trials with larger samples sizes would enable more appropriate conclusions 
to be drawn with greater confidence. 
This thesis placed a very strong emphasis on the effect of diet, specifically anthocyanins and their 
metabolites, on cardio-metabolic function. Naturally, dietary guidelines outlined in chapters 4-6 
likely influenced observed responses. In an attempt to uphold ecological validity this thesis did not 
take a fully reductionist approach; thus, participants maintained their normal habitual diet 
including polyphenol consumption primarily through fruits and vegetables. Contrary to other 
human anthocyanin-feeding studies (Basu et al., 2010ab, 2011; Basu, 2011; Barona et al., 2012ab; 
Stull et al., 2015; Keane et al., 2016ab) this was a strength of chapters 4-6, as the residual 
synergistic effect of MTC interventions with other dietary micronutrients and polyphenols could 
be assessed. However, this also limited the ability to completely attribute observed effects to MTC 
interventions alone.  
Additionally, dietary restrictions were enforced before each testing session to limit intra- and inter-
individual variability for measured variables. In chapters 4-6, participants used food diaries for 
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dietary recall, however this method is not 100% accurate (Mertz et al., 1991); therefore, absolute 
adherence to the same diet 3 days before each session could not be guaranteed. The overnight fast 
was another dietary restriction placed to limit intra- and inter-individual variability, at the expense 
of upholding ecological validity. Moreover, the overnight fast likely influenced the absorption and 
bioavailability of MTC polyphenols, as fasting has been shown to augment polyphenol 
bioavailability due to the absence of absorption inhibitors (Bohn, 2014). The pharmacokinetic 
profile of MTC suggests an overnight fast may not have limited its bioefficacy, since appearance 
of polyphenols and their metabolites at nM and µM concentrations (Fernandes et al., 2015; Keane 
et al., 2016a) were observed up to 48 hours post-consumption and not limited to just a few hours 
after intake (De Ferrars et al., 2014; Seymour et al., 2014). Consequently, another limitation would 
be the timeframe that variables were monitored (≤5 hours) was not long enough to study the 
biological effects of phytochemicals after enterohepatic metabolism. Future work should consider 
monitoring responses according to the pharmacokinetic profile of secondary metabolites and phase 
II conjugates and also after discontinuing supplementation. 
Section 2.1.4 outlined factors that affect batch-to-batch variation of the polyphenol content within 
foods. Due to limited resources this thesis was unable to measure polyphenol content in each batch 
of MTC juice and capsules used.  
Another limitation was the theoretical calculation of LDL based on total cholesterol, triglycerides 
and HDL concentrations using the formulae of Friedewald, Levy and Fredrickson, (1972) and 
Ahmadi et al. (2008). However, due to the resources available direct measurement of LDL was 
not possible, but future researchers would be advised to follow this approach if possible.  
Lastly, double or triple blinding would have made the study design of chapters 4-6 more robust. 
However, a major strength of the human trials within this thesis was its research design. Chapters 
4-6 employed crossover, randomised controlled trials; recommended for medical research (Sibbald 
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and Roland, 1998) and assessing dietary interventions (Lucey, Heneghan and Kiely, 2016). 
Furthermore, responses in chapters 4-6 were observed in humans rather than animal models, with 
measurement of clinically relevant, diagnostic functional and blood-based biomarkers. Application 
of research into practice was ensured through upholding ecological validity wherever possible; by 
maintaining habitual diet and using safe, pragmatic, feasible and economically viable 
supplementation strategies. 
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The global outlook relating to cardio-metabolic disease is bleak and projected to become worse! 
Therefore, it was important for the research within this thesis to contribute towards alleviating this 
major problem and ultimately, prevent unnecessary deaths arising from cardio-metabolic disease. 
This thesis set out to use lifestyle interventions to prevent the development of cardio-metabolic 
diseases in healthy and MetS populations, susceptible to greater risk of developing cardio-
metabolic diseases. Lifestyle interventions have become increasingly popular amongst 
policymakers and the public in the fight against disease (Arena et al., 2015). Subsequently, an 
overarching aim of this thesis was to conduct ecologically valid research with simple application 
to daily life. This was achieved through provision of a safe, readily available dietary intervention 
supplementary to habitual diet; used in conjunction with exercise. Specifically, this thesis 
examined the effects of Montmorency tart cherries, with and without FATMAX exercise on 
cardio-metabolic biomarkers in healthy and MetS populations. It was envisaged that these 
interventions would be used as preventative measures to lessen the global burden of cardio-
metabolic disease, and thus this thesis aimed to provide evidence for their use. 
9.1. Contribution to Knowledge 
The discoveries made in this thesis have contributed to knowledge and subsequently filled 
numerous gaps in literature.  
In summation, this thesis has shown MTCJ and FATMAX exercise was not effective in improving 
cardio-metabolic biomarkers in healthy individuals, however examination of responses within 
clinical populations is warranted. More significantly, this thesis has highlighted low-dose, short-
term anti-oxidant supplementation from MTCJ seems to be effective at improving certain aspects 
of cardio-metabolic function. Secondly, the potent anti-hypertensive properties of MTCJ were 
demonstrated in a population of humans with MetS and confirm similar observations from 
previous literature in other clinical populations. Importantly, the improvement in 24-hour BP, 
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demonstrated for the first time with a cherry intervention in chapter 6, indicates MTCJ should be 
considered as an anti-hypertensive therapy in future clinical trials. Furthermore, potential for 
physiological improvements in insulin sensitivity and insulin resistance in humans with MetS and 
underlying insulin resistance was shown after consuming MTC interventions, which may be of 
clinical value as it indicates MTC may be able to reverse MetS. Moreover, lipid profile 
improvements with MTCJ and a shift in substrate oxidation towards augmentation of resting fat 
oxidation may enhance metabolic flexibility and further contribute to reducing insulin resistance. 
The implications of such observations are notable, since health practitioners, clinicians and 
researchers may be able to exploit the benefits of MTC; to prevent and/or slow cardio-metabolic 
dysregulation and promote healthy ageing through encouraging positive lifestyle changes. 
Lastly, identification of the PPAR signalling pathway, in C. elegans, as the mechanism through 
which MTC likely operates, enables mechanism-based strategies using MTC to be formulated to 
target broader aspects of cardio-metabolic dysregulation, owing to cross-talk between pathways. 
Due to their specificity in mechanism of action, pharmacological interventions tend to treat only 
a single component of cardio-metabolic dysregulation; requiring consumption of multiple drugs 
each with associated side effects. In contrast, as a single, naturally-occurring, safe intervention 
with currently no reported side effects; this series of studies have shown MTC interventions may 
clinically improve various cardio-metabolic biomarkers in humans and perhaps be used as an 
adjuvant to, or replace, pharmacological drugs in the future. 
9.2. Future Research 
Throughout this thesis, specific recommendations for future work have been detailed. This section 
indicates directions that future research should pursue to further knowledge in this field. 
Given the limited resources, only small-scale studies were conducted within this thesis. 
Consequently, there is a need to conduct larger, multi-centre, clinical trials in healthy, MetS and 
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other clinical populations; to fully gauge the efficacy of MTC interventions on cardio-metabolic 
health. Furthermore, clinical trials with a longer duration (>6 months) of supplementation and 
monitoring would provide ecologically valid and clinically useful information pertaining to the 
effectiveness of MTC interventions on cardio-metabolic health. Identification of an optimal 
supplementation strategy is also required after consideration of the population being examined and 
the target cardio-metabolic condition to be improved. Overall, comprehensive, large-scale, long-
term, examinations of the effect of consuming MTC interventions in conjunction with habitual diet 
is ultimately required; to draw accurate conclusions on the use of MTC interventions to improve 
cardio-metabolic function in various populations. 
Chapters 4, 5 and 6 monitored habitual dietary consumption through food diaries, to assess 
compliance to dietary guidelines. Comprehension of the results from these studies would be 
enhanced by future work conducting detailed statistical analysis of cardio-metabolic responses to 
MTC interventions after consideration of habitual diet, particularly total polyphenol and 
anthocyanin intake. This would inform practitioners of the efficacy of MTC on cardio-metabolic 
function in relation to habitual dietary practices, thus assist in the decision to prescribe MTC 
interventions on an individual scale. 
Across research in the field of polyphenols and health, there is an inherent lack of understanding 
relating to mechanisms of action, which extends to MTC interventions. Chapter 6 isolated ACE 
inhibition to explain the anti-hypertensive properties of MTCJ but was unable to confirm this. 
Chapter 7 elucidated molecular mechanisms of action, along the PPAR pathway, with dilutions 
of MTC concentrate in C. elegans, however for clinical benefit a similar study in humans is 
necessitated. 
Recommendations for future mechanistic studies that would enhance current understanding 
include a comprehensive pharmacokinetic and pharmacodynamic analysis of MTCJ and MTCC in 
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various populations, including MetS. Analysis of the health effects related to compounds derived 
from MTC can be correlated if future work can identify compounds and the concentrations they 
appear in biological samples (Amiot, Riva and Vinet, 2016). Technological advances in recent 
years have assisted the ability to detect the myriad of parent polyphenolic compounds and their 
metabolites emanating from MTC. Subsequently, ‘omics’ technology, particularly nutrigenomics 
(Ferguson et al., 2016), metabolomics (Brennan, 2008) and epigenomics (Mathers, 2008), would 
be useful tools for future research to correlate the health benefits of MTC to its polyphenolic 
compounds. Furthermore, section 2.1.5.2.2 emphasised the strong influence of the gut microbiome 
on cardio-metabolic health and the role polyphenols play in that relationship. Given the recent 
upsurge in gut microbiome research and the revelation that polyphenol metabolism is based on an 
individuals’ enterotype and metabotype (Amiot, Riva and Vinet, 2016; Espín, González-Sarrías 
and Tomás-Barberán, 2017), future work should profile gut microbiome changes after MTC 
consumption and correlate this to cardio-metabolic responses. Ultimately, this conforms to the 
current ideology of ‘personalised nutrition’ (Perez-Martinez et al., 2012), as it would negate the 
inter-individual variance observed in chapters 4-6 and enable prescription of specific dietary 
strategies involving MTC on an individual case-by-case basis. 
Finally, the recommendations for future work outlined above can provide further clarity and 
understanding to the findings presented within this thesis. Although this thesis presents novel 
discoveries and corroborates previous literature, more clinical evidence is undoubtedly required 
to endorse MTC as an intervention against cardio-metabolic disease. Nevertheless, perhaps MTC 
and exercise are preventative lifestyle interventions to call upon in the battle against cardio-
metabolic disease. After all, prevention is better than cure, especially when there is no cure!
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Appendix 1 
Table 11.1. Limits of agreement for FATMAX and MFO for the two protocols assessed during 
pilot testing. 
 Protocol 1 
(15 W increments every 2 mins) 
Protocol 2 
(10 W increments every 3 mins) 
FATMAX (% of V̇O2peak) 4.50 [-11.50 – 20.50] 4.26 [-6.20 – 10.50] 
MFO (g.min-1) -0.04 [-0.23 – 0.14] 0.03 [-0.13 – 0.20] 
 
 
Table 11.2. Coefficient of Variation for FATMAX and MFO for the two protocols assessed during 
pilot testing. 
 
Protocol 1 
(15 W increments every 2 mins) 
Protocol 2 
(10 W increments every 3 mins) 
FATMAX 13.74% 6.17% 
MFO 22.71% 16.21% 
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Appendix 2 
 
Figure 11.1. Bland-Altman plot of MFO during the final minute of the stage representing 
FATMAX. Limits of agreement 0.03 [-0.13 – 0.20] g.min-1. Bias (solid line) and 95% limits of 
agreement (dashed lines). 
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Figure 11.2. Bland-Altman plot of MFO during the final 50 minutes of the one-hour sub-maximal 
trial at FATMAX. Limits of agreement -0.01 [-0.11 – 0.09] g.min-1. Bias (solid line) and 95% 
limits of agreement (dashed lines). 
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Figure 11.3. Bland-Altman plot of the final minute of the stage representing FATMAX presented 
in terms of %V̇O2peak. Limits of agreement -0.49 [-5.91 – 4.93] %V̇O2peak. Bias (solid line) and 95% 
limits of agreement (dashed lines). 
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Figure 11.4. Bland-Altman plot of FATMAX presented as %V̇O2peak during the final 50 minutes 
of the one-hour sub-maximal trial at FATMAX. Limits of agreement 0.45 [-2.93 – 3.83] %V̇O2peak. 
Bias (solid line) and 95% limits of agreement (dashed lines). 
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Appendix 3 
 
Figure 11.5. Bland-Altman plot comparing fat oxidation rates averaged for the final 50 minutes of 
the one-hour exercise and mean fat oxidation rates obtained during the final minute of the stage 
eliciting MFO in FATMAX determination test. Limits of agreement 0.00 [-0.09 – 0.09] g.min-1. 
Bias (solid line) and 95% limits of agreement (dashed lines). 
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Appendix 4 
Table 11.3. Mean ± SD absolute raw data for blood-based biomarkers per treatment condition from 
Chapter 5, Part A. 
 
 
 
 
 
 
 
 
 
 
 
    Post-bolus Time Points  
  
Pre-Bolus 
   
  1 hr 3 hr 5 hr 
      
Glucose 
(mmol.L-1) 
PLA 5.40 ± 0.11 5.75 ± 0.06 4.82 ± 0.07 4.77 ± 0.09 
MTCC 5.10 ± 0.13 4.99 ± 0.11 4.88 ± 0.14 4.82 ± 0.11 
MTCJ 5.50 ± 0.12 5.28 ± 0.09 4.71 ± 0.18 4.78 ± 0.10 
Insulin 
(pmol.L-1) 
PLA 115.51 ± 10.39 176.33 ± 7.51 106.52 ± 3.39 99.71 ± 7.00 
MTCC 108.18 ± 4.61 98.33 ± 5.12 77.42 ± 3.04 86.99 ± 1.81 
MTCJ 125.33 ± 10.45 149.15 ± 13.77 76.53 ± 8.59 96.27 ± 4.06 
Triglycerides 
(mmol.L-1) 
PLA 1.2 ± 0.0 1.3 ± 0.1 1.4 ± 0.1 1.5 ± 0.0 
MTCC 1.4 ± 0.1 1.3 ± 0.1 1.3 ± 0.1 1.3 ± 0.1 
MTCJ 1.5 ± 0.0 1.4 ± 0.1 1.5 ± 0.1 1.6 ± 0.1 
 
Total 
Cholesterol 
(mmol.L-1) 
PLA 3.51 ± 0.19 3.55 ± 0.21 3.67 ± 0.23 3.80 ± 0.19 
MTCC 3.45 ± 0.12 3.33 ± 0.23 3.33 ± 0.23 3.64 ± 0.07 
MTCJ 3.82 ± 0.09 3.77 ± 0.18 3.85 ± 0.11 3.91 ± 0.12 
 
HDL 
(mmol.L-1) 
PLA 1.31 ± 0.08 1.19 ± 0.03 1.21 ± 0.06 1.13 ± 0.02 
MTCC 1.27 ± 0.12 1.22 ± 0.04 1.23 ± 0.09 1.24 ± 0.02 
MTCJ 1.31 ± 0.12 1.24 ± 0.07 1.32 ± 0.05 1.22 ± 0.06 
LDL 
(mmol.L-1) 
PLA 2.44 ± 0.20 2.69 ± 0.25 2.80 ± 0.23 3.15 ± 1.48 
MTCC 2.53 ± 1.11 2.60 ± 0.23 2.46 ± 0.29 2.59 ± 0.18 
MTCJ 2.78 ± 0.12 2.86 ± 0.22 2.90 ± 0.11 3.02 ± 0.21 
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Table 11.4. Mean ± SD absolute raw data for cardiac haemodynamic parameters per treatment condition from Chapter 5, Part A. 
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Table 11.5. Mean ± SD absolute raw data for PWA parameters per treatment condition from Chapter 5, Part A. 
*Denotes significant main effect for time with post-hoc identifying differences between 30 minutes and 5-hours post-bolus. ^Denotes 
significant main effect for time with post-hoc identifying differences between 1-hour and 5-hours post-bolus. $Denotes significant 
main effect for time with post-hoc identifying differences between 2-hours and 5-hours post-bolus. 
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 Table 11.6.  Mean ± SD absolute raw data for resting metabolic rate parameters per treatment condition from Chapter 5, Part A. 
   Post-bolus Time Points 
  Pre-Bolus 30 mins 1 hr 2 hr 3 hr 4 hr 5 hr 
 
               
Resting EE 
(kcal.day-1) 
PLA 1685 ± 407 1798  ± 345 1779 ± 351 1720  ± 293 1830 ± 291 1815  ± 285 1810  ± 336 
MTCC 1739 ± 449 1784  ± 372 1791 ± 300 1871  ± 301 1778 ± 299 1882  ± 378 1976  ± 324 
MTCJ 1706 ± 394 1837  ± 415 1795 ± 340 1832  ± 358 1817 ± 363 1873  ± 433 1922  ± 466 
 
Resting 
RER 
(AU) 
PLA 0.89 ± 0.03 0.92  ± 0.07 0.87 ± 0.07 0.86  ± 0.08 0.82 ± 0.08 0.82  ± 0.07 0.81  ± 0.07 
MTCC 0.90 ± 0.09 0.87  ± 0.09 0.81 ± 0.08 0.80  ± 0.06 0.76 ± 0.06 0.76  ± 0.07 0.77  ± 0.08 
MTCJ 0.92 ± 0.08 0.95  ± 0.07 0.87 ± 0.07 0.84  ± 0.07 0.80 ± 0.07 0.81  ± 0.06 0.79  ± 0.05 
Resting Fat 
Oxidation 
(g.min-1) 
PLA 0.03 ± 0.01 0.01  ± 0.04 0.05 ± 0.04 0.05  ± 0.03 0.06 ± 0.06 0.07  ± 0.04 0.09  ± 0.04 
MTCC 0.04 ± 0.04 0.06  ± 0.04 0.07 ± 0.04 0.08  ± 0.03 0.11 ± 0.04 0.10  ± 0.03 0.10  ± 0.04 
MTCJ 0.04 ± 0.03 0.02  ± 0.04 0.06 ± 0.04 0.07  ± 0.04 0.09 ± 0.04 0.09  ± 0.04 0.13  ± 0.10 
 
Resting 
CHO 
Oxidation 
(g.min-1) 
PLA 0.21 ± 0.07 0.26  ± 0.10 0.20 ± 0.11 0.17  ± 0.11 0.17 ± 0.18 0.15  ± 0.13 0.12  ± 0.10 
MTCC 0.22 ± 0.13 0.18  ± 0.07 0.15 ± 0.09 0.13  ± 0.10 0.05 ± 0.07 0.09  ± 0.11 0.09  ± 0.12 
MTCJ 0.25 ± 0.11 0.27  ± 0.09 0.18 ± 0.08 0.15  ± 0.08 0.11 ± 0.09 0.12  ± 0.06 0.04  ± 0.19 
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Table 11.7. Mean ± SD absolute raw data for blood-based biomarkers per treatment condition from Chapter 6.  
    Post-bolus Time Points  
  
Pre-Bolus 
   
  1 hr 3 hr 5 hr 
      
Glucose 
(mmol.L-1) 
PLA 5.36 ± 0.25 5.83 ± 0.24 5.28 ± 0.13 5.49 ± 0.19 
MTCJ 5.39 ± 0.23 5.88 ± 0.24 5.13 ± 0.22 5.14 ± 0.13 
Insulin 
(pmol.L-1) 
PLA 136.59 ± 72.18 146.29 ± 76.90 104.26 ± 59.70 97.77 ± 64.19 
MTCJ 125.96 ± 65.57 153.23 ± 87.21 97.43 ± 54.57 93.76 ± 65.29 
Triglycerides 
(mmol.L-1) 
PLA 1.3 ± 0.1 1.4 ± 0.1 1.5 ± 0.1 1.6 ± 0.1 
MTCJ 1.3 ± 0.1 1.3 ± 0.1 1.5 ± 0.1 1.6 ± 0.1 
Total 
Cholesterol 
(mmol.L-1) 
PLA 4.03 ± 0.33 4.17 ± 0.34 4.23 ± 0.24 4.25 ± 0.19 
MTCJ 4.14 ± 0.41 4.17 ± 0.39 4.03 ± 0.45 3.96 ± 0.17 
HDL 
(mmol.L-1) 
PLA 1.30 ± 0.01 1.30 ± 0.02 1.27 ± 0.02 1.27 ± 0.02 
MTCJ 1.40 ± 0.02 1.40 ± 0.03 1.40 ± 0.01 1.36 ± 0.03 
LDL 
(mmol.L-1) 
PLA 2.65 ± 0.31 2.99 ± 0.37 3.14 ± 0.30 3.30 ± 0.28 
MTCJ 2.71 ± 0.46 2.77 ± 0.35 2.91 ± 0.36 2.83 ± 0.31 
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Appendix 6 
Table 11.8. Mean ± SD absolute raw data for cardiac haemodynamic and PWA parameters per treatment condition from Chapter 6. 
     Post-bolus Time Points 
  Pre-6 days 
Suppl. 
Post 6 days 
Suppl. 
30 minutes 1 hr 2 hr 3 hr 4 hr 5 hr 
Brachial SBP 
(mmHg) 
PLA 127 ± 16 128 ± 17 133 ± 13 130 ± 14 132 ± 19 132 ± 19 128 ± 10 129 ± 13 
MTCJ 134 ± 17 128 ± 15 127 ± 13 128 ± 13 121 ± 10 127 ± 12  129 ± 18 133 ± 14 
 
Brachial DBP 
(mmHg) 
 
PLA 
 
75 ± 10 
 
74 ± 7 
 
76 ± 8 
 
72 ± 5 
 
74 ± 5 
 
73 ± 8 
 
74 ± 7 
 
75 ± 5 
MTCJ 75 ± 10 72 ± 7 73 ± 4 74 ± 5 70 ± 7 74 ± 7 73 ± 6 75 ± 4 
MAP 
(mmHg) 
PLA 
 
98 ± 12 
 
93 ± 10 99 ± 9 94 ± 8 97 ± 8 96 ± 10 97 ± 10 97 ± 9 
MTCJ 98 ± 12 93 ± 9 95 ± 4 96 ± 7 93 ± 6 95 ± 8 95 ± 8 96 ± 8 
          
HR  
(beats.min-1) 
PLA 65 ± 12 67 ± 14 68 ± 16 67 ± 16 66 ± 17 66 ± 16 65 ± 15 65 ± 5 
MTCJ 65 ± 14 63 ± 11 66 ± 11 64 ± 12 62 ± 13 61 ± 11 62 ± 12 60 ± 11 
Cardiac Output 
(L.min-1) 
PLA 
 
6.85 ± 2.46 
 
6.64 ± 2.37 6.86 ± 2.46 7.05 ± 2.74 7.00 ± 4.07 7.10 ± 3.23 6.02 ± 2.22 6.44 ± 2.03 
MTCJ 6.19 ± 2.81 5.85 ± 2.02 5.69 ± 2.97 5.46 ± 2.64 5.52 ± 2.66 5.70 ± 2.36 5.60 ± 2.47 5.87 ± 2.72 
Stroke Volume 
(mL) 
PLA 
 
104 ± 26 
 
98 ± 21 100 ± 22 104 ± 21 101 ± 34 105 ± 23 103 ± 26 98 ± 17 
MTCJ 102 ± 20 110 ± 29 105 ± 25 98 ± 22 101 ± 27 100 ± 26 103 ± 29 109 ± 29 
 
TPR 
(mmHg·min-1·L) 
PLA 
 
1.03 ± 0.48 
 
0.91 ± 0.23 0.96 ± 0.33 0.89 ± 0.27 1.04 ± 0.44 0.93 ± 0.32 1.09 ± 0.38 0.99 ± 0.29 
MTCJ 0.93 ± 0.37 0.79 ± 0.28 1.00 ± 0.42 0.98 ± 0.29 0.95 ± 0.29 0.95 ± 0.31 0.97 ± 0.34 0.94 ± 0.38 
Aortic SBP 
(mmHg) 
PLA 
 
124 ± 12 
 
119 ± 15 120 ± 12 119 ± 12 121 ± 14 124 ± 13 119 ± 15 120 ± 13 
MTCJ 124 ± 15 120 ± 15 121 ± 14 118 ± 14 116 ± 13 120 ± 14 119 ± 15 120 ± 13 
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Aortic DBP 
(mmHg) 
PLA 
 
80 ± 7 
 
80 ± 9 82 ± 11 80 ± 11 83 ± 9 84 ± 11 84 ± 8 83 ± 7 
MTCJ 81 ± 9 79 ± 10 79 ± 9 80 ± 9 78 ± 8 83 ± 10 81 ± 7 80 ± 8 
AP (mmHg) 
PLA 
 
11 ± 6 
 
9 ± 6 8 ± 5 7 ± 5 9 ± 6 11 ± 8 9 ± 6 10 ± 8 
MTCJ 12 ± 7 9 ± 7 9 ± 8 9 ± 8 9 ± 7 10 ± 8 10 ± 8 11 ± 8 
Pulse Pressure 
(mmHg) 
PLA 
 
38 ± 9 
 
35 ± 11 38 ± 7 39 ± 7 38 ± 7 39 ± 13 35 ± 8 37 ± 10 
MTCJ 39 ± 11 38 ± 10 42 ± 10 38 ± 11 38 ± 10 37 ± 11 38 ± 11 40 ± 10 
 
AIx (%) 
 
PLA 
 
26 ± 13 
 
23 ± 12 
 
23 ± 12 
 
24 ± 12 
 
25 ± 13 
 
26 ± 15 
 
26 ± 14 
 
27 ± 14 
MTCJ 25 ± 14 24 ± 12 24 ± 14 24 ± 15 22 ± 14 23 ± 14 24 ± 14 26 ± 14 
AIx at HR75 (%) 
PLA 
 
22 ± 10 
 
19 ± 11 20 ± 11 21 ± 12 21 ± 11 22 ± 12 23 ± 11 23 ± 12 
MTCJ 21 ± 12 20 ± 11 20 ± 10 20 ± 12 19 ± 11 18 ± 12 19 ± 11 19 ± 12 
SEVR (%) 
PLA 
 
180 ± 30 
 
192 ± 36 187 ± 37 189 ± 35 192 ± 39 194 ± 43 197 ± 39 191 ± 37 
MTCJ 183 ± 39 178 ± 25 175 ± 29 177 ± 25 187 ± 40 189 ± 33 181 ± 29 177 ± 25 
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Appendix 7 
Table 11.9. Mean ± SD absolute raw data for resting metabolic rate parameters per treatment condition from Chapter 6. 
§Denotes significant difference against 30-minutes post-bolus for main effect of time. $Denotes significant difference against 1-hour 
post-bolus for main effect of time. *Denotes significant difference against 2-hours post-bolus for main effect of time. ^Denotes 
significant difference against 3-hours post-bolus for main effect of time. 
 
 
 
 
 
 
 
    Post-bolus Time Points 
  Pre-Bolus 30 mins 1 hr 2 hr 3 hr 4 hr 5 hr 
Resting EE  
(kcal.day-1) 
PLA 1847 ± 437 1895 ± 397 1890 ± 360 1835 ± 411 1827 ± 394 1785 ± 394 1785 ± 356 
MTCJ 1794 ± 489 1871 ± 467 1892 ± 408 1781 ± 439 1795 ± 459  1790 ± 443 1865 ± 451 
 
Resting RER  
(AU) 
 
 
PLA 
 
0.86 ± 0.06 
 
0.96 ± 0.10 
 
0.93 ± 0.08 
 
0.87 ± 0.08§$ 
 
0.84 ± 0.08§$* 
 
0.82 ± 0.08§$*^ 
 
0.81 ± 0.05§$*^ 
MTCJ 0.83 ± 0.04 0.98 ± 0.08 0.94 ± 0.08 0.89 ± 0.08 0.86 ± 0.08 0.82 ± 0.07 0.81 ± 0.05 
Resting Fat 
Oxidation  
(g.min-1) 
PLA 0.06 ± 0.03 0.04 ± 0.07 0.08 ± 0.09 0.06 ± 0.04§ 0.08 ± 0.05§ 0.08 ± 0.04§* 0.09 ± 0.04§* 
MTCJ 0.06 ± 0.02 0.01 ± 0.03 0.02 ± 0.04 0.05 ± 0.04 0.07 ± 0.05 0.08 ± 0.04 0.09 ± 0.05 
         
Resting CHO 
Oxidation 
(g.min-1) 
PLA 0.20 ± 0.13 0.25 ± 0.15 0.16 ± 0.20 0.18 ± 0.08§ 0.14 ± 0.08§* 0.13 ± 0.09§* 0.12 ± 0.09§* 
MTCJ 0.17 ± 0.08 0.33 ± 0.11 0.30 ± 0.14 0.21 ± 0.08 0.18 ± 0.09 0.14 ± 0.08 0.13 ± 0.05 
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Table 11.10. Mean ± SD change from pre-bolus values to post-bolus time points for selected blood-
based biomarkers based on MTCJ supplementation strategies. 
  Post-bolus Time Points 
  1 hr 3 hr 5 hr 
Insulin# 
(pmol.L-1) 
Single Day 23.80 ± 43.26 -48.80 ± 50.01 -29.10 ± 39.65 
6 days Loading 27.26 ± 42.20 -28.53 ± 29.30 -32.20 ± 32.60 
     
Triglycerides* 
(mmol.L-1) 
Single Day -0.1 ± 0.3 0.0 ± 0.2 0.1 ± 0.4 
6 days Loading 0.0 ± 0.2 0.2 ± 0.1 0.3 ± 0.2 
     
Total Cholesterol 
(mmol.L-1) 
Single Day -0.05 ± 0.25 -0.03 ± 0.18 0.13 ± 0.21 
6 days Loading 0.04 ± 0.33 -0.10 ± 0.34 -0.18 ± 0.49 
     
HDL$ 
(mmol.L-1) 
Single Day -0.07 ± 0.12 0.01 ± 0.11 -0.09 ± 0.17 
6 days Loading -0.01 ± 0.05 0.00 ± 0.04 -0.04 ± 0.07 
     
LDL 
(mmol.L-1) 
Single Day 0.08 ± 0.52 0.12 ± 0.33 0.24 ± 0.66 
6 days Loading 0.06 ± 0.49 0.20 ± 0.29 0.12 ± 0.39 
     
TC:HDL 
(AU) 
Single Day -0.01 ± 0.10 0.13 ± 0.35 0.17 ± 0.44 
6 days Loading 0.08 ± 0.40 -0.06 ± 0.28 -0.07 ± 0.44 
#Denotes significant difference between 1-hour and both 3-hours and 5-hours post-bolus time 
points.  
$Denotes significant difference between 3-hours and 5-hours post-bolus time points.  
*Denotes significant difference between 1-hour and 3-hours post-bolus time points. 
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Table 11.11. Mean ± SD change from pre-bolus values to post-bolus time points for selected cardiac haemodynamic, PWA and RMR 
parameters based on MTCJ supplementation strategies. 
   Post-bolus Time Points 
  30 mins 1 hr 2 hr 3 hr 4 hr 5 hr 
Brachial SBP# 
(mmHg) 
Single Day -1 ± 6* -2 ± 9* -8 ± 6 -2 ± 6* -1 ± 8* -3 ± 12* 
6 days Ldg -1 ± 8 1 ± 9 -7 ± 10 0 ± 10 1 ± 12 5 ± 11 
        
Brachial DBP# 
(mmHg) 
Single Day 3 ± 6 6 ± 4* 3 ± 4 7 ± 6 6 ± 8 6 ± 5 
6 days Ldg 1 ± 7 2 ± 9 -2 ± 7 2 ± 8 1 ± 7 3 ± 7 
        
MAP# 
(mmHg) 
Single Day 2 ± 3 2 ± 6 -4 ± 5 4 ± 7* 4 ± 8 -2 ± 12 
6 days Ldg 2 ± 9 3 ± 9 0 ± 7 3 ± 10 2 ± 7 3 ± 10 
        
HR#  
(beats.min-1) 
Single Day 0 ± 5 -1 ± 5 -5 ± 6§$ -7 ± 5§$ -7 ± 4§$ -8 ± 6§$ 
6 days Ldg 3 ± 3 1 ± 5 0 ± 5 -2 ± 6 -1 ± 5 -3 ± 5 
        
Cardiac Output 
(L.min-1) 
Single Day 0 ± 2 0 ± 1 0 ± 2 0 ± 2 1 ± 2 1 ± 2 
6 days Ldg 0 ± 2 0 ± 2 0 ± 1 0 ± 1 0 ± 1 0 ± 1 
        
Stroke Volume 
(mL) 
Single Day 1 ± 27 -4 ± 19 1 ± 27 -4 ± 30 1 ± 24 2 ± 23 
6 days Ldg -5 ± 29 -20 ± 33 -9 ± 25 -10 ± 32 -7 ± 19 -1 ± 27 
        
TPR 
(mmHg·min-1·L) 
Single Day 0.08 ± 0.33 0.07 ± 0.27 -0.03 ± 0.38 0.10 ± 0.34 0.10 ± 0.28 0.11 ± 0.35 
6 days Ldg 0.21 ± 0.44 0.19 ± 0.35 0.16 ± 0.41 0.15 ± 0.33 0.18 ± 0.29 0.15 ± 0.25 
        
Aortic SBP 
(mmHg) 
Single Day 0 ± 8 -1 ± 8 -2 ± 7 1 ± 4 2 ± 7 3 ± 7 
6 days Ldg 1 ± 5 -2 ± 6 -4 ± 8 0 ± 8 -1 ± 8 0 ± 5 
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Aortic DBP 
(mmHg) 
Single Day -2 ± 6 -2 ± 6 2 ± 4 1 ± 8 1 ± 7 1 ± 4 
6 days Ldg 0 ± 2 1 ± 5 -1 ± 5 4 ± 6 2 ± 6 1 ± 5 
        
AP# 
(mmHg) 
Single Day 0 ± 8 -1 ± 8 -2 ± 7 1 ± 4 2 ± 7 3 ± 7 
6 days Ldg 1 ± 2 0 ± 2 0 ± 2 1 ± 3 1 ± 3 2 ± 3 
Pulse Pressure 
(mmHg) 
Single Day 1 ± 6 1 ± 5 -4 ± 4 0 ± 8 1 ± 6 2 ± 5 
6 days Ldg 1 ± 4 -3 ± 7 -1 ± 6 1 ± 5 0 ± 6 2 ± 5 
        
AIx# (%) 
Single Day 0 ± 5 1 ± 9 -3 ± 6 -1 ± 6 2 ± 9 5 ± 7 
6 days Ldg 0 ± 5 0 ± 7 -1 ± 5 0 ± 5 0 ± 7 2 ± 8 
        
AIx at HR75 
(%) 
Single Day 0 ± 4 -1 ± 7 -2 ± 7 -2 ± 7 0 ± 8 2 ± 7 
6 days Ldg 0 ± 3 0 ± 3 -1 ± 5 -2 ± 5 -1 ± 5 -1 ± 6 
        
SEVR# (%) 
Single Day 6 ± 26 8 ± 22 31 ± 32 24 ± 31 21 ± 31 12 ± 20 
6 days Ldg -4 ± 23 -2 ± 21 8 ± 37 11 ± 33 3 ± 27 -2 ± 17 
        
RER#^ 
(AU) 
Single Day 0.03 ± 0.04 -0.05 ± 0.07§ -0.08 ± 0.08§$ -0.12 ± 0.11§$* -0.11 ± 0.09§$* -0.13 ± 0.10§$* 
6 days Ldg 0.15 ± 0.09 0.10 ± 0.10 0.05 ± 0.10 0.02 ± 0.10 -0.01 ± 0.10 -0.02 ± 0.08 
        
Resting Fat 
Oxidation#^ 
(g.min-1) 
Single Day 0.02 ± 0.05 0.03 ± 0.06 0.04 ± 0.06
§ 0.07 ± 0.05§$* 0.06 ± 0.05§$* 0.06 ± 0.04§$* 
6 days Ldg -0.05 ± 0.04 -0.04 ± 0.05 -0.01 ± 0.04 0.00 ± 0.05 0.02 ± 0.05 0.03 ± 0.05 
        
Resting CHO 
Oxidation#^ 
(g.min-1) 
Single Day -0.04 ± 0.13 -0.07 ± 0.13 -0.09 ± 0.15§ -0.17 ± 0.12§$ -0.13 ± 0.14§$* -0.13 ± 0.11§$ 
6 days Ldg 0.15 ± 0.10 0.12 ± 0.13 0.04 ± 0.11 0.01 ± 0.12 -0.03 ± 0.13 -0.05 ± 0.11 
Ldg (Loading); 
#
Denotes significant main effect for time; ^Denotes significant main effect for supplementation strategy. §Denotes significant difference against 30-
minutes post-bolus for main effect of time. $Denotes significant difference against 1-hour post-bolus for main effect of time. *Denotes significant difference against 2-
hours post-bolus for main effect of time.
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Appendix 11 
Effects of Montmorency Tart Cherry Supplementation on Cardio-Metabolic Markers in 
Metabolic Syndrome Participants: a pilot study 
 
Terun Desai, Michael Roberts and Lindsay Bottoms 
School of Life and Medical Sciences, University of Hertfordshire, Hatfield, UK. 
 
Abstract 
This study compared acute supplementation of Montmorency tart cherries in capsule (MTCC) 
and juice (MTCJ) forms in MetS humans, as potential prophylactic interventions against 
cardio-metabolic diseases. In an acute, single-blind, placebo-controlled, randomised, crossover 
trial, eleven participants with MetS (49 ±12 years; 6M/5F), consumed one bolus of MTCC, 
MTCJ or placebo (PLA) on different occasions. Blood-based and functional cardio-metabolic 
biomarkers were measured pre-bolus and up to 5 hours post-bolus. MTCJ significantly reduced 
systolic blood pressure compared to PLA at 2-hours post-bolus (P = 0.018). Insulin was 
significantly lower with MTCC (P = 0.016) and MTCJ (P = 0.028) than PLA at 1-hour and 3-
hours post-bolus, respectively. No significant differences between MTCC and MTCJ were 
seen. This study demonstrated for the first time that MTCC could reduce insulin concentrations 
in humans. Importantly, MTCJ induced a clinically relevant reduction in systolic blood 
pressure and also lowered insulin compared to PLA, in MetS humans. 
Keywords: polyphenols; anthocyanins; cardiometabolic health; functional foods; 
hypertension; diabetes 
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1. Introduction 
Often accompanied by endothelial dysfunction, a pro-inflammatory, pro-oxidant and pro-
thrombotic state (Srikanthan, Feyh, Visweshwar, Shapiro, & Sodhi, 2016), Metabolic 
Syndrome (MetS) encompasses a cluster of cardio-metabolic conditions including insulin 
resistance, central adiposity, dyslipidaemia and hypertension (Kaur, 2014). The presence of 
three or more of these symptoms combined, augments the incidence of chronic diseases such 
as cardiovascular disease (CVD) by 2-fold and type 2 diabetes (T2D) by 5-fold (Falkner & 
Cossrow, 2014). Ultimately, this highlights the strong association between MetS and higher 
rates of cardiovascular and total mortality (Falkner & Cossrow, 2014). Despite the difficulty in 
measuring MetS prevalence rates, it is accepted that global rates are on the rise (O'Neill & 
O'Driscoll, 2015). In the United States [~35% MetS prevalence rate (Aguilar, Bhuket, Torres, 
Liu, & Wong, 2015)], low fruit and vegetable intake accounted for 15.1% of all diet-related 
cardio-metabolic deaths (Micha et al., 2017). Therefore, fruit and vegetables rich in 
polyphenols, especially anthocyanins, are attractive interventions against cardio-metabolic 
disease risk factors (Vendrame, Del Bo, Ciappellano, Riso, & Klimis-Zacas, 2016); as 
supported by epidemiological evidence (Arts & Hollman, 2005; Cassidy et al., 2013; Wallace, 
2011).  
Substantial literature (Amiot, Riva, & Vinet, 2016; Basu et al., 2011; Basu et al., 2010; Basu 
& Lyons, 2012; Basu et al., 2009; Stull et al., 2015; Vendrame et al., 2016) exists suggesting 
consumption of anthocyanin-rich dietary interventions are beneficial for mitigating the 
development of symptoms associated with MetS. Montmorency tart cherries (MTC) is one 
such intervention not only abundant in anthocyanins, but also other phenolics, resulting in 
being one of the most potent dietary antioxidant interventions when consumed in habitual 
portion sizes (Ou, Bosak, Brickner, Iezzoni, & Seymour, 2012). As far as the authors are aware, 
no study has been published assessing the responses of human participants with MetS, to MTC 
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supplementation; however individual aspects of the MetS cluster have been explored in 
pathological populations. Keane et al. (2016b) showed significant reductions in systolic blood 
pressure (SBP) after acute ingestion of Montmorency Tart Cherry Juice (MTCJ) (60 mL 
concentrate) in hypertensive males. Additionally, Martin, Bopp, Neupane, and Vega-Lopez 
(2010) demonstrated significant reductions in serum triglycerides, triglyceride/HDL ratio and 
VLDL (very low-density lipoprotein) concentrations after 4 weeks tart cherry juice                  
(230 mL.day-1) supplementation in participants with central adiposity and dyslipidaemia. 
Moreover, Ataie-Jafari, Hosseini, Karimi, and Pajouhi (2008) reported 6 weeks concentrated 
sour cherry juice (40 g.day-1) supplementation improved glycated haemoglobin (HbA1c), in 
T2D females, along with total cholesterol and LDL (low-density lipoprotein) in those 
participants with hyperlipidaemia.  
Anthocyanin pharmacokinetics after consuming whole Montmorency tart cherries indicated 
parent anthocyanin concentrations in plasma peaked 2-4 hours post-ingestion, and excretion 
rates in urine peaked 6-8 hours post-ingestion (Seymour et al., 2014). Similarly, Bell et al. 
(2014a) reported increased uptake of cyandin-3-O-glucoside in plasma, compared to baseline 
at 3- and 5-hours post-consumption of 30 mL MTC concentrate in healthy humans. 
Correspondingly, Keane et al. (2016a) reported the secondary metabolites of cyandin-3-O-
glucoside, protocatechuic and vanillic acids were also elevated at 1-hour and 2-hours post-
consumption of 30 mL MTC concentrate, respectively, in healthy humans. The 
pharmacokinetics of powdered freeze-dried MTC anthocyanins and metabolites are currently 
unknown when administered in encapsulated form, but bioavailability is anticipated to be 
enhanced. Anthocyanin bioavailability is notoriously poor (Kay, 2006), hence capsules as a 
delivery vehicle of anthocyanins to target tissues via systemic circulation may be useful as they 
selectively degrade once in the gastrointestinal tract, therefore potentially maximising 
bioavailability (Oidtmann et al., 2012). This is achieved due to protection of anthocyanins by 
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the exterior capsule shell against factors known to influence anthocyanin stability such as pH, 
temperature, light, enzymes (particularly in saliva) and sugars (Robert & Fredes, 2015). 
Hydroxypropyl methylcellulose (HPMC) is a material used to form capsule shells and has been 
shown to delay the release of green tea catechins (Glube, Moos, & Duchateau, 2013) and 
mulberry extract anthocyanins (Lown et al., 2017). Consequently, this delayed glucose and 
insulin responses until 30 minutes after ingestion, coinciding with the disintegration and 
dissolution of the capsule shell (Lown et al., 2017). Subsequently, Montmorency Tart Cherry 
Capsules (MTCC) will be provided to assess whether encapsulation, and thus protection of 
MTC anthocyanins from premature degradation, potentially maximises bioavailability and 
therefore their beneficial effects on cardio-metabolic function. Furthermore, the high sugar 
content in polyphenol-rich juices (Vendrame et al., 2016), including MTCJ (Desai, Bottoms, 
& Roberts, 2018), are purported to nullify and mask some of the beneficial cardio-metabolic 
effects induced by the polyphenols. Thus, MTCC, with a significantly lower sugar content, 
may be more efficacious at improving cardio-metabolic markers compared to MTCJ. 
Centred around the pharmacokinetics of MTC parent anthocyanins and their metabolites, this 
study aimed to explore the short-term responses to acute supplementation of MTCJ and MTCC 
on cardiac haemodynamics, arterial stiffness by pulse wave analysis (PWA), substrate 
metabolism and various blood-based cardio-metabolic biomarkers in humans with MetS. 
Given that these subjects present at least three or more risk factors resulting in a holistic state 
of cardio-metabolic dysregulation, it was hypothesised that both MTC interventions would 
induce favourable responses on diagnostic cardio-metabolic markers, in particular glucose, 
lipids and SBP, based on previous human studies with tart cherry supplementation (Ataie-Jafari 
et al., 2008; Keane et al., 2016b; Martin et al., 2010). Furthermore, it was hypothesised that 
MTCC would be more effective than MTCJ or placebo in mediating these benefits, as the 
bioavailability of anthocyanins and their metabolites were anticipated to be superior. 
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2. Methods 
2.1. Participants  
Eleven (6 males and 5 females) participants (mean ±SD, age 49 ± 12 years, stature                     
1.72 ± 0.11 m, body mass 99.53 ± 20.49 kg) with Metabolic Syndrome (Table 1) volunteered 
for this pilot study. All participants were screened for MetS prior to formal inclusion onto the 
study according to the harmonised criteria outlined by Alberti et al. (2009), where 3 of the 5 
qualifying criteria [waist circumference: ethnicity and sex specific criteria; fasting 
triglycerides: ≥1.69 mmol.L-1; fasting high-density lipoprotein: <1.03 mmol.L-1 (men), <1.29 
mmol.L-1 (women); brachial blood pressure: ≥130 mmHg SBP or ≥85 mmHg DBP and/or 
fasting glucose: ≥6.1 mmol.L-1] had to be met. Recruitment (Figure 1) was conducted via word 
of mouth, flyers and email advertisements. Participants were excluded from the study if they 
did not meet the criteria for MetS at screening, were smokers, pregnant, heavy alcohol 
consumers (>14 units per week), current or previous diagnosis of chronic disease 
(gastrointestinal, cardiovascular, hepatic or renal), or were on statins, hyperlipidaemic, anti-
hypertensive, anti-diabetic, anti-inflammatory or steroidal medication. All participants were 
instructed to abstain from consuming any other multivitamin, antioxidant, fish oil, dietary or 
herbal supplementation two weeks prior to and for the duration of the study. Verbal and written 
information was provided to all participants regarding the study purpose and procedures. 
Ethical approval was obtained from the University of Hertfordshire HSET Ethics Committee 
(LMS/PGT/UH/02843) and the study’s experimental procedures followed the principles 
outlined in the Declaration of Helsinki. Written informed consent was provided by all 
participants prior to enrolment. This study was registered prospectively as a clinical trial on 
clinicaltrials.gov (NCT03615885). 
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*Denotes value met threshold for MetS inclusion criteria. AU (Arbitrary Units); BMI (Body Mass Index); bDBP (Brachial Diastolic Blood Pressure); 
bSBP (Brachial Systolic Blood Pressure); HDL (High-density Lipoprotein); HOMA2-IR (Homeostatic Model Assessment of Insulin Resistance); HOMA2-β 
(Homeostatic Model Assessment of pancreatic β-cell function); HOMA2-%S (Homeostatic Model Assessment of Insulin Sensitivity). 
Table 1. Baseline characteristics obtained during screening of all participants (n = 11). 
  Participant 
Characteristics Mean (95% CI) 1 2 3 4 5 6 7 8 9 10 11 
BMI (kg.m-2) 33 (30 – 37) 30 39 28 29 44 36 28 36 32 36 29 
Waist 
Circumference 
(cm) 
106 (97 – 115) 102.2* 133* 93 90.8 119* 119* 95 104.1* 94 112* 104* 
Fasting Glucose 
(mmol.L-1) 
5.63 (5.12 – 6.14) 6.20* 5.33 6.72* 4.48 5.93 6.50* 6.21* 5.12 5.78 4.85 4.79 
Fasting 
Triglycerides 
(mmol.L-1) 
1.9 (1.57 – 2.23) 1.9* 2.0* 2.6* 1.7* 0.9 1.5 2.6* 2.1* 2.0* 2.1* 1.5 
Fasting HDL 
(mmol.L-1) 
1.23 (0.99 – 1.48) 2.23 1.25 1.22* 0.94* 1.23* 0.83* 1.19* 1.30 1.06* 1.28* 1.01* 
bSBP (mmHg) 132 (127 – 138) 122 146* 130* 130* 136* 143* 129 132* 142* 120 126 
bDBP (mmHg) 80 (74 – 87) 67 90* 86* 87* 79 91* 72 72 88* 67 85* 
Fasting Insulin 
(pmol.L-1) 
115.85 (64.37 – 167.34) 53.10 81.65 182.85 72.37 216.88 280.16 116.33 56.81 91.83 62.09 60.29 
HOMA2-IR 
(AU) 
2.2 (1.2 – 3.2) 1.0 1.5 3.5 1.3 4.0 5.3 2.3 1.1 1.8 1.1 1.1 
HOMA2-β (%) 121.3 (97.4 – 145.2) 61.8 111.7 126.2 145.2 179.2 181.9 106.1 94.5 103.4 111.8 112.4 
HOMA2-%S (%) 61.8 (42.3 – 81.4) 95.5 64.9 28.2 76.5 24.7 19.0 44.3 93.6 56.7 87.0 89.8 
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Figure 1. CONSORT flow diagram of the participants recruited, screened, tested, analysed 
and excluded during the course of the study. 
Assessed for eligibility (n = 43) 
Excluded (n = 30) 
   Not meeting inclusion criteria (n = 27) 
   Declined to participate (n = 3) 
Analysed (n = 11) 
 
Allocated to Placebo intervention (n=5) 
 Received allocated intervention (n=5) 
 Not received allocated intervention (n=0) 
Allocation 
1 
Analysis 
Randomised (n = 13) 
Enrolment 
Allocated to MTCJ intervention (n=4) 
 Received allocated intervention (n=4) 
 Not received allocated intervention (n=0) 
Allocated to MTCC intervention (n=4) 
 Received allocated intervention (n=4) 
 Did not receive allocated intervention (n=0) 
Allocation 
2 
Allocation 
3 
Dropped Out (n = 2) 
   Personal reasons (n = 2) 
Allocated to Placebo intervention (n=4) 
 Received allocated intervention (n=3) 
 Not received allocated intervention (n=1) 
(Participant dropped out for personal 
reasons) 
Allocated to MTCJ intervention (n=4) 
 Received allocated intervention (n=4) 
 Not received allocated intervention (n=0) 
 
Allocated to MTCC intervention (n=5) 
 Received allocated intervention (n=4) 
 Did not receive allocated intervention (n=1) 
(Participant dropped out for personal reasons) 
 
Allocated to Placebo intervention (n=4) 
 Received allocated intervention (n=4) 
 Not received allocated intervention (n=0) 
Allocated to MTCJ intervention (n=4) 
 Received allocated intervention (n=4) 
 Not received allocated intervention (n=0) 
Allocated to MTCC intervention (n=3) 
 Received allocated intervention (n=3) 
 Did not receive allocated intervention (n=0) 
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2.2. Procedures 
2.2.1. Research Design 
A single-blind (blinded to participant), placebo-controlled, randomised, crossover design was 
implemented; each participant acted as their own control. During the 6-week study duration, 
all participants completed three testing sessions during which one of three [placebo (PLA) or 
MTCJ or MTCC] different supplements were provided each time. GraphPad software 
(GraphPad, QuickCalcs, San Diego, California, USA) was used to randomise supplementation 
order. A 14-day washout period (Cook, Myers, Blacker, & Willems, 2015; Howatson et al., 
2012; Keane et al., 2016c) was incorporated between testing sessions and between the 
screening and first testing sessions.  
Testing sessions lasted 6 hours and were identical in terms of design and testing procedures. 
Figure 2 depicts schematics of the overall study design and specific procedures during a testing 
session. Baseline anthropometric (stature, body mass, waist circumference) and functional 
(PWA, cardiac haemodynamics, RMR) measurements were obtained prior to consumption of 
the supplement. Functional measurements were recorded at 30 minutes, 1, 2, 3, 4- and 5-hours 
post-bolus. Venous blood sampling was performed at baseline, 1, 3- and 5-hours post-bolus 
only.  
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Figure 2. (A) Schematic representation of the overall study design. (B) Schematic 
representation of the specific procedures during each testing session.
A 
B 
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2.2.2. Dietary Guidelines 
All participants arrived at the laboratory between 7 – 10am, after an overnight fast of a 
minimum of 10 hours, to account for circadian variation (Bell, Walshe, Davison, Stevenson, & 
Howatson, 2014c). Participants were instructed to maintain their habitual polyphenol intake, 
including anthocyanins, as opposed to complete restriction throughout the study. This was to 
ensure that the polyphenols provided by MTCJ were supplementary to the existing habitual 
polyphenol intake of each participant representing normal daily activity and therefore 
upholding ecological validity. Fluids or food were not provided during testing sessions, but 
participants were able to drink water ad libitum, where volume of consumption was monitored 
during the first session and repeated in subsequent sessions (Keane et al., 2016b). 
Total energy, macronutrient and polyphenol intake of participants’ ‘Western’ habitual diet was 
analysed through food diaries. This was to assess compliance of replicating dietary intake for 
the 3 days prior to each testing session (Alkhatib, Seijo, Larumbe, & Naclerio, 2015; Nordby, 
Saltin, & Helge, 2006; Roberts, Roberts, Tarpey, Weekes, & Thomas, 2015). Participants were 
given instructions on how to complete the food diaries, including portion sizes. Dietary analysis 
software (Dietplan 7.0, Forestfield Software, UK) was used to monitor compliance of the           
3-day food diaries before each session. All participants complied with dietary guidelines upon 
analysis for percentage contributions of macronutrients to total energy intake [mean ± SD 
(protein 16 ± 23%), (CHO 45 ± 56%), (fat 39 ± 38%)], total polyphenols (70 ± 83 mg) and 
anthocyanins (26 ± 22 mg). 
2.2.3. Supplementation 
This study acutely administered three different supplements including a placebo which acted 
as the control condition and two experimental conditions, MTCJ and MTCC. The placebo was 
composed of 30 mL commercially available fruit-flavoured cordial (Cherries and Berries, 
Morrisons, Bradford, UK) mixed with 100 mL water. The placebo drink was also matched 
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against MTCJ for energy content, taste and visual appearance by adding a flavourless 
carbohydrate (Maltodextrin, My Protein Ltd, Northwich, UK), citric acid (100% Pure Citric 
Acid, VB and Sons, UK), red and black food colouring (Morrisons, Bradford, UK), 
respectively. MTCJ consisted of 30 mL Montmorency tart cherry concentrate (Cherry Active, 
Active Edge Ltd, Hanworth, UK) and 100 mL water. Each 30 mL serving of MTC concentrate 
provided a total anthocyanin content of 270 mg (9 mg.mL-1) (Howatson et al., 2010). In MTC 
concentrate, the most abundant anthocyanins include, cyanidin-3-glucosylrutinoside, cyanidin-
3-rutinoside and peonidin-3-rutinoside (Bell et al., 2014a). In order to match the anthocyanin 
content of MTCJ, participants consumed 10 Montmorency tart cherry capsules (Cherry Active 
Capsules, Active Edge, Ltd, Hanworth, UK) with 130 mL water. Each capsule contained        
435 mg of freeze-dried Montmorency tart cherry skin powder (Table 2). Independent analysis 
(AtlasBiosciences, 2018) showed total anthocyanin content in each capsule was 27 mg. The    
30 mL serving of Montmorency tart cherry concentrate contained ~90-110 whole 
Montmorency tart cherries whilst 10 capsules were made from ~100 whole cherries. 
Anonymity of supplementation was ensured by blinding the participants to the source of 
anthocyanins. This was achieved by explaining that an ‘anthocyanin-rich supplement’ would 
be provided rather than disclosing Montmorency tart cherries as the specific source.  
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Table 2. Nutritional information of each supplement provided. 
 Montmorency tart 
cherry concentrate  
(per 30 mL) 
Montmorency tart 
cherry capsules  
(per capsule – 435 mg) 
Placebo  
(per 30 mL) 
Energy (kcal) 102 1.3 102 
Carbohydrate (g) 24.5 0.3 25.35 
of which sugars (g) 17.9 0.1 25.32 
Protein (g) 1.1 Trace 0.03 
Fat (g) 0 Trace 0 
of which saturates (g) 0 0 0 
Fibre (g) 2.6 Trace Trace 
Total Anthocyanins 
(mg) 
270 27 0 
 
2.2.4. Measures and Equipment 
2.2.4.1. Blood Pressure 
Brachial systolic (bSBP) and diastolic (bDBP) blood pressure (Omron MX3, Omron, Japan) 
were measured four times in an upright seated position, with an average of the final three being 
taken as BP (Cook et al., 2015). 
2.2.4.2. Cardiac Haemodynamics 
Beat-to-beat resting cardiac haemodynamic parameters including heart rate (HR), cardiac 
output (CO), stroke volume (SV), mean arterial pressure (MAP) and total peripheral resistance 
(TPR) were measured non-invasively (Finometer MIDI Model-2, Finapres Medical Systems 
BV, Amsterdam, The Netherlands) at all time points, using the arterial volume clamp method 
(Penaz, 1992). To avoid data selection, recordings were averaged over 10 consecutive beats 
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with the lowest values for each parameter taken for statistical analysis (Cook, Myers, Gault, 
Edwards, & Willems, 2017). 
2.2.4.3. Pulse Wave Analysis 
Pulse wave analysis (PWA) was used to monitor arterial stiffness non-invasively using 
applanation tonometry (SphygmoCor, ScanMed Medical, UK), as there is a strong association 
between PWA and cardiovascular disease incidents, independent of traditional risk factors 
(Choi et al., 2004; Keane et al., 2016b). A pencil-type probe was placed over the radial artery 
on the right wrist which was slightly extended and rested on a pillow (Doupis, Papanas, Cohen, 
McFarlan, & Horton, 2016). Aortic pulse waveforms, aortic SBP, aortic DBP, pulse pressure 
(PP), augmentation pressure (AP), augmentation index (AIx), AIx normalised to                            
75 beats.min-1 (AIx at HR75) and subendocardial viability ratio (SEVR) were determined by 
the in-built software (SphygmoCor version 7.0, ScanMed, UK) using generalised transfer 
functions. Recordings with a quality-index ≥80%, as determined by the manufacturer, were 
selected for statistical analysis.  
2.2.4.4. Resting Metabolic Rate (RMR) 
RMR, resting energy expenditure, substrate oxidation rates and respiratory quotient (RQ) were 
measured using an open-circuit indirect calorimetry system (GEM Nutrition Ltd, Cheshire, 
UK). Participants lay supine for 20 minutes with data averaged for the final 17 minutes only, 
to achieve steady-state and account for any initial short-term variances in respiration (Kelly, 
King, Goerlach, & Nimmo, 2013). A ventilated hood was placed over the head with a flexible 
plastic seal around the neck and shoulders to prevent air inside and outside the hood from 
mixing. 
Resting fat and carbohydrate oxidation rates were calculated using stoichiometric equations, 
assuming negligible protein oxidation (Jeukendrup & Wallis, 2005). 
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Fat Oxidation Rate (g.min-1) = (1.695˙V̇O2) - (1.701˙V̇CO2)   (1) 
CHO Oxidation Rate (g.min-1) = (4.344˙V̇CO2) - (3.061˙V̇O2)  (2) 
2.2.5. Blood Sampling and Analysis 
2.2.5.1. Blood Sampling 
Venous blood was sampled through 4 individual venepunctures (one at each time point: pre-
bolus and 1, 3, 5 hours post-bolus), using the butterfly method (BD Vacutainer Safety-Lok 
Blood Collection Set 21G with Luer Adapter, Becton Dickinson and Co., Oxford, UK). A total 
of 5 mL venous blood was collected into serum-separation tubes (BD Vacutainer, Becton 
Dickinson and Co., Oxford, UK) for each sample. Tubes were centrifuged at 4000 rev.min-1, 
4°C for 10 minutes (Sorvall ST 8R, Thermo Fisher Scientific, USA). Serum supernatants were 
aliquoted and stored at -80°C for later analysis. 
2.2.5.2. Glucose 
Serum samples were assessed for glucose (range 0.5-50 mmol.L-1, CV ≤ 1.5%) (Biosen             
C-Line, EKF Diagnostics, Cardiff, UK) in duplicates.  
2.2.5.3. Insulin Assay 
Serum insulin samples were measured in duplicates using a human 96-well colorimetric insulin 
enzyme-linked immunosorbent assay (ELISA) (Insulin Human ELISA KAQ1251, Invitrogen, 
Thermo Fisher Scientific, USA), with a common sample measured on each plate for 
determining inter-plate CV. A four-parameter algorithm standard curve was generated using 
standard curve fitting software (SigmaPlot, Systat Software Inc, San Jose, USA), where values 
were converted from µIU.mL-1 to pmol.L-1 by multiplying by 6.945 (Bos et al., 2010). Inter- 
and intra-plate precision were 8.8% and 7.69%, respectively. 
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2.2.5.4. Insulin Resistance and Sensitivity Indexes 
Homeostatic Model Assessment (HOMA) was used to estimate fasting steady-state pancreatic 
β-cell function (HOMA2-β) and insulin resistance (HOMA2-IR index) through the HOMA2 
spreadsheet model (HOMA2-IR, available from https://www.dtu.ox.ac.uk/homacalculator/) 
(Levy, Matthews, & Hermans, 1998). Equations 1, 2 and 3 (Matthews et al., 1985), outline the 
determination of pancreatic β-cell function, insulin sensitivity (HOMA2-%S) and insulin 
resistance, respectively. As recommended by Wallace, Levy and Matthews (2004),         
HOMA2-%S was calculated to assist in the correct interpretation of HOMA2-β.  
HOMA2-β (%) = 
(20 ∙ Fasting Insulin (μIU.mL-1))
(Fasting Glucose (mmol.L-1)-3.5)
∙100   (3) 
HOMA2-%S (%) = (
1
HOMA-IR
) ∙100      (4) 
HOMA2-IR =
 [Fasting Glucose (mmol.L-1) ∙ Fasting Insulin (μIU.mL-1)]
22.5
   (5) 
2.2.5.5. Lipid Assays 
Serum lipids were determined in duplicates using commercially available colorimetric assays 
on a semi-automated spectrophotometer (RX Monza, Randox Laboratories Ltd, Antrim, UK), 
according to manufacturer’s guidelines. Triglyceride (Triglycerides TR210, Randox) values 
were corrected for free glycerol by subtracting 0.11 mmol.L-1 (Stinshoff et al., 1977), according 
to the manufacturer’s guidelines. Intra-assay CV for triglycerides, total cholesterol and HDL 
were 2.33%, 4.45% and 3.63%, respectively. LDL was determined indirectly using the formula 
below (Ahmadi, Boroumand, Gohari-Moghaddam, Tajik, & Dibaj, 2008). 
LDL (mmol.L-1) = (
Total Cholesterol
1.19
) + (
Triglycerides
0.81
) - (
HDL
1.1
) - 0.98  (6) 
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2.3. Data Analysis 
Statistical analysis was performed using SPSS v22.0 (IBM, Chicago, USA) where data are 
reported as means [95% Confidence Intervals] (CI). Data normality was checked using a 
Shapiro-Wilk test. Greenhouse-Geisser correction was applied upon violation of Mauchly’s 
test of sphericity for ANOVAs. Statistical significance was set at P < 0.05. Due to this being a 
pilot study and the lack of prior data on the effects of Montmorency tart cherry products in 
humans with MetS from which to conduct power calculations, a minimum sample size of 10 
was established (Udani, Singh, Singh, & Barrett, 2011). Subsequently, the statistics performed 
are exploratory given the small sample size. 
To account for day-to-day physiological variances at pre-bolus between conditions for each 
variable, data was analysed as change from pre-bolus for each time point measured post-bolus. 
This enabled a fair assessment of the post-bolus responses to each condition from pre-bolus 
across all variables. The pre-bolus time point was not included as a covariate, as one-way 
ANOVA analysis indicated no significant differences between conditions for all variables at 
the pre-bolus time point, hence two-way repeated-measures ANOVA was performed.  
A within-group two-way, 3 x 6, condition (PLA vs MTCC vs MTCJ) x time (30 minutes, 1, 2, 
3, 4- and 5-hours post-bolus), repeated-measures ANOVA design with post-hoc Bonferroni’s 
adjustment, measured differences for bSBP, bDBP, RMR, cardiac haemodynamic and PWA 
parameters on change from pre-bolus values for each condition. 
Blood-based biomarkers were analysed using the same model but with a 3 x 3, condition (PLA 
vs MTCJ vs MTCC) by time (1, 3- and 5-hours post-bolus) design on change from pre-bolus 
values for each condition. A paired-samples t-test was used to identify differences between 
individual data points within conditions and between conditions for the corresponding time 
point.  
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Partial Eta-Squared (
2
partial ) was used to report effect sizes for ANOVA where effects were 
classified as small (0.01-0.08), moderate (0.09-0.25) and large (>0.25) (Cohen, 1998). Cohen’s 
d effect size was used for paired-samples t-test and post-hoc interaction comparisons where 
effects were classified as no effect (0-0.1), small (0.2-0.4), moderate (0.5-0.7) and high (≥0.8) 
(Cohen, 1998). 
3. Results 
The present study measured variables relevant to MetS, and as the defining aspect is insulin 
resistance, serum insulin and glucose were regarded as primary variables. Other variables 
focused on the other two main aspects of MetS, cardiovascular dysfunction and 
lipidaemia. Raw data for all variables is provided in Supplemental Tables 1-4. 
3.1. Blood Biomarkers 
Analysis of change from pre-bolus responses for serum insulin (Figure 3) showed a significant 
main effect for condition (F(2, 20) = 3.653; P = 0.044, 
2
partial  = 0.27), time (F(1.07, 10.67) = 13.411; 
P = 0.000, 
2
partial  = 0.57) and interaction (F(4, 40) = 5.837; P = 0.001, 
2
partial  = 0.37). The 
change from pre-bolus to 1-hour post-bolus between PLA (60.84 [24.33 – 97.34] pmol.L-1) and 
MTCC (-9.86 [-25.16 – 5.46] pmol.L-1) was significantly different (P = 0.016, d = 1.70); 7/11 
participants lowered insulin with MTCC compared to PLA. The change from pre-bolus to         
3-hours post-bolus between PLA (-8.99 [-35.55 – 17.57] pmol.L-1) and MTCJ                                   
(-48.80 [-82.40 – -15.20 pmol.L-1) was significantly different (P = 0.028, d = 0.88); 9/11 
participants had lower insulin with MTCJ compared to PLA. Mean post-bolus responses 
showed PLA (12.01 [-4.42 – 28.44] pmol.L-1) increased more than MTCJ                                            
(-18.01 [-40.33 – 4.31] pmol.L-1) (P = 0.039). The change from 1- to 3-hours post-bolus was 
significant between PLA and MTCC (t(10) = -2.295; P = 0.045, d = 0.85) and between MTCJ 
and MTCC (t(10) = 3.361; P = 0.007, d = 1.06).  
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Figure 3. Response curves for the mean (error bars indicate 95% CI) change in insulin 
concentrations from pre-bolus values to time points post-bolus for each condition. *Denotes 
significant difference between PLA and MTCC at 1-hour time point. ^Denotes significant 
difference between PLA and MTCJ at 3-hour time point. $Denotes significant difference for 
change in insulin from 1-3 hours post-bolus between PLA and MTCJ against MTCC. 
 
Individual responses showed 10/11 participants responded with an increase in LDL 
concentrations at 5-hours post-bolus (P = 0.057, d = 0.77) with PLA (0.71 [0.33 – 1.09] 
mmol.L-1) compared to MTCC (0.10 [-0.27 – 0.47] mmol.L-1). Change from pre-bolus 
responses for serum glucose did not show significant main effects for condition, time or 
interaction (P > 0.05). Statistical analysis for total cholesterol (TC) (F(1.159, 11.587) = 6.470;            
P = 0.023, 
2
partial  = 0.39), indicated a main effect for time only (Table 3). No main effects for 
condition, time or interaction were detected for triglycerides and HDL (P > 0.05) (Table 3).  
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AU (Arbitrary Units); HDL (High-density Lipoprotein); LDL (Low-density Lipoprotein); TC 
(Total Cholesterol). *Denotes significant main effect for time with post-hoc identifying 
differences between 1-hour and 3-hours post-bolus. $Denotes significant main effect for time 
with post-hoc identifying differences between 3-hour and 5-hour post-bolus. 
 
3.2. Cardiac Haemodynamics 
No significant main effects for condition, time or the condition by time interaction were 
detected for bDBP, MAP, SV, CO, TPR (P > 0.05) (Table 4). 
The change from pre-bolus to 2-hours post-bolus between PLA and MTCJ tended to be 
significantly different (P = 0.051, d = 1.48); 9/11 participants had lower MAP with MTCJ 
compared to PLA.  
Despite there being no main effects for condition, time or interaction, pairwise comparisons 
revealed a significant difference (P = 0.018, d = 1.75) between PLA (3 [-1 – 8] mmHg) and 
Table 3. Mean [95% CI] change from pre-bolus values to post-bolus time points for selected 
blood-based biomarkers per treatment condition. 
  Post-bolus Time Points 
  1 hr 3 hr 5 hr 
Glucose 
(mmol.L-1) 
PLA 0.35 [-0.77 – 1.46] -0.58 [-1.16 – -0.01] -0.63 [-1.07 – -0.18] 
MTCC -0.11 [-0.37 – 0.12] -0.22 [-0.59 – 0.19] -0.28 [-0.80 – 0.25] 
MTCJ -0.22 [-0.66 – 0.24] -0.79 [-1.42 – -0.13] -0.72 [-1.55 – 0.10] 
Triglycerides 
(mmol.L-1) 
PLA 0.09 [-0.06 – 0.26] 0.11 [-0.15 – 0.38] 0.21 [-0.08 – 0.49] 
MTCC -0.05 [-0.09 – 0.08] -0.06 [-0.31 – 0.20] -0.05 [-0.29 – 0.18] 
MTCJ -0.05 [-0.10 – 0.15] 0.03 [-0.10 – 0.19] 0.09 [-0.17 – 0.33] 
Total 
Cholesterol*$ 
(mmol.L-1) 
PLA 0.04 [-0.16 – 0.23] 0.16 [-0.15 – 0.48] 0.29 [0.03 – 0.55] 
MTCC -0.16 [-0.50 – 0.19] -0.16 [-0.55 – 0.26] 0.15 [-0.31 – 0.57] 
MTCJ -0.05 [-0.21 – 0.11] -0.03 [-0.16 – 0.10] 0.13 [-0.02 – 0.27] 
HDL 
(mmol.L-1) 
PLA -0.12 [-0.15 – 0.06] -0.10 [-0.12 – 0.02] -0.18 [-0.26 – 0.09] 
MTCC -0.05 [-0.16 – 0.05] -0.04 [-0.11 – 0.03] -0.03 [-0.15 – 0.09] 
MTCJ -0.07 [-0.15 – 0.01] 0.01 [-0.06 – 0.09] -0.09 [-0.21 – 0.03] 
LDL 
(mmol.L-1) 
PLA 0.25 [-0.08 – 0.57] 0.36 [-0.04 – 0.76] 0.71 [0.33 – 1.09] 
MTCC 0.30 [-0.44 – 0.51] -0.07 [-0.64 – 0.51] 0.06 [-0.38 – 0.51] 
MTCJ 0.08 [-0.27 – 0.43] 0.12 [-0.10 – 0.34] 0.24 [-0.20 – 0.68] 
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MTCJ (-8 [-13 – -4] mmHg) at 2-hours post-bolus for bSBP (Figure 4). Individual responses 
showed 10/11 participants responded with a lower bSBP after MTCJ consumption compared 
to PLA. Moreover, the mean difference (-11 [-19 – -4] mmHg) in responses between PLA and 
MTCJ at 2-hours post-bolus was greater than the clinically relevant threshold of 5 mmHg in 
8/11 participants. 
Heart rate responses revealed a significant main effect for time (F(1.992, 19.917) = 6.854; P = 0.005, 
2
partial = 0.41) and the condition by time interaction (F(10, 100) = 5.301; P = 0.000,                 
2
partial = 0.35). Post-hoc analysis displayed a tendency towards significance for HR at 30 
minutes post-bolus between PLA (-1 [-3 – 1] beats.min-1) and MTCC (-5 [-9 – -2] beats.min-1) 
(P = 0.080, d = 0.27), where all 11 participants responded with lower HR at 30 minutes post-
bolus with MTCC compared to PLA. Individual responses at 30 minutes post-bolus showed 
SV increased in 8/11 participants with MTCC compared to PLA. 
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Figure 4. Mean (error bars indicate 95% CI) bSBP, augmentation pressure (AP) and 
augmentation index (AIx) response curves from respective pre-bolus time points for each 
condition. *Denotes significant difference between PLA and MTCJ at 2-hours post-bolus. 
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Table 4. Mean [95% CI] change from pre-bolus values to post-bolus time points for selected cardiac haemodynamic and PWA parameters per condition. 
   Post-bolus Time Points 
  30 minutes 1 hr 2 hr 3 hr 4 hr 5 hr 
Brachial DBP 
(mmHg) 
PLA 3 [0 – 5] 5 [0- 10] 5 [2 – 9] 8 [3 – 13] 5 [0 – 9] 4 [0 – 8] 
MTCC 1 [-5 – 7] 4 [-2 – 11] 2 [-4 – 9] 0 [-4 – 4] 1 [-5 – 6] 3 [-2 – 9] 
MTCJ 3 [-1 – 7] 6 [3 – 9] 3 [0 – 6] 7 [3 – 11] 6 [1 – 11] 6 [2 – 10] 
MAP  
(mmHg) 
PLA 1 [-2 – 5] 5 [0 – 10] 5 [0 – 9] 7 [1 – 13] 5 [-1 – 11] 5 [-1 – 11] 
MTCC 3 [-4 – 11] 6 [0 – 13] 2 [-5 – 9] 2 [-2 – 7] 1 [-5 – 7] 5 [0 – 11] 
MTCJ 2 [0 – 4] 2 [-2 – 6] -4 [-7 – 1]  4 [0- 8] 4 [-2 – 9] -2 [-10 – 6] 
Cardiac Output 
(L.min-1) 
PLA 0.11 [-0.53 – 0.75] -0.02 [-1.08 – 1.03] -0.31 [-1.20 – 0.58] -0.58 [-1.27 – 0.11] -0.53 [-1.64 – 0.57] -0.35 [-1.32 – 0.61] 
MTCC -0.10 [-0.56 – 0.35] -0.24 [-0.91 – 0.43] -0.13 [-0.90 – 0.64] 0.03 [-0.69 – 0.74] -0.31 [-1.31 – 0.68] -0.21 [-1.13 – 0.71] 
MTCJ -0.33 [-1.54 – 0.87] -0.46 [-1.45 – 0.52] -0.04 [-1.37 – 1.28] -0.34 [-1.64 – 0.97] -0.62 [-1.62 – 0.39] -0.61 [-1.66 – 0.43] 
Stroke Volume 
(L) 
PLA 1 [-9 – 12] -1 [-14 – 11] -1 [-11 – 9] -5 [-17 – 8] -5 [-21 – 12] 2 [-15 – 18] 
MTCC 6 [-1 – 13] -1 [-12 – 11] 4 [-1 – 10] 6 [-1 – 17] 1 [-12 – 13] 3 [-10 – 17] 
MTCJ 1 [-17 – 19] -4 [-16 – 9] 1 [-17 – 19] -4 [-24 – 16] 1 [-14 – 17] 2 [-14 – 17] 
TPR 
(mmHg.min-1.L) 
PLA 0.00 [-0.14 – 0.14] 0.15 [-0.10 – 0.40] 0.14 [-0.06 – 0.35] 0.26 [-0.05 – 0.57] 0.16 [-0.02 – 0.34] 0.09 [-0.09 – 0.26] 
MTCC 0.01 [-0.10 – 0.13] 0.09 [-0.10 – 0.28] 0.02 [-0.23 – 0.26] 0.08 [-0.14 – 0.29] 0.09 [-0.17 – 0.35] 0.12 [-0.11 – 0.35] 
MTCJ 0.08 [-0.14 – 0.31] 0.07 [-0.11 – 0.25] -0.03 [-0.29 – 0.23] 0.10 [-0.13 – 0.32] 0.10 [-0.09 – 0.28] 0.11 [-0.13 – 0.34] 
        
HR  
(beats.min-1) 
PLA -1 [-3 – 1] -3 [-6 – -1]  -5 [-8 – -1] -5 [-10 – -1]  -7 [-12 – -1] -7 [-11 – -2] 
MTCC -5 [-9 – -2]  -4 [-7 – 0] -4 [-9 – 1]  -6 [-11 – -2] -5 [-12 – 1] -4 [-10 – 3]  
MTCJ 0 [-3 – 4] -1 [-5 – 2] -5 [-9 – -1] -7 [-11 – -4] -7 [-10 – -4] -8 [-11 – -4] 
Aortic SBP 
(mmHg) 
 
PLA 
 
1 [-4 – 6] 
 
3 [-3 – 8] 
 
4 [-2 – 10] 
 
2 [-5 – 10] 
 
4 [-1 – 10] 
 
5 [2 – 8] 
MTCC 2 [-2 – 5] 4 [-3 – 10] 4 [-6 – 13] 2 [-5 – 8] 2 [-4 – 7] 4 [0 – 7] 
MTCJ -1 [-5 – 5] -1 [-6 – 4] -2 [-7 – 2] 1 [-2 – 3] 2 [-3 – 6] 3 [-2 – 8] 
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Aortic DBP 
(mmHg) 
PLA 0 [-4 – 4] 0 [-5 – 5] 3 [-6 – 12] 3 [0 – 6] 4 [-1 – 8] 2 [-3 – 6] 
MTCC 5 [1 – 9]  3 [-1 – 6] 4 [-2 – 9] 0 [-6 – 6] 3 [-2 – 8] 6 [1 – 10] 
MTCJ -2 [-6 – 2] -2 [-6 – 2] 2 [-1 – 4] 1 [-4 – 6] 1 [-4 – 6] 1 [-2 – 4] 
Pulse Pressure  
(mmHg) 
PLA 1 [-2 – 9] 3 [-2 – 9] 1 [-5 – 7] -1 [-4 – 7] 0 [-1 – 8] 3 [1 – 8] 
MTCC -3 [-6 – 4] 1 [-5 – 7] 0 [-3 – 6] 2 [-3 – 3] -1 [-5 – 4] -2 [-4 – 6] 
MTCJ 1 [-6 – 2] 1 [-5 – 2] -4 [-7 – 2] 0 [-3 – 7] 1 [-4 – 4] 2 [-1 – 6] 
AIx at HR75*^$  
(%) 
PLA 0 [-2 – 2] -1 [-3 – 1] 2 [-2 – 6] 2 [-1 – 5] 3 [-1 – 6] 5 [2 – 8] 
MTCC 0 [-4 – 4] -1 [-5 – 3]  -2 [-6 – 2] 0 [-3 – 4] 2 [-2 – 5] 3 [-2 – 8] 
MTCJ 0 [-2 – 3] -1 [-6 – 4] -2 [-7 – 2] -2 [-7 – 2] 0 [-5 – 5] 2 [-2 – 7] 
SEVR (%) 
PLA -1 [-24 – 21] 11 [-3 – 24] 15 [-3 – 33] 10 [-4 – 24] 16 [-1 – 34] 3 [-11 – 17] 
MTCC 15 [0 – 30] 9 [-1 – 20] 17 [3 – 31] 16 [1 – 31] 19 [3 – 35] 9 [-7 – 26] 
MTCJ 6 [-11 – 24] 8 [-7 – 23] 31 [10 – 52] 24 [3 – 46] 21 [0 – 41] 12 [-3 – 27] 
AIx at HR75 (Augmentation Index at Heart Rate 75 bpm); DBP (Diastolic Blood Pressure); HR (Heart Rate); MAP (Mean Arterial Pressure); mmHg (millimetres of Mercury); 
mmHg (millimetres of Mercury); MTCC (Montmorency Tart Cherry Capsules); MTCJ (Montmorency Tart Cherry Juice); PLA (Placebo); SEVR (Subendocardial Viability 
Ratio); TPR (Total Peripheral Resistance). *Denotes significant main effect for time with post-hoc identifying differences between 1-hour and 3-hours post-bolus. ^Denotes 
significant main effect for time with post-hoc identifying differences between 1-hour and 5-hours post-bolus. $Denotes significant main effect for time with post-hoc identifying 
differences between 3-hour and 5-hours post-bolus. 
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3.3. Pulse Wave Analysis (PWA) 
A main effect for time (F(5, 50) = 7.839; P = 0.000, 
2
partial  = 0.44) was observed for the change in 
AP from pre-bolus. No main effects for condition or interaction (P > 0.05) were found, yet post-
hoc revealed a difference (P = 0.001, d = 1.37) between PLA (2 [0 – 5] mmHg) and                       
MTCJ (-2 [-4 – 0] mmHg) at 2-hours post-bolus (Figure 4). Individual responses showed 10/11 
participants responded with a lower AP, 2-hours after MTCJ consumption compared to PLA. 
A main effect for time (F(5, 50) = 10.090; P = 0.000, 
2
partial = 0.50) was detected for AIx, but not 
for condition or interaction (P > 0.05). However as with AP, post-hoc comparisons identified a 
significant difference (P = 0.016, d = 1.22) at 2-hours post-bolus between PLA (4 [1 – 8] %) and 
MTCJ (-3 [-7 – 2] %). This indicates more compliant arteries with MTCJ at this time point whereby 
9/11 participants reduced arterial stiffness compared to PLA. There were no significant 
correlations between bSBP and AIx (ρ = 0.105; P = 0.401) or AP (ρ = 0.145; P = 0.247) at 2-hours 
post-bolus for MTCJ. 
No significant main effects for condition, time or the condition by time interaction were detected 
for aortic SBP, aortic DBP, and pulse pressure (P > 0.05). A main effect for time was detected for 
AIx at HR75 (F(5, 50) = 7.747; P = 0.000, 
2
partial = 0.44) and SEVR (F(5, 50) = 3.903; P = 0.005, 
2
partial  = 0.28), however no other main effects for condition or interaction were found (P > 0.05) 
(Table 4). 
3.4. Resting Metabolic Rate 
Resting RQ did not show a significant main effect for condition or interaction (P > 0.05). However, 
a main effect for time (F(1.938, 19.376) = 28.261; P = 0.000, 
2
partial  = 0.74) was found, post-hoc 
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analysis for the main effect of time showed all post-bolus time points to be lower than 30 minutes 
post-bolus (P < 0.05).  
No main effects for condition or interaction (P > 0.05) were seen, however significant main effects 
for time were observed for resting fat (F(5, 50) = 18.096; P = 0.000, 
2
partial  = 0.64) and carbohydrate 
oxidation (F(5, 50) = 16.750; P = 0.000, 
2
partial  = 0.63). Specifically, significant differences were 
observed between all post-bolus time points against 30 minutes post-bolus for fat and carbohydrate 
oxidation (P < 0.05). Finally, no significant main effects for condition, time or interaction were 
seen for resting energy expenditure (P > 0.05). 
4. Discussion 
The present study examined cardio-metabolic responses of humans with MetS to an acute bolus of 
MTCC and MTCJ in a randomised, placebo-controlled trial, for the first time. The hypotheses 
were partially accepted as the main findings from this research demonstrated significantly lower 
post-prandial responses to serum insulin with MTCJ compared to PLA and a blunted insulin 
response with MTCC compared to PLA, 1-hour post-bolus. In accordance with previous research 
(Keane et al., 2016b), bSBP was significantly lower with MTCJ compared to PLA, 2-hours post-
bolus. Finally, reported for the first time, responses between MTCC and MTCJ were not 
statistically different, thus refuting the hypothesis that MTCC may be superior than MTCJ; 
although physiological differences were apparent at particular time points for certain markers. 
A novel finding from the present research was mean post-bolus insulin responses were 
significantly lower with MTCJ than PLA, and also significantly lower at 3-hours post-bolus. 
Although not statistically significant, insulin responses between PLA and MTCC were also 
physiologically different. The mean change from pre-bolus across all post-bolus time points 
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increased with PLA, but decreased by 20.61 pmol.L-1 with MTCC. However, this was likely due 
to the carbohydrate content in the placebo beverage (99.88% of which sugars), where maltodextrin 
was added to match the energy content of the placebo to MTCJ. Consequently, this provoked a 
contrived response of the placebo on insulin, making comparisons against MTCC and MTCJ 
difficult. Nevertheless, as this was the first study to assess acute glycaemic and insulinaemic 
tolerability to MTCC and MTCJ consumption, it is possible to discern novel findings. A blunted 
insulin secretion response throughout the 5-hour post-bolus period with MTCC was observed, as 
participants only consumed 1 gram of carbohydrate from the 10 capsules ingested.  Additionally, 
in alignment with MTC pharmacokinetics (Keane et al., 2016a), absolute insulin concentrations at 
3-hours post-bolus were similar between MTCC (77.42 [54.44 – 100.39] pmol.L-1) and MTCJ 
(76.53 [49.07 – 103.99] pmol.L-1). Despite differences in glycaemic load, this highlights a potential 
action of MTC anthocyanins and their metabolites, given the only similarity between MTCC and 
MTCJ was the total anthocyanin content. Interestingly, the similar insulin concentrations suggest 
no difference between the delivery of MTC anthocyanins in capsule or juice form, indicating 
enhanced bioavailability of anthocyanins with capsules likely did not occur. The data indicates 
both MTC interventions effectively blunted insulin responses when parent anthocyanin and 
secondary metabolite plasma concentrations were likely elevated. 
The high glucose load in the placebo elicited a significantly higher insulin secretion response          
1-hour post-bolus compared to MTCC. Although not statistically different, a similar physiological 
response was found with MTCJ compared to MTCC (7/11 participants had increased insulin with 
MTCJ, 3/11 increased with MTCC). This may potentially be due to the lower sugar content in 
MTCJ than PLA, along with the effect of anthocyanins inhibiting glucose absorption across the 
apical membrane of enterocytes into systemic circulation via suppression of sodium-dependent 
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glucose transporter-1 (SGLT-1) (Alzaid, Cheung, Preedy, & Sharp, 2013). Likewise, insulinaemic 
and glycaemic responses to 7 days of New Zealand blackcurrant powder (NZBP) supplementation 
suggested a 14.3% reduction in fasting insulin compared to control (Willems, Silva, Cook, & 
Blacker, 2017). Crucially, the authors measured fasting insulin 1-hour post-consumption of the 
final bolus, implying an acute effect of NZBP anthocyanins and metabolites on insulin. Willems 
et al. (2017) explained that an increased glycaemic and insulinaemic response was expected, 
however the carbohydrate load was not sufficient to induce a glycaemic or insulinaemic response 
and ascribed the decline in insulin to improved insulin sensitivity. A similar mechanism may be 
cited to explain the smaller changes from baseline for insulin with MTCJ and MTCC in the present 
study, given baseline HOMA2-IR (2.2 [1.2 – 3.2]) and HOMA2-%S (61.8 [42.3 – 81.4] %) values 
indicated insulin resistance (Geloneze et al., 2009) and low insulin sensitivity respectively.  
The effect of lower insulin concentrations with normal glucose suggests MTC improved insulin 
sensitivity (Willems et al., 2017) which may prevent pancreatic β-cell glucotoxicity (Amiot et al., 
2016), reducing the burden on β-cells by averting excess insulin secretion (Alvarado et al., 2016). 
Additionally, the acute nature of this study limits the mechanisms through which MTC 
phytochemicals can operate. Hence, improved insulin sensitivity within 5-hours of ingesting MTC 
may have been mediated through enzyme-interactions involving adenosine monophosphate-
activated protein kinase (AMPK) (Tsuda, 2016) and/or receptor-interactions along the insulin 
signalling cascade. Specifically, binding of insulin to insulin-receptor substrate 1 (IRS-1) 
prompting glucose transporter 4 (GLUT-4) translocation to the cell membranes of adipocytes and 
myocytes (Belwal, Nabavi, Nabavi, & Habtemariam, 2017). Subsequently, adaptations may 
include greater expression of AMPK and GLUT-4 mRNA; more efficient insulin receptor activity 
through greater insulin receptors on hepatocytes, myocytes and adipocytes; and peroxisome 
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proliferator-activated receptor agonism (Seymour et al., 2009). Through the physiological 
mechanisms hypothesised above, improvements in insulin sensitivity may manifest to lower 
insulin resistance and theoretically reverse MetS; in the long-term. The direction of the 
insulinaemic response and its low carbohydrate content, provides evidence that MTCC may be a 
more tolerable intervention for individuals with dysfunctional glycaemic control and insulin 
resistance, such as type 2 diabetics. Moreover, the findings even hint at short-term improvements 
in insulin control with both MTC interventions, which may develop into long-term adaptations 
with consistent use; however, a direct investigation of this is required.  
The most noteworthy cardiovascular response observed in the present study was the significant 
reduction in bSBP at 2-hours post-bolus with MTCJ compared to PLA. This finding was consistent 
with previous literature assessing bSBP with cherry interventions (Chai, Davis, Wright, 
Kuczmarski, & Zhang, 2018; Keane et al., 2016b; Keane et al., 2016c; Kent, Charlton, Jenner, & 
Roodenrys, 2016). Keane et al. (2016bc) observed significantly lower bSBP with MTCJ compared 
to PLA for the first 3-hours after ingestion, with peak reductions of 7 mmHg occurring at 2-hours 
post-bolus (Keane et al., 2016b) and 6 mmHg at 1-hour post-bolus (Keane et al., 2016c). Similarly, 
the present study observed the greatest reduction in bSBP (-8 mmHg) also at 2-hours post-bolus, 
thus it can be hypothesised that MTCJ modulates bSBP during this time period as it likely 
coincides with parent anthocyanin and metabolite pharmacokinetics (Keane et al., 2016a). 
Likewise, sweet cherry juice also had its greatest effect on bSBP (-5.50 mmHg) 2-hours post-
prandially, in old and young adults (Kent et al., 2016), with the authors attributing the 
improvement to the parent anthocyanins but not phenolic metabolites, as peak metabolite 
concentrations did not coincide with the time course of the observed effect. Interestingly, 
modulation of bSBP with MTCC did not occur, despite administering the same total anthocyanin 
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content. Based on Keane et al. (2016b) explaining that phenolic metabolites (protocatechuic and 
vanillic acids) from MTCJ, likely exerted the dampened bSBP response, it may be that these 
metabolites were not present at physiologically relevant concentrations within systemic circulation 
with MTCC. This could be due to the variable mechanics of capsule shell disintegration impeding 
anthocyanin metabolism. 
Hypertension and isolated systolic hypertension increases risk of CVD, the leading cause of 
morbidity and mortality worldwide (Feresin et al., 2017), however mean bSBP reductions of at 
least 5-6 mmHg over 5 years has been linked with a lower risk of coronary heart disease and stroke 
by 20-25% and 35-40%, respectively (Collins et al., 1990). Bundy et al. (2017) reported that a 
reduction in bSBP of greater than 5 mmHg was clinically relevant and associated with lower 
CVD/mortality risk. Thus, the magnitude of change with MTCJ indicates clinically relevant 
reductions in bSBP; mean difference between MTCJ and PLA at 2-hours post-bolus was                      
-11 mmHg. Consequently, this emphasises the highly potent properties of MTCJ acutely 
improving bSBP and the effect of a lower MTCJ dosage compared to Keane et al. (2016b). This 
finding is of high importance in the context that approved anti-hypertensive drugs, with associated 
harmful side effects, comparably lower bSBP by a similar magnitude (Bramlage & Hasford, 2009) 
as MTCJ, which currently has no known side effects. A limitation of examining acute cardio-
metabolic responses is low ecological validity and biological significance of the results 
(Rodriguez-Mateos et al., 2013). However, long-term studies supplementing anthocyanins from 
tart (Keane et al., 2016c) and sweet (Kent et al., 2017) cherries have also been shown to lower 
bSBP, although only in subjects presenting elevated baseline bSBP. Furthermore, the significance 
of short-term decrements of bSBP in a MetS population may mean subsequent long-term 
improvements in arterial compliance and endothelial function. Consequently, this may reverse the 
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systemic pro-inflammatory and pro-oxidative state of MetS and reduce the risk of developing 
cardiovascular disease (Yanai et al., 2008); although this requires direct investigation. 
Arterial stiffness, particularly of the aorta, is an independent predictor of cardiovascular morbidity 
and mortality (Cecelja & Chowienczyk, 2012). Evidence exists that a higher consumption of 
anthocyanins is associated with reductions in aortic blood pressure and arterial stiffness (Jennings 
et al., 2012). Previous research pertaining to supplementation of MTCJ in healthy (Lynn et al., 
2014), early-hypertensive (Keane et al., 2016b) and MetS (Johnson et al., 2017) participants had 
not demonstrated improvements in arterial stiffness. Individual responses and statistical analysis 
from the present study demonstrated an improvement in arterial stiffness (AIx) only at 2-hours 
post-bolus with MTCJ compared to PLA. However, this finding remains dubious given that PP, 
aortic (AP) and peripheral (TPR) indicators of vascular stiffness were not improved with MTCJ. 
Furthermore, AIx and AP were not significantly correlated to bSBP at 2-hours post-bolus with 
MTCJ; suggesting modulation of arterial stiffness does not explain the reduction in bSBP at that 
time point. 
As the results from this research seem to not support a mechanical mechanism of action through 
improved arterial compliance, the findings may be explained by a chemical mechanism of action 
involving nitric oxide (NO) and/or inhibition of angiotensin-converting enzyme (ACE). However, 
Keane et al. (2016b) were unable to demonstrate augmented plasma nitrate/nitrite concentrations 
after 60 mL MTCJ consumption, suggesting NO mediated vasodilation may not be the responsible 
pathway. Conversely, Kirakosyan, Gutierrez, Ramos Solano, Seymour, and Bolling (2018) 
demonstrated MTC extract to inhibit ACE, potentially explaining reductions in bSBP from the 
present study; future work should assess ACE inhibition in humans following MTC consumption. 
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However, concomitant stimulation of endothelial nitric oxide synthase and ACE inhibition should 
not be ruled out. 
MTCC induced vasodilation may have facilitated greater venous return thus explaining HR, SV 
and CO responses at 30 minutes post-bolus. A similar mechanism was provided by Willems et al. 
(2017) in response to acute, encapsulated NZBP supplementation. The observed response with 
MTCC was remarkable, as disintegration of the capsule shell requires 30 minutes (Lown et al., 
2017), indicating that responses on HR and SV were immediate after dissolution. Subsequently, it 
was thought that provision of MTC in liquid form (MTCJ) would facilitate faster absorption of 
parent anthocyanins and metabolites (Bohn, 2014; McGhie & Walton, 2007) than MTCC. 
However, the lack of response with MTCJ would suggest either extensive degradation by salivary 
amylase (Kamonpatana et al., 2012) and/or a delayed uptake of secondary metabolites and phase 
II conjugates, due to gut metabolism of anthocyanins (Fernandes, Faria, Calhau, de Freitas, & 
Mateus, 2014). This delayed uptake of metabolites may be the rate-limiting step.  
In agreement with responses observed in participants with MetS during the present investigation, 
Johnson et al. (2017) reported 12 weeks MTCJ consumption had no significant effect on lipids. 
However, Johnson et al. (2017) observed a trend for lower total cholesterol with MTCJ compared 
to PLA. This suggests lipids may be more sensitive to improvement at higher anthocyanin, 
secondary metabolite and phase II conjugate concentrations; through higher dosages and/or longer 
supplementation length. 
As with all research, certain limitations are apparent with the present study. Firstly, the artificial 
effect of the placebo on glycaemic and insulinaemic responses influenced the data and nullified 
comparisons against MTCC and MTCJ. Subsequent studies should ensure the placebo is matched 
for relative percentage of each macronutrient to total energy or alternatively use a water placebo 
Chapter 11. Appendices 
402 
 
if aiming to evaluate the intervention as a whole, including detrimental effects of juices such as 
sugars (Peluso & Palmery, 2014). Furthermore, the parent anthocyanin and secondary metabolite 
pharmacokinetics of MTCC in humans was and remains unknown. Thus, there is a necessity to 
address this gap in the literature, to enable better understanding of the data from this study and 
future work incorporating MTCC. Additionally, any advantageous responses observed with MTC 
interventions may be due to a residual synergistic effect of habitually consumed polyphenols, as 
this study aimed to uphold ecological validity by permitting habitual polyphenol intake. The 
beneficial responses observed with MTCJ compared to MTCC and PLA, may be a consequence 
of other nutrients, such as fibre which was shown to reduce bSBP, total cholesterol and post-
prandial glucose and insulin (Hodgson, 2004); aligning with findings from the present study. 
Although much attention has been given to the beneficial effects of anthocyanins and their 
metabolites, the synergistic influence of other phytonutrients within MTC require consideration. 
Finally, acute cardio-metabolic responses were monitored during this study, however to enhance 
ecological validity and clinical relevance, monitoring data over a longer time frame is required. 
5. Conclusion  
This research is the first to present data that acute administration of MTC interventions in capsule 
and juice form can modulate certain cardio-metabolic markers in humans with MetS. Further 
evidence is provided that MTCJ is an effective, low-risk intervention for reducing bSBP in various 
populations and should be considered for individuals with isolated systolic hypertension. Despite 
recruiting humans with MetS, the effects of MTC on cardio-metabolic markers seemed to only 
apply to certain variables which were abnormal at baseline. The physiological responses to either 
MTC intervention differed depending on the cardio-metabolic marker examined, although there 
were no statistically significant differences between MTCC and MTCJ. Consequently, 
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recommendations for which MTC intervention is more suitable should be based on the cardio-
metabolic marker that requires most attention, with consideration of the individuals’ overall 
cardio-metabolic health. 
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